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The overactive bladder syndrome is a symptom complex incorporating 
urinary urgency, with or without urgency urinary incontinence and is highly 
prevalent in women throughout the world.  It can have a significant adverse 
impact on a woman’s quality of life both physical and psychological and has 
been shown to negatively impact on sexual function.  The mainstay of 
treatment has traditionally included conservative therapies such as lifestyle 
advice and bladder retraining and medication in the form of anticholinergics.  
Although there is a plethora of data detailing the effect of anticholinergics on 
lower urinary tract symptoms and general quality of life, scant data are 
available regarding the impact of anticholinergics on the sexual function of 
women with overactive bladder syndrome. 
This thesis presents an overview of the literature related to the definitions, 
assessment and management of sexual function and dysfunction in women.  
It also describes what is known of the impact of lower urinary tract symptoms 
and specifically overactive bladder on sexual function.  Following 
identification of a knowledge gap, a systematic review questioning “Do 
anticholinergics improve sexual function in women with overactive bladder 
syndrome?” was performed and reported.   
This led to the development of the research question - ‘Does fesoterodine 
have any effect on the sexual function of women with overactive bladder 
syndrome?’ and this thesis documents the development and initiation of a 
clinical trial of an investigational medicinal product entitled ‘A 12 week, multi-
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centre, open label study to evaluate the effect of fesoterodine flexible dosing 
regimen on the sexual function of women with overactive bladder’.    
Although only a fifth of the sample size was recruited, a statistically 
significant improvement in both the primary and many of the secondary 
endpoints was achieved indicating an improvement in sexual function.  
However, due to the lack of a comparison arm it is unclear if this is due to the 
effect of fesoterodine or a placebo effect.   A qualitative analysis of patient 
goals during the study provided new insights into the impact of overactive 
bladder on women’s quality of life both physically and psychologically.   
The clinical trial led to two new research questions -   
1. What is the prevalence of sexual activity in women with overactive 
bladder syndrome attending a London Urogynaecology Outpatient 
service?  
2. How do women want to be approached about the topic of sexual 
activity and sexual function? 
A prevalence survey was conducted which revealed that the levels of sexual 
activity were lower than expected among the population of women with 
overactive bladder under study.  It raised concerns over the reliability and 
validity of the questionnaire used and showed that women have a differing 
views and opinions of what the term ‘sexually active’ means.   
Focus groups were performed and analysed thematically to understand how 
women want to be approached about sexual activity and sexual function.  
The key points gained from the groups related to terminology, the desire for 
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pre-warning regarding discussion about sexual activity and the fact that 
women’s individual preferences need to be identified and considered.                                                                                                                                                                                                                                                           
This thesis highlights the inadequacies in current research related to sexual 
activity and sexual function and overactive bladder and makes 
recommendations to develop definitions and research methodology to enable 
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In 2008, the 4th International Consultation on Incontinence (ICI) took place in 
Paris.  At this meeting an international faculty of over 150 health care 
professionals came together to review current evidence in relation to the 
assessment, diagnosis and management of all aspects of incontinence.  
They not only published guidelines in relation to best practice but also made 
recommendations for future research in line with the gaps that they identified 
in the knowledge.  They recommended that:- 
 
‘Urinary incontinence, lower urinary tract symptoms (LUTS) and the 
treatment of these disorders all have potential effects on the sexual function 
of women yet little is known about the impact of incontinence treatment on 
sexual function.  It is therefore appropriate that sexual function be considered 
as one of the domains for investigation in all types of incontinence research.’ 
(Abrams et al 2009) 
 
Professor Cardozo was actively involved as a co-chairman in this meeting 
and also an editor of the book “Incontinence” published after this consultation 
detailing their recommendations.  At one of the Urogynaecology 
departmental research meetings following the ICI, Professor Cardozo 
discussed some of these recommendations for research and highlighted 
considering how these ideas could be incorporated into the current research 
strategy within the department.    
 
This thesis will describe the development and implementation of 
investigations that I have undertaken during the course of study and present 











The Urogynaecology Department at King’s College Hospital 
 
The Urogynaecology Department at King’s College Hospital (KCH) NHS 
Foundation trust was founded by Professor Cardozo in 1979 with a weekly 
urodynamics session.  It is set within a large teaching hospital in south east 
London that cares for an urban and suburban catchment area and a multi-
racial population.  It is both a secondary and tertiary referral service, 
providing expert assessment, diagnosis, conservative, pharmacological and 
surgical management of LUTS and pelvic floor dysfunction.  Figure 1.1 is a 
picture of the Golden Jubilee Wing at KCH, where the Urogynaecology 




Figure 1.1 Golden Jubilee Wing at King’s College Hospital 
 
Today the team comprises four Consultant Urogynaecologists, a sub-
specialty trainee, two clinical research fellows, three clinical nurse 
specialists, three women’s health physiotherapists and a health care 
assistant.  Figure 1.2 is a picture of the current team taken at the UK 
Continence Society (UKCS) Meeting in 2018.  The department was 
accredited by the British Society of Urogynaecology (BSUGs) in 2013 and in 
2014, received recognition as a subspecialist provider for complex 






Figure 1.2 The Urogynaecology Team at KCH 
 
The unit receives approximately 1650 new patient referrals per year into our 
main outpatient clinic and about 1200 patients are seen in our one stop 
urodynamics clinics per year.  On average the department reviews around 
250 women per week within the variety of clinical services (outpatient and 
one stop urodynamic clinics, nurse led clinics, physiotherapy clinics and 
outpatient, day surgery and in patient surgery lists).  
 
One of the most commonly reported conditions for which women are referred 
to the service is the overactive bladder syndrome (OAB).  OAB is a symptom 
complex incorporating urinary urgency, with or without urgency incontinence 
and is highly prevalent in women throughout the world.  The condition can 
have a significant adverse impact on a woman’s quality of life (QoL) both 
physical and psychological and has been shown to negatively impact on 
sexual function (SF).  The mainstay of treatment has traditionally included 
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conservative therapies such as lifestyle advice and bladder retraining and 
medication in the form of anticholinergic drugs.   
 
Given that a large proportion of the clinical workload in the unit at KCH 
involves assessment, diagnosis and treatment of women with OAB and the 
treatment involves commencing anticholinergic therapy it was decided that in 
line with the ICI recommendations, I would investigate this group of women 
further to see what had been studied with regards to anticholinergic therapy 




Having cared for women with OAB for many years, I had a good baseline 
knowledge of the condition, however, expertise in the field of sexual function 
was lacking.  This study therefore started with a review of the literature 
associated with female sexual function and dysfunction, including the models 
of sexual response, prevalence, aetiology, co-morbidities, assessment 
methods, investigations and treatments available.  An overview of my 
learning from this is presented in chapter 2.   
 
To ensure that I was up to date with my knowledge on the condition in 
question, a literature review was performed to provide an in depth 
understanding of the aetiology, prevalence and burden of the disease, as 
well as a review of the assessment, investigation and current treatment 
recommendations for OAB.  This was followed by a further literature review 
to understand the impact that OAB can have on SF and a woman’s QoL, 
before finally undertaking a scoping search of the literature to gain an initial 
understanding of what had been discovered already in relation to 
anticholinergics and SF.  Although there is a plethora of data detailing the 
effect of anticholinergics on LUTS and general QoL, scant data were 
available regarding the impact of anticholinergics on the SF of women with 




At that time there were only two clinical trials that had looked specifically at 
SF with one particular drug (Tolterodine) yet in these trials, SF was not a 
primary outcome measure.   A systematic review critiquing these trials 
entitled “Do anticholinergics improve sexual function in women with 
overactive bladder syndrome?” was originally performed in 2011 and 
updated in 2017 and is presented in Chapter 4.   
 
Following further discussions, it was decided that the whole scope of 
anticholinergic treatment for OAB was a far too vast an area to investigate 
and that we should start by focusing on one anticholinergic medication and 
performing a clinical trial with SF as the primary outcome measure.  
Fesoterodine was the chosen medication for this study and a review of the 
evidence related to its use is discussed in chapter 5. 
 
Research Grant Approval 
 
At the time these investigations were being developed, Professor Cardozo 
was the Principal Investigator (PI) on a national study entitled ‘A 12 Week, 
Multi-centre, Open Label Study to Evaluate the Efficacy, Tolerability And 
Safety Of Fesoterodine Flexible Dose Regimen In Patients With Overactive 
Bladder’.  (ClinicalTrials.gov identifier: NCT00806494) (Cardozo et al 2012).  
It was also known as the SAFINA trial and was sponsored by Pfizer INC.  
Fesoterodine is the newest of seven anticholinergic agents available on the 
UK market.  At an investigator meeting for this trial the idea of a study 
looking primarily at SF was discussed with the medical director for the 
urology division at Pfizer.  It was suggested that for health care professionals 
who would like to investigate a certain action or specific outcomes of one of 
their medications, an application could be submitted for an Investigator 
Initiated Research (IIR) Grant which would help fund and supply medication 
to perform these studies.   
 
A decision was made to apply for one of these IIR grants to perform a study 
looking at fesoterodine and SF.   The grant application (a copy can be found 
in the appendices) was submitted to Pfizer and after review by their 
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International Research Department they decided to look favourably on the 
application and approved the funding and supply of the drug so that the trial 
could be undertaken.  To ensure that I was fully conversant with the drug that 
would be used during further investigations, Chapter 4 was developed to 
provide a full review of the investigational medicinal product (IMP) - 
fesoterodine, including its pharmacodynamics and pharmacokinetic 
properties, dosing and treatment schedules, efficacy, tolerability and safety.     
 
To gain further insights into pharmacology and the application of drug 
therapy within Urogynaecology, I also completed a master’s level university 
programme which enabled me to qualify and practice as an independent 
nurse prescriber. 
 
Clinical Trial of Investigational Medicinal Product  
 
Based on the findings of the literature review and following grant approval, a  
clinical trial of investigational medicinal product (CTIMP) entitled: A 12 week, 
multi-centre, open label study to evaluate the effect of fesoterodine flexible 
dosing regimen on the sexual function of women with overactive bladder was 
developed and performed.  This was a mixed methods study where the effect 
on sexual function was the primary outcome.  Secondary outcomes 
considered the efficacy and tolerability of the IMP and exploratory studies 
related to changes in urodynamic parameters.   The investigation of patient’s 
goals provided a qualitative investigation of what women wanted to achieve 
from therapy. 
 
Chapter 6 of this thesis describes the decision making process behind many 
of the fundamental trial processes including the rationale for the primary and 
secondary outcome measures employed, the inclusion / exclusion criteria, 
sampling methods, feasibility and discussions surrounding the ethical 
considerations of performing this study.     
 
The final trial protocol, approvals process, study initiation and challenges 
faced in undertaking the study, including problems with recruitment and the 
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methodology requiring substantial amendments are explained in Chapter 7.   
Following completion of the study, the plans for the final statistical analysis 
are also detailed within this chapter.  
 
The presentation of results has been divided into three chapters.  Chapter 8 
highlights the quantitative results from the CTIMP undertaken.  The subject 
disposition and baseline characteristics are demonstrated along with the 
statistical analysis from all of the primary and secondary endpoints.  Tables 
and graphical representations are presented to demonstrate changes from 
baseline to 12 weeks and also include details relating to safety reporting in 
the study and the longer term follow up at six months.  
   
Chapter 9 discusses and critiques the findings and outcomes of the 
quantitative investigations comparing results with other relevant literature 
where available and highlighting new discoveries and hypothesising why 
these may have occurred.  The chapter also outlines the methodological 
weaknesses and limitations to the study that were identified in the process.  
Following on from these challenges identified, further research questions 
arose and additional investigations were performed.  The development of 
these new research questions are also detailed within chapter 9.   
 
Chapter 10 presents the qualitative outcomes of the study and demonstrates 
the goals women set during the clinical study and the level of goal 
achievement.  A description of the methodology used to analyse the goals is 
included along with a discussion about the themes that emerged and the 
relevance of these in the current literature.  The goals from the women in this 
study are also compared to the goals set in a UK wide study to assess for 
similarities and differences in our clinical population, to understand if we 









Additional research questions 
 
Following scrutiny of the substantial difficulties recruiting to the trial 
previously described, further research questions were identified, as 
illustrated in chapter 9.  To try to answer these additional questions further 
enquiries were developed and performed.   Chapter 11 details the 
methodology and research tools employed to complete these investigations. 
 
Chapter 12 details a prevalence study that was completed within the unit at 
KCH.  The primary aim of this investigation was to assess the prevalence of 
SA in our OAB population.  The secondary aims were to evaluate why 
women were not sexually active (NSA), to assess if this was bothersome to 
them, to evaluate variations in SA according to UDS diagnosis and to 
compare questionnaire responses between the SA and NSA groups.  This 
chapter not only presents the answers to these questions, discussions in 
relation to these and the impact this may have had on the main trial but also 
questions the validity of the tool used in the study.  It also highlights 
fundamental issues with terminology that may lead to challenges for all future 
research in the field of SF.   
 
The second research question identified was related to how women want to 
be approached about the topic of SF.  In a bid to answer this research 
question and gain insights that may benefit routine clinical practice and future 
research studies, Chapter 12 details findings from two focus groups for 
women with LUTS who attended the Urogynaecology outpatients department 
for assessment and treatment.  The aim of these focus groups was to 
understand how women want to be approached regarding the topic of sexual 
function along with any barriers they have encountered and what their 
preferences are regarding when the conversation should be introduced and 
by whom.  The evaluation of these focus groups has led to new insights that 
can help to develop our clinical practice and potentially help guide 
recruitment in future studies assessing SF in women with LUTS. 
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During this time I also took the opportunity to network with other international 
researchers with an interest in LUTS and SF and co-chaired a  “Think Tank” 
at the International Consultation on Incontinence Research Society (ICI-RS 
2015) entitled- How does lower urinary tract dysfunction affect sexual 
function in men and women?  This group not only looked at where the 
current knowledge gaps are but considered ideal research methodologies to 
investigate these. Two articles were produced by the group and published in 




Based on all the studies undertaken in this thesis, Chapter 14 summarises 
the conclusions and recommendations that have stemmed from the work 
presented throughout this thesis.  It includes discussions on the fundamental 
flaws that have been identified in current definitions and the research tools 
employed.  Suggestions for future research have been made based on what 
has been learnt from this extensive piece of work and the questions that 
have arisen from the analysis of the data gained during this study.    
 
Finally the Appendices include relevant original papers published as part of 
this thesis and additional material related to all the investigations undertaken, 
including the full protocol for the CTIMP and all the questionnaires employed.  
All patient literature and transcripts from the focus groups have also been 
included in the interests on transparency.   
 
Figure1.3 demonstrates the flow of investigation throughout the course of 


















This thesis documents the work that has been undertaken towards this 
higher degree.  It demonstrates not only the research performed, 
methodologies utilised and the knowledge gained in the specialist area but 























Sexual health is defined by the World Health Organisation (WHO 2006) as 
the integration of somatic, emotional, intellectual and social aspects in ways 
that are positively enriching and that will enhance personality, 
communication and love.  According to Masters and Johnson (1966), sexual 
function (SF) is defined as how the body reacts in different stages of the 
sexual response cycle.  Sexual activity (SA) is the manner in which we 
express our sexuality.  Optimal female sexual health comprises physical, 
mental, and emotional aspects and there are several variables that influence 
SF including physiological and psychosocial factors (Tsai et al 2011). 
 
Early research looking at female sexuality was conducted by Kinsey (1953).  
The sexual practices of American men and women were studied to try to 
dispel the misconception that women are not interested in sex.  It has been 
suggested that research on female sexuality lags behind research into male 
sexual function as some cultures have difficulty accepting that female sexual 
problems are as disruptive to a women’s health related quality of life (HRQL) 
as they are to a man’s (Kingsberg and Althof 2009). 
 
As the focus of this thesis is the sexual function of women with overactive 
bladder syndrome, this chapter aims to provide an overview of the female 
sexual response, in order to gain an understanding of normal sexual function 
before considering what female sexual dysfunction (FSD) is, including a 
review of the literature related to it’s prevalence and aetiology.  Assessment 
of sexual function will be described along with a critique of the questionnaires 
used to measure sexual function / dysfunction and finally a brief overview of 
treatments for FSD will be discussed.   
 
Models of sexual response 
 
The classic four phase linear model of female sexual response based on a 
physiological foundation was first introduced by Masters and Johnson 
(1966).  The four phases described are excitement, plateau, orgasm and 
resolution. Sexual response will vary between different women and for an 
individual woman on different occasions.  Women may not always reach the 
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orgasmic stage, and the resolution or refractory period is not always 
observed in women.  If they do not experience a refractory period, women 
cannot respond to additional stimulation.  However, in most cases women 
can respond to repeated stimulation and reach a second or third orgasm 
soon after the first (Chen C et al 2013).   
 
Similar linear models by Kaplan (1979) and Leif (1977) were also introduced 
which added desire into the model, however, all these suggested that sexual 
response is invariant, the same for men and women, and that desire always 
precedes arousal and is discussed below in more detail.  In the brain, a 
balance of the dopamine-sensitive excitatory center and the serotonin 
sensitive inhibitory center modulate the desire phase (Basson 2001).  The 
two basic physiological reactions that occur during sexual response are 
vasoconstriction of the genitalia and increased neuromuscular tension 
throughout the body (Masters and Johnson 1966).  There are, however, a 
number of other physiological changes that happen to the female body as a 
result of sexual response and these are described in Figure 2.1 (adapted 
from Chen C et al 2013). 
 





These models have been questioned over the years because they presume 
that men and women have similar sexual responses and do not take into 
account non biological experiences such as pleasure and satisfaction or 
place sexuality in the context of a relationship (Whipple 2002, Working Group 
2000, Whipple and Brash-McGregor 1997).  It is also noted that many 
women do not move progressively and sequentially through the phases as 
described.  For example they may move from arousal to orgasm and 
satisfaction without experiencing sexual desire, or may experience desire, 
arousal and even satisfaction but not orgasm (Whipple 2002) 
 
 
In 1997, Whipple and Brash-McGregor developed a circular sexual response 
model to address these issues (See Figure 2.2 from Association of 
Reproductive Health Professionals (ARHP) 2008).  This concept was built on 
four stages; seduction (encompassing desire), sensations (excitement and 
plateau), surrender (orgasm) and reflection (resolution).  By making the 
model circular, it demonstrated that pleasant and satisfying sexual 
experiences may have a reinforcing effect on a woman, leading in to the 






Figure 2.2 Circular Model of Female Sexual Response 
 
Basson (2001) further refined this into a non-linear model of female sexual 
response that incorporates the importance of emotional intimacy, sexual 
stimuli and relationship satisfaction, and acknowledges that female 
functioning is significantly affected by psychosocial issues e.g. satisfaction 
with the relationship, self-image and previous negative sexual experiences 
(Figure 2.3 adapted from ARHP 2008).  It suggests that women begin a 
sexual encounter from a point of sexual neutrality and the decision to be 
sexually active comes from a conscious wish for emotional closeness or as a 






Figure 2.3 Non Linear Model of female sexual response  
  
 
Studies by Cain et al (2003), Regan and Berscheid (1996) and Galyer et al 
(1999) have revealed common motivations for women to agree to or initiate 
sex including a desire to; enjoy the emotional closeness that accompanies 
and follows sexual activity with a partner, increase their own sense of well-
being and self-image, and reduce guilt or anxiety about sexual infrequency.  
The importance of sex to a woman and man is also a considerable factor in 










Definitions / Classifications of Female Sexual Dysfunction (FSD) 
 
In the first two versions of the Diagnostic and Statistical Manual of Mental 
Disorders (DSM) in 1952 and 1968, the concept of FSD did not exist and 
only the terms frigidity and vaginismus were included in a list of 
supplementary terms (Graham 2016).  As medicine was a very male 
dominated field at that time it could be suggested that it was not considered 
important or that women had not felt able to raise their concerns due to 
societal / gender constraints.  At this time, little had changed since the 
famous Imlach case of the 19th century, where the woman sued a 
gynaecologist for loss of sexual function after her ovaries were removed and 
the male dominated jury had to decide if the ovaries were important 
(Morants-Sanchez 2000).  It took a further 20-30 years to break down these 
barriers for FSD to be defined and classified and many of these new 
classifications were led by women. 
 
According to the WHO International Classifications of Diseases – 10 (ICD-
10), the definition of FSD includes ‘the various ways in which an individual is 
unable to participate in a sexual relationship as she would wish’ (WHO 
1992).  FSD can afflict women of any age, and its expression changes with 
the endocrinology of advancing years (Buster 2013).   
 
In 1998, The Sexual Function Health Council of the American Foundation for 
Urological Disease (AFUD) compiled the first consensus based definition and 
classification system for FSD.  They listed five major categories of 
dysfunction; desire, aversion, arousal, orgasmic and sexual pain disorders 










Table 2.1 Categories of dysfunction 
 
Sexual disorders Definition 
Hypoactive Sexual Desire 
Disorder 
The persistent or recurrent deficiency 
of sexual fantasies / thoughts and or 
receptivity to sexual activity that 
causes personal distress 
Sexual Aversion Disorder The persistent or recurrent phobic 
aversion to and avoidance of sexual 
contact with a sexual partner that 
causes personal distress 
Sexual Arousal Disorder The persistent or recurrent inability to 
attain or maintain sufficient sexual 
excitement causing personal distress 
Orgasmic Disorder The persistent or recurrent difficulty, 
delay in or absence of attaining 
orgasm after sufficient sexual 
stimulation and arousal which causes 
personal distress 
Sexual Pain Disorders Recurrent or persistent genital pain 
associated with sexual intercourse, 
including dyspareunia, vaginismus 
and non coital pain disorders 
 
 
These classifications, which may coexist, are sub-typed as life-long versus 
acquired, generalised versus situational and organic versus psychogenic 
(Basson 2000a).  FSD is not always a primary pathology but may be a 
symptom or a side effect of another. (Basson 2005a).  Mouritsen (2009) 
reported on the ‘vicious cycle of FSD and how all areas may be interlinked. 












Figure 2.4 The Vicious cycle of FSD. 
 
Following on from this, the DSM-IV defined FSD as ‘disturbances in sexual 
desire and in the psychophysiological changes that characterise the sexual 
response cycle and cause marked distress and interpersonal difficulty’ 
(American Psychiatric Association 2000). 
 
The classification of FSD was further updated in 2004 at the 2nd International 
Consensus of Sexual Medicine and guidelines were established to aid 
clinicians to evaluate the clinical significance of symptoms and further define 
the distress (Basson 2005b).    
 
However, throughout the literature many comments have been made 
regarding difficulties defining FSD in practice and when a sexual problem 
should be classified as a sexual dysfunction (Bancroft et al 2003, Chen C et 
al 2013, Latif 2013).  Bancroft and Graham (2011) suggest that the specific 
challenge is the recognition of the marked variability of women’s sexual 
experiences and the need to distinguish between transient problems in SF 
e.g. due to adaptive responses to stressful circumstances and more 
persistent problems.  Over a 10 year period a task force and working group 
for the American Psychiatric Association (APA) updated diagnostic 
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categories and criteria for FSD.  The DSM-IV was revised and the DSM-V 
(2013) was adopted.  Within this update, the definition of sexual dysfunctions 
was changed to ‘a group of disorders that are typically characterised by a 
clinically significant disturbance in a person’s ability to respond sexually or to 
experience sexual pleasure’ (APA 2013 p423).  Their symptoms have to 
have been present for at least six months and been experienced in 75-100% 
of sexual encounters.  The classification of female sexual desire disorder 
was removed and female arousal disorder was re-named female interest / 
arousal disorder to cover a more varied expression of sexual desires in 
females.  Sexual aversion disorder was also removed due to rare use and 
lack of supporting evidence.  Changes to terminology were also introduced 
and dyspareunia was revised to genital pelvic pain and the classification of 
vaginismus was replaced with the term penetration disorder (Chen C et al 
2013, Derogatis et al 2010).  As with all terminology changes, they have 
been made to either make terms more generalisable (eg. genital pelvic pain), 
more specific (eg. penetration disorder) or to come in line with new evidence.  
There are pros and cons to each of these in terms of broadening or 
narrowing diagnosis for patients, however, this can only make a difference if 
clinician’s are educated about the new terminology and advised about how 
this may change outcomes for patients or the treatments offered to them.  
Yet, in current practice in the UK these terms are not well known and not 
used in routine clinical practice.   
 
Prevalence of FSD 
 
Difficulties estimating the prevalence of FSD in women have been reported 
and this is thought to be due to the fact that the parameters of FSD are not 
as clear as those of male sexual dysfunction (MSD) (Laumann et al 1999), 
and because it is hard to determine the level of distress associated with 
sexual symptoms in a large-scale survey (Nappi et al 2016). Methods of 
evaluating FSD and outcomes assessments have varied widely between 
studies (Hayes et al 2006) and it has been suggested that many place an 
overemphasis on genital response rather than a subjective assessment of 
arousal and desire (Graham 2010) or even whether the event was sexually 
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satisfying despite a limited genital response. Prevalence data suggest that 
the rates of FSD in clinical populations (ie women attending gynaecology 
clinics) are between 40-50% (Geiss et al 2003, Nazareth et al 2003, 
Laumann  et al 1999).  However, there are very few studies looking at the 
prevalence of FSD in ‘real world’ populations, probably due to the difficulties 
accessing this population and the intimate nature of the subject being 
investigated.    Ventegodt (1998) performed an anonymised assessment of 
QoL amongst 2460 representative Danish women, which included five SF 
questions (out of a total of 317 questions).  They found that the QoL of 
individuals with sexual problems was between 1.2%-19.1% lower than the 
population means (range of population mean QoL 61.5-75.9, range of 
women with sexual problems mean QoL 57.3-67.5).  Lack of sexual desire 
and lack of a suitable partner were the two most commonly cited sexual 
problems for women, however, no data were provided relating the sexual 
problems to age of the respondent, relationship satisfaction, and general 
health to be able to further comment or justify the reduced QOL.   
 
The Global Study of Sexual Attitudes and Behaviour, included 27,500 
women over the age of 40 from 29 countries and considered the prevalence 
of FSD according to geographical location.  It was reported that lack of 
interest in sex varied from 17% in Europe to 34% in Southeast Asia, 
lubrication problems ranged from 12% in Europe and the Middle East to 28% 
in Asia.  Pain during intercourse ranged from 5% in Europe to 22% in 
Southeast Asia and the inability to reach orgasm varied from 10% in Europe 
to 34% in Southeast Asia (McCabe et al 2016).  This study suggests that 
women in Southeast Asia report the most sexual problems.  This could 
potentially be for a variety of reasons, for example the respondents in these 
surveys may not have been representative of the population especially given 
the rural nature of this part of the world or possibly issues with how the 
questions were translated.  Laumann et al (2005) reported early ejaculation 
and erectile dysfunction to be more prevalent amongst men from Southeast 
Asia than other parts of the world and that 20% of men in Southeast Asia 
lacked interest in sex.  This may also have a significant impact of the sexual 
health of the women in the region.  It is also important to consider the cultural 
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and socio-economic aspects that may contribute to these high figures as 
there is a significant prostitution / sex trafficking issue in that area that may 
also be impacting upon women’s long term sexual function.  
 
Ponholzer (2005) studied the prevalence and risk factors for FSD in a cohort 
of women undergoing a voluntary health assessment as part of a public 
health initiative.  703 women between the ages of 20-80 years completed a 
questionnaire on FSD.  22% reported desire disorders, 35% arousal 
disorders and 39% orgasmic problems, all of these issues increased 
significantly with age.   12.9% reported pain disorders but this was more 
common among the 20-39 age group. However, this study still relied on 
women volunteering to participate and disclose sensitive information and is 
unlikely to represent the population. 
 
Wolpe et al (2017) performed a systematic review to assess the prevalence 
of FSD in Brazil.  They reported that the prevalence of FSD ranged from 
13.3%-79.3% of the population studied.  When considering the specific 
aspects of FSD they found that sexual desire concerns ranged from 11%-
75%, arousal from 8%-68.2%, lubrication from 29.1%-41.4%, orgasm from 
18%-55.4% and satisfaction from 3.3%-42%.  It was suggested that the 
range in prevalence occurred due to the differences in the populations 
studied for example age, marital status, educational level, family income and 
associated co-morbidities.   
 
Causes of FSD 
 
Gladu (2002) reported four causes of FSD: medical illnesses, psychological 
illnesses, hormonal deficiencies or the effects of medications.  Examples of 
these causes can be found in table 2.2.  Sociocultural and relationship 
related causes have also been linked with dissatisfaction or discontent with 
sexual experiences (Tiefer 2002).  It is likely that in many cases no one 






















































Buster (2013) developed a table of all the medications associated with FSD 
which was adapted from the ARHP (2005).  It is interesting to note that 
anticholinergics, commonly used for the treatment of OAB are considered to 
be associated with arousal disorders but not desire or orgasm disorders. 
Further discussion of this topic will be included in the next chapter.    
 
























Psychotropics    
 Antipsychotics +  + 
 Barbiturates + + + 
 Benzodiazepines + +  
 Lithium + + + 
 SSRIs + + + 
 TCA + + + 
 MAO inhibitors   + 
 Trazodone +   
 Venlafaxine +   
Cardiovascular and 
antihypertensive medications 
   
 Antilipid medications +   
 Beta blockers +   
 Clonidine + +  
 Digoxin +  + 
 Spironolactone +   
 Methyldopa +   
Hormonal preparations    
 Danazol +   
 GnRH agonists +   
 Hormonal contraceptives +   
 Antiandrogens + + + 
 Tamoxifen + +  
 GnRH analogues + +  
 Ultralight contraceptive pills + +  
Other    
 Histamine H2 receptor blockers      +   
 Indomethacin +   
 Ketoconazole +   
 Phenytoin sodium +   
 Aromatase inhibitors + +  
 Chemotherapeutic agents + +  
Anticholinergics  +  
Antihistamines  +  
Amphetamines and related 
anorexic drugs 
  + 
Narcotics   + 
Note: SSRIs = selective serotonin reuptake inhibitors; TCA = tricyclic 
antidepressants; MAO = monoamine oxidase inhibitors. 
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Mouristen (2009) also suggested areas of pathophysiology that can cause 











Low oestrogen levels in the vagina, urethra, trigone epithelium and atrophy 
of the pelvic floor muscles have also been proposed as causes for FSD and 
lower urinary tract symptoms (LUTS) (Bligic and Beji 2010).  Oral 
contraceptives have been shown to reduce arousal and sexual interest and 
increase genito-pelvic pain in women (Lee et al 2017). 
 
Several studies have reported increased FSD in women with higher body 
mass index (BMI) (Assimakopulos et al 2006, Esposito et al 2007, Bond et al 
2009).  A recent study by Mostofa et al (2017) reported that in young, pre-
menopausal population, obese women were more likely to have desire, 
arousal and lubrication problems compared to overweight women.  However, 
the discussion did not consider whether this was due to hormonal / medical 
causes or psychological causes eg reduced body image / low self-esteem or 
functional issues with sexual activity due to body habitus. 
 
Nazarpour et al (2016) performed a systematic review to identify factors 
affecting SF following menopause.  Table 2.4 demonstrates some of the 
factors identified.  Although, this study only assessed women during the 
menopause, it highlights the complexity of the physical, emotional, social and 
interpersonal and intrapersonal factors that can all impact upon FSD.  These 
factors represent significant challenges in all research in SF as it is 
impossible to exclude all the compounding variables. 
Figure 2.5           Areas of pathophysiology of sexual dysfunction 
 
 Mind and age (neurotransmitters, medication) 
 Oestrogens and androgens 
 Vaginal epithelium and lubrication 
 Vaginal blood flow 
 Coital incontinence 
 Scar tissue / vaginal dimensions 
 Neuropathy 




Table 2.4 Factors affecting SF 
 
Physical Factors Psychological / Emotional 
































Access to health care 
 















History of divorce or  
widowhood 
 





Discussing sexual function 
 
According to O’Donnell et al (2005) only 24% of women were not at all 
embarrassed to discuss sexual problems with a doctor in comparison to 87% 
when discussing allergies or cold/flu.  According to Coyne et al (2007) 
approximately a third of women would not initiate a discussion about sexual 
issues with their doctors.  In a study of members of the Dutch Urology 
Association, 40.3% did not think that FSD was routinely relevant to urological 
practice (Siddall 2010).  It has also been suggested that concerns about time 
restraints, lack of effective treatments and embarrassment may prevent 
women initiating a discussion about sexual concerns with their doctors 
(Kingsberg 2006).  Rogers et al (2018) report that many women are hesitant 
to initiate discussions on SF but want their health care professional (HCP) to 
open the dialogue. It is felt that by asking these questions the HCP is 
acknowledging and prioritising the role that sexual health plays in overall 
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wellbeing and this will encourage the woman to openly discuss concerns so 
that an appropriate assessment can be performed.  Further research 
investigating communication between HCP’s and women regarding SF is 
discussed in chapter 13. 
 
Assessment of sexual problems 
 
Evaluation of FSD can be limited by time constraints, patient / clinician 
discomfort, difficulty with diagnosis, lack of available services and treatments 
(Frank et al 2008).  In order to perform a full assessment of sexual problems, 
it is important to create a conducive environment by establishing a rapport 
and putting patients at ease. It is recommended that a thorough sexual 
history should include medical, reproductive, surgical, psychiatric, social and 
sexual information (Hatzichristou et al 2004, Clayton 2003, Berman et al 
1999).  Many factors, including depression and other psychiatric disorders 
and medical comorbidities have been identified as confounders in the 
assessment of SF.  (Bancroft 2002).  Basson (2000b) published a list of 
essential questions to include in a sexual assessment (See Figure 2.6), 
however, the practicalities of asking these questions in a routine 
gynaecology clinic and the confidence of the clinician performing the 
assessment may not be conducive to these recommendations.   Following 
history taking a physical examination and or laboratory testing eg hormone 
profiles or pelvic MRI, and in specialist services or research settings vascular 
studies, vaginal photoplethysmography, vaginal and clitoral duplex doppler 
ultrasound and thermal imaging of the genital area may help to rule out 


























It has been reported that the most important factor in the diagnosis of a 
sexual dysfunction of any subcategory is the presence of personal distress 
caused by the dysfunction (Latif 2013).  More recently guidelines have been 
developed through expert consensus to establish the minimum elements 
needed in the assessment of female sexual pain disorders (Goldstein et al 














Essential questions to include in a sexual assessment 
 
 How does the patient describe the problem? 
 How long has the problem been present for? 
 Was the onset sudden or gradual? 
 Is the problem specific to a situation / partner or is it generalised? 
 Were there likely precipitating events (biological or situational)? 
 Are there problems in the woman’s primary sexual relationship 
 Are these current life stressors that might be contributing to the sexual 
problems? 
 Is there guilt, depression or anger that is not being directly acknowledged? 
 Are there physical problems such as pain? 
 Are there problems in desire, arousal or orgasm? 
 Is there a history of physical, emotional or sexual abuse? 
 Does the partner have any sexual problems? 
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Pain quality, time of onset, temporal pattern, duration, 




Surgeries, injury, fall to the lumbar-pelvic-hip region, 
coccyx, and sacrum 
 
Bowel and bladder 
Habits and function history 
 
Sexuality 
Desire, arousal, orgasm, frequency, satisfaction, sexual 
practice, and distress 
 
Psychological 
Thoughts, emotions, behaviours, couple interactions 
(avoidance, conflict, hypervigilance, partner responses, 
and self-efficacy) 
Childhood trauma 
Current romantic relationship 
 
Comorbidities 
Other medical and mental health conditions 
 
Treatment 
Previous treatment attempts, interventions, and outcomes 
 
Questionnaires 
Standardised self-report questionnaires, such as Female 




Questionnaires to Assess Sexual Function 
 
Patient reported outcome measures (PROM’s) are specifically validated 
questionnaires that can be used to identify or diagnose a particular 
dysfunction, assess the severity or impact on HRQL and measure 
improvement or satisfaction with treatment (Althof & Symonds 2007, Rogers 
2013a).  They are usually self administered and can be completed by a 
patient in her own time prior to assessment, encouraging reflection on 
symptoms and aiding discussion, however, due to the sensitive nature of SF 
some women may not wish to complete them.   
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The development of quality of life questionnaires is a complex and lengthy 
process.  It generally involves an initial stage of item generation, which is 
based on reviews of the literature and subject / expert opinions gained from 
focus groups / interviews.  This is followed by item reduction where subjects 
and experts express preferences to topics and questions and these views 
are then translated during an expert meeting to generate a questionnaire.  
This is then piloted in a small group of subjects prior to more formal testing to 
confirm content, face, criterion and construct validity and reliability of the 
measure.      
 
Given this arduous process, there are very few truly high quality 
questionnaires assessing SF in women.  The ICI have performed repeated 
literature searches over the years as part of the assessment chapter of the 
textbook to identify questionnaires to assess PROMS.  These tools are then 
subject to a stringent review of the reliability and validity of the measure and 
the quality of the evidence supporting its development and use in clinical 
populations.  Based on the levels of evidence, the ICI then make 
recommendations on which tools to use.  Gradings are from A+ to C and 
those with an A+ rating are highly recommended (Abrams et al 2017).   
 
Those available to identify or diagnose a sexual dysfunction include the Brief 
Index of Sexual Functioning for Women (Taylor et al 1994), the short scale 
McCoy Female Sexuality Questionnaire (Dennerstein et al 2001),  the 
Female Sexual Function Index (Rosen et al 2000), the Changes in Sexual 
Functioning Questionnaire (Clayton et al 1997), the Daily Log of Sexual 
Activities (Leonard et al 2010), the Sexual Interest and Desire Inventory 
Female (Clayton et al 2010) and the Multidimensional Sexuality 
Questionnaire (Snell et al 1993).    
 
The Sexual Quality of Life – Female (Symonds et al 2005) is used to assess 
the impact of FSD on QoL and the Sexual Function Questionnaire (Quirk et 
al 2002) addresses the consequences of FSD for the woman, her partner 
and their relationship.  Questionnaires regarding SF that are disease specific 




Table 2.6 lists all of the questionnaires available to assess sexual function in 
women and reports the specific aims of each questionnaire as well as the 
group of patients in which they are validated.  It is interesting to note that 
only one of the questionnaires is designed for couples to complete, not only 
to assess if the other partner has a sexual problem but also to assess the 
impact of their partner’s problem on them. The questionnaires rating as set 
by the ICI is also noted.  Further critique and the use of these questionnaires 


















22 Self administered questionnaire designed 
to assess current levels of female sexual 
functioning and satisfaction 
Hetero and homosexual 
women seeking routine 
gynaecological care with 
organic and inorganic 






19 Self administered questionnaire to assess 
aspects of female sexual function 




19 Self administered questionnaire 
assessing key dimensions of sexual 
function in women 
Normal women without any 
reported sexual problems 
and women with OAB, SUI 
and MUI 
A 




(CSFQ – F) 
35 A gender specific self reported inventory 
designed to measure illness and 
medication related changes in sexual 
functioning (Based on CSFQ structured 
interview design). 
Medical students and 
patients with depression 
B 
Daily log of Sexual 
Activities 
9 Self administered questionnaire designed 
to provide an outcome measure of the 
number of sexual events, the number of 
satisfactory sexual events, and the 
magnitude of sexual interest or desire 







13 Clinician administered tool to quantify the 
severity of symptoms in women with 
HSDD and change in HSDD in response 
to treatment 














12 Self administered questionnaire designed 
to measure psychological tendencies 
associated with sexual relationships 
Male and female university 
students 
Not rated 
Sexual Quality of 
Life Questionnaire 
Female   
(SQoL-F) 
18 Self administered questionnaire to assess 
the impact of FSD on a women’s sexual 
quality of life and to evaluate the benefits 
of therapeutic intervention 
Women B 
Female Sexual 
Distress Scale – 
Revised  
(FSDS-R) 
13 Self administered questionnaire that 
assess distress associated HSDD and 
other female sexual dysfunctions 
Pre and post menopausal 






25 A self reported version of semi structured 
interviews designed to provide a 
multidimensional assessment of sexual 
function in men and women 
Community samples of men 
and women – no validation 







56 A self administered questionnaire to 
evaluate both the quality of a 
heterosexual relationship and each 
partner’s level of sexual functioning within 
that relationship 
Heterosexual couples from 
general population, gynae 










Treatment of FSD 
 
Many different treatments have been suggested for FSD, however, these 
depend on the type of dysfunction experienced and many other factors 
independent to the individual.  Table 2.7 was developed based on the 
reviews by Clayton & Juarez (2017) and Tsai (2011) to consider many of the 
medical, physical and psychosocial treatments available to women with FSD.   
 
It is considered that most women will need a multimodal treatment package 
that initially includes education on health promotion and management of 
comorbidities, some form of psychological therapy and physical therapy and 
if the conservative measures are ineffective then pharmacological treatment 
is prescribed.   
 
Considering pharmacological treatments, testosterone has been shown to 
improve components of FSD including sexual desire, arousal, pleasure and 
overall satisfaction (Khera 2015).  Systemic oestrogen therapy alone is 
insufficient to cure symptoms of FSD (Lobo et al 2003).  However, topical 
oestrogen therapy is commonly used for dyspareunia (Rioux et al 2000).  
Many of the pharmacological treatments noted are used ‘off license’, only 
Flibanserin and Ospemifene are licensed for the treatment of FSD.   
 
Psychological therapies are often the most difficult to access in routine 
clinical practice and onward referral to specialist services with sex therapists 
/ psychosexual counsellors is preferable but in the UK very few of these 
services exist.  


























Self and/or partner 
exploration 
 






























Herbal therapies eg 






Eliminating risk factors 
eg smoking, illicit drug 
use, obesity 
 
Pelvic floor Exercises 
 
Trigger point therapy 
 
Vaginal dilator therapy 
 











SF is a complex process that includes physical, social and emotional factors.  
FSD appears to be a prevalent condition in clinical populations, however, the 
true prevalence in the general population is still not known.  It can however, 
have a significant impact on a woman’s QoL and relationships.   The 
challenges in assessing the prevalence of FSD in the general population 
include language variations, cultural differences and access to all 
populations.  As there are so many variables it may only be possible to 
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research certain groups of women individually.  Given that research into this 
field has only started to develop over the past 40 years it could also be 
considered that the definitions are still dominated by a ‘male’ model of sexual 
functioning rather than fully recognising the underlying psychological and 
emotional factors that are essential to a woman’s SF.  
 
A full sexual and medical history is an essential element to understand and 
categorise FSD and appropriate validated questionnaires should be used to 
aid this process.  Treatment is not only multimodal but also multidisciplinary, 
ensuring that both the physical and psychological health of women is 
addressed. 
 
The literature searching and writing of this chapter helped me to develop an  
understanding of sexual function and dysfunction in women including 
possible causes, confounding variables and available treatments. This 
knowledge has help with counselling women in the clinical setting who report 
sexual problems.  It has also provided the general knowledge base needed 
to be able to further investigate SF and FSD in a more specific clinical 
population.   Chapter 3 will describe the clinical population under 
investigation in this thesis and review the evidence related to the conditions 
impact on SF.   
 
The elements of sexual assessment and review of the tools / questionnaires 
to support an assessment of SF not only provided the theoretical basis to 
develop my clinical skills in this area, but also helped to guide the 
















Chapter 3  
 
Overactive Bladder Syndrome and its 






According to Haylen et al (2010), overactive bladder (OAB) is the term used 
to describe the symptom complex of urinary urgency with or without urgency 
urinary incontinence, usually with frequency and nocturia, in the absence of 
urinary tract infection or other obvious pathology.   It is estimated to affect 
17% of the adult female population in North America and Europe (Milson et 
al 2001, Stewart et al 2003). 
 
In this thesis, the population of women under investigation are those with 
OAB.  This chapter aims to provide an overview of the definitions, prevalence 
and aetiology of OAB.  It will discuss how OAB is diagnosed and consider 
current treatment recommendations.  Following on from this it will then 
consider the impact of OAB on women’s sexual function, reviewing the 
available literature and current assessment along with the impact it has not 
only on partners but on QoL.  It will finally consider the impact that treatment 




The definition of OAB reported above was established following a consensus 
report by IUGA and ICS as the most recent standardisation document 
defining terminology for Female Pelvic Floor Dysfunction.   In the report, 
urinary urgency was defined as a complaint of a sudden, compelling desire 
to pass urine which is difficult to defer.  Urgency urinary incontinence is the 
complaint of involuntary loss of urine associated with urgency.  Frequency is 
the complaint that micturition occurs more frequently during waking hours 
than previously deemed normal by the woman and nocturia was set as the 
complaint of interruption of sleep one or more times because of the need to 
pass urine when each void is preceded and followed by sleep.  OAB can be 
broken down into two subcategories, OAB dry and OAB wet.  The latter 
group experience urgency urinary incontinence whereas the former do not 
experience incontinence.  Coyne et al (2012) have suggested that women 
with OAB symptoms can distinguish between normal urge (or desire) and 
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“urgency” suggesting that urinary urgency is a continuum rather than an all-
or-none phenomenon. 
Other relevant definitions that may be discussed later include Urinary 
Incontinence (UI) defined as the complaint of involuntary loss of urine and 
Stress Urinary Incontinence (SUI) defined as the complaint of involuntary 




There is an inherent difficulty in trying to define the prevalence of OAB 
worldwide, based on the current literature.  This is because definitions have 
changed twice over the last 16 years, so a lot of the older studies are no 
longer comparable.  There are issues with terminology, as the term of 
urgency does not apply in all languages so it is difficult to assess if they are 
all measuring the same thing.  Also, more recently it has been suggested 
that prevalence studies reporting lower figures than earlier work is due to the 
fact that bothersomeness is now taken into account and although many 
women may experience symptoms, they do not all find then bothersome or 
consider then to be a problem.  
 
In 2001, Milsom et al conducted a population based survey across Europe in 
which 16,776 interviews were performed.  They reported that the overall 
prevalence of OAB in individuals 40 years and above was 16.6% and 
increased with age. They also found that frequency was the most commonly 
reported symptom (85%) whilst 54% complained of urgency and 36% UUI.  
However, in that study, OAB was defined here as the presence of chronic 
frequency, urgency and UUI (either alone or in any combination), which 
means these figures may not be accurate in line with current definitions. 
 
In 2006, Irwin et al performed a further population based survey (EPIC study) 
of LUTS among subjects in Canada, Germany, Italy, Sweden and the United 
Kingdom (UK) and reported on 19,165 men and women over the age of 18 
years.  11.8 % complained of symptoms suggestive of OAB (defined as 
urgency, with or without UUI) and 64.3% reported at least one urinary 
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symptom. In addition, OAB was found to be more prevalent than all types of 
UI combined (9.4%).  The prevalence of OAB is known to increase with age 
and Irwin et al (2011) predicted that in view of the aging population, by 2018, 
546 million individuals worldwide would be affected. 
 
A recent study by Chuang et al (2017), was performed to determine the 
prevalence of OAB in individual’s ≥ 40 years in China, Taiwan and South 
Korea.  It was reported that 1 in 5 individuals were affected by OAB with an 
overall prevalence slightly higher at 22.1% in women compared to men.  
However, in prevalence studies in Japan it is reported as 11.8% overall and 
only 10.1% in women, compared to 15.3% in men (Funada et al 2017).  This 
study also considered factors that influence OAB and found that 
environmental factors including age, depression and the consumption of 
cake to be more positively associated with OAB than genetic variants. 
 
A longitudinal population based survey by Wennberg et al (2009) assessed 
the prevalence of LUTS in a group of women in 1991 and again in the same 
group of women in 2007.  They found that although the overall prevalence of 
OAB symptoms was similar, the OAB wet group had increased from 15% in 
1991 to 28% in 2007 and the OAB dry group decreased.  In addition, the 
prevalence of urgency increased from 17% to 26% and nocturia increased 
from 38% to 58%.  This study supports the findings of the Milsom (2001), 
showing that the incidence of OAB symptoms increases with age.  It was 
also suggested that the natural progression of symptoms would account for 
the increase in incontinence as well as the increase in age of the patients.  
However, there was no evidence available regarding whether the women 
had received any treatment for their urinary symptoms and the impact this 
may have upon the findings.  Heidler et al (2011) also studied the natural 
history of OAB in women and suggested that OAB is a dynamic disease with 
long-lasting stable disease courses as well as remissions and progressions.  
However, this could be associated with the time of year the survey was 
performed, whether they were receiving treatment and were adherent to 




OAB is a chronic long-term condition and in a study of 174 women, 88% had 
persisting OAB symptoms lasting >10 years (Garnett et al 2009).  Reeves et 
al (2006) suggested that due to the aging population the prevalence of OAB 
will rise by 24% over the next 20 years.  Bladder symptoms and sensations 
of urgency are highly variable in the general population however a study by 
Stewart et al (2010) found that the longer duration of time with urinary 
symptoms predicts more persistent symptoms. 
 
 
Anatomy and Aetiology 
 
The lower urinary tract is controlled by both the central and peripheral 
nervous systems in addition to local regulatory factors (Andersson 1993).  
This is demonstrated in Figure 3.1. Contraction of the detrusor smooth 
muscle and relaxation of the internal urethral sphincter result from activation 
of parasympathetic neurons located in the sacral parasympathetic nucleus at 
the level of S2 – S4 (De Groat et al 1981, Shah & Leach 2001). The axons 
pass through the pelvic nerve and synapse with postganglionic nerves in 
either the pelvic plexus, the ganglia on the surface of the bladder (vesical 
ganglia) or within the walls of the bladder and urethra (intramural ganglia) 
(Lincoln & Burnstock 1993).  
 
The sympathetic innervation of the bladder and urethra arises mostly from 
the thoraco-lumbar region T10 – L2 of the spinal cord. The axons travel 
mainly in the hypogastric nerve but also pass through the paravertabral chain 
and enter the pelvic nerve. The predominant effects of the sympathetic 
innervation of the lower urinary tract are inhibition of the parasympathetic 
pathways at spinal and ganglion levels thus causing relaxation of the 
detrusor muscle and contraction of the internal urethral sphincter. 
 
Bladder sensation is transmitted via several different neuronal connections. 
Proprioception is relayed by the mechanosensitive, myelinated alpha delta 
(Aδ) fibres and long latency unmyelinated C fibres in parasympathetic 
afferents travelling in the pelvic nerve to sacral segments S2 – S4. The Aδ 
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fibres respond to passive distension and active contraction, therefore 
conveying information regarding bladder filling (Janig & Morrisson 1986). C-
fibres have a high mechanical threshold and respond mainly to chemical 
irritation of the bladder urothelium or cold (Habler et al 1990). Abnormal 
sensation may be produced by differing systemic medical conditions 





Figure 3.1 Innervation of the lower urinary tract. The bladder and urethra 
receive parasympathetic and sympathetic as well as somatic innervation. 
Sensory afferents can be found in the pelvic hypogastric and pudendal 
nerves. (Adapted from Andersson 1993) 
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Normal adult bladder function is characterised by inactivity of the 
parasympathetic efferent pathways and absence of involuntary bladder 
contractions during the filling (storage) phase. In addition, the pressure in the 
bladder remains low during filling because of the compliance of the bladder 
wall until capacity is reached. This is largely achieved by the arrangement of 
detrusor muscle fibres, reflex inhibitory pathways and the absence of 
connective tissue restriction. A disturbance in any of these factors may result 
in increases in intravesical pressure at a lower capacity and the bladder may 
become hypertonic due to poor compliance. A significant increase in 
intravesical pressure may lead to incontinence, particularly if the urethral 
sphincter is compromised, whereby the threshold at which the intravesical 
pressure exceeds the urethral closure pressure is reduced. 
 
The bladder physiologically fills at a rate of 0.5 – 5 ml/min until it reaches its 
capacity (Monga & Sultan 2003). The maximum capacity of the bladder is 
determined by the vesico-elastic properties of the bladder, the physical limits 
of smooth muscle strength and the resistance of the outflow tract. However, 
in normal women the maximum capacity is rarely reached since voiding is 
prompted when the bladder has filled to functional capacity. This is generally 
between 400mls – 600mls (Cardozo et al 1993) and depends upon bladder 
sensation, activity, compliance and voluntary voiding patterns. 
 
Micturition is not completely understood although several key events are 
known to occur, these are co-ordinated by the pontine micturition centre 
(PMC) in the brain stem. The PMC receives information from afferent 
neurones in the bladder and also from the cerebral cortex and hypothalamus. 
It also has a role in controlling the descending pathways of the micturition 
reflex. At a socially acceptable and convenient time, following central 
initiation and then activation of the sacral parasympathetic nucleus, there is a 
co-ordinated release of acetylcholine from the parasympathetic post 
ganglionic nerve terminals in the bladder (De Groat et al 1993). Following 
this there is a depolarisation of smooth muscle cells with an inward flow of 
calcium ions. Actin/myosin activation leads to a sustained contraction of 
detrusor smooth muscle fibres which provide the power to micturate and 
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empty the bladder. The urethra normally opens during the first phase of the 
voiding cycle but it is unclear if this is an active or passive phenomenon 
secondary to an increase in intra-vesical pressure. In some women gravity 
alone may lead to the expulsion of urine with the subject simply having to 
relax the external urethral sphincter and pelvic floor.  
 
The symptoms of OAB are thought to primarily be due to involuntary 
contractions of the detrusor muscle during the filling phase of the micturition 
cycle. These involuntary contractions, when observed during urodynamic 
studies (UDS), are termed detrusor overactivity (DO) and are mediated by 
acetylcholine-induced stimulation of bladder muscarinic receptors (Anderson 
1997).   Previous studies have reported that approximately 44% of women 
with OAB symptoms have DO on UDS (Hashim & Abrams 2006).   
 
Acetylcholine is a neurotransmitter released from parasympathetic nerves.  
Bladder contraction occurs when acetylcholine binds to muscarininc 
receptors on the detrusor muscle.  There are five types of muscarinic 
receptor, but only M1, M2 and M3 have been identified in the lower urinary 
tract (Rigby 2003).  These receptors can be found in other tissues including 
the salivary glands, the heart, intestines and respiratory system.   
Noradrenaline is released by the sympathetic nervous system and when it 
binds with adrenergic receptors it causes the detrusor muscle to relax and 
the internal urethral sphincter to contract.   
 
Anticholinergics are the most commonly used pharmacological treatment for 
OAB. They are usually muscarinic receptor antagonists and are thought to 
suppress bladder afferent activity by blocking muscarinic receptors in the 
urothelium, myofibroblasts and detrusor, thereby reducing intravesical 
pressure and involuntary detrusor contractions and improving overactive 
bladder symptoms.  However, the fact that the muscarinic receptors are 
commonly found in other tissues accounts for the significant side effects 




The true aetiology of OAB continues to be a widely debated topic and many 
different theories have been proposed within the studies reviewed.        
Harrison (1987) suggested that bladder outflow obstruction may lead to OAB 
through cholinergic denervation of the detrusor and subsequent super-
sensitivity to acetylcholine  Chu & Dmochowski (2006) report that ischemia 
may injure nerves and lead to smooth muscle damage and impaired 
contractility.  Myogenic dysfunction secondary to altered structure or 
disordered function of the detrusor smooth muscle (Brading 1997) and 
bladder inflammation resulting in increased neuroplasticity in sensory nerves 
(Dupont et al 2001) have also been considered as a cause for OAB, yet the 
true aetiology of OAB is still poorly understood and may be subject to many 
confounding factors such as genetics, poor toilet training and bad habits, and 
psychosomatic factors eg anxiety.  
 
Physical Burden of OAB 
 
Coyne et al (2004) performed a study to evaluate the burden of OAB, 
specifically urinary urgency and frequency on Health Related Quality of Life 
(HRQL).  This was part of the National Overactive Bladder Evaluation 
Program (NOBLE).  919 participants completed HRQL questionnaires.  They 
found that the experience of urinary urgency has a significant negative effect 
on HRQL and increases symptom bother, more so than incontinence, 
frequency or nocturia in this sample.   
 
Women with OAB report an increased prevalence of depression, skin 
infections, vulvo-vaginitis, falls and fractures and UTI compared to age 
matched controls. (Darkow et al 2005) 
 
Psychological burden of OAB 
 
The symptoms associated with OAB have been reported as detrimental to 
psychological well-being (Toozs-Hobson 2010).  Nicholson et al (2008) 
described specific emotions experienced by individuals with OAB including 




The EpiLUTS study was a cross sectional population-representative survey 
performed in the USA, Sweden and the UK.  It was designed to evaluate the 
impact of LUTS on urinary specific HRQL.  They reported that both men and 
women with LUTS had the lowest levels of HRQL (compared to those 
without LUTS) and 53% of women with LUTS meet the self-reported 
screening criteria for clinical anxiety (Coyne et al 2009a) and associated 
depression (Coyne et al 2011).  The negative impact of OAB on family 
members has also been demonstrated (Coyne et al 2009b). 
 
Kinsey et al (2016) performed a systematic review of the psychological 
impact of OAB.  Their review of 32 papers found that people with OAB had 
greater levels of depression, anxiety and embarrassment / shame.  In 
comparison to people without OAB they also reported difficulties with social 
life, impact on sleep and sexual relationships and a lower QoL.  Generally 
people with OAB wet reported a greater impact than those with OAB dry.   
 
It is interesting to note that a study by Pretorius et al (2014) suggested that 
even if medication is effective in alleviating symptoms of OAB and the 
physical burden they impose, it may not improve the psychological effects 
associated with OAB.  This was further investigated by Kinsey et al (2017) 
who found that even when OAB symptoms had improved, patients did not 
feel better and found it difficult to let go of worries and fears around OAB.  
The need for ongoing support even after successful treatment of symptoms 
was recommended. 
 
The link between anxiety and OAB has been considered in previous studies 
and is being investigated further.  Currently, researchers are considering that 
there might be an association between an anxious temperament and OAB 







Economic burden of OAB 
 
Prevalence data from the EPIC study have also been used to investigate the 
economic impact of OAB (Irwin et al 2009). The estimated total direct cost of 
OAB for the UK is just over €1 billion per year.  These costs include 
prescriptions, pad provision, diagnostics, medical consultations and 
management of medical sequelae such as clinical depression, UTIs, skin 
infections and fractures.  This total cost did not include admission and care 
provided in nursing homes for patients with OAB wet which was estimated at 
€579 million.   
 
Tang et al (2014) reported that patients with OAB and UI have a significantly 
higher health resource utilisation, lower HRQL and reduced productivity 
compared to adults with OAB without incontinence. A population based cross 
sectional internet survey has been reported involving 2876 men and 2820 
women in the US looking at the impact of OAB on work productivity (Sexton 
2009).  Overall those men and women complaining of OAB wet reported the 
lowest levels of work productivity and the highest levels of daily work 
interference.  Wu et al (2005) determined that employees with OAB have an 
average of 2.2 more days per year of medical absenteeism. The total cost of 
absenteeism associated with OAB has been estimated at €233 million per 
year in the UK (Irwin et al 2009).  
 
The cost implications associated with OAB increase as the treatments 
become more invasive, therefore all patients should start with simple 
measures and therapy should only graduate in invasiveness as necessary 
(Sanford 2014). 
 
Help seeking behaviour 
 
OAB is a distressing problem that can lead to depression and social isolation 
(Bradway et al 2008).   However, OAB remains underreported as many 
sufferers are still reluctant to discuss their condition with their health care 
provider (HCP) or their family despite increased awareness and improved 
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diagnosis and treatment (Abrams et al 2000).   There is also a misconception 
that urinary symptoms are an inevitable outcome of advancing age (Keller 
1999).   The Wennberg study (2009) showed that only 6-7% of participants 
sought help from the healthcare system for their UI.  Benner et al (2009) 
found that although 45.7% of patients with the symptoms of OAB had 
discussed these with their HCP, only 8.1% were currently receiving treatment 
for their symptoms, despite 22.5% being prescribed medication for their 
symptoms in the last year.  This is likely to be related to women’s perception 
of what is bothersome to them.  
 
O’Donnell et al (2005) performed a study to assess the proportion of women 
who consult their doctor about UI and explored factors associated with help 
seeking behaviour in France, Germany, Spain and the UK.  Overall, only 
31% of women had consulted a doctor but women in France and Germany 
were more likely to seek help than those in Spain and the UK.  The reasons 
for these differences are unclear but may be related to culture, or the health 
systems available and access to health care.  Although in the UK a National 
Health Service (NHS) is available to all, challenges in getting appointments 
in primary care and the potential for having to disclose personal information 
to GP receptionists in order to get an appointment may prevent embarrassed 
patients from seeking help.   They also noted that women who reported using 
pads were significantly more likely to consult a doctor.  Willingness to stay on 
a prescription medication and women who had spoken to others about UI, 
were the two most predictive factors for help seeking behaviour.  Older age, 
UI subtype and bother have also been shown to be predictors of care 
seeking in women with UI (Minassian et al 2012). 
 
It has been suggested that reluctance to seek help or mention urinary 
symptoms during clinical consultations may be due to the patient’s belief that 
the symptoms are not severe enough to warrant review, or the 
misconception that they are an unavoidable outcome of aging or child 
bearing and do not represent a valid medical condition (Dmochowski & 
Newman 2007).  Filipetto et al (2014) reported that on average the length of 
time from symptom onset and seeking help for urinary symptoms was 
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3.5years, and patients expressed a preference for clinicians to initiate the 
conversation about symptoms. 
 
A systematic review of the impact on QoL of OAB concluded that at variance 
with other chronic conditions, QoL deterioration in OAB patients is 
characterised by its hidden and embarrassing nature.  This suggests that 
clinicians need to raise awareness of the impact that these symptoms can 
have, help patients to improve their self-confidence to report symptoms, as 
well as, encouraging sufferers to have treatment for their condition to 
overcome its hidden nature (Bartoli et al 2010). 
 
Assessment and Diagnosis of OAB 
 
During the course of this thesis and working in clinical practice an exploration 
of the assessment and diagnosis of OAB was undertaken with a particular 
focus on National and International recommendations and guidelines.  An 
article providing an overview of best practice in the assessment of women 
with LUTS and making a diagnosis of OAB was written and published in the 
Nursing Standard journal in 2013 and is included in the appendix.   
 
Initial assessment should include a full medical history (including 
gynaecological, obstetric, surgical and neurological history, abdominal and 
vaginal examinations, rectal examination (if indicated to rule out faecal 
loading), completion of a three day bladder diary, urinalysis and 
measurement of post void residual urine.  The impact that these symptoms 
have on QoL and desire for treatment should also be assessed.  There are 
many condition specific questionnaires that can be used in the screening and 
assessment of LUTS, the impact that they have on QoL and overall bother. 
The most commonly used questionnaire to assess the symptoms impact of 
LUTS is the Kings Health Questionnaire also known as the ICIQ-LUTSqol 
(Kelleher et al 1997). There are also more condition specific questionnaires 
such as the International Consultation on Incontinence Overactive bladder 
questionnaire also known as the ICIQ-OAB, which was designed to evaluate 
both continent and incontinence symptoms of OAB, their impact on QoL and 
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the outcome of treatment.  Further discussion on questionnaires will be 
included in Chapter 6.   
 
Management of OAB 
 
There is a raft of clinical guidelines available e.g. NICE CG171 (2013), ICI 
(Abrams et al 2017), EAU (Lucas et al 2012) that all make practice 
recommendations for the management of OAB.  The general consensus is 
that conservative management of OAB, including bladder retraining (BRT), 
lifestyle advice, weight loss, pelvic floor muscle training (PFMT), review of 
concurrent medications and adjustment of other modifiable risk factors e.g. 
constipation, smoking and environment should be first line therapy for all 
women.  In the UK it is usually considered that this stage of management 
should take place in primary care. 
 
BRT involves a programme of patient education and a scheduled voiding 
regimen.  The goals of bladder retraining are to normalise urinary frequency, 
improve control over urinary urgency, increase bladder capacity, decrease 
incontinence episodes, prolong inter-voiding intervals and improve the 
patient’s confidence in bladder control.  This is achieved through teaching 
patients urge-suppression techniques, such as distraction, curling toes or 
perineal pressure (Wyman et al 2009).  There are many different methods of 
urge suppression and strategies that can be adopted.  These methods when 
combined with delayed voiding aim to ultimately expand the voiding interval 
and bladder capacity.  The mechanism by which BRT works is not clear, 
however it is thought to improve central control of the bladder.  But, its 
success takes time and is highly dependent on the motivation of the patient 
and enthusiasm of the health care professional.  There is currently no 
consensus on the optimal regimen. 
 
The next stage is pharmacological management and this traditionally starts 
with the prescription of anticholinergic agents (also known as 
antimuscarinics) and these will be discussed in more detail later in this 
chapter.  It may also include the use of the Beta 3 agonist, tricyclic 
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antidepressants, synthetic vasopressin analogue and topical vaginal 
oestrogens for post-menopausal women.  Women often try several different 
types or combinations of medications during the course of their treatment.  If 
pharmacological treatment is unsuccessful they will then go to third line 
therapies which are more invasive and costly such as intra-detrusor 
injections of onabotulinum toxin A, neuromodulation (either sacral or 
percutaneous) or surgical augmentation of the bladder e.g. clam cystoplasty 
or ileal conduit diversion.  For women who are unsuitable for, or do not wish 
to have major surgery, insertion of a suprapubic catheter may be considered 
or some women may choose to just manage containment with absorbent 
products and pads. 
 
Role of UDS 
 
Referral into secondary care services for women with OAB is usually 
considered for those who have failed conservative therapy and have tried at 
least one anticholinergic without significant benefit.  At this point, more 
invasive diagnostic investigations may be performed such as subtracted 
cystometry (also known as urodynamic studies (UDS)).   
 
Cystometry is the method by which the pressure/volume relationship of the 
bladder is assessed during filling and voiding. It involves the simultaneous 
measurement of intravesical and intra-abdominal pressures. Electronic 
subtraction of the intra- abdominal pressure from the intravesical pressure 
enables the detrusor pressure to be calculated and compared with changes 
in bladder volume and flow rate. Cystometry aims to characterise detrusor 
and urethral function during the filling and voiding phases.  This is 













The presence of involuntary detrusor contractions during filling or on 
provocation that the patient cannot suppress is diagnostic of detrusor 
overactivity. These may or may not be associated with symptoms of urgency.  
If there is a gradual rise in detrusor pressure during filling to >15 cmH2O, but 
without phasic contractions, this is termed ‘low compliance’. This can be 
artefactual owing to superphysiological or fast bladder filling. If there is a 
neurological condition present, such as multiple sclerosis, this is often 
accompanied by marked low compliance. If leakage occurs on coughing, 
with an associated rise in intra-abdominal pressure, but in the absence of 










Should remain closed and 
competent but can: 
 be incompetent  due to 
physical  stress, but 
without an associated  rise 
in detrusor  pressure  
(stress incontinence) 
 be incompetent as a direct 
result of an involuntary 
rise in detrusor pressure 
(detrusor overactivity) 
 
Should remain relaxed/stable 
throughout filling but can: 
 show abnormal 
involuntary contractions 
(detrusor overactivity) 
 show a gradual rise in 





Should be appropriately 
relaxed but can: 




Should contract efficiently 
under voluntary instruction but 
can: 
 be under-active or 
acontractile (possible 
neuropathic cause) 
 show high-pressure 
contractors (if over-active 
or needing to overcome 
an outflow obstruction) 
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Questions have been raised over the years regarding the role of UDS in 
women with OAB given that less than half of women will be found to have 
DO and successful responses to nonsurgical and surgical interventions for 
OAB do not absolutely correlate with a finding of pre-intervention DO on UDS 
(Nitti et al 2010a, Malone Lee et al 2009, South 2007).  This links to the 
potential other causes of OAB symptoms. Lee et al (2010) reported that 
patients with OAB have increased bladder sensitivity and Finney et al (2006) 
suggest a sensory disorder is the principal cause of OAB symptoms in some 
individuals as they found that, at clinically relevant doses, antimuscarinics 
have little effect on bladder contractility. It could therefore be suggested that 
these agents primarily act on sensory variables such as urgency, time to first 
sensation to void, and urinary frequency.   
 
However, it is considered  a need to rule out those women with idiopathic 
OAB from those with other underlying pathology that may be adding to or 
complicating symptoms eg voiding dysfunction or mixed urinary incontinence 
(MUI) or where there is suspicion that there is risk to the upper tracts eg due 
to decreased compliance.  Failed or unsatisfactory response to empirical 
pharmacological therapy is also considered an appropriate indication for 
performing UDS in women (Abrams et al 2018, Rovner & Goudelocke 2010).    
 
It is also important to consider the difference in those women who are found 
to have DO on UDS.  The presence of DO has been shown to have a more 
negative impact on the quality of life of women compared to those with OAB 
symptoms (Giarenis et al 2013) and this information may change how 
women are counselled in real life practice and what treatments they are 
offered.   
 
In the researcher’s place of work, women are referred following failed 
conservative or medical therapy in primary care.  In line with the above 






Effectiveness of anticholinergics 
 
A systematic review was performed by Herbison et al (2003) to determine 
the effectiveness of anticholinergic drugs for the treatment of OAB.  It 
reported that although there were statistically significant differences between 
anticholinergic drugs and placebo, the effect was small and may be of 
questionable clinical significance.  However, a report by Hartmann et al 
(2009) reviewed the evidence regarding treatment of OAB, UUI and related 
symptoms and found that even though treatment effects were quite modest, 
HRQL and treatment satisfaction measures imply that such improvements 
are important to women.  Jonas (2007) suggested that what matters to 
patients when seeking treatment for OAB goes beyond the mere presence of 
symptoms, and the bother and discomfort the symptoms cause are more 
important in their personal assessment of condition severity and hence the 
satisfaction with and perceived value of treatment.   
 
A study by Herschorn et al (2014) considered whether patient characteristics 
could predict the responsiveness to treatment of OAB with antimuscarinics.  
They reported that shorter duration of OAB symptoms, younger age, female 
gender and lack of previous antimuscarinic pharmacotherapy are all factors 
that predict a greater change in outcomes and the response to treatment. It 
has also been suggested that the ability to predict who will respond to 
therapy may help to guide treatment decisions e.g. who will need to take 
prescribed medication, who will need to be titrated to higher doses of 
medication.  This may help to optimise outcomes through individualisation of 
pharmacotherapy.  Ultimately, treatment is usually multimodal and far more 
complex than the prescription of medicines, however, understanding the 
wishes of patients will help guide treatment choices and thus their efficacy.   
 
Adherence and persistence 
 
Adherence to anticholinergic medication has always been a concern and in a 
review of patients taking anticholinergics, 12 months after therapy was 
initiated, the persistence rate was 14-35% (lower with generic and higher 
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with branded medication) depending on the drug treatment (Wagg et al 
2012).  A systematic review of persistence and adherence to anticholinergic 
therapy was conducted in 2011 (Sexton et al).  They found that in 12 week 
clinical trials, rates of discontinuation ranged from 4-31% and in every day 
clinical practice from 43-83% within the first 30 days of treatment with rates 
rising over time.  It was reported that over half of patients never refill their 
initial prescription and the most common reason was concern about the 
balance between the efficacy and tolerability of the anticholinergic agents.  
Sears et al (2010) designed a study to see if patients who do not pay for 
medication were more likely to adhere to therapy.  However, still 35% of 
patients did not refill a prescription for anticholinergic medication.  The most 
common reasons for discontinuation with treatment are dissatisfaction / lack 
of efficacy to control symptoms (Benner et al 2009, Campbell et al 2008, 
Basra 2008).   
 
A recent study by Tran et al (2016) reported that the persistence is better 
when the patient’s care is under subspecialist supervision rather than a 
general community setting.  Although specialist education on OAB has not 
been shown to improve persistence (Sung et al 2015, Schneider et al 2014). 
 
Over the years the lack of persistence with treatment has been a focus for 
drug development, with treatment moving from immediate release 
preparations requiring multiple daily doses to modified / extended release 
preparations allowing single daily dosing.  Alternative routes of administration 
have been developed eg transdermal patch, topical gel, and an intravaginal 
ring to try to avoid the adverse effects associated with first pass metabolism. 
New classes of drugs (eg a beta 3 agonist) have been developed to try to 
improve efficacy and tolerability of treatment.  However, in the real world 
studies, persistence with treatment remains low.   
 
There is a lack of evidence relating to the duration of treatment with 
anticholinergics and it could be considered that patients believe that they are 
only having ‘a course’ of treatment and then discontinue treatment.  Lee et al 
(2011) reported that discontinuation of anticholinergics resulted in higher 
77 
 
symptom relapse and retreatment rates regardless of treatment duration.  It 
has been suggested by Nazir et al (2015) that branded drugs may be more 
cost effective in the treatment for OAB than low cost generic treatment due to 
better efficacy and tolerability which in turn improves symptom control and 
persistence.  This could be because of supportive patient programmes 
provided with some of the branded products.   
 
Despite all these concerns with efficacy and tolerability a report from the ICI 
(Andersson et al 2017) states that anticholinergics remain the first line 
pharmacological treatment for OAB.   
 
Impact of LUTS / UI on SF 
 
Although LUTS have been shown to affect many aspects of women’s QoL, 
one aspect that is often overlooked is the impact that it has on a woman’s 
sexual function.  The importance of HCP’s assessing both urinary and sexual 
health concerns during patient encounters is emphasised by Chen J et al 
(2013).  Sutherst and Brown (1980) stated that 43% of women attending an 
incontinence clinic felt that their urinary symptoms were adversely affecting 
their sexual lives.  Pauls et al (2006) reported that up to 64% of sexually 
active (SA) women attending a urogynaecology clinic suffer from FSD.   
 
To enable measurement of SF and LUTS, researchers have focused on 
developing questionnaires to measure the impact of symptoms.   Quality of 
life questionnaires have not only been developed to assess SF function in 
women (as discussed in chapter 2), but disease specific questionnaires to 
assess SF in women with LUTS / UI have also been developed and are 
discussed in more detail later in this chapter.   
 
There are significant variations in prevalence figures seen however, this is 
often because of the populations being assessed, the definitions being used, 
the evaluation method used or the fact that in many studies all women with 
any form of UI are grouped together and they do not differentiate for each 
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subtype of incontinence.   Aslan et al (2005) designed a study to evaluate the 
impact of UI on SF and recruited 21 incontinent women (3 with SUI, 9 with 
OAB and 9 with MUI) and 18 healthy controls.  SF was assessed using the 
Female Sexual Function Index (FSFI) which is a validated and reliable 
questionnaire assessing desire, arousal, lubrication, orgasm, satisfaction and 
pain.  All domain scores were significantly lower in incontinent women with 
the exception of pain.  However, they did not demonstrate any differences 
between the different types of incontinence but the number of women in this 
study is too small to draw conclusions.   
 
In 2015, Su et al explored the association between UI and SF in a non-
clinical population.  They found that all types of UI showed a significant 
association with FSD with an odds ratio of 1.6-1.8.  When breaking down the 
outcomes to individual symptoms, UUI was a risk factor for decreased sexual 
lubrication and increased pain, while MUI was associated with reduced 
sexual satisfaction.  A recent case control study in Brazil performed by 
Felippe et al (2017) evaluated sexuality in continent and incontinence 
women. Incontinent women presented a higher prevalence of sexual 
abstinence than their counterparts (53% vs 29.2%).  Women with UI also 
have less sexual desire, foreplay, harmony with partner, sexual comfort and 
satisfaction. These associations are correlated so that the greater the 
severity of UI the worse the impact on SF.   
 
Age and postmenopausal status have been shown to be associated with 
increasing severity of UI and compromised SF (Zohre 2014).  In 2011, 
Ghannam et al measured the impact of UI on sexual dysfunction in older 
Americans.  Of 3000 adults aged between 57-85 years, 46% reported UI.  
Incontinent women were 1.89 times more likely to have anorgasmia and 2.4 
times more likely to lack sexual interest compared to continent women. 
 
Many studies assessing LUTS and SF have specifically looked at those who 
report some form of urinary incontinence during sexual activity.  Munaganuru 
et al (2017) performed a study to evaluate the prevalence and impact of UI 
during sex and 25% reported experiencing coital incontinence (CI).  19% of 
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the women reported being subjectively bothered by this and 16% restricted 
SA for fear of UI.  According to a systematic review by Pastor (2013) the 
prevalence of CI ranges from 0.2%-66%. 
 
Shaw (2002) undertook a systematic review of the literature to assess the 
prevalence of sexual impairment in women with UI and the prevalence of 
urinary leakage during sexual activity from publications between 1980 - 
2001.  Prevalence of CI in clinical settings ranged from 10-56% and 
impairment in SF was reported as 0.6-64%.  However, there are significant 
challenges in comparing data due to differing definitions, and methods of 
assessment.  The review suggested recommendations for standard 
definitions and measures of CI and sexual impairment to establish reliable 
prevalence estimates.  Most recently Grey et al (2018) assessed the self-
reported prevalence of CI in a large cohort (2312 women) in a 
Urogynaecology setting using the ePAQ-PF.  The overall prevalence of CI 
was reported as 21%, 24% reported CI at orgasm and 15% reported CI at 
penetration.  It was also found that symptoms of OAB and SUI were 
independently associated with both types of CI.   
 
It is only recently in 2018 that ICS / IUGA have published a joint report on the 
terminology for the assessment of sexual health of women with pelvic floor 
dysfunction (Rogers et al 2018).  Within this report, Coital urinary 
incontinence (CUI) (previously only written as CI) is defined as UI occurring 
during or after vaginal intercourse.  However, it goes further to define specific 
times of UI and introduces the terms of orgasmic urinary incontinence (UI at 
orgasm)(previously known as climacturia), penetration UI (UI at penetration 
including penile, manual or sexual device) and for those with OAB dry, coital 
urinary urgency (CUU) which is defined as the felling of urgency to void 
during vaginal intercourse.  A final new term of post coital LUS symptoms – 
such as worsened urinary frequency or urgency, dysuria, suprapubic 
tenderness has also been added.  However, it may take several years from 
now for clinical trials to adopt this new terminology and report findings in line 




It is also important to acknowledge that there may be other types of fluids 
that women may expel during sexual activities.  Female ejaculation (FE) is 
the secretion of a few millilitres of a thick, milky fluid by the female prostate 
(Skene’s glands) during orgasm.  Squirting (SQ) is defined as the orgasmic 
transurethral expulsion of tenths of millilitres of a form of urine containing 
various concentrations of urea, creatinine and uric acid (Pastor & Chmel 
(2018).   However, this thesis will not address these phenomena which are 
poorly understood and still contentious within the published literature. 
 
OAB and SF  
 
Intercourse and orgasm have been reported as triggers for OAB symptoms 
and are associated with significant distress (Zilberlicht 2018).  There have 
been many studies that show the negative impact of OAB on SF (Salonia et 
al 2004, Milson et al 2009, Coyne 2008a, Chen J et al 2003, Kim et al 2005, 
Sand et al 2006, Sen et al 2007, Walters et al 1990, Sen et al 2006, Cohen 
et al 2008, Hansen 2004, Dmochowski & Newman 2007, Pace et al 2011, 
Nilsson et al 2011).  Heidler et al (2010) found that one in four patients with 
OAB wet reported a negative impact on their sex life.  One of the largest 
prevalence studies performed was by Coyne et al (2011) as part of the 
EpiLUTS study.   Its aim was to describe sexual health outcomes in men and 
women with continent and incontinent OAB compared to those with no or 
minimal urinary symptoms, and to evaluate correlates of decreased SA and 
enjoyment.  8,085 women completed the survey and all women with OAB 
experienced worse sexual health compared to those with no symptoms.  
Those with OAB who were incontinent were significantly more likely to report 
diminished SA and enjoyment with sex.  They also reported that women with 
OAB wet are less likely to be SA than OAB dry women and women without 
OAB. 
 
A smaller prevalence study was completed by Heidler et al (2010) as part of 
a health screening project in Vienna.  17.7% of respondents reported 
symptoms of OAB and 38.1% complained of OAB wet.  28% of those with 
81 
 
OAB felt that it had a negative effect on their sexual lives and in women with 
OAB wet this effect was more significant than in those with OAB dry.  
 
Oh et al (2008) also evaluated the impact of SUI and OAB on HRQL and SF 
in Korean women and concluded that although both have a detrimental 
impact on HRQL, women with SUI experienced more pain during intercourse 
and CI.  A study by Schimpf et al (2009) reported that women with UUI and 
MUI have lower HRQL score that those that are continent or only report SUI.  
The study by Coksuer et al (2011) and Karbage et al (2016) corroborate 
these findings. 
 
Juliato et al (2017) evaluated women with OAB to correlate the severity of 
their urinary symptoms with their SF.  They found that women reporting 
greater symptom severity (according to the ICIQ-OAB score) have worse SF, 
in the arousal, lubrication, orgasm and pain domains of the FSFI.  Chuang 
(2017) also reported that increased symptoms severity of OAB is associated 
with a poorer sexual QoL.    
 
Controversies in the diagnosis of FSD in women with UI 
 
At the start of this project when the protocol was developed and the initial 
literature search was performed a variety of studies demonstrated the 
prevalence and impact of FSD in women with pelvic floor disorders.  
However, with the update of the DMS-V in 2013, not only was the 
terminology and classification changed but new criteria for the diagnosis of 
FSD were added (Graham 2016).  Female sexual dysfunction now includes 
the following criterion: ‘the sexual dysfunction is not better explained by a 
nonsexual mental disorder or as a consequence of severe relationship 
distress or other significant stressors and it is not attributable to the effects of 
a substance / medication or another medical condition’ (APA 2013 p424).  
Given this criterion sexual disturbances associated with incontinence or any 
other pelvic floor disorder should not be classified as a sexual dysfunction, 




For many women, sexual difficulties may be multifactorial and the presence 
of urinary symptoms may not be bothersome or impact on their sexual 
functioning so it raises the question of how to differentiate which factors 
impact the most on sexual functioning, in order to define a dysfunction or 
disorder? 
 
Questionnaires to assess the impact of LUTS on SF 
 
Chapter 2 discussed the PROMs used to assess SF in women.  This section 
will specifically examine those PROMs identified by the ICI (Abrams et al 
2017) that have been validated to assess the impact of UI / POP on SF in 
women 
  
The PISQ-12 assesses sexual function after surgery in women with UI and 
POP (Rogers et al 2003).   The Prolapse and Incontinence Sexual 
Questionnaire – IUGA revised (PISQ-IR) (Rogers et al 2013b) was 
developed to assess the impact of pelvic problems on sexual desire, 
frequency, satisfaction, orgasm and discomfort (Abrams et al 2017).  The 
Sexual Function Questionnaire (SFQ) is the only questionnaire specifically 
designed to assess SF in women with OAB.  Table 3.2 presents all the 
identified questionnaires by the ICI to assess SF in women with LUTS, 
reporting their primary goal and their ICI rating.  These will be discussed 
further in Chapter 6 when justifying the questionnaires used in the main 
study in this thesis.     
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Table 3.2 Condition specific questionnaires to assess the impact of LUTS on SF 
 
Questionnaire name Number 
of 
questions  







questionnaire – Vaginal 
symptoms ICIQ-VS 
14 Self administered questionnaire to 
assess the effects of vaginal symptoms 
and associated sexual matter on sexual 




Questionnaire – female 
Lower Urinary Tract 
Symptoms Sex  
(ICIQ-FLUTSsex) 
4 Self administered questionnaire to 
assess sexual matters associated with 
urinary symptoms and related bother 
 A 
Pelvic Organ Prolapse / 
Urinary Incontinence Sexual 
Questionnaire (PISQ)  
31  To assess sexual function after surgery 





Pelvic Organ Prolapse / 
Urinary Incontinence Sexual 
Questionnaire short form 
(PISQ-12) 
12 To assess sexual function in women with 







Questionnaire name Number 
of 
questions  





Pelvic Organ Prolapse / 
Urinary Incontinence Sexual 
Questionnaire IUGA revised 
(PISQ-IR) 
19 Self administered questionnaire 
assessing key dimensions of sexual 
function including bother in women who 
are sexually active and those who do not 




31 Self administered questionnaire used to 
assess the impact of OAB on sexual 
health / function in the male and female 
population 
Men and women 
with with OAB 
C 
 






Urodynamic diagnosis and SF 
 
In order to understand the pathophysiological mechanisms of incontinence 
during orgasm, Serati et al (2008) recruited women with incontinence during 
intercourse and divided them into two groups: women with CUI at orgasm or at 
penetration.  These forms of CUI were then correlated with the urodynamic 
finding of DO.  Of the 49 women who reported incontinence at orgasm, 69.4% 
had DO compared to only 28.9% of the 83 women who leaked on penetration.  
They concluded that in the majority of cases of incontinence at orgasm is 
associated with DO.   
 
Khan et al (1988) had previously tried to understand the mechanism of 
incontinence during orgasm and UDS studies demonstrated simultaneous 
bladder contractions and urethral relaxation.  This theory is supported by the 
work of El-Azab et al (2011) and Moran et al (1999) who report that CUI is 
almost invariably a symptom of SUI with urethral sphincter incompetence.  
According to Lua et al (2017) a maximal urethral closure pressure < 30 cmH2O 
was associated with CUI again demonstrating that urethral function plays a vital 
role in maintaining continence during coitus  
 
Hilton (1988) performed cystometry to establish the prevalence of UI occurring 
during intercourse and to define the UDS diagnosis of sufferers.  Of 400 
consecutive women questioned, 324 were SA and 24% experienced 
incontinence during intercourse (two thirds on penetration and one third on 
orgasm).  For the group who leaked on penetration 70% were shown to have 
urodynamic stress incontinence (USI) and 4% DO.  However, for the group who 
experienced incontinence at orgasm, 42% had USI and 35% were found to have 




Cohen et al (2008) reported that women with DO and UI have significantly 
worse SF than women with normal urodynamics.   Yip et al (2003) showed that 
marital relationships and sexual function were negatively affected in women who 
had USI or DO. In a report that studied the relation between different types of 
incontinence and sexual health, Urwitz-Lane (2006) showed that among SA 
women with UI, SF as assessed by the PISQ-12 does not differ according to 
type of incontinence.  These papers suggest many different reasons for this 
effect including embarrassment, fear of CUI on penetration and orgasm, loss of 
confidence, fear of smelling, loss of libido.   
 
Madhu et al (2015) reviewed data from a UDS clinic with a total of 11,689 
women over a 10 year period.  They reported that the prevalence of CUI was 
11.8% of women with LUTS undergoing UDS.  The majority of the women 
described mixed symptoms and CUI was associated with USI (OR=2.35) and 
DO (OR=1.22) but not DO incontinence.  Associated risk factors included parity, 
obesity, smoking and antidepressant drug usage.   
 
Further work by Serati et al (2011) has tried to measure bladder wall thickness 
in women with CUI to consider if this could predict DO.  They found that women 
with DO and CUI at orgasm had significantly greater bladder wall thickness 
values and that CUI at orgasm could be a marker of a more severe form of DO. 
 
A study by Gordon et al (1999), prospectively evaluated the relationship 
between sexual dysfunction and UDS diagnoses in 100 consecutive women.  
SF was assessed with a detailed questionnaire that calculated a total sexual 
function score (TSF).  They found that women with DO had lower TSF scores 
than those with SUI and MUI. 
 
Although all of these studies have performed UDS in women who report specific 
symptoms.  None of them have performed the cystometry whilst they are having 
intercourse or during orgasm or during masturbation to confirm the UDS 
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mechanism at the time of penetration or orgasm, or to assess UDS parameters 
associated with coital urinary urgency.  This is likely due to the significant 
artefact that would be produced on the UDS trace as symptoms were 
reproduced and the potential for errors in pressure measurement related to 
vaginal intercourse and repeated thrusting let alone the issues related to 
privacy, dignity, consent and ethical approval as this would need to be in a 
research setting. 
 
Psychological Impact of OAB on SF 
 
There have been several qualitative studies assessing the psychological impact 
of OAB on SF.  Coyne et al (2007) led six focus groups for women with OAB 
(three continent and three incontinent).  Half of the incontinent women cited 
OAB, aging and the menopause as the reason for their reduction in sexual 
desire.  The majority of the incontinent women were embarrassed by their 
incontinence resulting in a loss of self-image.  Embarrassment is also 
associated with loss of urine during intercourse, malodour, and the need to 
dispose of pads before intercourse (Clark & Romm 1993).  All women with OAB 
complained of difficulty achieving orgasm.  The causative factors cited included 
fear of incontinence, pain and anxiety related to intercourse.   
 
Coyne et al (2007) found that OAB often put strain on relationships because of 
loss of intimacy, body image concerns and fears of incontinence.  They also 
reported less SA due to leakage and interruptions during sex (Coyne et al 
2009a) and have significantly more worry about their future sexual life than 
healthy controls (Coyne et al 2011) .  Low body image was also cited as a 
reason for having less sex in the study by Nicolson et al (2008).  Roos et al 
(2014) also found that body image plays a key role in the SF of women with 




Qualitative research involving interviews with Turkish women to identify the 
feelings and experience of the effect of UI on SF reported themes such as 
shame, blame and guilt, fear that UI symptoms could occur during intercourse, 
individual coping mechanisms such as going to the toilet frequently before SA, 
avoiding SA were considered and many women did not discuss their concerns 
with their partners.  The overriding theme was that embarrassment had led to an 
inability to enjoy SA (Akyuz et al 2014).  
 
The impact of women’s coping methods when trying to self-manage CUI 
including urinating prior to sexual intercourse, deferring intercourse, interrupting 
intercourse prematurely, avoiding certain positions, hurrying through sex and 
avoiding orgasm may also significantly strain relationships and prevent the 
woman from relaxing and enjoying sex. 
 
Pelvic organ prolapse, UI and SF 
 
POP is often cited as associated with symptoms of OAB.  However, when 
reviewing the evidence of the impact of POP and OAB on SF most studies 
again do not differentiate and just report figures for UI as a whole.  Rogers et al 
(2001) compared SF in women with and without UI and/or pelvic organ prolapse 
(POP) using a validated condition-Specific questionnaire, the Pelvic Organ 
Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ), and concluded 
that PISQ scores were significantly lower among women with UI/POP than in 
those without (P = 0.003). Women with UI/POP have poorer SF, as measured 
by the PISQ, and report less frequent SA. In addition, women with UI/POP are 
more likely to restrict SA for fear of incontinence. Women with POP and UI are 
more likely to report decreased libido, decreased sexual excitement, and 
difficulty achieving orgasm during intercourse when compared to women with UI 
alone (Ozel et al 2006, Handa et al 2004).  This is potentially as the prolapse 




Barber et al (2002) suggested that POP is more likely than UI to result in sexual 
inactivity and be perceived as affecting sexual relations.  Jha and Gopinath 
(2016) confirmed this and reported that patient and partner avoidance of SA 
was greater in women with POP than those with UI. A literature review by Yount 
(2013) on the impact of pelvic floor disorders and pelvic surgery on women’s 
sexual satisfaction and function conveyed a warning, that although surgical 
procedures can alleviate symptoms they cannot guarantee optimal sexual 
satisfaction, SF or cure of the disorder. 
 
It has been suggested that evaluation of the effects of SUI and other LUTS on 
SF is often biased by their common association with other pelvic floor disorders 
including POP which also affects sexual satisfaction (Fatton et al 2014).  In 
clinical practice it is very common for women to have concomitant UI and POP. 
In the main trial described in this thesis, women with significant POP were 
excluded.  To fully understand the effect of POP (and treatment of POP) on SF 
in this group of women a review of the literature was performed and an article 
entitled ‘Assessment of the impact of urogenital prolapse on sexual dysfunction’ 
was published in Maturitas in 2016.  This is included in the appendix. 
 
Impact on partners 
 
Bekker et al (2010), identified that several studies had revealed that UI impairs 
women’s sexual functioning and satisfaction, however there was no knowledge 
about the effects of UI on the functioning of their male partners.  They asked the 
women attending an outpatient appointment for urological assessment and their 
partners to complete the Golombok Rust Inventory of Sexual Satisfaction 
questionnaire (GRISS).  Of the 189 couples who completed the questionnaires 
42.9% of the women reported UI.  The women with UI demonstrated lower 
overall SF, lower frequency of intercourse, were more likely to show avoidance 
behaviour and have more problems with communication.  Men with partners 
with UI also reported an overall diminished SF, lower frequency of intercourse, 
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reduced satisfaction and were more likely to have erectile problems.  However, 
there were no questions as to whose problems started first. 
 
Face to face interviews were performed by Beji et al (2005) with 32 incontinent 
women who reported urinary leakage during intercourse and 60 asymptomatic 
controls.  When compared to the control group, incontinent women were 4.7 
times less satisfied with their sexual lives and their partners had ejaculation 
without full erection 3.1 more times (which may have added to the decreased 
satisfaction).  During these interviews several methods of coping with leakage 
during intercourse were volunteered and these are shown in table 3.3 below. 
 










Micturating prior to sexual intercourse 6 18.8 
Keeping the partner unaware of the problem 16 50 
Deferring intercourse 9 28.1 
Partner suggests anal coitus 2 6.3 
Ignoring the problem 8 25 
Interrupting intercourse prematurely 6 18.8 
  
 
Cassells and Watt (2003) examined the carer’s perspective on the effect of 
incontinence on sexuality and found that although UI did not affect sexual 
intimacy, it did affect sexual intercourse and sleeping in separate bedrooms was 
common.  Faecal incontinence was found to have a far greater effect on SF 




It has also been reported that significantly more women with OAB had 
previously been sexually abused than women with SUI or a control group (Jundt 
et al 2007) 
 
Impact of treatment for OAB on SF – Antimuscarinics 
 
Successful treatment with first, second and third line therapies (conservative 
therapies, medical therapy and invasive therapies eg SNS) have been shown to 
improve female SF scores (Moore 2016).  However, there is still sparse 
evidence to evaluate the benefits to SF with drug management of incontinence 
(Mota 2016).  It has been suggested that medical therapy for OAB may reduce 
the fear of urgency and/or leakage during SA (Wehbe 2010).  If women are to 
have fewer anxieties surrounding their bladder, this may improve desire and  
may also help them to relax which may reduce pain and improve orgasm.  
However, antimuscarinics are associated with side effects including dry mouth, 
and it could be considered that this could negatively affect a woman’s ability to 
kiss as well or perform oral sex.  Given the ‘drying effect’ that they have on the 
body it could also be considered that there might be an adverse effect on 
lubrication and therefore increase pain during intercourse, all of which would 
negatively affect SF.    
 
Sand et al (2006) analysed the sexual domain of the KHQ in a group of 2878 
patients receiving transdermal oxybutynin for their OAB symptoms over a six 
month period.  They showed a reduction in CI from 22.8% to 19.3%, partner 
relationships improved in 19.6% but worsened in 11.9% and the effects of OAB 
on their sex lives improved in 19.1% but again worsened in 11.2% of patients.  
However, although 87% of this patient cohort were women, the paper does not 
separate out the groups in the analysis so these results may be biased. In a 
further paper by Sand et al (2009) there was a recommendation for future 
research into the effect of treating OAB symptoms with fesoterodine on sexual 
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function and quality of life in women.  A full systematic review of the literature 
related to this is presented in chapter 4. 
 
Impact of treatment for OAB on SF – other treatment modalities 
 
A small prospective controlled study by Zachariou et al (2018) examined the 
effect of mirabegron on female sexual function.  The demonstrated statistically 
significant changes in the total score and each domain score of the FSFI 
following three months of treatment compared to the control group.  
 
For MS patients receiving onabotulinum toxin A, regaining continence following 
treatment was associated with a statistically significant improvement on total 
FSFI scores  however,  remaining wet left impact unchanged (Giannatoni et al 
2015).  This outcome is different to the study of onabotulinum toxin A in 
idiopathic OAB patients where 90% of participants saw an improvement in FSFI 
score post treatment regardless of continence status (Miotla 2017). 
 
A study by Ingber et al (2009) assessed the effect of sacral neuromodulation 
(SNS) for OAB on FSF.  They found that SNS does not significantly improve 
female SF.  However, a more recent study by Gill et al (2011) reported 
significant improvements in overall SF although this was not associated with 
improved lower urinary tract function.  A further study by Yih et al (2013) looked 
at changes in SA follow SNS and found that 14% of women who had not 
previously been became SA following treatment.  Overall however, for the 
women who had been SA throughout the study there was not a significant 
improvement in their SF post SNS.   
 
Work by Musco et al (2016) evaluated the impact of percutaneous tibial nerve 
stimulation (PTNS) on FSD in women undergoing PTNS to treat their OAB 
symptoms.  Using validated questionnaires they found that using PTNS 




A review by Proietti et al (2012) recommends that more therapeutic 
interventions, including new anticholinergics and other methods, in both men 





OAB is a prevalent condition affecting the physical and psychological health of 
many women and presenting a wider economic burden.  For those who do seek 
help, the evidence would indicate that assessment is essential to rule out 
underlying causes and clinical care should start with conservative therapies and 
if necessary drug treatment with antimuscarinics.   
 
In this chapter I have described the impact OAB has on SF and reviewed the 
different methods of assessment and treatment available with a focus on 
antimuscarnincs and SF.  One of the challenges identified during this literature 
review is that assessment of sexual function / dysfunction is varied amongst all 
the studies.  There does not appear to be a set criteria for sexual activity and 
exactly what it entails.  According to the new terminology report, assessment of 
sexual activity status should be self-defined and not limited to women who 
engage in sexual intercourse, but this definition is still subject to significant 
individual interpretation.  All the studies use varying frequency of intercourse 
within their cohorts preventing reliable comparisons between studies.  
Standardised assessment and reporting methods for these clinical trials would 
help to overcome this. 
  
Anticholinergics remain the mainstay of treatment, however, although there is a 
multitude of evidence available assessing efficacy in terms of reducing OAB 
symptoms, very little known about the impact of treatment on a woman’s SF.  
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This has led to the development of the next chapter where a more in depth 
















Do anticholinergics improve sexual function 
in women with overactive bladder 
syndrome? 





According to Moher et al (2015), systematic reviews and meta analyses are the 
reference standard for synthesising evidence in health care due to their 
methodological rigor.  They are not only used by clinicians to inform clinical 
decision making, but are often the starting point or supporting evidence used for 
clinical practice guidelines.  Within the research setting, systematic reviews are 
also used to ensure that there is a justification for novel or further research in a 
particular field (Moher et al 2009).    
 
At the start of this thesis, the area of interest was identified as the impact of 
treatment for OAB on women’s sexual function.  In order to gain an in depth 
understanding of the available literature, identify the knowledge gaps, develop 
and justify a research question, a systematic review was undertaken and is 
described in this chapter.   The Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses (PRISMA) guidelines were published to provide a 
set of evidence based minimum standards for the reporting of systematic 
reviews to ensure quality and clarity and they have been utilised in the reporting 
of this review (Moher et al 2009).  
 
Current Evidence Base 
 
There is a large evidence base (Cochrane reviews, NICE guidelines etc) to 
support the use of anticholinergics and other treatment modalities in managing 
the urinary symptoms of OAB.  However, in these reviews there are no 
references to the impact of anticholinergics and other treatments specifically on 
SF, yet this is an important and common problem encountered by many women 
with OAB as demonstrated in chapter 3. 
 
To investigate in detail the sexual dysfunction of women with OAB and the 
impact of antimuscarinic drug therapy, this systematic review explores the 
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currently available literature regarding the use of anticholinergic medication, for 
the treatment of OAB on the SF of women.   
 
To assist the search and to formulate a precise question, four parts to the 
clinical question were set using a PICO analysis.  Table 4.1 demonstrates the 
PICO analysis set for this review. 
 
Table 4.1 PICO analysis 
 
Population Sexually active women with OAB 
Intervention Anticholinergics 
Comparison No anticholinergics (including cohort studies 
comparing baseline to end of treatment) 
Outcome Sexual function 
 
When setting these variables women included all females over the age of 18 
who were SA.  However, no limits were put on the frequency of SA within a 
defined period.  The intervention of anticholinergics included all of the 
preparations currently licensed in the treatment of OAB that are available on the 
NHS.  The comparison with no other anticholinergics (ie no treatment or 
placebo) allowed this search to be objective, avoiding comparisons regarding 
which individual anticholinergic drug had the largest impact on SF, but it 
addressed the effect of anticholinergics as a whole.  Comparisons with 
conservative therapies such as lifestyle advice were accepted depending on the 
forms of therapies offered.  The outcome was measured using data from 
validated questionnaires that have been designed to assess SF in women.    
From this analysis I formulated the following question for investigation:  
 







Following the preliminary identification of my question, an initial scoping search 
was performed to ensure that a review of this question had not previously been 
performed or was currently in progress.  The Cochrane Library held several 
reviews relating to anticholinergic medication in the treatment of OAB but none 
of these addressed SF.  A scoping search on Medline was also performed and 
did not reveal any systematic reviews in the area.  These initial searches 
confirmed the lack of evidence and the need for a review of the relevant data.  
From this I was able to formulate my search plan to assist in my search of the 
literature.  A facet analysis was performed to identify keywords to be used in the 
search and variations of these terms that helped to ensure that all relevant 
literature was found.  The facet analysis and search plan is shown in table 4.2. 
 
Table 4.2 Facet analysis and search terms 
 
Population Intervention Outcome 
















Marital relationship$  
Overactive bladder  








Searches were performed initially using the Cochrane library and then two 
further databases.  Medline and Embase were chosen for this search so that 
studies from America and Europe would be included.  The databases also hold 
studies from over 60 years ago.  This was not necessarily relevant to this search 
as most of the anticholinergics currently available have been developed in the 
last fifteen years with the exception of one (oxybutynin) which has been 
available for over 30 years, however, it ensured that no seminal studies were 
missed.  Keywords were used to search as MeSH terms and as free text.   
Boolean operators allowed searches to be combined and truncations 
(demonstrated by the ? and $ signs in the facet analysis) were used to ensure 
that the different variations of a word were also included in the search.   
 
The generic names of each of the available anticholinergics were used in the 
search.  Brand and trade names were not included as these differ around the 
world and may have led to important international papers being missed in the 
search.   
 
Inclusion and exclusion criteria were set before the start of the search and are 
listed in table 4.3.  These were set to limit the search to relevant studies that 
would help answer the research question and ensure that the data reviewed 
were of good quality.  As the question outlined is looking at the effectiveness of 
an intervention, the ideal method to assess this would be randomized controlled 
trials (RCTs) or a systematic review.  As the scoping search showed a lack of 
studies in this area, quasi-experiments and prospective cohort studies were also 
to be included to ensure sufficient data to review.  Qualitative studies were 
excluded as the subjective nature of these studies means that validated 
outcome measures are not generally used and therefore there is no 
standardised way to assess SF among the population.  Case reports and case 
series were also excluded as they are classed as level three evidence and do 




Table 4.3 Inclusion / Exclusion criteria 
 
Inclusion Criteria Exclusion Criteria 
 
Written in English 




Prospective cohort / observational 
studies / pre-post intervention 
studies 
Using validated outcome measures 
Accessible online via KCL 
 
Not written in English 
Unable to obtain full text 
Non validated outcome measures 




As the field of practice being reviewed is very specialised, searches were also 
performed on the ICS and IUGA database and ICI-RS website to find relevant 
abstracts that have been presented at international meetings, which may have 
led to publications.  To ensure that I also identified any relevant grey literature, 
abstract books and urology / urogynaecology / SF textbooks were hand 
searched and clinical trial databases were reviewed.  Once I had gathered all 
the relevant studies, I discussed the search with two Professor’s (Professor 
Cardozo and Professor Norton) who specialise in this field of practice to ask if 
they were aware of any other sources of information or current trials in progress 








Findings of the review 
 
The search spanned from 1966-2011 and a small number of studies was 
identified.  These included one systematic review, 18 RCT’s, 5 comparative 
studies, 4 clinical trials, 2 journal articles and a conference abstract.  Of these 
30 studies, 16 were excluded on title alone and a further 7 were excluded after 
reading the abstract.  For the 7 remaining studies the full text was read to 
assess their suitability for inclusion.  Based on this a further 5 studies were 
excluded.   The reasons for exclusions are listed in table 4.4. 
 
Figure 4.1 is a PRISMA flow diagram to demonstrate the findings of the review.  
 
Table 4.4 Studies excluded after reading full text. 
 
Study Reason for exclusion 
Rogers et al 2008 Contains the same cohort of patients 
as a study already included in review 
Serati et al 2008 Assesses sexual function as a 
reduction in episodes of orgasm 
incontinence and not by a validated 
questionnaire  
Khullar et al 2006 Reviews sexual function as part of 
health related quality of life and not as 
an individual outcome 
Bachmann et al 2007 Abstract only from international 
conference same cohort of patients 
as study already included 
Sand et al 2006 Study includes men and women and 
does not separate the results per 










Records identified through 
database searching 




























 Additional records identified 
through other sources 
(n = 1) 
Records after duplicates removed 
(n = 30) 
Records screened 
(n = 30) 
Records excluded 
(n = 23) 
Full-text articles 
assessed for eligibility 
(n =  7) 
Full-text articles 
excluded, with reasons 
(n =  5) 
Studies included in 
qualitative synthesis 
(n =2) 
Studies included in 
quantitative synthesis 
(meta-analysis) 
(n = 0) 
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Two of the studies read met the inclusion criteria and will be critiqued for this 
review.  The characteristics of these studies including the type of study, 
sample size, length of the study etc have been included in Table 4.5.  The 
levels of evidence have been graded according to the levels set for 
intervention studies in the SIGN guidelines (2001).   
 
 




Hajebrahimi et al 2008 Rogers et al 2009 
Study type Open label Prospective 
observational study 
12 week open label 
extension observational 
study 
Population Sexually active women 
with OAB 
Sexually active women 
with OAB 




Sample size 30  163 
Length of 
intervention 






Pelvic organ prolapse - 
urinary incontinence 
sexual questionnaire 
(PISQ) and Sexual quality 
of life female questionnaire 
(SQOL-F) 
Comparison Pre and Post treatment 
and at set time intervals 
during study 
Placebo and pre and post 
treatment at set time 




Funding Pfizer Inc Pfizer Inc 
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Description and Critical Appraisal of Included Studies 
 
The SIGN critical appraisal checklist for an article describing a cohort study 
was used to guide the critique of the studies included in this review.  The 
PRISMA checklist was also utilised.   
 
Paper 1 Hajebrahimi et al 2008 
 
In this study, the population included 30 women from Iran with a diagnosis of 
OAB aged between 20 to 32 years.  Women who were NSA or in unstable 
relationships were excluded from the study.  These women were not 
randomly selected from a defined population but were identified 
prospectively from a urogynaecology clinic, however it does not suggest how 
many women attending this clinic were unsuitable or declined participation. 
The intervention was tolterodine IR 2mg twice daily (bd) for a three month 
period.  There was no control group or placebo arm in this study and 
comparisons were made from pre-treatment status to post treatment and at 
monthly intervals during the study.  The outcome of this study was to 
evaluate the effect of tolterodine IR on the SF of women with OAB using the 
Arizona Sexual Experience Scale (ASEX) which had been validated for the 
Persian language.   The ASEX scale assesses SF under five domains: - 
desire, arousal, vaginal lubrication, orgasm and orgasm satisfaction.  
Analysis was performed for each of these topics at baseline and at monthly 
intervals until the completion of the trial.  Ethical approval was gained for this 
study and all patients provided written consent.   As this was an open label 
study no blinding took place however there is no evidence to suggest 
selection or performance bias as all participants were assigned the same 
dose of medication for the length of the trial and treated equally throughout. 
However, as this study is not placebo controlled it is not possible to assess 
the potential of the placebo effect. 
 
The paper reports that a McNemar test was performed to assess if the 
change in status of SF was statistically significant and this was 
predetermined at 0.05 point level.  The study states that two patients did not 
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return for follow up but final analysis was performed on 28 subjects.  
Demographic characteristics of the subjects were reported.   Rationale was 
provided for the choice of statistical methods used to analyse the data.  
Sexual dysfunction was defined by an ASEX score of 17 or above and this 
was set following a validation study.  
 
Although this study only had a small number of subjects the methods 
reported are easily reproducible.   
 
It could be considered that an RCT would have been a more robust 
methodology to evaluate the effect of tolterodine on the SF of this cohort.  
Firstly, this is because the process of randomization would ensure that the 
impact of all confounding variables are distributed equally within both groups. 
Secondly, it would allow the researchers to know the impact of the placebo 
effect that is observed when subjects enter a clinical trial and receive a 
package of care (even if they do not receive an active treatment) as a 
comparator.  Within pre and post intervention studies such as the one 
reported in paper 1 (and later in paper 2) there is no comparison group.  The 
difference that is measured is from the start to the end of the trial and 
therefore includes all the placebo effects within this.  An RCT allows you to 
understand the effect of an intervention over and above the placebo effect, 
thus providing far more clinically relevant information.  The challenge with 
this methodology, however, would be in the number of women that would 
need to be recruited as the population size would need to be considerably 
larger and this adds considerable expense and time to the study and it is 
likely that this would not be possible in a single center. 










Paper 2 Rogers et al 2009 
 
This study was a planned secondary analysis of data from a 12 week open 
label extension of a multi-center, double blind placebo controlled trial 
conducted in America.  The first paper published from this study detailing the 
results from the original RCT has been excluded in this review as the same 
cohort of patients are included in the analysis of this paper and the original 
publication focused on the OAB outcomes of the study and not the SF data.  
In the 12 weeks of this trial, SA women over the age of 18 diagnosed with 
OAB and UUI were recruited from 54 outpatient sites across America.  
Extensive inclusion/exclusive criteria were set to ensure the appropriate 
population of women was observed in the study.  Eligible women were 
randomised 1:1 in double blind fashion to placebo or tolterodine ER 4mg OD 
to be taken within four hours of bedtime for 12 weeks.  A fixed block size of 
four was used to generate the randomisation schedule.  This method and the 
double blinding ensured minimal selection bias.  The primary outcome of this 
study was to evaluate the efficacy of tolterodine ER in treating the OAB 
symptoms in women with OAB and UUI.  The secondary outcome was 
whether treatment of OAB symptoms was associated with improvements in 
sexual health.   As multiple outcomes were investigated in this trial many 
different questionnaires were completed to evaluate these but I have not 
included a review of them all as they are not applicable to my research 
question.   
 
SF was assessed using two validated questionnaires completed at baseline 
and at 12 weeks.  The pelvic organ prolapse / urinary incontinence sexual 
questionnaire (PISQ) was used to assess SF in SA heterosexual women in 
three domains – behavioral / emotive, physical and partner related and the 
sexual quality of life questionnaire – female (SQoL-F), which assesses 
sexual quality of life and is validated in women with and without FSD.  A 
power calculation was performed and recruitment was in line with this 
suggested sample size.  In total 436 subjects were screened and 413 who 
meet the inclusion / exclusion criteria were randomised into the two arms 
(211 in the placebo group and 202 in the active treatment arm).  There was 
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no evidence to suggest performance bias or that the two groups were treated 
differently throughout the course of the study.  Analysis was completed on a 
total of 330 patients (based on a power calculation to assess OAB 
symptoms), 167 and 163 respectively demonstrating a follow up and 
completion rate of 81%.  Reasons for withdrawal were included in the paper.  
Following this initial 12 week blinded period all patients then completed a 12 
week open label extension.  The primary aim of this part of the study was to 
assess if the improved outcomes that had occurred in the first 12 weeks of 
investigation persisted or improved with continued use to 24 weeks.  Only 
women who had received 24 weeks of tolterodine ER were included in this 
analysis.  Of the 163 women in this group, 161 completed the open label 
phase.  Descriptions and rationale for statistical methods were provided in 
the paper.  Ethical approval was gained from all participating centers and 
informed consent was obtained from all subjects.  
 
The first phase of this RCT appears to have very robust methodology starting 
with a predetermined sample size from the power calculation and then 
encompassing double blinding, and a placebo controlled arm to the study.  
These factors helped to minimise bias in the trial and allowed the 
investigators to assess the placebo effect. However, assessment of SF was 
a secondary outcome and not the primary endpoint for this study and it is 
unknown if the power calculation and number of subjects is adequate to 
robustly assess this.  By only assessing patients in the open label phase who 
had received 24 weeks of active treatment the investigators could observe 
continued or persistent improvements in symptoms over a longer time frame.  
If patients from the placebo arm who then initiated active treatment had been 
included it would not be possible to reliably assess the intended outcome of 











The two included studies have used different outcome measures to assess 
SF.  Although these are all validated scales it is difficult to combine the 
results of these studies in one table to assess the overall impact of 
anticholinergics on SF.  Therefore the results of each study have been 
recorded separately in table 4.6 for paper 1 and table 4.7 for paper 2 and no 
meta-analysis was performed. 
 
Table 4.6 reports the mean scores for each item in the ASEX scale from 
baseline and at each subsequent visit.  Table 4.7 reports the mean 
improvement in scores of each domain on the PISQ and on the SQoL-F.   
 
 







First follow up 
 
Second follow Up 
 






























































































































































This study showed statistically significant improvements in all domains of the 
ASEX scale over the three month study period with most p values <0.01.  
Confidence intervals (CIs) were not reported in this paper but they could be 
calculated from the data provided. As an example the Arousal domain 
demonstrated the least change in ASEX score.  At baseline patients reported 
a mean score of 4 (95% CIs 0.55 range 3.45-4.55) and this improved to a 
mean score of 2.21 at 12 weeks (95% CIs 0.4 range 1.81-2.61).  The 
calculated CIs are very narrow and the ranges do not overlap suggesting in 
the absence of known minimal important difference, a high probability that 
the majority of patients did experience an improvement in levels of arousal 
after 12 weeks of treatment.  Also at baseline 70% of subjects were classed 
as having sexual dysfunction compared to 16.3% after three months of 
treatment.  This could be considered a clinically significant improvement in 
SF.   
 
Table 4.7 Results from Rogers et al 2009  
 


























































































































            
 
























PISQ total scores range from 0 – 125: higher scores indicate better sexual function 





This study showed statistically significant improvements in all domains of the 
PISQ and SQoL-F from baseline to 12 weeks and baseline to 24 weeks.  
However, from 12 to 24 weeks there was no further significant improvement 
in scores with the exception of the Physical domain, but initial improvements 
were maintained.  Again this study did not include confidence intervals in the 
published data.  Although, I did not calculate these for all the data in this 
table I looked at the results for SQol-F at baseline where the mean was 69.8 
(95% CIs 3.65 range 66.15-73.45) to 24 weeks with a mean improvement of 
8.7 (95% CIs 3.14 range 5.56-11.84).   
 
In summary, both studies showed statistically significant improvements in SF 
as measured by their chosen questionnaire for patients on anticholinergic 




The first limitation of this review is that the search did not reveal a great 
variety of studies that met the quality criteria set.  , There were no RCT’s 
identified to answer the research question. It could be considered that this 
may because it would be deemed unethical to leave the primary health 
condition (OAB) untreated in order to investigate a potential effect of 
treatment, when the efficacy and safety in treating the primary health 
condition has already been established.  Potentially, the control group could 
be offered bladder retraining compared to bladder retraining and medication 
in the active arm, although the bladder retraining itself may have an effect on 
SF.   Alternatively, a crossover design could be employed to overcome this, 
however, it is possible that the subjects would be able to identify which 
treatment they are on due to side effects of the treatment eg dry mouth and 
this may lead to difficulty in recruitment and retention to the study as women 
may not want to continue in the trial if they are not receiving active treatment 
and their symptoms continue to be bothersome.  The lack of RCT’s could 
also be because the impact of anticholinergics on sexual function and 
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subjects overall sexual health is not taken seriously or considered to be 
important enough to warrant the time, expense and multi-center co-
ordination needed for such an investigation.   
 
As the only studies identified in this review are pre and post intervention 
studies with no comparison groups, the quality of the evidence to identify the 
impact of anticholinergics was found to be low.    
 
For a systematic review two independent assessors should be involved.  
This would help to rule out bias based on my preconceptions which may be 
wrong and my existing knowledge which may alter the inclusion / exclusion 
criteria to include other papers.  However, in order to reduce this area for 
potential bias I tried to ensure that my search plan was explicitly set out and 
reproducible with regards to the studies identified and the data extracted.  My 
facet analysis and search plan helped my search to be sensitive to identify 
the relevant information and specific to exclude irrelevant studies.  Also the 
inclusion / exclusion criteria were set before the search as were the appraisal 
methods for the review to ensure that quality issues and standards were 
considered and a recognised structure for the appraisal was employed, thus 
improving the validity of the review. 
 
This review explored studies using all the antimuscarinics currently available 
on the UK market.  It is acknowledged that there may be data missing from 
trials using drugs that are no longer available eg terodiline which was 
commonly used as a treatment of OAB for many years but was withdrawn 
from the market in 1991 due to cardiotoxicity.  
 
Qualitative data were excluded from this review, however, during the 
literature searching it was noted that a lot of research on SF uses qualitative 
outcomes.  This could mean that a lot of useful information was missed, 
however, as qualitative research may not be generalisable, comparisons 
could have been invalid.  In the future, a separate review of all the qualitative 




For the studies that were reviewed, the anticholinergic used in the treatment 
arms was the same drug but just different preparations.  Although, this would 
be a positive finding if my research question had been ‘Does tolterodine 
improve SF in women with OAB?’  It does not help me to reliably answer my 
question on anticholinergics as a class of drugs, as there is no evidence on 
any of the other anticholinergics available. Possible explanations for this 
could be publication bias if the results of other trials were equivocal or 
detrimental, and the impact on the pharmaceutical industry who would not 
want data released that shows that their product is not effective.  It is also a 
possibility that my research question is too broad and if I was to make it more 
specific I may have gained sufficient evidence to be able to make 
recommendations for best practice. 
 
The different outcome measures used in each study also made it difficult to 
appropriately compare the results between the trials and a meta-analysis 
was not possible.  Although SF was measured using validated 
questionnaires, each of these does have its own limitations.  For example the 
ASEX scale does not assess levels of distress caused by the urinary 
symptoms but the PISQ does.  Also the scales measure different domains of 
SF so these cannot be individually compared.  It was therefore only possible 
to compare overall improvement in scores in each individual study. 
 
Many of the studies initially identified used validated QoL questionnaires that 
had a single item score assessing SF as part of general QoL.  Although, 
inclusion of these studies may have garnered a lot more data, many of the 
publications do not provide the individual item scores but a total QoL score 
meaning that specific data regarding SF cannot be elicited.  Also, as the 
focus of this review was SF, it was considered that only SF specific 
outcomes should be included to ensure quality, rather than any QoL outcome 
that may mention SF.  However, given the lack of data using SF specific 
outcomes, it could be useful to assess the more generic measures to get an 




Excluding non-validated outcome measures resulted in many early studies 
being missed as it was not routine to use validated subjective outcome 
measures and researchers developed their own tools.  However, this would 





Following appraisal of the relevant studies I do not think that there is 
sufficient evidence to answer my research question.  Although, the two 
studies report statistically significant improvement in the SF of women with 
OAB with anticholinergics, I feel that there are too many limitations to the 
evidence and I do not feel that the data have great clinical significance.  
Therefore, I would suggest that the review uncovered the need for more data 
on the effectiveness of this intervention in clinical practice. 
 
Considering that this is an area that has a significant impact of women’s 
QoL, my final recommendation for this review is the need for high quality 
research in this area, focusing on SF as the primary outcome and adopting a 
standardised outcome measure so that improvements could be compared to 
others studies looking at different anticholinergics with similar designs.   
 
Update of the literature 
 
As the initial systematic review was performed at the start of this PhD 
pathway, I can no longer assume that it is valid.  Therefore a 2017 update to 
the review entailed the replication of the literature search performed in 2011 
using the same methods previously discussed.   
 
The search yielded a small volume of new studies published from 2011 - 
2017.  Most of these were review articles and excluded after reading the 
abstract.  One study was excluded after reading the full text (see table 4.8) 
and one further study was included in the review, the characteristics of which 
have been reported in table 4.9.    
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Reason for exclusion 
 
Chughtai et al 2016 
 
Study assesses the combined effect of 
antimuscarinics and topical oestrogens 
on sexual function  
 
 
Table 4.9 Characteristics of included studies – 2017 update. 
 
Author and date Jha  2016 
Study type Prospective observational questionnaire study 
Population Sexually active women with OAB 
Intervention Tolterodine, solifenacin, oxybutynin and Kentera patch 




Outcome measure Electronic Pelvic Assessment Questionnaire – Pelvic 
Floor (ePAQ-PF), Pelvic organ prolapse - urinary 
incontinence sexual questionnaire short form  (PISQ-12) 
and Patient Global Impression of Improvement (PGI-I) 
Comparison Pre and Post treatment and at set time intervals during 
study 
Level of evidence 2- 









Description and Critical Appraisal of Included Studies 
 
Paper 3 Jha 2016 
 
In this study, the population included 34 women from Sheffield with a 
symptomatic diagnosis of OAB.  The mean age was 40.9 years however, the 
range was not provided.  The majority were Caucasian (88%) and pre-
menopausal (80%).  Women were identified by the author by review of 
referral letters to secondary care and were asked to complete the ePAQ-PF 
as part of routine practice. 
 
The ePAQ-PF is an electronic Pelvic Floor Assessment Questionnaire that is 
an interactive, web-based HRQL Questionnaire.  It assesses four dimensions 
- urinary, bowel, vaginal and sexual symptoms and their related impact.  It 
has undergone extensive psychometric testing.  On completion, the four 
dimensions are further subdivided into 19 clinical domains, one of the urinary 
domains is OAB, and the sexual dimension provides three domain scores 
related to pelvic floor symptomatology that may impact SF including urinary, 
bowel and vaginal.  Each domain has an associated score ranging from 0 
(best health status) to 100 (worst health status).  Women who scored over 
33% bother on the OAB domain of the urinary dimension and the urinary 
domain of the sexual function dimension were invited to participate in the 
study.   All patients were treatment naive in relation to starting anticholinergic 
therapy.  Exclusion criteria were noted including the presence of POP and 
voiding dysfunction.  Ethical approval was obtained for this study but there is 
no mention on the method of consent by participants. 
 
The intervention was either tolterodine, solifenacin, oxybutynin or oxybutynin 
patches.  No information is provided as to whether the tolterodine and 
oxybutynin were the immediate release or modified release preparations and 
there is no breakdown to notify how many women received each different 
treatment or why the decision was made to use each treatment.  Although 
this is an open label study and no blinding took place, the women received 
different treatments and potentially different doses (as no information 
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regarding dose escalation is provided in the paper) there is the potential for 
selection and performance bias in the study.  There was no control group or 
placebo arm in this study and comparisons were made from pre-treatment 
status to post treatment and at three monthly intervals during the study.   
 
The PISQ-12 was used to assess SF in three domains – behavioral / 
emotive, physical and partner related.  In this study a 20% improvement in 
total PISQ-12 scores was considered clinically significant.  The PGI-I was 
used to establish treatment response.  It asks women to rate the outcome 
from ‘very much worse’ to ‘very much improved’ over a 7 point Likert scale.  
The outcome of this study was to establish whether an improvement in OAB 
symptoms by treatment with anticholinergics is associated with 
corresponding improvement in SF. 
 
A power calculation was performed based on a clinically significant change in 
PISQ-12 scores and recommended that 74 participants (allowing for a 20% 
drop out rate) would be required to take each different anticholinergic to 
prove the effectiveness of individual anticholinergics.  It was suggested that a 
large multicenter trial was necessary to recruit this number of women so this 
paper was classed as a pilot feasibility study.  
 
The statistical plan aimed to analyse and establish the impact of a 20 point 
improvement in OAB symptoms and correlate to changes in SF.  Rationale 
was provided for the choice of statistical methods used. Significance was set 
at a p value of <0.05.  Analysis was completed on 24 of the 34 women 
recruited, reasons for withdrawal were not included in the paper.  
 
There are a lot of details missing in the methodology to make this study 
reproducible and it seems to be more an assessment in real world practice 
rather than the controlled conditions of a clinical trial.  Although, 
understanding how women respond to treatment outside of a clinical trial 
setting can be hugely valuable, due to variations in practices it means that 






Paper 3 Jha 2016 
This study used different outcome measures from the two previous studies 
so cannot be combined and has been recorded separately in table 5.10. The 
only outcome provided was the mean PISQ-12 scores at baseline and at 3 
and 6 months post commencement of treatment (Table 4.10).  Meta-analysis 
is still not possible as the search is still unable to identify the minimum 
requirement of 2 relevant RCT’s to answer the research question.   
 






























This study showed no significant improvement in PISQ-12 scores pre and 
post treatment with a p value of 0.909 at 3 months and 0.458 at 6 months. A 
secondary analysis was performed following exclusion of the post-
menopausal women but this still did not reveal any statistically significant 
difference.  There was no association between any of the PISQ-12 domains 
to changes in OAB scores following treatment demonstrated.  16/24 (67%) 
women reported an improvement in OAB symptoms on anticholinergics but 
only 8% reported an improvement in SF.  Improvement in OAB symptoms 
were not associated with an improvement in SF.  Confidence intervals were 




In summary, this study did not find any statistically significant improvement in 
SF for women taking anticholinergics for OAB symptoms, in comparison to 




Having repeated this literature review six years later, there is still limited and 
insufficient evidence to answer the research question.  The outcomes of the 
additional paper conflict with the findings of the two previous studies.   
 
Potentially, this is because of the different anticholinergics used.  The first 
review may have shown a positive effect of a single anticholinergic 
medication, whereas the Jha paper considered the effect of anticholinergics 
as a class of drugs rather than the individual compounds. However, the Jha 
paper does appear to have an increased risk of bias compared to the two 
earlier papers due to the methodology so this may also have an impact on 
the outcomes.   
 
The previously noted limitations of the study remain unchanged in the update 
as I was still the only assessor of the evidence, and each paper used 
different outcomes making comparisons difficult.  However, the explicit 
criteria, search terms and methods originally set allowed for an easily 
reproducible updated review of the literature which has reiterated the lack of 
high quality evidence when assessing the impact of anticholinergics on the 
SF of women with OAB.   
 
This confirmation of the knowledge gap justifies the need for further research 
in this area and from a methodological consideration the investigation of a 
single compound appears to introduce less bias to a study.  These findings, 
in combination with the grant approval from Pfizer (and supply of study drug 
led to the development of the research question discussed in the next 
section of this thesis:-   








No Checklist item 
Reported 
on page No 
Title 
Title 1 Identify the report as a systematic review, meta-





2 Provide a structured summary including, as 
applicable, background, objectives, data sources, 
study eligibility criteria, participants, interventions, 
study appraisal and synthesis methods, results, 
limitations, conclusions and implications of key 






Rationale 3 Describe the rationale for the review in the context of 
what is already known 
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Objectives 4 Provide an explicit statement of questions being 
addressed with reference to participants, 






5 Indicate if a review protocol exists, if and where it can 
be accessed (such as web address), and, if 
available, provide registration information including 
registration number 
no 
Eligibility criteria 6 Specify study characteristics (such as PICOS, length 
of follow-up) and report characteristics (such as 
years considered, language, publication status) used 




7 Describe all information sources (such as databases 
with dates of coverage, contact with study authors to 
identify additional studies) in the search and date last 
searched 
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98Search 8 Present full electronic search strategy for at least one 





9 State the process for selecting studies (that is, 
screening, eligibility, included in systematic review, 




10 Describe method of data extraction from reports 
(such as piloted forms, independently, in duplicate) 
and any processes for obtaining and confirming data 
from investigators 
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Data items 11 List and define all variables for which data were 
sought (such as PICOS, funding sources) and any 
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12 Describe methods used for assessing risk of bias of 
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108 
Risk of bias 
across studies 
15 Specify any assessment of risk of bias that may 
affect the cumulative evidence (such as publication 




16 Describe methods of additional analyses (such as 
sensitivity or subgroup analyses, meta-regression), if 
done, indicating which were pre-specified 
n/a 
Results 
Study selection 17 Give numbers of studies screened, assessed for 
eligibility, and included in the review, with reasons for 




18 For each study, present characteristics for which 
data were extracted (such as study size, PICOS, 
follow-up period) and provide the citations 
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19 Present data on risk of bias of each study and, if 






20 For all outcomes considered (benefits or harms), 
present for each study (a) simple summary data for 
each intervention group and (b) effect estimates and 




21 Present results of each meta-analysis done, 
including confidence intervals and measures of 
consistency 
n/a 
Risk of bias 
across studies 
22 Present results of any assessment of risk of bias 




23 Give results of additional analyses, if done (such as 
sensitivity or subgroup analyses, meta-regression) 





24 Summarise the main findings including the strength 
of evidence for each main outcome; consider their 
relevance to key groups (such as health care 
providers, users, and policy makers) 
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incomplete retrieval of identified research, reporting 
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Funding 27 Describe sources of funding for the systematic 
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The literature review presented in Chapter 4, showed that there is a 
knowledge gap in our understanding of the impact of anticholinergics on SF 
and that this thesis would focus on developing a clinical trial to further 
investigate this area.  This chapter will focus on fesoterodine which was the 
anticholinergic selected for use in the clinical trial described in Chapters 6-
10.   Fesoterodine is the newest antimuscarinic agent available on the UK 
Pharmaceutical market.  It gained marketing approval in 2007 and was 
launched in 2008 and is available as sustained release tablets in flexible 
once daily dosing (4mg and 8mg).  It was developed and marketed by Pfizer 
Ltd until 2015 when Pierre Fabre took over the marketing. 
 
As discussed in Chapter 1, fesoterodine was selected for convenience as at 
the time there was opportunity for research grants where it was new to 
market and an IIR was awarded by Pfizer to fund this work and supply all 
study medication.   This chapter provides an overview of the 
pharmacodynamic and pharmacokinetic properties of fesoterodine and the 




Fesoterodine is isobutyric acid 2-((R)-3-diisopropylammonium-1-
phenylpropyl)-4-(hydroxymethyl) pheyl ester hydrogen fumarate.  The 
empirical formula is C30H41NO7.  The structural formula is shown in figure 5.1 
(Taken from Rantell et al 2014).  
 
Fesoterodine functions as an orally active prodrug that is rapidly hydrolysed 
to its active metabolite 5-hydroxymethyltolteroine (5-HMT) by non-specific 
esterases (Cole 2004).  The parent drug fesoterodine is not a potent 
antimuscarinic; its antimuscarinic activity results from the active metabolite 
(5-HMT) which is a balanced muscarinic receptor blocker without selectivity 





Figure 5.1 The chemical structure of fesoterodine. 
 
 
Fesoterodine is the sister drug of tolterodine which has been used for the 
treatment of OAB for over 20 years and was the market leader for the 
majority of this time.  Tolterodine is available as an immediate release (IR) 
preparation at a dose of 1mg and 2mg and as an extended release (ER) 
preparation at a single dose of 4mg.  Both fesoterodine and tolterodine share 
the same active metabolite but how the 5-HMT is generated differs between 




Tolterodine is converted to 5-HMT by the cytochrome P450 2D6 enzyme 
system (CYP 2D6) (Nilvebrant 1997).  Tolterodine has antimuscarinic activity 
similar to that of 5-HMT however fesoterodine is inactive and undetectable in 
plasma after oral dosing therefore functioning as a prodrug of 5-HMT (Simon 
and Malhotra 2009). 
  
Hydrolysis to its active metabolite bypasses the hepatic CYP pathway (Vella 
2011).  5-HMT then requires liver involvement for its biotransformation and 
elimination via the CYP 3A4 and CYP 2D6 isoenzymes (Cole 2004).  The 
pharmacokinetic properties of 5-HMT are independent of sex or age 




Studies have been performed assessing the effects of hepatic dysfunction 
and renal impairment on the pharmacokinetic (PK) profile of fesoterodine.  
De May et al (2010) conducted a prospective, open label, parallel group, 
single dose trial of the PK of 5-HMT and its metabolites after administration 
of fesoterodine 8mg to subjects with hepatic cirrhosis and matched healthy 
controls.  They reported that fesoterodine 8mg was well tolerated in patients 
with hepatic cirrhosis and based on these results the product label specifies 
that fesoterodine is safe in subjects with moderate hepatic impairment.  
Malhotra (2009b) performed an open label, parallel-group, single-dose trial 
with administration of fesoterodine 4mg in subjects with renal impairment 
compared to healthy subjects.  It was reported that fesoterodine 4mg was 
well tolerated in healthy subjects as well as subjects with mild, moderate or 
severe renal impairment. However, it is recommended based on their 
findings that only patients with mild or moderate renal impairment should be 
dose increased to fesoterodine 8mg if clinically necessary.  
 
Subsequent studies have evaluated the effect of fesoterodine in conjunction 
with warfarin and fluconazole.  Malhotra (2011a) reported that the 
pharmacokinetics and pharmacodynamics of warfarin 25mg in health adults 
are unaffected by fesoterodine 8mg and that co-administration of warfarin 
and fesoterodine is safe and well tolerated.  Malhotra et al (2011b) looked at 
whether dose adjustment is necessary when fesoterodine is administered 
with a moderate CYP3A4 inhibitor.  They used fluconazole to assess this and 
found that adjustment of fesoterodine dose is not warranted when co 
administered with a moderate CYP3A4 inhibitor. 
 
Flexible dosing and treatment schedules 
 
Staskin et al (2010) performed a post hoc analysis on data from two 
randomised, double blind, placebo controlled, 12-week Phase III trials in 
which 1674 subjects were treated with morning doses of fesoterodine 4mg, 
8mgs, or placebo.  Their objective was to evaluate the efficacy of 
fesoterodine versus placebo over selected intervals during a 24-hour period.  
They divided the day into three 8-hour time intervals, daytime (08.00-15.59), 
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evening (16.00-23.59) and night-time (00.00 – 07.59) and assessed changes 
in the number of micturition’s, urgency episodes, UUI episodes and mean 
volume voided (MVV).   The results showed that at the end of treatment the 
mean change from baseline for all efficacy endpoints were significantly 
greater with fesoterodine 4mg and 8mg compared to placebo during each 8-
hour time interval.  There was also a significantly greater improvement in the 
number of UUI episodes and number of micturitions with both fesoterodine 
doses versus placebo at each time interval.  They concluded that 
fesoterodine 4mg and 8mg given once daily demonstrated efficacy over 
placebo during all three time intervals supporting once daily dosing. 
 
Malhotra (2009c) investigated whether fesoterodine should be taken in the 
morning or in the evening and if there were any diurnal variations in the 
pharmacokinetics of fesoterodine.  This was achieved through a randomised, 
open label, two period, two treatment crossover, single-dose study, where 14 
healthy subjects received daytime and night-time oral dosing of fesoterodine 
8mg and blood samples for 5-HMT PK determination were collected at 
specified intervals before and after dosing.  They found that plasma 
concentration versus time profiles were equivalent for daytime and night-time 
supporting administration at either time. 
 
There have been many studies looking at the dosing of fesoterodine, when it 
should be taken and the importance of flexible dosing.  This is because 
individuals differ in their sensitivity to drug treatment due to a combination of 
pharmacodynamics and pharmacokinetic reasons (Michel & Staskin 2011).  
Dose titration is important for selection of the more effective dose of 
treatment which is associated with minimal side effects.  In a study by 
Cardozo et al (2012) looking at flexible dosing 59% of patients opted to dose 
escalate after four weeks of treatment with 93% of escalators stating that this 
decision was based on insufficient clinical response.    
 
In 2010, Wyndale et al reported a post hoc analysis of data from a 12-week, 
open label, flexible dose study to assess changes in OAB symptoms and 
patient reported outcomes and stratified their data according to whether the 
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patients opted for dose escalation.  They found that 50% of patients opted to 
dose escalate at week 4 of treatment and those patients who opted to dose 
escalate had significantly higher means for all bladder diary variables except 
UUI episodes.  The group of dose escalators also had significantly lower 
health related quality of life (HRQL) scores at baseline suggesting that they 
were significantly more bothered by their bladder symptoms than the non-
escalators.  At 12 weeks, both groups reported significant improvements in 
all outcomes and there were no significant differences between escalators 
and non-escalators.  However, the escalators had significantly greater 
improvements in urgency episodes and total HRQL scores.  They surmised 
that flexible dose fesoterodine significantly improved OAB symptoms and 
patient reported outcomes in subjects who stayed on the initial 4mg dose as 
well as the 50% who chose to dose escalate. They observed that those who 
chose to dose escalate reported more severe symptoms at baseline and that 
this group had fewer improvements than non-escalators before dose 
escalation.  It was suggested that these findings may help clinicians to 
identify patients who are more likely to require fesoterodine 8mg to achieve 
maximum relief of symptoms and facilitate dose escalation in these patients. 
 
Following on from the Wyndale study, Cardozo et al (2010a) investigated 
whether the severity of baseline UUI can predict dosing requirement.  This 
was a pooled analysis of data from two double blind, placebo controlled trials 
where patients were randomised to fesoterodine 4 or 8mg or placebo for 12 
weeks.  The subjects were stratified into tertiles (>0-<2, 2-<4, or >4) 
according to the number of UUI episodes per day reported at baseline and 
compared at the end of treatment.  It was reported that fesoterodine 4mg and 
8mg significantly reduced UUI episodes compared to placebo and that the 
effects appeared to be greater in the 8mg group.  It was suggested that 
clinical identification of patients could be used to assist in the decision as to 
who would benefit most from dose escalation. 
 
Cardozo et al (2010b) developed a predictive model for dose response 
relationships to describe the effects of fesoterodine in patients with OAB.     
They used data collected from double blind placebo controlled phase II and 
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III trials to develop longitudinal dose response models.   The models 
predicted that within 3-4 weeks after treatment initiation, clinically significant 
and near-maximum treatment effects would be seen.  They found that there 
was a consistent dose response for fesoterodine in bladder diary endpoints 
supporting the greater efficacy of fesoterodine 8mg.  It was suggested that 
this model could be used to predict outcomes for doses not studied and for 
under-represented patient sub groups in clinical trials. 
 
In 2014, Wyndale et al performed a systematic review of dose escalation 
data from flexible dose studies.  10 studies were reviewed and overall, 51-
63% of patients opted to dose escalate in clinical trials with efficacy cited as 
the main reason.  Escalators generally reported more severe symptoms and 
impact on QoL. They concluded that the true dose response effect 
demonstrated in the studies provides treatment benefit to patients with OAB 
and recommends dose escalation to 8mg in individuals who require 
additional efficacy benefit.   
 
Overall, all of these studies support once daily dosing of fesoterodine and 
resulted in the prescribing regulations suggesting that all patients start on 
4mg daily and this can be escalated to 8mg daily if necessary and tolerated 
after four weeks.  
 
Treatment response and UDS variables 
 
A study was performed by Nitti et al (2009) to determine whether the 
presence of DO in patients with OAB and UUI is a predictor of the response 
to fesoterodine.  They designed a phase 2 randomised, multicentre, placebo 
controlled trial with a one week placebo run in phase followed by an eight 
week double blind period.  210 patients were stratified into two balanced 
groups depending on the outcome of their baseline UDS assessment.  They 
found that there were no significant differences in treatment responses 
between patients with and without DO.  It was concluded that regardless of 
the presence of DO, patient’s response to fesoterodine was dose 
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proportionate ie increasing the dose led to greater symptom improvement 
and is independent of the UDS diagnosis.   
 
In contrast a smaller study (n=79) by Kim et al (2011), looking at predictors of 
response to fesoterodine in patients with OAB, showed that more patients 
who reported improvement post treatment were found to have DO on UDS 
pre-treatment.   
 
A study by Winkleman et al (2017), suggests that responses to treatment 
with fesoterodine are not related to UDS variables but related to increasing 
age, higher parity and marital status (being married).   
 
Efficacy, tolerability and safety of fesoterodine 
 
There have been several studies looking at the early onset of efficacy for 
patients taking fesoterodine.  Goldman et al (2010) assessed the efficacy of 
fesoterodine 4mg after one week of treatment.  This was a pre-specified 
analysis collected during the first week of a 12 week, open label, single arm, 
flexible dose study of fesoterodine involving 516 subjects.  These patients 
had all been previously treated with tolterodine or tolterodine ER and been 
dissatisfied with treatment.  They reported that there were significant 
improvements in all bladder diary variables at the earliest point of 
assessment after one week of treatment with fesoterodine 4mg and the diary 
dry rate was 38% (this relates to the number of patients who at baseline 
reported UUI episodes but did not at one week).  It was concluded that 
fesoterodine 4mg showed a rapid onset of efficacy at one week. 
 
Corcos et al (2011) performed a study to assess the onset of efficacy of 
fesoterodine 4mg versus placebo.  This analysis was from data collected 
during the first week of a 12 week double blind trial. Eligible subjects were 
randomised to fesoterodine 4mg, tolterodine ER 4mg or placebo.  Only 
patients who had received fesoterodine or placebo were included in this 
analysis which totalled 936 subjects.   They found that fesoterodine 4mg was 
associated with significantly greater improvements compared with placebo in 
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several endpoints including number of micturitions, UUI episodes and dry 
rates.  They also reported that these differences were significant as early as 
day 5 of treatment.  Their findings agreed with the Goldman study (2010) 
which states that patients receiving fesoterodine 4mg may expect to 
experience a response as early as one week after initiating treatment.  
Although this observed early effect may be due to the pharmacokinetics of 
fesoterodine and its ability to reach its therapeutic window rapidly, however, 
it could also be postulated that by asking patients to monitor their symptoms 
regularly and complete multiple bladder diaries there may be a cognitive 
effect (similar to the principles of bladder retraining) that may also lead to 
reductions in bladder diary variables.  It would have been useful in these 
studies to have some blood samples assessing PK values to confirm or 
refute the rapid onset of action.       
 
There have also been many studies looking at the efficacy and tolerability of 
fesoterodine.  In 2009, Sand et al performed a post hoc analysis of pooled 
data from two clinical trials which included 1,548 women with OAB who were 
randomised to placebo, fesoterodine 4mg or 8mg or tolterodine ER 4mg for 
12 weeks.   Three day bladder diaries and treatment response were rated at 
baseline, 2 weeks and 12 weeks.  They found that fesoterodine 8mg was 
significantly more efficacious than fesoterodine 4 mg, tolterodine 4mg and 
placebo in improving UUI episodes and continent days per week.   
 
A similar post hoc analysis of a phase III clinical trial had previously been 
undertaken by Chapple et al (2008) to compare improvement in OAB 
symptoms and HRQL in patients taking fesoterodine 8mg and tolterodine 
4mg.  Although both groups showed statistically significant improvements in 
bladder diary variables and treatment response rates, those on fesoterodine 
again had greater improvement in UUI episodes and number of continent 
days. 
 
Kraus et al (2010), looked at the efficacy and tolerability of fesoterodine in 
older and younger subjects with OAB.  This involved data from two 
randomised, 12 week studies of 1681 adults who were treated with 
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fesoterodine 4mg, 8mg or placebo and these data were stratified by age.  All 
patients completed 3 day bladder diaries at 3 points in the study, treatment 
response scales and a King’s Health Questionnaires (KHQ) which is a 
disease specific questionnaire for assessing men and women with LUTS.  It 
comprises nine domains, one of which is personal relationships.  They 
divided the patients into three groups, those under 65 years, the second 
group were 65-75 years and finally those over 75 years.  They found that in 
the under 65 year group, fesoterodine 4mg and 8mg was associated with 
statistically significant improvements at week 12 versus placebo in the 
bladder diary variables.  However, fesoterodine 8mg provided greater 
improvements in UUI episodes compared to 4mg.  For the middle group (65-
75 years), they experienced significant improvements in most diary variables 
with fesoterodine 4mg and 8mg versus placebo.  In the older group (>75 
years), fesoterodine 8mg significantly improve all diary variables except for 
mean voided volume versus placebo.  However, there were no statistically 
significant improvements between fesoterodine 4mg and placebo.  They also 
reported that the >75years group had more adverse events including dry 
mouth and constipation but this did not increase the discontinuation rate.  
They concluded that fesoterodine 4mg and 8mg was efficacious in patients 
aged <75years but only fesoterodine 8mg was effective in those over 
75years. 
 
A double blind, placebo controlled, Pan European trial assessing 
fesoterodine treatment in older people with OAB was performed by Wagg et 
al (2011).  All 794 subjects were over 65yrs with a mean age of 72yrs.  They 
found that fesoterodine was well tolerated in these elderly subjects and was 
associated with statistically and clinically significant improvements in urgency 
episodes, number of micturitions and patient reported outcomes.   
 
The long-term safety, tolerability and efficacy of fesoterodine was assessed 
by Scarpero et al (2011).  They performed a post hoc analysis of data pooled 
from two open label extensions of double blind studies. In these, all subjects 
began open label treatment with fesoterodine 8mg and had the option to 
voluntarily dose reduce to 4mg and re-escalation to 8mg permitted once 
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annually.  Maximum duration of treatment ranged from 24-36 months.  A total 
of 439 out of 890 subjects (83 men and 356 women) continued open label 
treatment for >24 months.  Statistically significant improvements in UUI 
episodes, number of micturitions and MVV between double blind baseline 
and open label baseline were sustained and further improved through to 
month 24.  They concluded that long term fesoterodine was well tolerated 
and associated with sustained improvements in OAB symptoms in men and 
women. 
 
In 2009, Wyndale et al investigated the efficacy and tolerability of flexible 
dose fesoterodine in patients who were dissatisfied with previous tolterodine 
treatment.  This was a 12 week, open label study which recruited 516 adults.  
Fifty percent of subjects opted to dose escalate at week 4 and endpoints 
were assessed using bladder diaries as well as the Patient Perception of 
Bladder Condition (PPBC), the Overactive Bladder Questionnaire (OAB-q) 
and a Treatment Satisfaction Questionnaire (TSQ).  They found that at the 
end of 12 weeks 80% were satisfied with treatment and there were 
significant improvements from baseline in the PPBC and in HRQL. 
 
The SAFINA (UK Study Assessing Flexible Dose Fesoterodine in Adults) 
was an open label, flexible dose study of patients in the UK to assess the 
efficacy, tolerability, safety and patient reported treatment satisfaction 
(Cardozo et al 2010c).  They found that 74% of subjects reported treatment 
satisfaction after 12 weeks of therapy with fesoterodine.  They also 
performed exploratory analyses to understand the impact of cessation of 
fesoterodine after 12 weeks of therapy, showing that for all bladder diary 
variables there was significant deterioration in symptoms four weeks later. 
 
Many trials have looked at the impact of fesoterodine on patient’s QoL.  
Kelleher et al (2008) pooled data from two randomised placebo controlled 
phase III trials and evaluated the effect of fesoterodine on HRQL in patients 
with OAB.  In these studies patients were randomised to placebo, 
fesoterodine 4mg, fesoterodine 8mg, or in one trial, tolterodine ER 4mg for a 
period of 12 weeks and patients completed the KHQ.  In total 1669 patients 
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completed these studies.  The fesoterodine 8mg group had statistically 
significant improvements over placebo in eight of the 9 KHQ domains 
including the personal relationship domain.  Fesoterodine 4mg and 
tolterodine showed statistically significant improvements over placebo in 
seven of the nine domains of the KHQ but this did not include personal 
relationships.  A further study by Kelleher et al (2012) evaluated sustained 
improvement in patient reported outcomes during long term fesoterodine 
treatment.  This was a pooled analysis of two open label extension studies of 
864 subjects.  It found that treatment with fesoterodine for up to 24 months 
resulted in sustained improvement in measures of HRQL and severity of 
bladder related problems.  They concluded that long term treatment with 
fesoterodine is beneficial to patients with OAB. 
  
The two biggest studies using fesoterodine are the FACT studies.  This 
stands for Fesoterodine Assessment and Comparison versus Tolterodine.  
FACT 1 (Herschorn et al 2010a) was the first head to head, placebo 
controlled trial with the primary objective of assessing superiority of 
fesoterodine 8mg over tolterodine ER 4mg.  Subject were randomised to one 
of three arms (fesoterodine 4mg for one week then 8mg for 11 weeks, 
tolterodine ER 4mg or placebo with a sham dose escalation after one week 
in the tolterodine and placebo arm).  FACT 2 (Kaplan et al 2011) was the 
largest placebo controlled head to head superiority study of antimuscarinics 
designed to make predefined comparisons for both diary based measures 
and patient reported outcomes.  1712 subjects were enrolled into FACT 1 
and 2417 subjects to FACT 2.  These studies showed that fesoterodine 8mg 
was superior in efficacy to tolterodine ER 4mg and placebo in reducing UUI 
episodes as well as other bladder diary variables and in improving patient 
reported outcome measures.   
 
The outcome measure used was the OAB-q.  This is a validated tool 
assessing symptom bother and HRQoL.  It is split into four domains.  One of 
these is based on social interaction and includes items on partners and 
spouses.  Improvements in OAB-q scores from baseline to week 12 were 
significantly greater in the fesoterodine group than the placebo group.  In a 
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post hoc statistical comparison, improvements from baseline to week 12 in 
the fesoterodine group were also significantly greater than in the tolterodine 
ER group. 
 
In 2010, Gupta et al, performed a review of the literature for the use of 
fesoterodine for OAB.  They reviewed a total of 20, phase II, III and IV trials 
and concluded that fesoterodine is an efficacious and well tolerated 
treatment option for patients with OAB.  This was updated in 2012 (Dell’Utri 
et al 2012) and added that the once daily flexible dosing regimen is an 
appealing factor in clinical decision making. 
 
Weiss et al (2013) looked specifically at the effect of fesoterodine on 
nocturnal urgency and found a significant reduction in nocturnal urgency 
episodes compared to placebo. 
 
One criticism with clinical trials is that often results and conditions involved 
do not correlate with routine clinical practice.  Kim et al (2016) performed a 
study using fesoterodine in over 3000 patients in clinical practice in Korea as 
a post marketing surveillance and confirmed that fesoterodine is a well-
tolerated and effective treatment for patients in routine practice with OAB. 
 
A recent review in primary care in Spain, reported that at twelve months, 
persistence with fesoterodine was greater than with two other common 
antimuscarinic agents (solifenacin and tolterodine) and resulted in the 
reduced need for concomitant medication (Sicras-Mainar et al 2016). 
 
Fesoterodine and special populations 
 
In 2012, Sand et al, published a pooled analysis of two open label extension 
studies to review the long term safety, tolerability and efficacy of fesoterodine 
stratified by age.  They reported that long term fesoterodine was well 
tolerated and irrespective of age provided sustained improvements in OAB 




There have been several studies specifically looking at the impact of 
fesoterodine in the older and frail populations.  The SOFIA study by Wagg et 
al (2013) was a 12 week, randomised, double blind placebo controlled study 
that assessed the efficacy and safety of flexible dose fesoterodine in elderly 
adults.  794 men and women took part in the study and 71% opted for dose 
escalation.  Fesoterodine was associated with significantly greater 
improvements in most bladder diary variables and PROMs and was 
generally well tolerated.   
 
DuBeau et al (2014) evaluated the efficacy and safety of fesoterodine in 562 
complex vulnerable elderly subjects with UUI in the community.  Participants 
within this trial had a high level of comorbidities, polypharmacy and functional 
impairment. However, fesoterodine was found to significantly improve UUI 
and QoL and most other diary variables.  There was no deterioration in the 
mean Mini Mental State Examination (MMSE) seen in this study and work by 
Kay et al (2012) also confirmed that fesoterodine at both doses had no 
statistically significant effect on any cognitive function assessed including 
memory.    
 
Following a systematic literature review and international consensus 
validation process on the appropriateness of oral drugs for long-term 
treatment of LUTS in older persons, Fesoterodine was the sole 
anticholinergic to be given a Grade B recommendation (all others graded C 
or D) however, it should be noted that this process was funded by Pfizer 
introducing a potential conflict to the recommendations (Oelke et al 2015). 
 
There have been studies looking at the effectiveness of fesoterodine in 
patients that have previously failed to receive therapeutic benefit from other 
anticholinergic medications. Garcia-Baquero et al (2013) reported that 
fesoterodine was an optimal treatment option when previous clinical 
response to anticholinergics had been sub-optimal or not tolerated.  
However, in a review article by Morris & Wagg (2014) it was suggested that 
there was limited evidence to confirm the efficacy of fesoterodine in patients 
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with well-defined suboptimal response to all anticholinergics, however it 
appears to have a role in patients with insufficient response to tolterodine. 
 
Chapple et al (2015) performed a systematic review of the clinical efficacy 
and safety of fesoterodine in the treatment of OAB in relation to patient 
profiles and confirmed that there is now extensive evidence to demonstrate 
the safety and efficacy of fesoterodine in relieving OAB symptoms in patients 
with various clinical and demographic profiles including the elderly and 
vulnerable patients. 
  
In 2017, Heesakers et al published a review of the evidence for fesoterodine 
in the management of complex OAB patients.  They described three complex 
groups of patients:   
 
1. Women who have specific risk factors and conditions 
 
2. Patients at risk of cognitive impairment who may have comorbidities, take 
multiple medications, or show Blood Brain Barrier deterioration  
 
3. Elderly patients who are frequently frail and vulnerable and should be 
treated with caution    
 
They reported that fesoterodine 4 mg and 8 mg have been studied 
extensively in these three patient groups, and has been shown to have 
pharmacological properties that confer clear clinical advantages.  The review 
concluded that fesoterodine is efficacious, irrespective of sex or age, is well 
tolerated in older and vulnerable patients, and does not cause impairment in 
cognitive function. 
 
Fesoterodine and Sexual Function 
 
In all the literature reviewed, there were no trials identified that considered 
SF as a primary outcome and no trials using fesoterodine that assessed 
women with a validated SF questionnaire pre and post treatment.  Many of 
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the phase 3 trials eg FACT 1 and 2, used QoL outcome measures that did 
not have SF or personal relationship domains so there are very few data.  
The SAFINA study did use the KHQ and overall in the study there was a 
change in the personal relationships domain of -16.1 points, suggesting an 
improvement in symptoms.  However, when this change is viewed in 
comparison to the other domains, this is the second lowest change post 
treatment with only general health perception ranking lower.   Therefore, 
further research into this aspect is needed.  
 
Adverse effects  
 
The most common side effects are related to the antimuscarinic properties of 
fesoterodine and are dry mouth, dry eyes, constipation and dyspepsia. The 
commonest side effect occurring was a dry mouth. This is representative of 
all antimuscarinics. It was however generally perceived to be mild to 
moderate in severity and discontinuation due to it is 1% or less in clinical 
trials (Pfizer 2011).  Weissbart et al (2016) found that in women with OAB 
who were taking fesoterodine, although dry mouth prevented them from 
restricting their fluid intake, it did not diminish the treatment efficacy.  Clinical 
experience has shown that side effects seem to decrease with time, possibly 
because of the natural course of the disease, and because the patients 
adapt their treatment accordingly (Heesakers et al 2017). 
 
Studies by Chapple et al (2007) and Nitti et al (2007) showed that there was 
no difference in vital signs such as heart rate and blood pressure 
measurements when taking fesoterodine. There were also no significant 
changes in the QT interval on the electrocardiogram. Table 12 shows pooled 
data from two phase III randomised controlled trials (RCTs) detailing the 
most common adverse events i.e. those occurring > 2% of subjects. Other 







Table 5.1 Common adverse events  
 












Any adverse event 107 (38) 144(50) 135(50) 167(58) 
Dry mouth 20 (7.1) 49(16.9) 59(21.7) 97(33.8) 
Constipation 4(1.4) 8(2.8) 9(3.3) 13(4.5) 
Headache 14(4.9) 14(4.8) 12(4.4) 7(2.4) 
Dry eye 0 1(<1) 6(2.2) 12(4.2) 
Dizziness 7(2.5) 4(1.4) 4(1.5) 3(1.0) 
Other adverse 
events 
16(15.7) 31(10.7) 22(8.1) 26(9.1) 
 
 
A study to evaluate the short and long term effects of fesoterodine on the eye 
reported that it increased the pupil diameter and decreased the 
accommodation amplitudes of the eye, but did not significantly affect the 
intraocular pressure.  These changes were not deemed to be clinically 
important and no patients developed visual disturbances in the study (Acar et 
al 2016).  
 




In the UK, fesoterodine is recommended as a second line pharmacological 
therapy for OAB and has similar monthly prescription costs to other branded 
options at the lower dose.  However, as the monthly price is the same 
regardless of dose, for patients on the higher dose it is cheaper per month 




In Spain, two assessments of the cost effectiveness of fesoterodine have 
been performed.  One assessing flexible dosing and the use of fesoterodine 
as a first line therapy for newly diagnosed OAB in clinical practice (Peral et al 
2016) and one comparing the use and health economics of fesoterodine 
versus tolterodine or solifenacin as a first line therapy in primary care 
(Sicras-Minar 2013).   When compared to other anticholinergics, fesoterodine 
was found to be a cost-saving therapy for the treatment of OAB.  When 
considering dosing regimens, for women who had had their symptoms for 
less than one year, fast escalation straight to the 8mg dose at the time of 
review was found to be more cost effective than the traditional 




Fesoterodine has been shown to be an effective drug in the treatment of 
OAB in women based on a number of good quality studies discussed within 
this chapter.  Throughout the range of studies that have been performed, it 
appears to be well tolerated, cost effective and it is versatile and can be used 
in many different clinical populations.  However, as with all antimuscarinic 
medications, there are still problems with long term persistence.      
 
There is a lack of knowledge regarding its impact on SF as this has only 
been observed as a secondary outcome and not with a validated sexual 
function measure and there is not adequate evidence to answer the research 




































Following on from the review of the literature, securing a research grant and 
the development of a research question as described in the previous 
chapters, the next stage of this thesis was to plan the methodology for a 
clinical trial to try to answer the question –  
 
‘Does fesoterodine have any effect on the sexual function of women with 
OAB?’  
 
Based on this question the null Hypothesis was as follows: 
 
‘Fesoterodine has no effect on sexual function in women complaining of 
overactive bladder syndrome’. 
 
This chapter aims to discuss the process of the development of the clinical 
trial of investigational medicinal product (CTIMP) that was performed, 
providing the rationale for the primary and secondary endpoints chosen,  
justifying the tools used for data collection, sampling methods and the 
methodological and ethical issues that were considered during the planning 
stages.  The final protocol adopted will be included in the appendices.   
 
Initial trial decisions 
 
When trying to answer a research question, it is important to adopt an 
appropriate, robust research methodology to ensure high quality, reliable and 
valid data are produced.  RCT’s are considered the gold standard for trial 
design, however, for this study there were several factors that made this 
design neither feasible nor justifiable.  As part of the IIR grant awarded for 
this study, it was agreed that Pfizer would provide the fesoterodine 
medication for all women in the trial, however they were unable to provide a 
placebo version.  Further enquiries at the clinical trials pharmacy revealed 
that if we were to consider a placebo arm it would have a significant cost 
implication for which the study budget would have been inadequate and also 
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there would be a time implication to develop a placebo tablet that would 
negatively impact upon proposed time lines.  Secondly, it would considerably 
increase the number of women that needed to be recruited into the study 
making it unfeasible for a single centre setting within the proposed time lines.  
Finally, as fesoterodine was already a licensed treatment for OAB and its 
efficacy and tolerability had already been extensively evaluated, it was 
considered that it could be deemed unethical to withhold treatment from 
women when it could be provided as routine care.   A randomised cross over 
study design was also considered so that comparisons between groups 
could still be made, yet the same issues as identified in the RCT meant that 
this was not feasible.   
 
This combination of methodological, ethical and practical concerns led to the 
decision for this to be an open label, prospective cohort study where the 
women taking part would act as their own controls and comparisons would 
be made by assessing the change in outcomes from baseline, till the end of 
the trial (ie a before and after intervention study).  However, it did mean that 
the study would not be able to assess the potential of a placebo effect 
compromising the internal validity of the study and meaning that we cannot 
be sure that any observed changes can be attributed to the intervention (in 
this case fesoterodine), and not to other possible causes.  
 
In an ideal study, not only would there be a comparison group but both 
groups would be blinded to their treatment allocation.  In this study, blinding 
does not take place as all patients will receive active treatment and their 
decision to dose escalate based on treatment efficacy and tolerability will be 
sought.  It has been identified that subjective estimates of intervention effects 
are exaggerated by 7% in non-blinded studies compared with blinded studies 
(Wood et al 2008).  This may be part of the placebo effect, or the subjects 
desire to’ please their clinician’ with good outcomes.  In order to potentially 
detect if the results are exaggerated in this study, a combination of subjective 
and objective outcome measures will be utilised as discussed later under the 
primary and secondary outcomes and physiological measures of bladder 
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function will also be undertaken and compared to the patient’s clinical 
symptoms.  
 
According to Ho et al (2018), before and after intervention studies are 
susceptible to selection / assignment bias, and instrument / measurement 
bias.  Whilst Setia (2016) reported that cohort studies are useful for 
investigating multiple outcomes, there are some limitations that need to be 
considered during the design stage as they can introduce bias due to loss to 
follow up, confounding factors, measurement errors in the tools selected, 
classification issues and the possibility that participation in the trial may alter 
the subject’s behaviour.  It is therefore essential that outcomes need to be 
well defined and measured similarly in all subjects and this will be dependent 
on the measures chosen and when they are completed.  The outcome 
measures should include both objective and subjective measures and should 
be of a high quality and validated in the population under investigation to 
reduce measurement error.  All patients should complete the same 
assessments at each time point in the study and all subject to rigorous 
assessment to ensure that they do fit the classification and the patient group 
under investigation. These issues were all considered within the discussions 
later in this chapter regarding timelines, outcome measures / endpoints and 
inclusion / exclusion criteria. 
 
Setting the Primary Objective 
 
In order to answer a question, research objectives must be set.  Objectives 
are specific targets set in order to achieve the research aim.  Endpoints 
divide research objectives into several parts and address each part 
separately.   Based on the literature reported in previous chapters and the 
identification of a knowledge gap, it was decided that SF would be the main 
focus of this trial and it was set as the primary outcome. According to the 
clinical trials reported in Chapters 2-5, SF has previously only been 
investigated as a secondary outcome and to our knowledge this is the first 
trial to do so as a primary outcome.  This would ensure that it was 
appropriately powered to answer the research question, as previous trials in 
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this area had either been powered according to their primary outcome, which 
was generally impact on OAB symptoms, or had not included a power 
calculation.  This was important as an underpowered study may not be able 
to detect a difference between the groups and the study may turn out to be 
falsely negative leading to a type II error.  This could account for the 
differences it outcomes in the trials discussed in Chapter 4.   
 
Timeframe for the intervention 
 
For many of the OAB studies discussed in Chapter 3 and the fesoterodine 
efficacy studies reported in Chapter 5, assessments were performed at 
baseline and again after 12 weeks.  At this time point it is reported that 
improvement in symptoms / effects of medications have been noticed and 
compliance with treatment is 69-96% as reported in a systematic review by 
Sexton et al (2011).  Any longer and the compliance rate significantly 
reduces (up to 72% dropout rate reported by Sexton et al 2011) and this 
increases bias to the study due to subjects dropping out or not attending 
follow up resulting in incomplete data sets.  There were no guidelines or 
recommendations suggesting optimal timelines for studies of SF so in line 
with the previous OAB studies and compliance date, the timeline was set to 
measure outcomes at baseline and 12 weeks.  The primary objective set 
was:-  
 
‘To assess the impact of flexible dose fesoterodine on SF in women with 
OAB after 12 weeks compared to baseline’ 
 
Primary Outcome tools selected 
 
As reported in Chapters 2 and 3, there are two main types of tool available to 
assess SF.  The first is a generic measure of SF and the second is a 
condition specific assessment of SF. It was considered that the strengths of 
a condition specific tool would be that it is more sensitive in the population 
under investigation.  However, it was also considered that problems with SF 
may not only be related to a woman’s bladder condition and that a generic 
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measure may also be useful to identify general SF concerns that were not 
necessarily related to bladder symptoms.  At the time of study set up, none 
of the available tools had been validated in women with OAB therefore it was 
decided by the team to include two tools to measure the primary outcome, 
one generic and one condition specific.   
 
An appraisal of available questionnaires was performed as part of the 
literature review (See Chapter 2 and 3) and the final choices for all the 
questionnaires used in this study were based on a set of criteria pre-
determined by the team. These criteria were:   the quality and length of the 
tool, clinical experience with its use, its accessibility and ease of scoring 
system.   
 
Quality of the tool 
 
At the time of developing the study, the 4th ICI Incontinence textbook 
(Abrams et al 2009) was consulted to determine the recommendations for 
questionnaires (based on assessments of reliability and validity described in 
chapter 2, p51).  At the time of protocol development, there were no generic 
SF measures validated in women with OAB that had a grade A rating (as 
described in chapter 2).  There were four measures that had a grade B 
rating, these were the female sexual function index (FSFI), the Derogatis 
sexual functioning inventory (DSFI), the Sexual Quality of Life – Female 
Questionnaire (SQoL-F) and the Brief Index of Sexual Functioning in Women 
(BISF-W).  The questionnaire descriptions and rationale for rejection have 











Table 6.1 Questionnaire descriptions and rationale for rejection 
Questionnaire 
(ICI rating) 









A self reported version of semi 
structured interviews designed 
to provide a multidimensional 
assessment of sexual function 
in men and women 
 
Validated in community 
samples of men and 
women – no validation in 
women with FSD so may 
not be valid in this study 
population 
 








questionnaire designed to 
assess current levels of female 
sexual functioning and 
satisfaction 
 
Only validated in women 
seeking routine 
gynaecological care but 
not those with urinary 
symptoms so may not be 








questionnaire assessing key 
dimensions of sexual function 
in women 
 
Would have been 
acceptable for use   
 
Sexual Quality of 
Life Questionnaire 





questionnaire to assess the 
impact of FSD on a women’s 
sexual quality of life and to 






The FSFI had been validated in a population of women with OAB and had an 
acceptable quality rating so may have been a suitable tool.   The SQOL-F 
was developed and validated by Symonds et al (2007) to assess the impact 
of FSD on a woman’s sexual quality of life.  It consists of a set of 18 
statements, each asking about thoughts and feelings that subjects may have 
about their sex life. The statements may be positive or negative.  Subjects 
respond on a 6-point Likert scales ranging from completely agree to 
completely disagree.  A higher score represents a better quality of life.  The 
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development of this questionnaire was sponsored by Pfizer and the inclusion 
of this tool as one of the primary outcome measures was specifically 
requested by Pfizer when approving the grant.  As it was one of the tools 
with a grade B rating from the ICI and the Rogers study (2008) discussed in 
chapter 5 had used this to assess outcomes, it allowed their data to be used 
to determine the power calculation for the study and it was included as a 
measure of the primary outcome instead of the FSFI.   
 
For the condition specific questionnaire, there were three measures that had 
a grade A rating at that time.  The first was the GRISS, the second was the 
PISQ and the third was the International Consultation on Incontinence 
Questionnaire – female lower urinary tract symptoms – sex (ICIQ-FLUTS-





























Description Rationale for 
rejection / selection 
 
Golombuck Rust 





A self administered 
questionnaire to evaluate 
both the quality of a 
heterosexual relationship and 
each partner’s level of sexual 
functioning within that 
relationship 
 
Assess’ both the 
partners sexual 
functioning in a 
relationship and this 
trial is only considering 














questionnaire to assess 
sexual matters associated 
with urinary symptoms and 
related bother 
 
Good Quality but lack 
of experience and 
potential delay to 










To assess sexual function 
after surgery in women with 
pelvic floor dysfunction 
 
Short form version 
proven to reduce 
burden on patients 
whist maintaining 
reliability and validity 
 
Pelvic Organ 

















The ICIQ-FLUTS-sex was developed to assess sexual matters associated 
with urinary symptoms and related bother.  It consist of four items - 
pain/discomfort because of dry vagina, impact of urinary symptoms, pain with 
sexual intercourse and urine leakage with sexual intercourse.  The PISQ was 
developed to assess SF in women with pelvic floor dysfunction before and 
after surgery.  It is a 31 item questionnaire that is validated in women with 
both UI and POP.  In 2007, Barber developed a short form of the 
questionnaire known as the PISQ-12.  It is a self-administered questionnaire 
consisting of 12 items. The short form has been proven to demonstrate 
excellent correlation with the full version but reduces time and burden on the 
patients who are completing the questionnaire (Rogers et al 2003).  A lower 
score represents better SF.   
 
Clinical experience, accessibility and scoring systems 
 
At the time of study development, it was not routine practice to use a tool 
assessing SF as part of a standard patient assessment.  SF measures had 
only ever been used in other research studies and were always secondary 
outcomes.   
 
The research team had prior experience using the PISQ-12 so it was readily 
available, and there was knowledge and experience of the scoring systems.  
There was no experience with the use of the ICIQ-FLUTS-sex and there 
would be a time delay to apply for the tool and scoring system.  As both had 
a Grade A rating and neither had been specifically validated in women with 
OAB (only women with LUTS), it was decided to use the tool that was 
already accessible and the PISQ-12 was selected as the second 
measurement of the primary endpoint.  
 
In summary, the final decision made was to include the SQoL-F as a generic 
and the the PISQ-12 as a condition specific measure of SF.  The primary 




Change in item scores of the Pelvic Organ Prolapse and Urinary 
Incontinence Sexual Questionnaire – short form (PISQ-12) and the Sexual 
Quality of Life- Female questionnaire (SQOL-F) at week 12 relative to 
baseline 
 
Selecting the Secondary Objectives 
 
Chapter 3, presented the existing evidence that women with OAB have a 
poorer SF and it is presumed that this is due to the impact of their symptoms.  
Although the focus of this study was to assess the impact of fesoterodine on 
women’s SF, it was hypothesised that treatment with fesoterodine should 
improve / reduce their OAB symptoms and this in turn will improve their SF.  
If SF outcomes were to change without any change in OAB symptoms then 
further investigation into the mechanisms for poor SF in women with OAB 
would have to be considered.  It could also be hypothesised that the known 
adverse effects of fesoterodine in women such as constipation, dry mouth / 
eyes, somnolence could potentially negatively impact on SF.  Therefore, 
discussions regarding the secondary outcomes focused on criteria that would 
not only determine the impact of treatment on OAB symptoms but also on 
the adverse effects that would potentially negatively affect the primary 
outcome.  The secondary objectives therefore included bladder diary 
variables (to assess change in OAB symptoms), quality of life assessment 
(to assess the impact of medication and their general health on symptoms), 
adverse event reporting (to assess tolerability of the medication), 
assessment of bowel function (to determine the impact of one of the most 
common side effects of treatment that may impact upon the outcome) and 
pre and post UDS (to help with classification of patients and assess 
treatment response).    
 
These secondary objectives can be summarised as assessing the effect of 




 micturition frequency per 24 hours, nocturnal micturition’s per 24 hours, 
urinary urgency incontinence episodes per 24 hours and urgency episodes 
per 24 hours after 12 weeks compared to baseline 
 treatment satisfaction and HRQL measures at 12 weeks compared to 
baseline 
 tolerability and compliance with therapy  
 on bowel function 
 on UDS variables 
 
 
Selecting the secondary outcome measures and endpoints 
 
The secondary objectives above have been selected to assist in answering 
the research question as well as minimising sources of measurement bias 
and reduce confounding variables.  An example of a confounding variable 
could be a change in volume of fluid intake over the course of the study.  
Although the subjects will not be actively attending bladder retraining during 
the course of the study, attendance in the department will expose them to 
information and leaflets on display providing advice on good bladder health.  
If the subjects take this on board and reduce their fluid intake this may 
account for changes in bladder diary variables rather than the effect of drug 
and can be assessed with the completion of pre and post intervention 
bladder diaries.  To answer the research question in this study, a 
combination of objective (bladder diaries) and subjective tools (QoL 
assessment, goal achievement, bowel symptoms) are required along with 
physiological measurements of bladder function (subtracted cystometry).   









Bladder diaries are commonly used, recommended tools in the investigation 
and management of patients with LUTS (Lucas et al 2012).  They can be 
completed as part of the initial assessment of women with LUTS and 
throughout routine care to assess the impact of treatment on their symptoms.  
They may also be used to aid in the diagnosis of certain conditions.  At the 
time of study design, the diagnosis of urinary frequency and nocturia were 
set in relation to an abnormal number of voids as demonstrated on a bladder 
diary (ie more than 8 voids per 24 hours or more than 1 void at night as 
defined by Abrams et al 2002) therefore, bladder diary variables were not 
only used to assess and monitor but also to classify and confirm a diagnosis 
as part of the inclusion criteria.   
 
It was decided that each subject would complete a bladder diary for 3 
consecutive days immediately preceding each study visit to record details 
including the time and volume of every void, time and volume of fluid intake, 
the time the subject arose and went to bed and urgency was assessed using 
a validated scale.  A three-day diary has been demonstrated to provide 
better accuracy and increased patient compliance and convenience 
compared to 5 or 7 day diaries (Dmochowshi et al 2005). This meant that the 
common symptoms of OAB (eg urgency, urgency urinary incontinence, 
frequency, and nocturia) could be objectively assessed and monitored as a 
secondary endpoint as well as forming part of the screening criteria and 
inclusion requirements. 
 
The Patient Perception of Intensity of Urgency score (PPIUS) is a single item 
tool used to assess patient perception of urgency intensity in women with 
UUI. It is a valid and reliable tool in the assessment of urgency in women 
with and without urgency incontinence (Cartwright et al 2011). The subject 
rates their feeling of urgency associated with each micturition episode using 




The diary utilised in this study was the one that is currently used as part of 
routine care.  It has been developed over many years and the subjects all 
had experience in completing the diary.  A copy of the diary can be found in 
the appendices.  At the time of setting the trial up, there was no validated 
bladder diary in existence as it was not until 2014 that the ICIQ bladder diary 
was developed and validated as a robust measure (Bright et al 2014). 
 
Summary of Bladder Diary endpoints selected 
 
 Change in mean number of micturitions per 24 hours at week 12 relative 
to baseline 
 Change in mean number of nocturnal micturitions per 24 hours at week 
12 relative to baseline in subjects with >0 episodes during the 3-day 
baseline diary period. (Nocturnal micturitions were defined as those 
occurring between the time the subject goes to bed with the intention of 
sleeping and the time she rises to start the next day) 
 Percentage change in UUI episodes per 24 hours at week 12 relative to 
baseline in subjects with >0 UUI episodes during the 3-day baseline diary 
period 
 Change in mean number of urgency episodes per 24 hours at week 12 
relative to baseline. (Urgency episodes were defined as those with a 
Patient Perception of Intensity of Urgency Score (PPIUS) rating of ≥ 2 in 
the diary 
 Percentage change in urgency episodes per 24 hours at week 12 relative 
to baseline 
 
Measurement of quality of life 
 
Patient’s symptoms and improvement following treatment provide subjective 
assessment whereas investigations provide an objective measure.  However, 
neither of these represent the patient’s perception of her condition nor its 
impact on her quality of life.  Thus it is important to have meaningful 
measurements to evaluate what patients want and how well this can be 
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achieved following appropriate intervention.   For the last 30 years there has 
been an increasing interest in health related QoL and patient reported 
outcomes.  It is essential to use appropriate tools depending upon what is to 
be measured.   
 
At the time of protocol development, the department was involved in 
recruiting patients for the SAFINA trial (Cardozo 2010), investigating flexible 
dose fesoterodine in men and women with OAB.  To measure the outcomes 
under investigation in this study, the Patient Perception of Bladder Condition 
(PPBC) and the King’s Health Questionnaire (KHQ) were used.   
 
The PPBC is a self-administered, single item, validated questionnaire that is 
used to assess patient’s subjective impression of their current urinary 
problems.  It was originally developed by Coyne and Matze (2002) as a 
global assessment of bladder condition and is a recommended measure by 
the European Medicine Evaluation Association and has an A grading from 
the ICI.   
 
The KHQ (also known as the ICIQ-LUTSquol) was developed by Kelleher et 
al (1997) and provides a HRQL assessment for those with urinary symptoms 
and measures associated bother.  It is a self-administered disease specific 
questionnaire containing 21 questions that are scored in nine domains 
(general health perception, incontinence impact, role limitations, physical 
limitations, social limitations, personal relationships, emotions, sleep/energy, 
and severity of urinary symptoms).  It is one of the most extensively validated 
and reliable questionnaires and has an A+ grading from the ICI. 
 
As the study team had experience using these measures, they were readily 
available and they had been validated demonstrating robust measures in the 
patient population under investigation it was decided to include these as 
measures of the secondary outcome 
 
Originally, when I was registered with the School of Nursing it was felt that 
the outcomes were too quantitative and that a mixed methods approach 
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would allow for further insights to be gained.  It was requested by the 
academic supervisors at that time, that a mixed methods questionnaire 
should be added with the aim of investigating patient’s goals from treatment.  
It was considered that this approach would allow for the subjects to consider 
their own personal goals from treatment and determine what is most 
important to them.  This would enable us to gain further insights into the 
ways in which symptoms may impact on an individual’s quality of life and 
how as clinicians we can individualise treatment for women.  Although, the 
addition of a further questionnaire could potentially add burden to the 
subjects, it was deemed that the advantages of including this additional 
dimension to the study outweighed the disadvantages and that this would be 
a positive inclusion.   
  
The SAFINA study had been the first trial in the UK to include the Self 
Assessment Goal Achievement Questionnaire (SAGA) as one of the 
outcomes.  The SAGA questionnaire is a patient completed, physician 
reviewed tool to assess treatment goals and achievement of goals for 
subjects suffering from OAB and/or other LUTS (Brubaker et al 2011).  It is 
comprised of two parts, the first questionnaire rates the importance to the 
subject of her treatment goals.  It contains 9 fixed goals and a further 5 open 
ended goals.  The follow up questionnaire asks the subject to rate the degree 
of achievement of the subjects goals set at the beginning of the treatment.  
There is also a one item measure relating to subjects rating the extent to 
which they have achieved all their goals set.  It was designed in 2008 by 
Kopp et al and further validated by Khullar et al (2010) so it was not available 
when the ICI book was published in 2009. It currently has a grade B 
recommendation (Abrams et al 2017).   
 
As part of the SAFINA study, the researcher was given the opportunity to 
lead on the qualitative analysis of the SAGA questionnaire and published the 
findings in 2016.  This then allowed for the results of the population in this 
study to be compared to those from all over the UK to look for similarities and 
variations in patients goals within the two cohorts.  This work is presented in 




The final endpoints assessing QoL and patient satisfaction / goal 
achievement were:- 
 
Patient Perception of Bladder Condition (PPBC) 
 
 Change in PPBC at week 12 relative to baseline 
 
King’s Health Questionnaire (KHQ) 
 
 Change in total score of each domain at week 12 relative to baseline 
 
Self Assessment Goal Achievement Questionnaire (SAGA) 
 
 Achievement of patient orientated goals at 12 weeks relative to baseline.  
 
Adverse events / treatment tolerability  
 
It was decided that subjective assessment of adverse events through self-
reporting at each visit would be the simplest way to assess side effects and 
the tolerability of the treatment.  However, it would not adequately address 
the two main concerns related to the potential detrimental effects of 
medication on SF (ie the ‘drying effect’ as discussed in Chapter 3, and the 
impact of constipation).  The primary outcomes do assess arousal and pain 
during sex which can potentially be used to investigate a drying effect if this 
is noted by women.  However, it was decided to include a tool that could 
assess changes in bowel habit whilst on medication and the impact that this 
could have on QoL.   
 
Assessment of bowel symptoms 
 
One of the most common adverse effects associated with antimuscarininc 
treatment is that of constipation.  This is not only uncomfortable for the 
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patient but can also cause a worsening of OAB symptoms.  A tool to 
measure constipation and its impact on patients would allow for this adverse 
event to be evaluated. However, it was also acknowledged that many 
individuals report side effects from medications, but it is only when these 
worsen presenting symptoms or significantly impact upon patient’s QoL that 
medication is discontinued.  Therefore, we needed a tool that could assess 
changes in constipation over time and the impact that constipation may have 
on the individuals QoL.  In order to identify the most suitable tool expert 
opinion was sought (Professor Christine Norton).  The Patient Assessment of 
Constipation Quality of Life (PAC-QoL) questionnaire was recommended.  
The PAC-QOL was developed by Marquis et al (2005) to address the need 
for a standardised, patient-reported outcome measure to evaluate 
constipation over time.  It is a self-administered questionnaire containing 28 
items group into 4 subscales covering worries and concerns, physical 
discomfort, psychosocial discomfort and satisfaction.  Responses are 
measured on a five point Likert scale.   
 
Within the final design, there are a total of 6 questionnaires to be completed 
on two occasions during the study.  This may have introduced an element of 
questionnaire fatigue or respondent burden described by Parahoo (2006) as 
the discomfort put on participants by making use of their effort and time in 
completing the questionnaires.  The short versions of questionnaires have 
been utilised where available and valid to reduce the time taken to complete 
questionnaire and ease respondent burden.  Having time at study visits 
dedicated to reviewing the questionnaires with the subjects hopefully 
reduced any non-answer error. 
 
Patient Assessment of Constipation Quality of Life Questionnaire (PAC-
QOL) 
 






Subtracted Cystometry  
 
There are a number of measures of physiological assessment of bladder 
function that have been used in clinical studies to assess the impact of 
antimuscarinic drugs on bladder function.  Traditionally these investigated 
during phase 2 and 3 of the drugs trials process.   
 
Subtracted cystometry measures the relationship between the detrusor 
pressure and bladder volume on filling and between the detrusor pressure 
and urine flow rate on voiding.  During the procedure a pressure line and 
filling catheter are inserted into the bladder and a pressure line into the 
rectum (or vagina) and the bladder is filled with saline.  Any changes of 
pressure in the bladder are recorded during this time.  Once the bladder is 
full the patients are asked to perform a cough provocation test to assess for 
USI and provoked DO and other methods of provocation eg handwashing, 
star jumps may be performed to trigger symptoms.  Finally patients void into 
a flowmeter to assess the pressure changes within their bladder and their 
flow rate as they void.  As previously discussed in Chapter 3, all women 
presenting to the department with LUTS have this test performed as part of 
their routine investigation.  Although this study will investigate women with 
OAB symptoms, a proportion of them will have been diagnosed as having 
DO on subtracted cystometry.   
 
Originally, cystometry was not planned to be included as an outcome 
measure.  However, when transferring this PhD from the School of Nursing 
to the School of Life Sciences, an additional objective measure was 
requested to compare outcomes in women with and without DO.  This work 
had already been performed by Nitti et al (2009) who found that regardless of 
the presence of DO, patient’s response to fesoterodine was dose 
proportional and independent of the UDS diagnosis.  It was therefore 
suggested that the UDS could be used to assess if changes in SF were 
related to UDS variables or if it was independent of the UDS diagnosis.  Due 
to the ethical considerations of performing additional tests, time and 
associated costs it was agreed that subtracted cystometry would be 
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performed at the end of treatment in a pilot group of women.  The first forty 
subjects who consented to this additional assessment were included and the 
data from their test performed at initial assessment in the department was 
used to compare with the end of treatment data.  The specific parameters in 
the bullets summarised below were chosen to reflect the expected effect of 
fesoterodine.  Traditionally anticholinergics are thought to increase the first 
sensation of bladder filling, increase the cystometric capacity and reduce the 
amplitude or frequency of detrusor contractions, therefore these variables 
were set for investigation.  However, as this study is for women with OAB, 
only a percentage of them with have DO hence the need to assess and then 
subgroup analyses can be performed if appropriate.   
The summary of UDS parameters to be included are:- 
 
 Change in first sensation of filling / desire to void 
 Change in maximum cystometric capacity 
 Change in time to first detrusor contraction 




To ensure that the subjects had the characteristics that matched the study 
population under investigation and prevent classification error, stringent 
inclusion criteria were set.  These needed to ensure that the women had 
OAB symptoms and were sexually active.  In order to define OAB, the 
inclusion criteria from other clinical trials for antimuscarinics were reviewed.  
In all the big studies eg STAR trail (Chapple et al 2005), SUNRISE Trial 
(Cardozo et al 2008), FACT studies (Herschorn et al 2010a, Kaplan et al 
2011), SAFINA study etc OAB inclusion criteria was not only based on the 
ICS definition but had included a requirement of a frequency of micturition of 
8 or more voids in a 24 hour period, at least three episodes of urgency per 
24 hours on a three day diary assessed using a validated urgency scale and 
evidence that the symptoms have been present for at least three months. To 
be able to compete the bladder diaries, the subjects had to be able to and 
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willing to complete the diaries and be able to read and write in English.  The 
SAFINA trial inclusion criteria covered all of these and they were deemed 
relevant to this study so it was decided to copy these (Inclusion criteria 1-4 
and 5-7 below.  The only missing criterion was related to sexual activity.   
 
When this protocol was developed the definition of SA was poorly defined in 
the literature and there were no recommendation on how to ask.  Women 
were asked if they were SA, and the woman made her own interpretation of 
what that entailed and either responded yes or no.  It was considered that 
adding a criterion to just confirm that the subject was sexually active could 
present uncertainty into the study as it did not determine a frequency of SA.  
Given that the intervention and plan of assessments were time bound, we 
needed to ensure that the subjects had been SA regularly during the time 
period to have noticed a potential change in SF.  If we did not define or 
quantify SA, there would be the potential that women who may identify 
themselves as SA, were enrolled in the study but not be SA within the course 
of the study providing unreliable post intervention assessments.  The 
challenge with defining SA was a lack of literature regarding ‘normal’ 
frequency of SA or variations of this with age and a lack evidence to suggest 
how many times it is appropriate to be SA with the time frame for any change 
in SF to be recognised.       
 
After many discussions with supervisors and lack of comparable studies to 
review their criteria, it was set that a mean frequency of once per week was 
the minimum level of SA (Criterion 5 below).    
 
Summary of Inclusion Criteria 
 
Subjects must have met all of the following inclusion criteria to be eligible for 
enrolment into the trial. 
1. Female outpatients aged 18 – 80 years 
2. Overactive bladder symptoms (subject reported) for ≥ 3 months prior 
to screening visit according to ICS guidelines 
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3. Mean urinary frequency of ≥ 8 micturitions per 24 hours as verified by 
the screening bladder diary prior to baseline / Visit 2 
4. Mean number of Urgency episodes ≥ 3 per 24 hours as verified by the 
screening bladder diary prior to baseline / Visit 2 
5. Sexually active with a mean frequency of sexual activity ≥ 1 per week. 
6. Able and willing to complete the micturition bladder diaries and all trial 
related questionnaires, comply with scheduled clinic visits and clinical trial 
procedures 
7. Capability of understanding and having signed the informed consent 
form after full discussion of the treatment and its risks and benefits 
 
Exclusion Criteria 
Exclusion criteria are a set of predefined definitions that is used to identify 
subjects who will not be included or who will have to withdraw from a 
research study after being included. Exclusion criteria are guided by the 
scientific objective of the study and have important implications for the 
scientific rigor of a study as well as for assurance of ethical principles 
(Salkind 2010).  Inclusion and exclusion criteria are meant to provide 
justification of subject appropriateness for the study, to minimise withdrawal 
(loss to follow up) and ensure that primary end-points of the study are 
reached.   
The exclusion criteria set in the SAFINA study ensured that all the 
confounding variables that could introduce bias to the outcome of the study 
and could impact upon the effect of fesoterodine were ruled out.  These 
included allergy to the drug (Criterion 1), concomitant medications 
(discussed later and criterion 11), along with identifying other medical 
problems that may be the underlying cause of OAB symptoms or may 
exacerbate symptoms including, UTI’s, bladder pain, long term catheter use, 
previous incontinence surgery, current pelvic malignancy or previous 
radiotherapy in the area (Criteria 3-7, 9-10, 15).  Contraindications or safety 
concerns including pregnancy and breastfeeding or history of drug / alcohol 
abuse or participation in another clinical trial were interactions were unknown 
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were included (criteria 11-14) .  As these were readily available and had 
already been used in practice to recruit women they were adopted for this 
study.   
 
It was noted, that the exclusion criteria did not sufficiently cover other 
urogynaecological problems that may impact upon SF so criteria were added 
to ensure that women with a significant prolapse were excluded (Criterion 2).   
Although women with mixed urinary incontinence would be screened for 
inclusion in the trial, it was decided that the urgency / OAB needed to be their 
predominant symptoms, therefore those with stress predominant MUI were 
also added as an exclusion (Criterion 8).   An exclusion criteria was also set 
to leave out subjects not complying with follow-up visits (Criterion 17).  It was 
hoped that this comprehensive and extensive list of exclusion criteria would 
reduce the potential bias from confounding factors, loss to follow up and 
ensure that patients are correctly classified prior to enrolment in the study.   
 
Summary of Exclusion Criteria 
 
Subjects presenting with any of the following were not included in the trial. 
1. Any condition that would contraindicate the use of fesoterodine 
including, but not limited to: hyposensitivity to the active substance 
(fesoterodine fumarate) or any of the excipients, or to peanut or soya; urinary 
retention; gastric retention; uncontrolled narrow angle glaucoma; myasthenia 
gravis; moderate or severe hepatic impairment (Child Pugh C); severe renal 
impairment; severe ulcerative colitis; and toxic megacolon 
2. Stage 3 or greater pelvic organ prolapse, defined as tissue protruding 
to or beyond the introitus in lithotomy position at rest (without increase in 
intra-abdominal pressure) 
3. History of lower urinary tract surgery (eg. Incontinence surgery, 
diverticulectomy, OTIS urethrotomy) with the exception of any minor surgery 
(eg. Cystoscopic procedures) 
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4. A known history of interstitial cystitis or a significant pain component 
associated with OAB symptoms, uninvestigated haematuria, urogenital 
cancer, interstitial or external radiation to the pelvis or external genitalia, or 
bladder outlet obstruction, radiation cystitis, genito-urinary tuberculosis, 
bladder calculi, urethral obstruction or detrusor-sphincter dysenergia 
5. Subjects with bladder stones.  Subjects with a previous history of 
bladder stones may be included   
6. Previous history of acute urinary retention requiring catheterisation, 
clinically relevant bladder outlet obstruction or severe voiding difficulties in 
the judgement of the investigator prior to Visit 2 (baseline) 
7. Use of an indwelling or an intermittent self-catheterisation programme 
8. Symptoms of incontinence being predominantly stress urinary 
incontinence as determined by the investigator 
9. Urinary tract infection (UTI) as shown by the results of the urinalysis at 
screening or recurrent urinary tract infections (RUTIs) defined as treatment 
for UTI ≥3 times in the last year 
10. Use of any electrostimulation, bladder training, or pelvic floor 
exercises (with certified incontinence practitioners) within 4 weeks prior to 
Visit 1 (Screening) 
11. Participated in any clinical trial or received an investigation drug within 
4 weeks prior to Visit 2 
12. History of alcohol abuse and /or any other drug in the opinion of the 
investigator 
13. Subjects who were pregnant, nursing, or who intended to become 
pregnant during the trial or within three months after the completion of the 
trial 
14. Subjects of childbearing potential who are heterosexually active but 
not using an adequate form of contraception.  Reliable contraception 
methods were defined as hormonal methods of contraception (including oral, 
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patches, injected, implants, IUDs, condom with spermicidal 
foam/gel/film/cream/suppository, tubal ligation or male partner who has had a 
vasectomy for a least 4 months) 
15. Subjects who had any medical (including known history of major 
haematological, renal, cardiovascular or hepatic abnormalities) or 
psychological condition or social circumstances that would impair their ability 
to participate reliably in the trial, or those who may increase the risk to 
themselves or others by participating 
16. Had any current malignancy except 
a. Those ≥5 years ago without recurrence 
b. Excised basal cell skin carcinoma or squamous cell cancer 
17. Subjects who, in the opinion of the investigator, were not likely to 




A confounding factor that can introduce bias into a study is the effect of 
concomitant medication.  If a subject is already taking a drug that may impact 
upon OAB symptoms (either positively or negatively) these need to be 
identified and ruled out (either by stopping treatment for the trial or if this is 
not possible then screen failing the subject).  Criteria 1 and 2 recognise other 
drugs that may be used to treat OAB and criterion 3 details the drugs that 
may worsen symptoms.    
 
Drug interactions are possible whenever medication is ingested.  During 
phase 1 and 2 of the clinical trials process many of these interactions will be 
identified and warnings put in place to recommend that the drugs (or drug 
and food substance) are not taken in conjunction with each other as they 
may potentiate or reduce the effect / or metabolism / or excretion of the drug.  
This may introduce a bias into the study, therefore criteria 4-6 were set in line 
with the manufacturers and BNF recommendations.    
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Summary of Concomitant medications 
 
All medications with the exceptions of those listed below were permitted 
concurrently with the study medication.  If a subject needed to start one of 
the excluded medications during the study she was withdrawn. 
       1. Treatment with antimuscarinic OAB medication within 2 weeks prior 
to Visit 2      (baseline), including any preparation containing: 
darifenacin, oxybutynin, propiverine, tolterodine, fesoterodine, 
solifenacin and trospium.  If any of these preparations were started 
during the study the patient would be withdrawn 
       2.  Initiation of treatment during the 12 week trial period with: 
a. Any other drug treatment for OAB including all the 
antimuscarinics listed in point 1 and mirabegron 
b. Any drugs with significant anticholinergic, antispasmodic, 
parasympathetic, or cholinergic agonistic effects 
3. Intermittent or unstable use of diuretics or alpha blockers, or tricyclic 
antidepressants, oestrogen therapy and any 5AR inhibitors or 
initiation of such treatment(s) within 2 weeks prior to Visit 2 
(baseline) or during the study 
4. Treatment with moderate or potent CYP3A4 inhibitors, such as 
grapefruit juice, macrolide antibiotics (erythromycin, clarithromycin), 
immunosuppressants (cyclosporine), azole antifungal agents 
(ketonazole, itraconazole), protease inhibitors within 3 weeks prior 
to Visit 2 (baseline), or the expectation to start such a treatment 
during the trial 
5. Administration of medication capable of inducing hepatic enzyme 
metabolism or transport (eg. rifampicin, carbamazepine, 
phenobarbital, phenytoin, or St John’s Wort) at any point during the 
study or within the 6 weeks prior to Visit 2 (baseline) 
6. Treatment with potent CYP2D6 inhibitors such as bupropion, 






Plan of Assessment - Investigations 
 
As part of the screening assessment, it was recognised that basic 
investigations would be required to ensure that women meet the inclusion / 
exclusion criteria, the rationale for each test performed is discussed below.   
 
Urine dipstick analysis 
 
Urinary tract infection (UTI) may cause or exacerbate urinary symptoms and 
in line with the ICS / IUGA definition of OAB must be excluded (Haylen et al 
2010). If a subject had a UTI it may negatively affect the outcomes of the 
study therefore a dipstick urinalysis was taken from all women at the 
screening visit or if they attended for an unscheduled visit.  A mid-stream 
urine sample was sent for culture and sensitivities in all suspected UTI’s and 
enrolment delayed until the subject was infection free.  
 
Urine Pregnancy test 
 
Pregnancy and breastfeeding are listed as exclusion criteria for this study as 
the effect of fesoterodine on these is unknown.  Therefore prior to starting 
medication, potential pregnancy needs to be ruled out. For such an important 
concern, patient reporting is not enough and an objective measure is needed 
to confirm that the patient is not pregnant. At the screening visit all women of 
childbearing potential had a urine pregnancy test performed to ensure that 
they were not pregnant prior to starting medication.   
 
Post void residual (PVR) 
 
Incomplete bladder emptying can be associated with an increased risk of UTI 
and worsen urgency and frequency hence the presence of a significant PVR 
may negatively impact on the outcome of this study as incomplete bladder 
emptying can cause symptoms of OAB.  Urinary retention is also a risk 
associated with fesoterodine.  Following micturition an assessment of 
bladder emptying was undertaken using an either a bladder scanner or in 
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and out catheter in line with the departmental policy.  A significant PVR was 
set as 100ml or greater and if subjects were found to have a significant PVR 





As with routine clinical practice, normal dosing of fesoterodine starts at 4mg 
once daily for four weeks and can then be escalated to 8mg once daily if 
clinically indicated and tolerated.  This is known as flexible dosing.  It was 
decided therefore that this should form the basis of the timeline where all 
women would be started on 4mg once daily and then after four weeks given 
the option to stay on the same dose or escalate to 8mg.  In many clinical 
trials cited earlier in Chapter 4 assessing the efficacy of fesoterdine, the final 
assessment was performed after 12 weeks of therapy.  To keep in line with 
other studies it was decided that this would be the point of reassessment for 
this trial and whichever, dose of medication the patient chose at week 4 
would be continued until week 12.    This choice of 4 or 8 weeks for 
treatment should also aid the dispensing of medication as commercial stock 




This study aimed to investigate change in SF, using the SQOL-F and the 
PISQ-12 as measures of SF at baseline and 12 weeks after intervention. 
Sample size calculations were performed by the study statistician.  Prior data 
by Rogers et al (2008) indicated that a difference in the response to SQOL-F 
(Primary outcome) of matched pairs is normally distributed with standard 
deviation 19.2 and a difference in the mean response of 6.4. These 
estimates were used to calculate the sample size using 95% power, and a 
two sided alpha level of 0.05. The number of participants required to detect 
the difference described at the significance level described, was 120 





 Pilot study 
 
According to Leon et al (2011) a pilot study can be used to evaluate the 
feasibility of recruitment, randomisation, retention, assessment procedures, 
new methods, and implementation of novel interventions.  Although a pilot 
study would have been beneficial to ensure that the study design was 
appropriate, the department has had a lot of clinical trial experience with 
anticholinergic drugs at Phase 2, 3 and 4.  The research design reflected the 
experience that had been gained and methodological issues identified in 
previous trials had helped to inform this study design.  These included strict 
adherence to specific inclusion / exclusion criteria and the use of short forms 
of questionnaires where available to minimise responder burden.      
 
Feasibility / Timetable 
 
For a single centre study, recruiting 132 patients could be considered quite 
ambitious.  However, the department had a flow of about 180 new patients a 
month.  Of these, approximately half (90 women) reported OAB symptoms 
and about two thirds (60 women) of these would start medication for their 
symptoms.  All of these patients were offered the opportunity to participate in 
the trial if they meet the inclusion / exclusion criteria.  It was planned that 10 
patients would be recruited per month over a 15 month period.  Long 
standing patients would also be recruited from the nurse led and outpatient 
clinics when they attend for medication reviews.  It was planned that the 15 
month period would allow for an attrition rate of approximately 20%, 
however, recruitment could be terminated early once 132 patients had 
completed the trial.   The study site was and still is active in many areas of 
research, however, during the time plan for this study there were not any 







Ethical Issues Considered   
 
As this was a CTIMP, all practice adhered to the standards set by the Good 
Clinical Practice in Research Trials (ICH 1997).  Good clinical practice is a 
set of internationally recognised ethical and scientific quality requirements 
which must be observed for designing, conducting, recording and reporting 
clinical trials that involve the participation of human subjects.  It was also 
registered with the Medicines and Healthcare products Regulatory Agency 
(MHRA).  All trial personnel completed training courses in these principals.  
 
Patient counselling and future considerations 
 
Patients were provided with an information sheet about the purpose of the 
trial, what they could expect from the trial and what was required of them (A 
copy of the patient information sheet (PIS) has been included in the 
appendix).  Women had the opportunity to further discuss any questions or 
concerns with the investigator before providing informed consent for 
participation (the informed consent form can be found in the appendices).  
Current best practice in trial development includes patient involvement to 
ensure that protocols are feasible, all trial information is appropriate and easy 
to understand, however, this protocol was developed in 2010 before this was 
embedded in practice.  In this study there was no patient involvement in the 
original development of the PIS, but the ethics committee lay members 
suggested some changes to the language that were made as part of the 
ethical approval process.  
 
There may have been implications with the sample as they were from the 
investigators clinical setting and there was a risk that some people may feel 
that their medical or nursing care may have been negatively affected if they 
did not agree to be research subjects (Burns & Grove 2003).   To reduce this 
effect, participants were informed that if they did not enter the trial or if they 
withdrew from the trial at any point, that it would not affect the standard of 




As the effect of fesoterodine on SF was unknown, it reduced the influence 
the investigator had over the patients when counselling them with regarding 
participation and hopefully further reduced any effect of coercion. 
 
This was a particularly sensitive area to discuss with patients; however, all 
patients seen in the department were asked about their SF on initial 
assessment so it did not require a change in routine practice or introduce any 
additional embarrassment or invasion of privacy for the patients considering 
participation in the trial. 
 
Another area that was considered was regarding what services could be 
offered to patients if they continue to complain of sexual dysfunction on 
completion of the trial.  The standard department procedure following 
treatment for their bladder condition is onward referral for psycho-sexual 





The study was funded through an IIR Grant from Pfizer LTD who 
manufactured fesoterodine.  However, they had no involvement with the 
design of the trial (except the use of the SQOL-F), data collection or data 
analysis.  Also they are not in a position to withhold the results should the 
findings be negative.  Over the course of this thesis, the marketing and 
commercial sales of fesoterodine has been taken over by a different 
pharmaceutical company - Pierre Fabre but this has not had any implications 
for this study.  
 
Patient beneficence and reimbursement 
 
As participation in the trial entailed two additional visits to the department 
over routine care this may have placed a financial burden on the patient.  To 
compensate for this, patients were offered reimbursement for their travel 
costs up to £20 per visit on receipt of a valid train ticket or car park voucher.  
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Participants were also given the option of where they would like to complete 
the questionnaires.  They had the option to take them home to complete at 
their leisure or offered a private room in the department.  For those subjects 
who agreed to have the additional subtracted cystometry at visit 4, they were 
reimbursed £50 for the additional time and discomfort. 
 
It was hoped that this study would prove to be worthwhile for the participants 
as they would receive a treatment that could provide a solution or resolution 
to their problems with few limitations (2 extra visits) whilst also providing 




This chapter describes and justifies the methods used in this CTIMP of 
fesoterodine.  The following chapter will go on to describe the trial 































Based upon the decisions discussed in Chapter 6, the first complete CTIMP 
protocol was developed in 2010 and titled:- 
 
‘A 12 week, single centre, open label study to evaluate the effect of 
fesoterodine flexible dosing regimen on the sexual function of women with 
overactive bladder.’ 
 
This full protocol is included in the appendix.  The protocol was reviewed and 
authorised with the relevant bodies.  This chapter details some of the final 
decisions not previously discussed in relation to drug administration, 
dispensing, assessment of compliance and the final plan of trial activities.     
It will also detail the changes to the trial as it progressed and the significant 
issues with recruitment that led to an increase in study sites, a review of the 
inclusion criteria and amendments to the protocol.  Finally a detailed plan of 
the statistical analysis of the trial is described prior to the presentation of the 
results in Chapter 8. 
 
Trial Medication – Investigational Medicinal Product (IMP) 
 
Fesoterodine fumarate is an antimuscarinic agent that was developed and 
licensed for the treatment of the symptoms that may occur in patients with OAB 
syndrome.  It is manufactured and supplied by Pfizer Ltd (Now Pierre Fabre in 
Europe). 
 
The study drug was supplied in bottles with two different strengths as described 
below (see Table 7.1 For description of IMP): 
 
 Fesoterodine fumarate prolonged release 4mg tablets 





Table 7.1 Description of IMP 
 



























 Dosing Regimen 
 
The study drug was dispensed according to the following schedule: 
 
 Visit 1 – screening – no medications dispensed 
 Visit 2 (Week 0) – one bottle (28 tabs) of  4mg tablets  
 Visit 3 (Week 4) –One bottle (56 tabs) of 4mg tablets or one bottle (56 tabs) of 
8mg tablets, depending on the dose selection for each individual subject at this 
visit (based upon a discussion between the subject and the investigator of the 
efficacy and tolerability reported by the subject, the investigator either increased 
the dose to 8mg for those subjects who desired greater symptom improvement 
and reported good tolerability, or continued the subject on the 4mg dose for the 
remaining 8 weeks of the study).   
 
No dose adjustments were allowed after visit 3 during the last eight weeks of the 
treatment phase.  Subjects were advised to take one tablet with water at 
approximately the same time every day and that it should be swallowed whole 







CTIMPS are subject to regulatory processes that needs to be adhered to eg those 
set by the MHRA and the International Conference on Harmonisation (ICH) Good 
Clinical Practice (GCP) principles.  These are set to protect the safety, well being 
and right of subjects in clinical trials. Drug accountability is one particular area 
where specific requirements were essential and the details of how we adhered to 
this are noted below.  
  
All IMP supplies were stored in accordance with applicable regulatory 
requirements.  IMP was stored separately from normal hospital stocks.  Until 
dispensed to the subjects all IMP was stored in a securely locked area, only 
accessible to authorised personnel. 
 
The investigator was responsible for recording the receipt, administration and 
return of all trial medication, and for ensuring the supervision (via the hospital 
pharmacy) of the storage and allocation of trial medication.  A complete inventory 
was performed of the trial medication upon delivery to the site.   
 
Overall IMP accountability logs were completed during the trial.  The subjects were 
asked to return all trial medication bottles, whether full, partially full or empty, to 
the investigator and the investigator retained these bottles at the site until 
accountability had been completed.  Compliance was agreed as taking at least 





An investigator initiated unrestricted research grant was awarded by Pfizer to 
cover pharmacy costs, patient expenses and administration of the trial. All 





As this was a pharmaceutical trial the Principal Investigator (PI) needed to be 
a medical doctor or a qualified nurse prescriber, educated to at least 
master’s level.  As I did not meet these requirements at the start of the study, 
the Professor of the department assumed the role of PI and I was the Chief 
Investigator. 
 
The Study was sponsored by the Joint Clinical Trials Office (JCTO) and they 
were responsible for the monitoring and auditing of trial practices and 
conduct.   
 
Plan of Assessment 
 
This was designed as a single centre open label prospective observational 
study which aimed to enter 132 SA female subjects with OAB symptoms.  
The study was carried out at the Urogynaecology department at KCH, 
London.  Convenience sampling was used to recruit patients to this study 
from UDS clinics, the nurse led service and general outpatient clinics.   
Due to challenges with recruitment with this study three additional study sites 




A trial activities log was developed to show all the assessments and 
investigations that took place at each visit and this is displayed in figure 7.1. 
 
To ensure that all required data were captured and to assist with monitoring 
of the trial a paper clinical research form (CRF) was developed, along with 
an informed consent form, patient information leaflet and GP letter, in line 













Visit 2  
Baseline 
Week 0 




Visit  4  
End of TX  





Written informed consent X     
Demographics & History X     
Physical exam X     
Inclusion / exclusion criteria X X    
Body mass index (BMI) X     
Urine dipstick test and PVR  X     
Urine pregnancy test  X   X  
Menopausal status X   X  
PISQ-12   X  X  
SQoL  X  X  
PPBC  X  X  
KHQ  X  X  
PAC-QoL  X  X  
SAGA  X  X  
Dispense 3 day bladder 
diary 
X X X   
Evaluation of bladder diary  X X X  
Adverse events  X X X x 
Concomitant medication X X X X  
Dose assessment and 
titration 
  X   
Dispense study medication  X X   
Study medication return   X X  
Subtracted cystometry    X   
Assess drug compliance   X X x 
Assess treatment 
continuation 





A range of recruitment methods were used including the use of posters and 
flyers in clinical areas, waiting rooms and in the toilets.  Women attending 
appointments within the department eg for bladder retraining and medication 
reviews were sent a leaflet with appointment letters and the new women 
referred in to the department for urodynamics were also sent flyers.  Women 
identified in the urodynamcis, main outpatient and nurse led clinics were 
provided with a PIS and for those who had contacted the department having 
seen a poster, they received a PIS by either post or email dependent on their 
individual preferences.   All women provided with a PIS were contacted 48 
hours later (by phone or email) by the investigator to see if they were 
interested in taking part in the study and to arrange a screening visit.    
 
If the subject agreed to take part in this study, a date for a screening visit was 
set, at which point written consent was taken and the following tests were 
carried out to determine whether they were eligible to take part in this study.  
 
Visit 1 (Screening visit)  
 
At the screening visit:  
 Weight, medical history (including any medication and non-drug 
treatment) and demography taken  
 Sitting blood pressure and pulse taken  
 A physical examination conducted by a HCP 
 Subjects provided a sample of urine for the following-:  
- A urine dipstick test performed to exclude blood and infection  
- A urine pregnancy test for women of child bearing potential 
performed  
 Subjects issued with a 3-day bladder diary to complete and provided with 
instructions on how and when to complete the diary. The diary was to be 




If subjects meet all of the study entry requirements at this point and they agree 
to participate in the study, they were invited to return for Visit 2 (baseline visit).  
 
A patient card was provided to the subjects to act as an appointment 
reminder which also included emergency contact details of the research 
team. 
 
Visit 2 (Week 0) (Baseline)  
 
At this visit, following assessment of eligibility by a delegated HCP, subjects 
were informed whether they were eligible to take part in this study. If they were 
eligible and still wished to participate, a baseline visit was performed.  
 
At the baseline visit-:  
 A completed bladder diary was collected and evaluated  
 Subjects were asked to complete 6 questionnaires which took 
approximately 30 minutes (These could completed at home and returned 
if preferred) 
 Subjects were asked if they have had any new symptoms or worsening of 
existing symptoms and if they have taken any new medication or 
treatments since the last visit.  
 Subjects were given another 3-day diary (plus instructions) to complete 
the three days prior to the next visit (visit 3)  
 Subjects were given a supply of IMP (fesoterodine 4mg) to take once a 
day at approximately the same time each day over the next 4 weeks  
 
Visit 3 (Week 4)  
 
Four (4) weeks later subjects returned for visit 3.  
During this visit: 
 A completed bladder diary was collected and evaluated 
 Subjects were asked if they have had any new symptoms or worsening 
of existing symptoms and if they have taken any new medication or 
treatments since their last visit  
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 The investigator reviewed the amount of unused study medication 
subjects had returned to assess compliance 
 Subjects were given another 3-day diary (plus instructions) to complete 
the three days prior to the next visit (visit 4)  
 The dose of IMP was reviewed by the study team and if required the 
dose increased and recorded in notes and CRF 
 Subjects were given a supply of IMP, either fesoterodine 4 mg or 
fesoterodine 8 mg depending on discussions with the investigator  
 
Visit 4 (Week 12 End of Treatment or Early Termination Visit)  
 
Eight (8) weeks later subjects returned for visit 4.  
During this visit: 
 A completed bladder diary was collected and evaluated  
 Women of child bearing potential provided a sample of urine for a 
pregnancy test  
 Subjects were asked to complete questionnaires which took 
approximately 30 minutes (These could be completed at home prior to 
the visit if preferred) 
 Subjects were asked if they had any new symptoms or worsening of 
existing symptoms and if they have taken any new medication or 
treatments since their last visit  
 The investigator reviewed the amount of unused study medication 
subjects have returned to assess compliance 
 For those women who had consented to having urodynamics they 
underwent subtracted cystometry at this visit. (This was only for the first 
40 subjects in the trial who consent to having subtracted cystometry 
performed at week 12) 
 
Telephone Follow UP (24 Weeks) 
 
 Subjects were asked if they were still taking fesoterodine (as 
prescribed by their GP) or if they were taking any other anticholinergic 
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medication or no therapy 
 If subjects had decided to stop all therapy they were asked to explain 
their decision for this 
 Subjects were asked if they had experienced any adverse events on 




In the Urogynaecology unit at KCH the majority of women reporting LUTS 
complete a 3 day bladder diary and undergo video UDS as part of their 
routine care.  If the subject had received information related to the trial prior 
to this routine care (to meet GCP consent requirements) the screening visit 
and visit 2 were performed concurrently and the bladder diary that they 






The primary outcomes variables in this study were looking for the difference 
between the PISQ-12 total score and the SQoL-F total score over the course 
of the study.  The mean difference in questionnaire scores between week 0 
and 12 was analysed using dependent T-tests. This test measures the 




Dependent T-test were completed for the KHQ, and Pac-QoL (As the “How 
Satisfied” domain was scored on an ascending scale, while the others were 
scored on a descending scale, the inverse of this domain score was used in 
all analyses) and examined differences within individual domains, as well as 




Dependent T-tests were also used to examine changes in PPBC score and 
urodynamic parameters between weeks 0 and 12.  
 
Descriptive statistics were used to analyse and compare bladder diary 
variables. 
 
Effect size was calculated using Hedge’s g, as it is less prone to upward bias 
in sample sizes under 20 when compared with other measures such as 
Cohen’s d. To further reduce the overestimation of effect sizes among this 
small sample, a correction factor was applied (Hedges and Olkin 1985). 
 
The relationship between UDS parameters and the baseline total scores for 
each questionnaire were examined using multinomial regression analyses. 
These were also used to examine any association between changes in UDS 
parameters with changes in total score for each questionnaire. All 
urodynamic parameters were entered as covariates in the models via a 
forced entry method. The goodness-of-fit of the resulting models was 
determined using the F-ratio.  
 
For the SAGA questionnaire, a non-parametric rank correlation analysis was 
used to examine the relationship between the perceived importance of a 
patient’s self-determined goals and the attainment of that goal.  Kendall’s tau 
statistic was reported as this is more accurate than Spearman’s rho when 
using small sample sizes.  All analyses were completed using IBM SPSS 22 
(for Mac). 
 
Table 7.2 describes all the statistical abbreviations used in the text and the 














x̅ Symbol for the mean 
SE The standard error around each coefficient 
BCa Bias-corrected and accelerated – the method of 
bootstrapping used 
Df The degree of freedom 
t(19) Symbol for the t-test (DF in brackets) 
P The probability value 
g Hedge’s g – a measure of effect size 
Sig The statistical significance of the test 
Wald Wald test – used to determine whether each predictor 
variable affects the outcome variable 
B Unstandardized beta - equation coefficient for each 
predictor variable 
SE B Standard error for the unstandardized beta 
β The standardised beta 
t The t-test statistic calculated for the individual predictor 
variables 
VIF Variance Inflation Factor – measure of validity of 
regression model 
(2) Symbol for the chi-square test (DF in brackets) 
Exp(B) Odds ratio in logistic regression 
R^2 Coefficient of determination in regression analysis to 
assess goodness of fit 
F ratio Used to determine if there are differences between 
groups 






Amendments to the study 
 
This project experienced many delays and challenges along the way which 
resulted in multiple amendments and several protocol changes.  From the 
time of funding approval in April 2010, ethical approval was not gained until 
June 2012 and the first subject was not enrolled into the study until October 
2012 due to a delay in getting IMP on site.  Recruitment to the study proved  
difficult and despite changes to the inclusion criteria, the addition of three 
external research sites and one patient identification centre and an active 
recruitment period over four years until 31st December 2016, only a fifth of 
the sample size was met.  Table 7. 3 details the problems that were 
identified, the amendments made to the protocols to address the issue and 
the associated protocol numbers. 
 
Table 7.3 Amendments to the protocol 
Problem identified Amendments Associated 
protocol 
Inclusion criterion for 
frequency of SA negatively 
impacting upon 
recruitment 
Changes to the inclusion 
criterion in line with new 
literature regarding frequency 
of SA 
2.5 
Lack of women being 
recruited to the study  
Study changed from single 
centre to multi centre by 
addition of one patient 




Inclusion criterion for 
urinary frequency / 24 
hours negatively impacting 
upon recruitment 
 
Changes to the inclusion 
criterion in line with new ICS / 
IUGA definitions  
 
2.5 
Study due to end without 
opportunity for new criteria 
to improve recruitment 
 
Extension to study time lines  2.6 
Pfizer unable to provide 
clinical research supply of 
fesoterodine 
 







In view of the amendments summarised above there have been many minor 
and substantial amendments submitted to the REC and R&D and multiple 
versions of the research protocol as it has been updated.  Lists of all the 
regulatory submissions over the course of the study and details all of the 
protocol versions and dates for this study along with a brief description of the 
changes applied have been included in the appendix.  A full discussion 




This chapter has described the processes that were involved for each of the 
participants who enrolled into the trial, the plans for statistical analysis and 
the major changes and amendments that were made to the study protocol. 




















This chapter will report the findings of the CTIMP previously outlined in 
chapter 7.  Following the description of the subject disposition and baseline 
characteristics, the results of all the primary and secondary outcomes will be 
presented.  The discussions and analysis of the results will be reported in 
Chapter 9.   
 
Recruitment by Site  
 
All recruits into the trial were from the initial study site.  Two of the additional 
sites did not manage to recruit any subjects.  The third additional site did 
manage to successfully screen and identify one subject.  When the subject 
was due to start treatment, however, there had been a temperature violation 
in the storage of IMP in the pharmacy department and all the stock had to be 
destroyed.  The subject did not want to wait for a new supply to be delivered 
to the site so decided to withdraw and start an alternative treatment.  This 




Thirty subjects were screened, 28 were allocated to treatment of which 20 
completed treatment.  The screen failures were due to one patient failing 
eligibility on her bladder diary variables (prior to the protocol change) and the 
other had just been started on a contraindicated medication so did not meet 
the inclusion criteria.   
 
Of the eight subjects who discontinued treatment, four withdrew consent (one 
prior to starting treatment decided she no longer wanted to try another 
medication so did not collect her prescription, one because she wanted to 
start a family and therefore would not use the necessary contraception, one 
as her relationship status changed and she was no longer sexually active, 
one as she was starting a new job and felt she could not commit to the trial 
procedures).  Two subjects were lost to follow up at the 12 week stage (one 
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did make contact to say that she was not available to attend and then failed 
to attend three further appointments, one moved out of the area and could 
not return to complete trial procedures).  One subject was withdrawn from the 
trial as she was not complying with trial procedures.  The final subject was 
removed from the trial due to a serious adverse event (SAE).  Despite a 
negative pregnancy test on the initiation of treatment, when the subject 
returned for the week four visit she reported that she had not yet had a period 
since the last visit.  A pregnancy test was performed and was positive and 
the subject was withdrawn from the study and an SAE declared.   Complete 
data sets are available for 19 subjects as one did not complete her final 
bladder diary.  The flow of subjects through the study is demonstrated in 
figure 8.1.  
 
Figure 8.1 Subject Flow Chart 
 
30 Patients Screened for 
eligibility 
   
 
 
28 consented to take part 
















- Withdrew consent (n=4) 
- Lost to follow up (n=2) 
- Serious adverse event (n=1) 




Baseline Demographics and Clinical Characteristics 
 
The median age of subjects in the trial was 40 years with a median BMI of 29 
and median parity of 2.  The median length of time that OAB symptoms had 
been present was 1 years with a range of 3 months – 25 years and only one 
patient in the study was treatment naive in relation to antimuscarinic therapy 
(all other subjects having received at least first line therapy from their GP 
prior to referral to the department).  60.7% were Caucasian and 35.7% post-
menopausal.    
 
When considering the clinical characteristics, 64.3% had DO on UDS, 81.5% 
reported UI (2 subjects with OAB were found to have mild USI but the OAB 
was their most bothersome problem).  Overall, 53.7% of subjects opted to 
dose escalate during the study.  When dose escalation was broken down 
according to UDS diagnosis and patients who withdrew from the study prior 
to dose escalation were removed, 75% of subjects with OAB opted to dose 




















Table 8.1 Baseline demographics and clinical characteristics 
Demographic Median Range 95% Confidence 
Intervals 
Age 40 years 20-73 years 37 - 47.2 
BMI 29 21-44 26.7 - 31 
Parity 2 0-6 0.847 – 2.07 
OAB symptoms 1 years 0.25-25 years 1.99 – 5.91 
    
Menopausal Status   
Pre menopause 64.3%  
Post menopause 35.7%  
   
Ethnicity   
Caucasian 60.7%  
Black  32.2%  
Asian 7.1%  
   
Baseline diagnosis   
OAB 35.7%  
DO 64.3%  
   
Incontinence Status   
No 18.5%  
Yes 81.5%  
   
Dose Escalation   
No (n=8) 28.7%  
Yes (n=15) 53.7%  
N/A (n=5) 17.6%  
Diagnosis Dose escalated Non escalated 
OAB (n=8) 75% 25% 








Paired T-Test PISQ-12 Total Score 
 
Of the 20 subjects tested, the average PISQ-12 score decreased between 
week 0 (x̅ =15.85, SE =1.74) and week 12 (x̅ = 11.5, SE = 1.52). This difference 
of 4.35 points, BCa 95% CIs [7.35, 1.572], was statistically significant t(19) = 
3.159, p = 0.005, and reflects a moderate effect size, g = 0.542. 
 
Table 8.2 Demonstrates the breakdown for each question on the PISQ-12 
and the mean score at week 0 and week 12.   
 
Figure 8.2 Displays the change in PISQ-12 domain scores between week 0 
and week 12. 
 
Overall there was mean reduction in PISQ-12 score of 4.35 which was 
significant (p=0.005).   When considering specific questions related to desire, 
there was very little change in the frequency of sexual desire, the number of 
orgasms experienced or whether women feel “turned on”.  However, by week 
12 there was a significant improvement in satisfaction with the variety of 
sexual activities in the women’s sex lives. 
 
When looking into the effect of study medication on SA there is an observed 
reduction in the frequency of CI (mean difference -0.5) but this is just short of 
significant (p=0.056) (see table 8.3) and there is no change in the number of 
patients who never experience CI, yet there is a significant reduction in the 
restriction of sexual activity caused by fear of incontinence (mean -0.75 









Mean at week 0 (SE) Mean at week 12 (SE) Mean difference 
BCa 95% Confidence Interval of 
the Difference  
Lower Upper t df Sig. (2-tailed) 
 PISQ 1 1.75 (0.16) 1.7 (0.11) 0.050 -0.200 0.350 0.326 19 0.748 
 PISQ 2 1.7(0.26) 1.6 (0.29) 0.100 -0.250 0.450 0.623 19 0.541 
 PISQ 3 0.85 (0.18) 0.85 (0.17) 0.000 -0.350 0.350 0.000 19 1.000 
 PISQ 4 1.35 (0.2) 0.8 (0.23) 0.550 0.200 0.850 2.604 19 0.017 
 PISQ 5 1.9 (0.25) 1.25 (0.25) 0.650 0.250 1.102 2.557 19 0.019 
 PISQ 6 1.5 (0.3) 1.0 (0.22) 0.500 0.150 0.950 2.032 19 0.056 
 PISQ 7 1.65 (0.34) 0.9 (0.26) 0.750 0.300 1.300 3.290 19 0.004 
 PISQ 8 0.8 (0.3) 0.45 (0.22) 0.350 0.000b 0.800b 1.505 19 0.149 
 PISQ 9 1.15 (0.34) 0.55 (0.21) 0.600 0.100 1.200 2.108 19 0.049 
 PISQ 10 0.3 (0.15) 0.3 (0.15) 0.000 -0.300c,d 0.300c 0.000 19 1.000 
 PISQ 11 0.4 (0.17) 0.2 (0.12) 0.200 0.000e 0.450e 1.285 19 0.214 
 PISQ 12 2.5 (0.19) 1.9 (0.22) 0.600 0.250 1.050 2.349 19 0.030 
 PISQ Total Score 15.85 (1.74) 11.5 (1.52) 4.350 1.900 7.030 3.159 19 0.005 





Table 8.3 Are you incontinent of urine with sexual activity? 
 
PISQ-12 Question 6 No of patients at  
Week 0 
No of patients at  
Week 12 
 
Always 3 1 
Usually 0 0 
Sometimes 7 3 
Seldom 4 10 




Table 8.4 Does fear of incontinence restrict your sexual activity? 
 
PISQ-12 Question 7 No of patients at  
Week 0 
 
No of patients at 
Week 12 
 
Always 4 1 
Usually 1 1 
Sometimes 6 3 
Seldom 2 4 































































Change in PISQ-12 domain scores between 







Paired T-Test SQOL-F Total Score 
 
Of the 20 subjects tested, the average SQOL score increased between week 
0 (x̅ = 66.1, SE = 3.62) and week 12 (x̅ = 73.45, SE = 2.42). This difference of 
7.35 points, BCa 95% CIs [-2.55, -13], was statistically significant t(19) = -2.673, 
p = 0.015, and reflects a moderate effect size, g = -0.486. 
 
Table 8.5 displays the mean change for each of the 18 questions on the 
SQOL-F from week 0 to 12. 
 
Figure 8.3 demonstrates the mean change in SQOL-F scores between week 













Change in SQOL-F domain scores between 






Mean at week 0 
(with SE reported in 
brackets) 
Mean at week 12 
(with SE reported in 
brackets) 
 Paired Differences 
Mean difference 
BCa 95% Confidence Interval 
of the Difference  
Effect Size (corrected 
Hedge’s g) 
Lower Upper t Df 
Sig. (2-
tailed) 
SQOL1 2 (0.251) 1.75 (0.28) -.250 -.200 .700 -.960 19 .349 0.191 
SQOL2 4.2 (0.374) 4.5 (0.336) .300 -.950 .200 .922 19 .368 -0.171 
SQOL3 4.5 (0.394) 5.15 (0.31) .650 -1.250 -.150 2.292 19 .033 -0.372 
SQOL4 4.35 (0.443) 5.3 (0.309) .950 -1.550 -.400 2.826 19 .011 -0.506 
SQOL5 2.5 (0.267) 2.15 (0.274) -.350 .050 .650 -1.926 19 .069 0.263 
SQOL6 3.9 (0.397) 4.2 (0.408) .300 -1.100 .400 .825 19 .419 -0.152 
SQOL7 3.45 (0.4) 4.75 (0.354) 1.300 -1.950 -.700 3.577 19 .002 -0.751 
SQOL8 4.95 (0.4) 5.5 (0.295) .550 -1.100b -.150b 1.993 19 .061 -0.318 
SQOL9 2.3 (0.356) 1.8 (0.268) -.500 -.036 1.150 -1.602 19 .126 0.323 
SQOL10 3.15 (0.393) 4.3 (0.43) 1.150 -1.750 -.600 3.092 19 .006 -0.568 
SQOL11 4 (0.503) 4.6 (0.373) .600 -1.400 .200 1.390 19 .181 -0.275 
SQOL12 4.15 (0.449) 5 (0.324) .850 -1.650 -.050 2.031 19 .056 -0.441 
SQOL13 2.4 (0.336) 2.3 (0.356) -.100 -.550 .650 -.335 19 .741 0.059 
SQOL14 4.6 (0.413) 5.05 (0.312) .450 -1.100 .250 1.280 19 .216 -0.250 
SQOL15 4.5 (0.444) 5.35 (0.335) .850 -1.600 -.200 2.165 19 .043 -0.439 
SQOL16 4.2 (0.462) 5 (0.348) .800 -1.600 .000 1.823 19 .084 -0.397 
SQOL17 4 (0.47) 4.6 (0.387) .600 -1.400 .200 1.352 19 .192 -0.283 
SQOL18 2.95 (0.426) 2.15 (0.357) -.800 -.250 -1.500 -2.320 19 .032 0.413 
SQOL Total 66.1 (3.615) 73.45 (2.416) 7.35 13 2.55 2.673 19 .015 0.191 
Table 8.5 Mean change for SQOL-F from week 0 to 12
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Secondary Outcomes  
 
Bladder diary variables 
 
Complete bladder diaries were available for 17 subjects.  Paired T-Tests 
were performed to establish differences in bladder diary variables from week 
0 to week 12.  
 
Number of episodes of micturition per 24hrs 
 
The average number of episodes of micturition per 24 hrs decreased 
between week 0 (x̅ = 10.05, SE = 0.63) and week 12 (x̅ = 6.95, SE = 0.72). 
This difference of 3.11 episodes, BCa 95% CIs [1.98, 4.26], was statistically 
significant t(16) = 4.839, p < 0.001, and reflects a large effect size, g = 0.993. 
 
Number of Episodes of nocturia per 24hrs 
 
The average number of episodes of nocturia per 24hrs decreased between 
week 0 (x̅ = 0.82, SE = 0.12) and week 12 (x̅ = 0.32, SE = 0.10). This 
difference of 0.51 points, BCa 95% CIs [0.26, 0.75], was statistically 
significant t(16) = 4.441, p < 0.001, and reflects a large effect size, g = 0.973. 
 
Number of Episodes of UUI per 24hrs 
 
The average number of episodes of UUI per 24hrs decreased between week 
0 (x̅ = 1.68, SE = 0.43) and week 12 (x̅ = 0.65, SE = 0.45). This difference of 
1.02 points, BCa 95% CIs [0.49, 1.59], was statistically significant t(16) = 
3.096, p = 0.007, and reflects a moderate effect size, g = 0.502.  This 
represents a 61.3% reduction in UUI episodes per week. 
 
Number of Episodes of U per 24hrs 
 
The average number of episodes of U per day decreased between week 0 (x̅ 
= 4.65, SE = 0.55) and week 12 (x̅ = 1.31, SE = 0.38). This difference of 3.34 
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points, BCa 95% CIs [2.38, 4.39], was statistically significant t(16) = -5.95, p = 
0.00, and reflects a large effect size, g = 1.524. 
 
Number of Episodes of U per 3 day diary 
 
The average number of episodes of U per week decreased between week 0 
(x̅ = 13, SE = 1.4) and week 12 (x̅ = 4.12, SE = 1.13). This difference of 8.88 
episodes, BCa 95% CIs [6.14, 11.5], was statistically significant t(16) = 6.862, 
p < 0.001, and reflects a large effect size, g = 1.51.  This represents a 68.3% 
reduction in urgency episodes per week. 
 
24 hour Fluid Intake Volumes 
 
The average 24 hour fluid intake decreased from 1507mls at week 0 to 
1246mls at week 12 (t=2.545, p value=0.021).  This is a significant finding 
and equivalent to an 18% reduction in total fluid intake over the course of the 
study.  The average 24 hour fluid output decreased from 1576mls at week 0 
to 1355mls at week 12 (t=1.922, p value=0.072).  However, this did not quite 
reach significance.    
 
 
Table 8.6 shows the mean change in bladder diary variables from week 0 to 
12.  Figure 8.4 demonstrate the changes in bladder diary parameters 






































Change in bladder diary parameters 






  Table 8.6 Mean change in bladder diary variables 
Bladder Diary 




Mean at week 









BCa 95% Confidence 
Interval of the Difference  
Lower Upper t df 
Sig. (2-
tailed) 
Number of Episodes of 
micturition per day 
10.05 (0.63) 6.95 (0.72) 3.11 1.98 4.26 4.839 16 0.000 
0.993 
Number of Episodes 
of nocturia per day 
0.82 (0.12) 0.32 (0.10) 0.51 0.26 0.75 4.441 16 0.000 
0.973 
Number of Episodes 
of UUI per day 
1.68 (0.43) 0.65 (0.45) 1.02 0.49 1.59 3.096 16 0.007 
0.502 
Number of Episodes 
of U per day 
4.65 (0.56) 1.31 (0.38) 3.34 2.38 4.39 5.95 16 0.000 
1.524 
Number of Episodes 
of U per week 







Paired T-Test King’s Health Questionnaire (KHQ) Total Score 
 
Of the 20 subjects tested, the average KHQ score decreased between week 0 
(x̅ = 520.18, SE = 40.2) and week 12 (x̅ = 288.21, SE = 43.48). This difference 
of 231.97 points, BCa 95% CIs [302.41, 164.64], was statistically significant 
t(19) = 6.892, p <0.001, and reflects a large effect size, g = 1.126. 
There were significant changes in every domain of the KHQ with the greatest 
changes observed in role limitations, emotions and incontinence impact 
domains (mean difference of 35.01, 32.8, 30.84 respectively) (see table 8.7).  
The least change was seen in the general health perception and present 
problems domains (mean difference 5.0 and 5.15 respectively). Figure 8.5 
















Change in KHQ domain scores between 









Mean at week 0 
(SE) 





BCa 95% Confidence Interval 
of the Difference 
t df 
Sig. (2-
tailed) Lower Upper 
KHQ1 General Health Perceptions  27.5 (5.71) 22.5 (5.41) 5.0000 2.5000b 8.7500b 2.179 19 0.042 
KHQ2 Incontinence Impact  84.98 (4.51) 54.14 (7.12) 30.8350 18.3302 44.5580 5.434 19 0.000 
KHQ3 Role Limitations  66.64 (6.05) 31.63 (6.39) 35.0050 23.3308 46.6746 5.688 19 0.000 
KHQ4 Physical Limitations  60.23 (6.09) 32.46 (6.67) 27.7700 14.4426 40.8666 3.906 19 0.001 
KHQ5 Social Limitations  51.65 (6.93) 24.15 (6.99) 27.5000 15.8200 39.1725 4.205 19 0.000 
KHQ6 Personal Relationships  45.8 (7.73) 23.32 (7.29) 22.4900 6.6650 39.9897 2.862 19 0.010 
KHQ7 Emotions  59.44 (6.16) 26.64 (5.66) 32.7950 23.9450 41.1158 7.188 19 0.000 
KHQ8 Sleep/Energy 50.8 (6.34) 27.46 (5.71)   23.3450 12.5349 35.8300 3.909 19 0.001 
KHQ9 Severity Measures 58.31 (5.41) 36.23 (5.74) 22.0800 17.0750 27.0838 8.110 19 0.000 
KHQ Present problems 14.85 (1.03) 9.7 (1.2) 5.1500 3.5503 6.8500 7.054 19 0.000 
KHQ Total Score  520.18 (40.2) 288.21 (43.48) 231.9700 170.4986 297.2971 6.892 19 0.000 
  a. Unless otherwise noted, bootstrap results are based on 1000 bootstrap samples 






Paired T-Test PAC-QOL Total Score 
 
Of the 20 subjects, the average PACQOL score decreased between week 0 (x̅ 
= 28.25, SE = 5.57) and week 12 (x̅ = 25.6, SE = 4.5).  This difference of 2.65 
points, BCa 95% CIs [8.97, -3.65], was not statistically significant t(19) = 0.716, 
p = 0.483, it reflects a small effect size, g = 0.106. 
There were no significant differences noted in any domain of the PAC-QOL 
questionnaire as demonstrated in table 8.8 and Figure 8.6 
 
Only one subject reported constipation as an adverse effect and for majority 





















Change in PAQ-QoL domain scores between 





Table 8.8 Table to show the paired t-tests for individual PAC-QOL domains and overall PAC-QOL scores from week 0 to week 12. 
PAC-QOL Domains 
Mean at week 0 
(SE) 





BCa 95% Confidence 
Interval of the Difference 
t df 
Sig. (2-
tailed) Lower Upper 
PAC-QOL Domain 
total score: "Intensity" 
2.1 (0.55) 2.0 (0.53)  
0.100 -0.678 0.950 0.237 19 .815 
PAC-QOL Domain 
total score: "Daily Life" 
7.25 (1.86) 4.8 (1.16) 
2.450 -0.258 5.100 1.907 19 .072 
PAC-QOL Domain 
total score: "Feelings" 
7.7 (2.0) 6.65 (1.63) 
1.050 -2.251 4.500 0.663 19 .515 
PAC-QOL Domain 
total score: "Life with 
Constipation" 
2.6 (0.72) 2.85 (0.77) 
-0.250 -1.970 1.370 -0.333 19 .743 
Inverse score of PAC-
QOL Domain total 
score: "How Satisfied" 
8.6 (1.13) 9.3 (1.3) 
-0.700 -3.000 1.400 -0.636 19 .532 
PAC-QOL Total  28.25 (5.57) 25.6 (4.5) 2.650 -5.250 10.444 0.716 19 .483 





Paired T-Test Patient Perception of Bladder Condition (PPBC) 
 
Of the 20 subjects, the average PPBC score decreased between week 0 (x̅ = 
4.55, SE = .24) and week 12 (x̅ = 3.2, SE = .24). This difference of 1.35 points, 
BCa 95% CIs [1.8, 0.9], was statistically significant t(19) = 5.81, p < 0.001, and 
reflects a large effect size, g = 1.165.  This is displayed graphically in Figure 
8.7. 
 
Overall this represents:- 
Improvement from baseline – 63% 
No change form baseline – 29.6% 
Deterioration from baseline 7.4% 
 
Mean score at week 0 = 4.55 = my bladder causes me moderate problems  





























Paired T-Test First Sensation 
 
Of the 16 subjects, the average bladder capacity (in ml) at which participants 
first experienced the sensation to void increased between week 0 (x̅ = 193.4, 
SE = 31.3) and week 12 (x̅ = 232.5, SE = 29.6). However, this difference of 
39.1 ml, BCa 95% CIs [31.05, -93.13], was not statistically significant t(15) = -
1.41, p = .179, and reflected only a modest effect size, g = 0.28. This is 
demonstrated in figure 8.8. 
 
Paired T-Test Maximum Cystometric Capacity 
 
The average maximum cystometric capacity (in ml) prior to voluntary void 
increased between week 0 (x̅ = 383.4, SE = 25.6) and week 12 (x̅ = 420.6, SE 
= 28.7). However, this difference of 37.2 ml, BCa 95% CIs [17.72, -85.35], was 
not statistically significant t(15) = 1.62, p = 0.126, and reflected only a modest 
effect size, g = 0.3.  Demonstrated in figure 8.9. 
 
Paired T-Test Time to First Detrusor Contraction 
 
The average time to first detrusor contraction (in minutes) decreased between 
week 0 (x̅ = 5.1, SE = 1.80) and week 12 (x̅ = 4.53, SE = 1.13). However, this 
difference of -0.17minutes, BCa 95% CIs [2.1, -0.9], was not statistically 
significant t(15) = 0.572, p = 0.598, and reflected only a modest effect size, g = 

























Table 8.9 Mean changes in urodynamics variables
Urodynamics variables 




Mean at week 









BCa 95% Confidence 
Interval of the Difference  
Lower Upper t df 
Sig. (2-
tailed) 
 First Sensation 193.38 (31.27) 232.5 (29.62) 39.13 -93.13 31.05 -1.411 15 0.179 -0.284 
Maximum Cystometric 
Capacity 
383.44 (25.6) 420.63 (28.7) 37.19 -85.35 17.72 -1.621 15 0.126 -0.302 
Time to first detrusor 
contraction 
5.1 (1.80) 4.53 (1.13) -0.57 -0.9 2.1 0.572  15 0.598 0.094 
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In order to determine if SF and QoL outcomes were independent of UDS 
variables regression models were developed and analysed at week 0 and 
week 12.  UDS variables were not a good predictor of any of the scores on 
the PISQ-12, SQOL-F or PAC-QOL.  The results of the regressions with the 
KHQ were not significant. All the regression models at week 0 and week 12 




All subjects completed the first assessment, SAGA questionnaire.  The 
subject’s own treatment goals and assessment of achievement will be 
discussed in Chapter 9 and have not been included in this analysis. 
The three most important goals for the subjects in this trial were to ‘reduce 
the sensation of pressure that prompts me to go to the toilet’, ‘reduce the 
sudden need to rush to the toilet’ and to ‘reduce the number of times I go to 
the toilet throughout the day’.   
 
Table 8.10 Demonstrates results of the pre-set goals related to symptoms 
and goal achievement.  The mean importance and mean goal achievement 
for each pre-set goal has been calculated.   
 
Overall the goal ‘to reduce the number of times I go to the toilet throughout 
the day’ was the only one that was achieved by most of the subjects and this 
is reflected in the bladder diary results.  All of the goals linked to symptoms 
associated with OAB were somewhat achieved with the exception of ‘reduce 
the sensation of pressure in my lower abdomen’, whereas goals associated 





Table 8.10 SAGA Questionnaire results 
 
 
Pre Set Goals  
(SAGA Domains)  
Mean Importance 
of achieving goal  













1. Reduce the number times I go 
to the toilet throughout the day 
4.52 3.15 
2. Reduce the number of times I 
get up at night to go to the 
toilet 
3.81 2.65 
3. Reduce the sensation of 
pressure in my lower abdomen 
3.59 1.95 
4. Reduce the sensation of 
pressure that prompts me to 
go to the toilet 
4.78 2.45 
5. Reduce the difficulties I have 
completely emptying my 
bladder  
2.93 1.3 
6. Reduce the difficulty starting or 
maintaining a urinary stream 
2.63 1.65 
7. Reduce the urine loss when I 
cough, laugh, exercise or 
sneeze 
2.96 1.7 
8. Reduce my urine leakage 3.96 2.55 
9. Reduce the sudden need to 









The correlation between the self-reported importance of a goal and the 
extent of its actualisation after 12 weeks was evaluated using Kendall’s tau 
statistic. The correlation parameters for each SAGA domain are reported in 
the table 8.11 below (BCa bootstrap 95% CIs reported in square brackets).  
The only domain that reached significance was 9. ‘Reduce the sudden need 
to rush to the toilet’. 
 
Table 8.11 The correlation between goal importance and goal achievement 
for each SAGA domain  
 
SAGA Domain 
(As described in 
Table 8.18) N Coefficient Significance 
1 20 -0.57 [-0.365, 0.268] 0.775 
2 18 -0.71 [-0.410, 0.279] 0.737 
3 15 -0.413 [-0.656, -0.095] 0.084 
4 19 -0.315 [-0.561,-0.081] 0.145 
5 12 -0.22 [-0.648, 0.252] 0.413 
6 12 -0.221 [-0.619, 0.241] 0.415 
7 13 -0.33 [-0.666, 0.142] 0.184 
8 17 -0.191 [-0.694, 0.361] 0.385 







When considering overall goal achievement in the study only one subject did 
not achieve her goals with a further 35% somewhat achieving their goals.  
60% of subjects achieved their goals with 40% of those exceeding or greatly 
exceeding their expectations.  Table 8.12 Demonstrates the breakdown of 
goal achievement. 
 
Table 8.12 Overall goal achievement according to the SAGA questionnaire 
 
Goal Achievement Number of subjects (%) 
1. Did not achieve goals 1 (5) 
2. Somewhat achieved goals 7 (35) 
3. Achieved goals 4 (20) 
4. Exceeded goals 7 (35) 
5. Greatly exceeded goals 1 (5) 
 
 
Safety & Tolerability 
 
Fesoterodine was well tolerated and no subjects discontinued the medication 
due to poor tolerability.  There were no new safety concerns reported or 
cases of urinary retention.  The serious adverse event of pregnancy in one 
patient resulted in the patient being withdrawn from the trial.  Appropriate 
scans and assessments were performed along with the necessary 
documentation and notification to the MHRA.  It transpired that the subject 
had had an episode of unprotected sex the weekend before starting the trial 
and had taken the morning after pill. When the baseline visit pregnancy test 
had been performed it was only 2 days after the unprotected sex, hence it 
was negative.  Given the lack of information regarding the impact of 
fesoterodine in the early stages of pregnancy the subject was counselled 
accordingly.  However, even before this information she had decided that 
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she did not wish to continue with the pregnancy and was referred to the 
termination of pregnancy service.  
 
The most common AE reported by subjects was dry mouth by 37% of 
subjects with 60% reporting this as mild and 40% stating that it was 
moderate in severity.  Two subjects were treated for a urinary tract infection 
during the course of the study.  Bloating, constipation and blurred vision are 
also commonly associated side effects with fesoterodine but were only 
reported by one subject each.  The subject who reported a chest infection 
was enrolled in the trial over the winter period and it is presumed that this 
was associated with the time of year rather than fesoterodine. 
 
All the AE’s reported are documented in table 8.13. 
 
Table 8.13 Adverse events reported   
 
Subjects with AE’s No of subjects affected (%) 
Dry mouth 10 (37) 
UTI 2 (7.4) 
Bloating 1 (3.7) 
Constipation 1 (3.7) 
Blurred vision 1 (3.7) 
Chest infection 1 (3.7) 
Labrynthitis 1 (3.7) 








Six months follow up 
 
No new AE’s were reported. 60% continued on fesoterodine and were happy 
with their LUTS. 10% chose to try an alternative anticholinergic to see if that 
would improve their OAB whilst 10% opted to try the addition of mirabegron 
to their fesoterodine to see if this would improve efficacy.  One subject was 
referred for further investigation in view of other LUTS and two were 
escalated onto more invasive treatment in the form of Percutaneous Tibial 
Nerve Stimulation (PTNS) and Intra-detrusor injections of Botox.   One 
subject chose to try to manage her symptoms conservatively without any 
medication.  These are demonstrated in table 8.14 
 
Table 8.14  Treatment at six months 
 
Treatment at the 6 months point No of Patients (%) 
Continued with fesoterodine 12 (60) 
Alternative anticholinergic 2 (10) 
Combination therapy of fesoterodine 
and mirabegron 
2 (10) 
Further investigations 1(5) 
PTNS 1(5) 
Botox 1(5) 












These results have demonstrated that in this cohort of women fesoterodine 
appeared to improve sexual function as well as improve their OAB 
symptoms, QoL and most of the women achieved their goals with therapy.  A 
more detailed discussion linking these findings to the current literature and 
suggesting new areas for investigation will be presented in Chapter 9.   
 
Although there are trends noted within the data collected, as the recruitment 
figures were so low it is difficult to comment on what would have been a 
significant result.  It is possible that a statistician could perform a new power 
calculation based on these results to see if they generate a smaller sample 














Discussions of quantative results and 
development of the further research 
















Following on from the analysis of the trial data presented in Chapter 8, this 
chapter aims to discuss the quantative findings of the study, reviewing the 
baseline demographics of the participants and examining the results of both 
the primary and secondary outcomes.  Comparisons to published studies will 
be highlighted and possible rationales for observations will be suggested.   
 
The chapter will detail the limitations and weaknesses of the study and the 
potential impact that they may have had on the final results presented and 
what has been learnt from these.  Challenges with the local clinical trials 
office, ethical, MHRA and national portfolio approvals are addressed and 
explained.  Finally, as the study progressed and during the analysis, there 
were several challenges that arose and further research questions that 
developed.  These new areas of investigation which were pursued will be 
introduced prior to further discussion in later chapters.  The results of the 
qualitative findings will be presented in chapter 10. 
 
Despite the fact that this study only recruited 28 subjects, we were able to 
show statistically significant results in both the primary and many of the 
secondary endpoints albeit with wide confidence and a moderate effect size 
(as presented in Chapter 8).    Typically, the smaller the study population the 
more variation in outcomes and the larger the study population the more 
likely to find statistically significant differences in outcomes.  Given the fact 
that this study showed significant results with the small sample, it is likely 
that a bigger group may have just narrowed the CIs and increased the effect 
size.  In this case a type 1 error is unlikely as the study showed statistically 
significant results in both the primary and many of the secondary outcomes.     
 
This means that we have been able to show an improvement in SF following 
treatment with fesoterodine in women with OAB.  However, the fundamental 
issue with the methodological design of the study means that due to the lack 
of a comparison group in this study it cannot be determined if this effect is 
related to fesoterodine or due to a placebo effect.   Traditionally in OAB 
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studies, the placebo effects accounts for approximately a 30% improvement 
in symptom outcomes.  This effect in this study is of that order, however, the 
placebo effect on SF in OAB trials has not been studied so we cannot say if 
the results are due to the effect of the drug or the potential therapeutic effect 
of having a personal conversation with a health care professions about SF 
and an opportunity to discuss concerns / understands norms etc. 
 
Therefore, this study has either demonstrated the placebo effect of a clinical 
trial on SF or the potential for fesoterodine to improve SF in women with 
OAB.      
 
Baseline demographics  
 
The cohort of subjects recruited into this study were similar to other OAB 
trials reported with the exception that there were a slightly higher number of 
ethnic minorities, however, this is in keeping with our local population.  
 
All bar one subject had previously tried another medication for her bladder 
symptoms.  This was to be expected as the study recruited women from a 
secondary care setting and in line with NICE CG171 (2013), first line drug 
therapy should have been commenced in primary care by the GP.  The only 
treatment naïve subject had declined first line drug therapy by the GP opting 
for conservative management only until she had a definitive diagnosis.   
The length of time that subjects had been experiencing OAB symptoms was 
wide ranging and if the trial had met recruitment targets it may have been 
interesting to investigate whether the length of time a subject has been 
symptomatic influences outcomes.  However, there are too few patients to 
make any further comment on this. 
 
There was a greater OAB wet population than OAB dry in this study (81.5%), 
however, the frequency of UUI was low with a baseline UUI rate of 1.68 
episodes per week. This low frequency of UUI may bias the group as 
increased frequency of UUI has been reported to result in increased 
bothersomeness or impact on quality of life (Cetinel et al 2006).  If this had 
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been the case and the analysis met the appropriate power it could be 
suggested that this study sample was not representative of the OAB 
population yet with such small numbers no further speculation is warranted. 
 
The percentage of subjects who chose to dose escalate was 53.7%.  This is 
in keeping with the findings from the systematic review on dose escalation in 




Overall both of the primary outcome measures demonstrated improvements 
in SF following twelve weeks of treatment with fesoterodine.  The Minimally 
Important Difference (MID) is defined as the difference in score that is 
representative of what patients and clinicians perceive as beneficial or 
harmful and which would justify (in the absence of bothersome side effects or 
cost) a change in the patients management (Barber et al 2009).  According 
to Mamik et al (2014) the MID for the PISQ total score is 6 points and 
improvements that meet this threshold can be considered clinically important.  
In order to compare the long and short form scores the mean change from 
baseline to week 12 is multiplied by 2.58, therefore, for this study it is 11.223 
so well above the MID.  This may indicate the potential benefit of 
fesoterodine in improving the SF of women with OAB, but may also be a 
placebo effect.    The differences in PISQ-12 scores in each subject over the 

















The SQOL-F questionnaire assesses sexual quality of life in three different 
dimensions: self esteem, emotional issues and relationship issues, however, 
no MID has been reported in the literature for this questionnaire. 
 
The greatest change in a single item score on the PISQ-12 was seen in Q7 
“Does fear of incontinence restrict your sexual activity?”  It has previously 
been reported that UI during SA can increase anxiety and psychological 
burden on the patient and this can cause pain and discomfort during SA and 
difficulty achieving orgasm (Coyne et al 2009a).  In Italian women, fear of 
leakage and its consequent embarrassment has been shown to prevent 
women from participating in sexual activities (Tubaro 2004)  Nicolson et al 
(2008) performed focus groups and interviews with people with OAB to 
understand the psychological consequences of their symptoms and the 
impact on their QoL.  Participants described anxieties related to body image / 
self-esteem and the fear of leakage that was triggered by anxiety and 






















Differences In PISQ-12 scores for each subject between 
week 0 and week 12
Week 0 Week 12
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In this study, many of the women reported a reduction in incontinence during 
SA following 12 weeks of fesoterodine (see table 8.3) and it could be 
hypothesised that in line with this reduction of leakage experienced, the 
anxiety / fear of UI reduced and resulted in less restrictions in SA.   A larger 
cohort would be needed to fully assess this idea. 
 
In the literature review, it had been noted that typically anticholinergic 
medication can have a negative impact on the arousal domains of SF but in 
this cohort there was no difference noted between week 0 and week 12 in 
the arousal domains of the PISQ-12 (Questions 1 and 3). 
 
The greatest improvements from baseline (eg reduction in score) on the 
SQOL-F were seen in Q7 ‘When I think about my sex life I feel anxious’ and 
Q10 ‘I worry about the future of my sex life’.  This mirrors the findings in the 
EPILUTS study where participants with OAB reported significantly more 
worry over the future of their sexual life (Coyne et al 2011). 
 
It has been demonstrated that symptoms associated with OAB can be 
detrimental to psychological wellbeing as well as on a physical level (Toozs-
Hobson 2010).  A systematic review by Kinsey et al (2016) reported on 
seven studies that compared anxiety levels in OAB patients to non OAB 
controls.  All the studies described significantly higher levels of anxiety in the 
OAB groups compared to the controls, with OAB wet patients reporting 
higher levels of anxiety compared to those with OAB dry.  Additional studies 
corroborate these results in older populations and in other types of urinary 
incontinence (Mehta et al 2003, Lim et al 2007, Knight et al 2012, Alves et al 
2014).   
 
For many years it has been suggested that psychosomatic disorders e.g. 
anxiety may play a role in the pathogenesis of OAB (Freeman et al 1985).  
According to a prospective longitudinal study by Perry et al (2006), 56.6% of 
women with UUI report symptoms of anxiety and 37.6% described symptoms 
of depression.  However, incident cases of UUI can be predicted by anxiety 
at baseline and it was noted in the study that anxiety, UUI and frequency 
222 
 
appear to interact and exacerbate each other.  Sakakibara et al (2013) 
reported that anxiety and depression are a cause of bladder dysfunction, 
particularly OAB, and that the bladder is under emotional control.  This would 
then pose the question of which came first – the OAB or the anxiety / 
depression?   In the study for this thesis, this question was not considered 
when recruiting women but it is unlikely that it would have had any impact on 
the outcomes due to the small numbers in the trial.  In future however, one 
may consider adding this question to the baseline assessment.   
 
It would have been interesting to compare the psychological domains of the 
QoL and SF questions in the OAB wet and dry groups to see if there are any 
differences in the outcomes of treatment.  However, due to the small 
numbers of women recruited into the study, the groups would have been too 
small for meaningful analysis.   
 
There were also considerable improvements seen in the single item scores 
on the PISQ-12 related to pain during intercourse / negative emotional 
reactions / intensity of orgasms and fear of UI.  It could be hypothesised that 
if women no longer fear UI during intercourse, it may reduce their anxiety, 
improve body image and allow them to relax during sex, reducing pain and 
potentially improving orgasms. 
 
When looking at the difference in individual questions on the PISQ-12, no 
difference was reported in Q3. ‘Do you feel sexually excited when having SA 
with your partner?’ And Q10 ‘Does your partner have a problem with 
erections that affects your SA?’   This could be expected as all subjects 
recruited were in stable sexual relationships so there were no new sexual 
partners introduced and no intervention was provided for the partners.  
However, for the women who’s SF improved during the study, as they started 
to feel better about sex it could have increased sexual excitement but this 
was not observed ,  If partners had pre-existing problems with erections, it 
was presumed that this would be the same throughout the course of the 
study.  Although there is evidence to suggest that the partners of women with 
UI have reduced SF (Beji et al 2005, Bekker et al 2010), no assessments of 
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partners were included in this study and there is no evidence that partners 
experienced improvements in SF or erection quality if the woman’s UI was 
treated.   
 
The smallest changes on the SQOL-F was also seen in the partner related 
aspects of the questionnaire with most women reporting that they feel close 
to their partner and that they are able to talk to them about sexual matters.  
Only a few women in this cohort worried that their partner felt hurt or rejected 




When reviewing the efficacy outcomes it is important to consider what a 
clinically important difference is to the patient.  The minimal clinically 
important change in the number of UUI episodes has been shown to be a 
reduction of more than three UUI episodes per week from baseline (Homma 
& Koyama 2006).  In this study 81.5% of subjects were wet at baseline.  
According to the bladder diaries, the mean change in number of UUI 
episodes per day was -1.02 and this would result in a reduction of over 
double the threshold of 3 episodes per week, indicating a clinically important 
change.  Within the primary outcomes, the impact of anxiety associated with 
UUI was highlighted as a significant factor for women.  Yet in the study 
quoted above it was not recorded how many episodes of UUI make 
somebody anxious.  Due to the subjective nature of this, a future study 
investigating anxiety levels and UUI episodes would be interesting, although 
one would hypothesise that this is multifactorial based on personality and 
resilience as well as the physical symptoms. 
 
Another measure that can also be considered is dry rates (ie those who 
reported UUI at the start of therapy but this has now resolved).  In this study 
64.7% of subjects reported no longer experiencing UUI after 12 weeks on 
fesoterodine.  This is in keeping with other studies where the dry rate was 
64% (Herschorn et al 2010a).  Women also reported a 68.3% reduction in 
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urgency at the 12 week point and again this is in keeping with the FACT 
study which showed a 71.4% reduction in urgency (Herschorn et al 2010a).    
 
Nocturia was not found to be a particular problem within the current study 
with the median number of nocturia episodes per 24 hours was only 1 at 
baseline and 0 at week 12.  When considering the prevalence of nocturia in 
women it has been reported to affect between 5.4-7.9% of pre-menopausal 
women and 13.3-17.6% of post-menopausal women (Rekers et al 1992, 
Samuelsson et al 1997). A systematic review of nocturia reported that 
women over 60 years old are four times more likely to report nocturia than 
women under 60 years (Pesonen et al 2016).  Given that only three women 
(35.7%) in this group were over 60 and 14 (64.3%) were pre-menopausal 
these low rates of nocturia are not unexpected.   
 
Overall, a 30% reduction in the number of voids per day from baseline was 
reported.  This is slightly higher than in some of the other studies which have 
reported reductions in frequency of 18.9-23.5% (Kaplan et al 2011, 
Herschorn et al 2010a).  There was however a significant reduction in fluid 
intake (18%) over the course of the 12 weeks of the study that may account 
for this.  This effect could just be a result of the small numbers in this cohort 
and unrepresentative of the OAB population or as a result of inadvertent 
advice given to patients in the study as they were attending our 
Urogynaecology unit where information leaflets are freely available and 
posters are on display recommending lifestyle changes that may help 
improve bladder symptoms.    
 
The minimal improvement in HRQL that confers clinical benefit to the patient 
is a change in KHQ domain scores of ≥ 5 points from baseline (Kelleher et al 
2004).  This was seen in every domain of the questionnaire in this analysis.  
The highest domain scores at baseline, indicative of greatest impairment, 
was reported for incontinence impact, followed by role limitations and 
physical limitations.  The greatest improvements at week 12 were seen in 
role limitations, followed by emotions and incontinence impact.  This 
improvement in emotions may also link in with the reduction in anxiety / 
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depression and improvement in self-esteem noted in the primary outcomes.  
In the pooled analysis of fesoterodine on QoL, the greatest improvements 
were seen in incontinence impact, role limitations and physical limitations so 
the findings of this study are in keeping with previous work (Kelleher 2008).  
These improvements in HRQL are not just similar to other studies using 
fesoterodine but are also in line with other treatment modalities eg 
onabotulinum toxin A (Botox) (Nitti et al 2013, Ginsberg et al 2017).  The 
least change was seen in the general health perceptions domain but this is to 
be expected as it is a marker to show that the questionnaire works in this 
population.   
 
The PAC-QoL questionnaire provided us with very little information in this 
study.  This may be because none of the subjects had specific problems with 
constipation at the start of the study and only one reported constipation as an 
adverse event.  When the study was designed, this outcome was added as 
constipation is often quoted as the second most common adverse effect of 
anticholinergic medications after dry mouth, yet there is little understanding 
regarding how bothersome this is, hence the choice of questionnaire.  It is 
difficult to predict based on these results if this outcome would be different 
had full recruitment targets been met.  However, if designing this study 
again, potentially the International Consultation on Incontinence- bowel 
symptoms questionnaire (ICIQ-BS) would be adopted, as by using this 
modular questionnaire, results can be pooled and compared with other 
studies.   Constipation is reported as an adverse event in many studies using 
anticholinergics and often quoted as a reason why people stop therapy. The 
lack of impact on constipation and QoL in this study is surprising and 
deserves further investigation.   
 
When reviewing the outcome of the PPBC, 20% of the subjects did not report 
any difference after 12 weeks of treatment with fesoterodine and this is in 
keeping with the findings of the FACT studies.   
 
The UDS outcomes were added to the study when supervision for this 
degree was changed from the School of Nursing to the Faculty of Life 
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Science and Medicine.  It was considered an exploratory idea to investigate 
whether SF and QoL outcomes were independent of UDS variables.  
Originally, the plan was to recruit 40 subjects into this arm but only 16 were 
included in the final analysis.   
 
When comparing pre and post treatment UDS, there were no significant 
increases in first sensation to void, maximum cystometric capacity or time to 
first detrusor contraction.  For those who had DO at baseline, 50% did not 
have repeat UDS  (either because they were no longer in the study or did not 
consent), 31% still had DO at 12 weeks and 19% DO did not occur on UDS.   
 
Regression models were developed to determine if the outcomes of the 
PISQ-12, SQOL-F, KHQ and PAC-QoL at week 0 and 12 were independent 
of UDS variables.  However, no trends could be identified.  Again this could 
be because recruitment to this part was still under 50% of the original target, 
however, as this was an exploratory idea it could also mean that SF and QoL 
outcomes are independent of UDS variables but this cohort is not large 
enough to confirm this.  Previous work has demonstrated that treatment 
efficacy with fesoterodine is independent of the UDS diagnosis (Nitti et al 
2010a).   
 
The most important goals set by subjects were ‘to reduce the sensation that 
prompts me to go to the toilet’, ‘reduce the sudden need to rush to the toilet’ 
and ‘to reduce the number of times I go to the toilet throughout the day’.  
These are the same as those reported in the SAFINA Study and relate to the 
cardinal symptom of OAB, which is urgency and associated urinary 
frequency (Cardozo et al 2012).  The least important goals were related to 
maintaining urinary stream, emptying the bladder and reducing stress 
incontinence and none of these goals were achieved.  This is to be expected 
as this cohort have all been assessed to ensure that they were emptying 
their bladders and all had urgency predominant symptoms.  The only goal 
completely achieved was related to reducing urinary frequency.  This is not 
surprising considering the 30% reduction in urinary frequency noted on the 
bladder diaries that has previously been discussed. The goals related to 
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reduction in urgency and UUI were somewhat achieved and this is in line 
with the 64.7% dry rate and 68.3% reduction in urgency demonstrated.   
 
Overall goal achievement was 60%  compared to the 50% in the SAFINA 
study but this may be due to the difference between having men and women 
in the study and issues around maintaining urinary stream which was flagged 
as an important goal in the SAFINA study but not in this group and mainly 
relate to men rather than women.  
 
In line with many other studies previously discussed, fesoterodine proved to 
be a safe and well tolerated drug.  As with all studies on antimuscarinincs, 
the most common adverse effect was dry mouth.  The rate of dry mouth in 
this cohort was 37% and this is in line with findings from other studies where 
it ranged from 33.8-37.7% (Herschorn et al 2010b, Kelleher et al 2012).  
However, it was not severe enough to result in any discontinuations from the 
study.   
 
Literature has reported 6 months persistence rates for anticholinergics in the 
real world ranged from 28% to 46% (Yeaw et al 2009, Wagg et al 2012).   In 
a pooled analysis of the Chapple (2007) and Nitti (2007) long term extension 
trials, 49% of subjects continued on fesoterodine for two years (Kelleher et al 
2012).  In this study, 60% of subjects continued with therapy at the six month 
stage.  This is quite high and could still be due to the effect of being 
monitored in a clinical trial and would be likely to reduce over time were they 
to be assessed at the one or two year point.  The most common reason for 
stopping treatment was lack of efficacy in line with most other trials of 












Issues with study set up 
 
Once confirmation that funding had been awarded was received in 2010, the 
first stage of the approvals process was to get the Joint Clinical Trials Office 
(JCTO) involved as they would be sponsoring the project.  They provided 
specific guidelines and structures that were necessary for CTIMP’s and 
would be checking the protocol and submissions to the REC, R & D and 
MHRA.  Unfortunately, the clinical research associate (CRA) assigned at the 
beginning of this study did not make decisions well and did not manage 
processes in a timely manner.  A table has been included in the appendix to 
demonstrate the time delays and barriers faced at each step of the way when 
trying to get this protocol and IRAS form fit for submission and approval.   
 
During the course of this study the JCTO underwent a major restructuring 
and management changes and is now called the King’s Health Partners 
Clinical Trials Office (KHPCTO).  There have been many staff changes and 
this study has had six different CRA’s throughout its course which has 
caused endless delays / confusion and duplication of work within the 
monitoring process.  In the light of other research issues within the hospital, 
a meeting was convened between the hospital R&D team, all the local PI’s 
and the JCTO.  This study was used as an example of barriers in the 
research process and a full apology has been issued by the KHPCTO.    
 
Issues with recruitment 
 
The most fundamental issue with this study has been with the lack of 
recruitment.  Once approvals were in place and IMP was available, it was 
hoped that 10 women per month could be recruited from clinics.   
 
However, the site had real difficulty finding women who met the inclusion and 
exclusion criteria who were willing to take part.  After the first couple of 
months of only recruiting one subject per month, action was taken so that 
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research posters were put up in all the toilets in the women’s outpatients 
department, and flyers were in all waiting rooms.  Research flyers were also 
sent out to all patients in their UDS appointment packs and to all those 
attending the bladder retraining classes.  Women were approached in their 
clinic appointments to enquire about joining the study but still the site was 
struggling.   
 
After 9 months, discussions took place with the investigators clinical 
supervisors to try to enhance recruitment.  It was suggested that the second 
supervisor’s hospital – Guy’s and St Thomas’ Hospital (GSTT) could be used 
as a patient identification centre (PIC) and potential subjects could be 
directed to the study team for screening.  A substantial amendment was 
successfully submitted to the REC and research posters and flyers were 
again put up in the toilets in the women’s outpatient department and provided 
in waiting areas at a second hospital.  Although this resulted in a substantial 
number of women phoning the research site or contacting the investigator by 
email, unfortunately none of them were suitable to recruit due to a variety of 
issues but most commonly that women had not correctly read the poster and 
were not sexually active (NSA).   
 
After a further 3 months, recruitment had still not improved so the decision 
was made to include additional research sites.  Through discussion with the 
PI, three additional sites were identified in large Urogynaecology units across 
London.   
 
The units were all well versed in carrying out CTIMP’s in women with OAB 
and given that the study was on the National Portfolio it made it profitable to 
their departments to be involved.  In September 2013, Imperial College 
Hospital Trust were confirmed as a recruitment site and then in May 2014 
(due to delays in the JCTO with contracts) Croydon University Hospital and 
Medway Hospital were also initiated as research sites.   
 
The investigator performed the set up visit at all of these sites, created all of 
their site specific documentation and site files and to encourage competitive 
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recruitment offered a night out for dinner in London for the research team 
that recruited the most subjects.   Sites were emailed every other month for 
updates on recruitment.  
 
One year later in July 2015, recruitment was still very low at the index site 
and none of the additional sites had managed to recruit a single subject.  A 
meeting was held with the investigators clinical supervisors and questions 
raised to identify why we could not recruit women into this study.  From the 
investigators own experience, reasons for poor recruitment included a lack of 
women who were actually SA, and for those who were SA many did not meet 
the inclusion criteria frequency of once a week.  Several women had failed 
screening due to their bladder diaries not meeting inclusion criteria of 8 voids 
per 24 hours.  Feedback was sought from the other sites who also reported 
women screen failing on the once a week sexual frequency as well as 
women not wanting to discuss the issue or complete personal 
questionnaires.  One site reported that the reason women had declined was 
because they did not want to complete so many bladder diaries.   
 
Based on these discussions the investigator and PI went back to the 
research protocol and reassessed each of the inclusion / exclusion criteria.  
The two main concerns identified were inclusion criteria 3 and 5.  Inclusion 
criterion 3 was one of the criteria taken from the SAFINA study as was a 
common requirement in all OAB trials.  However, in 2010 the definition of 
frequency according to the joint terminology report from ICS / IUGA changed 
from ‘voiding 8 or more times per day’ to ‘voiding a number of times deemed 
bothersome by the individual’ but this was not reflected in our protocol and 
preventing women from entering the study (Haylen et al 2010).   
 
Issues with SA 
 
When inclusion criterion 5 was set, it was to provide an arbitrary frequency of 
SA so that subjects were SA regularly during the course of the 12 weeks of 
treatment and hence may notice a difference.  It was felt that if women were 
only SA one or twice during this time changes may not be noticed.  However, 
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many women were reporting that they were NSA that often and this meant a 
lot of women failed the screening.  One of the difficulties of setting this figure 
had been in relation to variations in SA according to age especially as the 
age range for this study was 18-80 years.  In 2013, data were published 
quoting the average frequency of SA per month according to age range and 
it varies from 5.8 to 1.4 times per month (Mercer et al 2013).  When 
considering the frequency set in the study on average only women aged 
under 44 years of age would meet the entry criteria.   
 
Based on these findings a substantial amendment was submitted to the REC 
requesting a change to the protocol so that the value of more than 8 voids 
per 24 hours on the bladder diary was removed and replaced with the 
inclusion of frequency as deemed bothersome by the patient and the 
frequency of SA of once per week was also removed and replaced with the 
more open inclusion of SA within the course of the trial but without any set 
arbitrary figures. 
 
Finally, to allow maximum time for recruitment, study timelines where 
changed to extend the recruitment period. 
 
 
Amendments to the study 
 
In view of all the changes to the study related to the recruitment issues 
discussed above and other logistical issues related to the supply of IMP and 
extension of timelines there have been many minor and substantial 
amendments submitted to the REC and R&D and multiple versions of the 
research protocol as it has been updated.  For reference these have been 








Limitations / weaknesses of the study 
 
There are several limitations that have been identified in this study.  The 
most important problem identified was in the lack of a comparator arm for the 
study.  Although the study was consistent with a significant positive effect of 
fesoterodine on the SF in women, it is not possible to be confident that this is 
a true result and not just a placebo effect from a health care professional 
taking an interest in this aspect of their life or from the thought and 
deliberation on the topic required to complete the questionnaires.  The fact 
that the initial criteria of the study required women to be SA at least once per 
week, may have invigorated and renewed an interest in their sexual lives not 
only for them but also their partner and this potential increase in attention 
may also have had an impact on the results.  Looking back at the results 
there was no significant difference in the desire question on the PISQ-12 or 
the SQOL_F, however, there was a significant positive change in the score 
on the SQOL-F related to happiness with frequency of sexual activity which 
may be related to this. 
 
Since the original power calculation was performed there have still been very 
few studies performed in women with OAB where SF outcomes are the 
primary endpoint.  However, if the study were to be redesigned now then 
potentially an alternative SF questionnaire would be employed in the study 
(the Female Sexual Function Index FSFI) and there are many studies using 
this questionnaire in a variety of populations.    Potentially, with this increase 
in available data, an alternative power calculation based on a different 
questionnaire could lead to a reduced number of women required to reach 
statistical significance which would result in a far more feasible study in this 
population.   
 
It would be interesting to perform a longitudinal observational study in a 
cohort of women who are SA, where the only intervention received is time 
with a HCP when they have the opportunity to discuss their SF and complete 
questionnaires relating to SF and to repeat the assessment over several time 
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points to understand not only variations over time but also the impact of this 
potential package of care.  This potential for improvement in symptoms could 
be considered the same as the learning aspects associated with the use of 
bladder diaries and improvements seen in diary variables.   
 
The lack of a placebo arm could also be considered as a limitation in this 
study as it means that findings were not comparable to no treatment (other 
than a package of care).  There have previously been many studies 
confirming the efficacy of fesoterodine in comparison to placebo (Chapple et 
al 2007, Nitti et al 2007, Herschorn et al 2010, Kaplan et al 2011).  As all 
subjects in this trial received open label treatment there should be no 
intervention bias.  It also empowered the subjects to choose therapy with the 
option to dose escalate and the intention of this was to ensure optimum 
treatment efficacy in the hope that it would in turn result in optimum impact 
on the primary outcomes.  However, it is known that the placebo effect in 
LUTS has a strong behavioural component as patients become aware of 
their voiding habits and potential risk factors (Van Leeuwen et al 2006), and 
this may have had a confounding effect on the efficacy outcomes. 
 
In retrospect we recognise that the trial inclusion / exclusion criteria were too 
stringent.  The main criteria were originally from a trial looking at efficacy and 
tolerability of flexible dose fesoterodine.  The exclusion criteria included an 
extensive list to try to recruit a ‘pure’ group with few confounding variables so 
women who had previously had pelvic surgery, or who took certain 
medications or were receiving other conservative therapies were all 
excluded.  This allowed the trial to focus on patients most likely to respond to 
treatment who were unlikely to have an alternative aeitiology behind their 
SDF.  In this study, many women did not even make it to the screening 
stage, for example those with de novo OAB post successful incontinence 
surgery.  In clinical practice these women would still be offered the same 
therapy and they may be experiencing the same problems with SF.   Thus it 
is possible that if the exclusion criteria were relaxed to open up the study 
population, recruitment would be improved.  It is appreciated that this would 
increase the heterogeneity of the group but the study of SF in women with 
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OAB symptoms and the impact of an intervention such as drug therapy is not 
an exact science and this may have provided us with a more ‘real world’ 
view. 
 
Discussions in relation to the lack of probability sampling methods used in 
the recruitment of subjects for this study and the rationale for this have been 
previously provided in the methods chapter.  As all patients were recruited 
from one single site and all data collection performed by one single 
investigator, this could introduce a selection bias into the findings.  Although 
a single investigator collected all the data and performed all the trial visits, 
the use of validated and reliable self-reported questionnaires, filled out at 
appropriate time intervals should prevent any measurement and recall bias.    
 
In total, recruitment to this study took place over four years.  It is possible 
that there may have been confounding factors affecting the results of the trial 
dependent on the time of year the subjects were recruited.  It has been 
demonstrated that cold weather can negatively impact upon OAB symptoms 
(Victor et al 2012) and this may result in poorer outcomes.  However, in 
reality the numbers in this study are too small for this to have a significant 
impact.   
 
Another limitation of this study could be considered with the sample 
population itself.  As this study was recruiting women with OAB and not just 
DO, some of the subjects may have had the OAB symptoms due to 
underlying causes which would never respond to an antimuscarinic despite 
them being widely available and employed for women with OAB not just DO.  
It is however, hoped that the screening measures employed and exclusion 
criteria set may have prevented this being an issue.  Also, work by Malone 
Lee & Al‐Buheissi (2009) reported that treatment response to 
antimuscarinics is no different dependent on whether the subject has DO or 






Reflections on Methodology 
 
This study has confronted many problems along the way, not only from a 
sponsorship / regulatory point but the main issue has been related to the lack 
of recruitment to the study.  Despite multiple attempts to change the protocol 
and increase the study population available by the addition of research sites 
only a fifth of the intended numbers of subjects were recruited.   
 
When the protocol was first developed, it was naively believed that due to the 
extensive experience in the department of conducting CTIMP’s assessing 
treatment efficacy for women with OAB that by adopting a similar approach 
for this study a pilot study to test the research methodology would not be 
required.  In reality, this study, instead of meeting recruitment targets and 
allowing the analysis to provide us with statistically significant results based 
on an appropriate power, has become its own pilot study helping to identify 
ways in which research methodology needs to differ when assessing sexual 
function outcomes.   
 
It has highlighted how our knowledge of this patient population, particularly in 
relation to the prevalence of women with OAB that are sexually active, is 
deficient and has helped to identify the need for further investigation in 
women who are not currently sexually active and the reasons why this may 
be.  It could be hypothesised that women may not be sexually active due to 
their bladder symptoms and that treatment of those symptoms may enable 
them to re-engage with sexual relationships.  Due to the design of this trial, 
these women would have been excluded therefore future studies in this area 
should be considered.   
 
Throughout this study there have been many discussions regarding the 
methodology and what could be the barriers to recruitment.  Potential 
concerns with the inclusion criteria were identified and addressed and no 
concerns were raised in relation to the tools used to measure outcomes, the 
sampling methods or trial processes.  However, considerations were not 
made to the non-standardised aspects of this trial, most importantly how the 
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clinicians approached the women regarding SA and how they took a sexual 
history.  With multiple research sites and trial personnel, there may have 
been a significant variation in the way in which women were approached, 
and the depth of discussion on sexual function.  One possible change for 
future studies would be to develop a recommendation of how to take a 
sexual history and to ensure all study staff are educated appropriately to use 
standardised introductions to the subject for women and clinicians.  This may 
reduce variations in the discussions regarding SF and foster more open 




Although this study did not proceed as planned, the results of the secondary 
outcomes are in keeping with most other clinical trials using fesoterodine.  
Given these similarities, it is considered that as there were statistically 
significant improvements in the primary and secondary outcome measures, 
this does confirm that this is an appropriate area for investigation.  There is 
potential for a positive benefit of fesoterodine for the treatment of OAB on 
women’s SF.  However, the design of this study means that we cannot 
confirm that this was not due to a placebo effect rather than drug effect. 
Further investigation into the sample population is necessary to determine 
the scope of the problem and understand how to identify these women in 
practice so that appropriate and reliable sampling methods can be developed 
























This study used a mixed methods approach.  A quantitative approach to 
measuring changes in sexual function associated with the use of 
Fesoterodine was used and the results are reported in the previous chapter. 
In addition to this, the Self Assessment Goal Achievement (SAGA) 
questionnaire was used to allow patients to report their own treatment goals 
and desired outcomes from therapy.   
 
As previously described in Chapter 6, the SAGA questionnaire contains 9 
fixed goals and a further 5 open ended goals where patients were able to set 
any individual goals or outcomes that they wanted to achieve.  The 
qualitative component of this study involved analysing the data from the open 
ended patient centred goals to focus more on what is actually important to 
patients and the true impact of their symptoms on everyday life rather than 
just using fixed outcomes.   
 
By using qualitative as well as quantitative methods we were able to gain 
deeper insights and a broader perspective into the ways in which symptoms 
impact on an individual’s quality of life in a manner that captures their own 
thoughts, views and subjective opinions alongside the objective data gained 
from the main study.   
 
This chapter describes not only describes the use and analysis of the SAGA 
questionnaire in this study but I was also offered the opportunity to analyse 
the qualitative results of the SAGA questionnaire from the UK multicentre 
SAFINA study.  It will therefore include the analysis of the goals from the 
SAFINA study and comparisons with the cohort of patients from this thesis 
will be discussed.    
 
Patient centred outcomes 
 
In clinical practice and in research, patient centred outcomes are often 
utilised to help improve communication between patients and clinicians and 
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to help manage expectations from treatment.  However, many of these goals 
are generic and do not adequately capture the details of day to day life that 
bother patients the most and that they hope will improve with therapy.    
 
Patient centred outcomes in Urogynaecology were first described by 
Brubaker and Schull (2005) who coined the term EGGS to facilitate 
communication about patient-centred treatment outcomes —E expectations, 
G goal setting, G goal achievement, S satisfaction.  It has been reported that 
positive physician - patient communication, and setting individualised 
treatment goals can lead to improved patient satisfaction (Marchall-Kehrel & 
Spinks 2011).  Also, by allowing patients to set their own goals for treatment, 
and then to self-assess achievement of those goals it may help to capture 
the effect of OAB and the impact of treatment in a more individualised, 
patient centred way than disease specific QoL questionnaires  in common 
usage (Cartwright et al 2010).  According to Hullfish et al (2002), assessment 
of patient goals is quick and easy and may help clinicians better understand 
and care for their patients. 
 
Although goal attainment scoring has been used for different conditions until 
the development of the SAGA questionnaire by Brubaker et al (2011), there 
were no self-completed instruments that would allow patients with LUTS to 
proactively capture their treatment goals for discussion with their healthcare 
provider in a routine clinical or research setting.  The SAGA questionnaire 
was designed to improve physician-patient interaction and to allow goal 
achievement to be assessed in research studies.  It has been validated and 
its clinical utility assessed and it has been used in many different research 
trials for patients with OAB as discussed in Chapter 6 (Brubaker et al 2011, 
Brubaker et al 2013, and Khullar et al 2013).  
 
The SAGA questionnaire was incorporated as an outcome measure in the 
study described in this thesis (which will be called Feso and SF for the 
subheadings in this chapter) and also in the UK Study Assessing Flexible-
dose fesoterodine in Adults (SAFINA) (Cardozo et al 2012).   The SAFINA 
study was a 12 week, multi-centre open label study which recruited 331 
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adults with OAB at 39 sites in the UK from February 2009 to January 2010.  
During the initial stages of this thesis, the student was offered the opportunity 
to perform the qualitative data analysis on all the patient goals set in the 
SAFINA study.  This was completed and published as an article entitled 
‘Personal goals and expectations of OAB patients in the UK’ in Neurourology 
and Urodynamics as well as being presented at National and International 
meetings.   
 
SAFINA Study – Methodology 
 
The aim of the study was to evaluate the efficacy and safety of flexible dose 
fesoterodine and the factors associated with dose escalation in subjects with 
OAB.  All subjects were treated with fesoterodine 4mg once daily for the first 
four weeks and were then given the option to dose escalate up to 8mg for 
the next eight weeks.  Treatment was stopped at twelve weeks and subjects 
were reassessed at 16 weeks (Khullar et al 2013).  At each visit in the study 
patients completed a 3 day bladder diary and multiple questionnaires to 
identify patient reported outcomes.  A preliminary version of the SAGA 
questionnaire was included in the study as an exploratory endpoint.  
Inclusion / exclusion criteria can be found in the main study publication.  This 
study was approved by the appropriate Independent Ethics Committee and 
conducted in compliance with the ethical principles of the Declaration of 
Helsinki and the International Conference on Harmonisation Good Clinical 
Practice Guidelines.  Written informed consent was obtained from each 
subject before entering the study.   
 
Fesoterodine and Sexual Function Methodology 
 
These were the same as described in Chapters 6 and 7. 
 
SAGA Analysis Methodology (as applied to both studies) 
 
The SAGA questionnaire is a patient completed, physician reviewed tool to 
assess the patient’s goals for treatment and whether the goals have been 
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achieved for subjects suffering from OAB and/or other LUTS.  The SAGA 
questionnaire is in two parts.  The first part contains nine fixed goals with a 
further five open-ended goals.  These goals are reviewed with the clinician in 
order to assess whether they were realistic.  The SAGA follow up 
questionnaire asks the patient to relate the degree of achievement of the 
original treatment goals set prior to the start of treatment.  Multiple clinicians 
completed the SAGA questionnaire with subjects in the SAFINA study, 
compared to the single clinician in the Fesoterodine and SF study.   
 
Qualitative Analysis Methodology    
 
This chapter specifically examines the open ended goals that patients chose 
in relation to what they would most like to achieve from therapy, therefore, in 
order to determine the most appropriate method of data analysis to be used 
in this enquiry a review of the literature was performed.   
 
Thematic analysis is a method for identifying, analysing and reporting 
patterns (themes) within data and is considered as a foundational method for 
qualitative analysis (Braun & Clarke 2006).  It is one of the most commonly 
used methods for data analysis in qualitative research, however, according 
to Boyatzis (1998) thematic analysis is not a specific qualitative data analysis 
method but a tool to use across methods.   It is reported that thematic 
analysis is well suited to large data sets as it allows for categories to emerge 
from the data and that the interpretation of these themes are supported by 
the data, however reliability can be of concern if there are different 
interpretations of the data from multiple researchers (Guest 2012, Saldana 
2009).  Considering that there would be a large data set and only two 
researchers it was thought that thematic analysis was the most suitable tool 
for data analysis and that an inductive approach should be adopted but 
further decisions on an appropriate methodology was required.   
 
The three most common qualitative approaches used in health research are 
Phenomenology, Discourse Analysis and Grounded Theory (GT).  Discourse 
analysis aims to understand how people use language to create and enact 
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identities and activities and was not thought to be relevant to this study.  The 
goal of phenomenology is to describe the meaning of a lived experience of a 
phenomenon.  It uses the description and analysis of a lived experience to 
understand how meaning is created through embodied perception (Starks & 
Brown Trinidad 2007).  Phenomonologies are often written as stories that 
allow the reader to get a feel for what it is like to have the experience.  GT is 
used to develop explanatory theory of basic social processes.  The idea is 
that theory is grounded in data and that theory evolves and emerges from 
the analysis of those data.  Thematic analysis takes the concept of 
supporting assertions with data from GT (Charmaz 2006).   
 
For this analysis it could be considered that both of these approaches have 
attributes that may seem appropriate, and table 10.1 demonstrates the 






















Table 10.1 Similarities and Differences of the two methods (adapted from 
Starks & Brown Trinidad 2007) 
 
 Phenomenology Grounded Theory 
Philosophy There exists an 
essential perceived 
reality with common 
features 
Theory is discovered 
by examining concepts 
grounded in the data 
Goal To describe the 
meaning of the lived 
experience of a 
phenomenon 
Develop an 
explanatory theory of 
basic social processes 








Typical sample size 1-10 persons 10-60 persons 
Analytic methods Identify descriptions of 
the phenomenon; 
cluster into discrete 
categories; taken 
together these describe 
the ‘essence’ or core 
commonality and 
structure of the 
experience 
Open, axial and 
selective coding; 
examining concepts 
across their properties 
and dimensions; 
develop an explanatory 
framework that 
integrates the concepts 
into a core category 
Audience Clinicians, practitioners 
and other who need to 
understand the lived 




practitioners who seek 
explanatory models 
upon which to design 
interventions 
Product A thematic description 
of the pre-given 
essences and 
structures of lived 
experience 
Generate theory from 
the range of 
participants experience 
 
Although the goal of phenomenology seems to fit the research question, the 
sampling, sample size and analytical methods of GT appear more suitable 
for the data set given the size, the fact that subjects are coming from many 
different populations and the depth of coding.  The concern with GT 
methodology is whether theory can be generated from the data.  However, 
according to Stark and Brown Trinidad (2007) although the goal of GT is to 
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produce theory, it is not uncommon for researchers to identify patterns only 
within and between categories producing conceptual thematic descriptions 
rather than explanatory theories.   Therefore the decision was made to 
perform a thematic analysis based on a GT approach. 
 
Grounded Theory Methodology  
 
This methodology was founded by Glaser and Strauss in 1967 in response to 
a lack of contextualised theories in sociological research (Glaser & Strauss 
1967).  There have been several versions of grounded theory (GT) methods 
which have emerged since the original.  McCallin (2004) suggests that three 
main versions of GT dominate, including the original version, Strauss and 
Corbin’s (1998) more structured approach and Charmaz’s (2006) 
constructivist version.   
 
According to Charmaz (2006) GT is:- 
 
‘An inductive, comparative, and interactive approach to inquiry that offers 
several open ended strategies for conducting emergent inquiry’. 
 
Strauss and Corbin (1998) suggest that:-  
 
‘GT examines the 6 ‘Cs’ of social processes (causes, contexts, 
contingencies, consequences, covariances, and conditions) to understand 
the patterns and relationships among these elements’. 
   
In GT methods, the researcher serves as both data collection instrument and 
analysis method and is trying to develop / induce theory.  This starts with the 
process of coding which is iterative and non-linear.  Strauss and Corbin’s 
method divides the coding into three stages.  Review of the original data line 
by line into codes that the researcher determines to be valuable is known as 
open coding.  Axial coding involves combining original codes into major 
categories and defining subcategories and their relations to the majors 
(Developing themes and sub-themes) (Kendall 1999).  Finally restricted 
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coding identifies the relationships among codes and categories.  Constant 
comparison is key to the method, where data collection and analysis occur 
simultaneously and each datum is compared with every other datum (Cutliffe 
2000).  At times, one or more categories will be found to emerge with high 
frequency of mention and be connected to many other categories which are 
emerging.  These are described as core categories.   
 
Data saturation is achieved when additional data adds nothing to what you 
already know about a category, its properties and its relationship to the core 
category.  The methods of coding and data analysis are slightly different in 
each of the versions of GT and it has been suggested that the Strauss and 
Corbin method is more of a science and the Glaser method is more of an art 
(Walker & Myrink 2006). 
 
The fundamental components of a GT study include openness, analysing 
data immediately, coding and comparing, memo-writing, theoretical 
sampling, theoretical saturation and production of a substantive theory 
(Sbaraini 2011).  The theory is dependent on context and never completely 
final (Charmaz 2006).  GT has been criticised over the years, with 
suggestions that it oversimplifies complex meanings and constrains analysis 




In this analysis, all goals were transcribed onto individual cards.  Each 
patient goal was compared with the goals from previous and subsequent 
subjects.  I used descriptive labelling for each of the common sets of data 
and this gave rise to themes and sub-themes (also know as categories and 
sub-categories) which summarise patient’s views.  Examples of these 







Figure 10.1 Examples of comparisons 
 
Example 1.  ‘Reduce the number of times I go at night’, ‘to sleep through the 
night’, ‘better quality sleep’, ‘to get up less at night’ are all examples of 
patient set goals relating to nocturia, therefore these were sorted into a 
subcategory of nocturia and as it is one of the symptoms of OAB the core 
category was OAB    
 
Example 2, ‘To go on journeys without worrying about toilet’,’ to take dog for 
a walk without needing the loo’, ‘watch a film without going to the toilet’, 
‘complete a meeting at work without leaving to go to the toilet’ are all 
examples of patients goals relating to specific tasks that they wish to 
complete therefore each individual task was formed as a subcategory while 
the core category developed was related to finishing the task in hand. 
 
Data saturation was achieved when further set goals could add nothing to 
what was already known about a category, its properties, and its relationship 
to the core category.  Two researchers, myself and Carlos Curtis (a medical 
student wishing to gain research experience) independently performed the 
analysis and categorising of open ended goals and then discussions ensued 
to compare categories and agree terminology used. 
 
Goal achievement was graded as follows:  did not achieve, somewhat 
achieved, achieved, exceeded expectation and greatly exceeded 




Baseline demographics of both studies 
 
The baseline demographics of subjects are shown in table 10.2  
 
Table 10.2 Baseline demographics and clinical characteristics  
Variable SAFINA Fesoterodine 





































Duration since first 











Incontinence, n (%) 39.9 81.5 
Bladder diary variables per 























SAFINA Study – Results 
 
The results of the nine fixed goals from the SAGA questionnaire can be 
found in the paper by Cardozo et al (2012).  Of the 331 subjects who were 
assigned to treatment, 1137 open ended goals were set.  The themes and 
sub themes that emerged from the data are listed in table 10.3 along with the 
number of patients expressing that subject as a treatment goal. 
 
All goals were included in the analysis regardless of whether it was thought 
that these were unrealistic.  Examples of what may be considered as 
unrealistic goals include ‘to not have any pain’, ‘to sneeze without leaking’,  





Table 10.3 List of themes and sub-themes from SAFINA study  
 
 Theme 




A) OAB Reduce nocturia 
Reduce urgency 
Reduce frequency 
Reduce urgency urinary 
incontinence 
Reduce pain   
Not have to wear pads 










B) Other LUTS Reduce leakage on coughing 
Reduce leakage on exercising 
Empty bladder completely 
Improve weak stream 
Reduce leakage during housework 








C) Finishing the task in hand Car / coach journey without 
stopping 
Shopping trip without finding loo 
Walk dog  
Watch entire film / TV show  / 
theatre 
Evening out for meal 
Finish activity (eg church service, 
football match, bingo, hair-cut. 
Visit family / friends 
Go on holiday 
Use public transport 
To queue without having to leave 















D) Psychological impact To stop toilet mapping 
Reduce anxiety / embarrassment 
Feel in control 
Feel normal / confident 
To not smell 
To not plan life around bladder 









E) Work Not leave meetings to go to loo 
To not keep leaving desk 
Complete an operating list 















Fesoterodine and Sexual Function Results 
 
The results of the nine fixed goals and the correlation between the self-
reported importance of a goal and the extent of their actualisation after 12 
weeks can be found in Chapter 8.  (Table 8.11 and 8.12) 
 
Of the 27 patients who were assigned to treatment, 109 open ended goals 
were set.  The themes and sub themes that emerged from the data are listed 




























Table 10.4 List of themes and sub themes from Fesoterodine and Sexual 
Function study 
 Theme 
Goals related to :- 
Sub-themes Number 
A) OAB To improve bladder control 
Reduce frequency 
Not have to wear pads 
Reduce frequency of the urgency 
Reduce nocturia 
To have warning time 










B) Sex To not leak during sex 
To be more sexually active with my partner 
No anxiety of leakage during sex 
Letting partner touch without worrying about 
needing the loo 







C) Finishing the task in 
hand 
Go out socially 
Go to market / shops without needing the 
loo 
Take part in sports activities 
Walk dog  
Go for long walks 








D) Psychological impact To stop toilet mapping 
Reduce anxiety / embarrassment 
To not smell 
To not plan life around bladder 
No stress 
To have peace of mind 








E) Other LUTS To be dry 
Empty bladder completely 
Improve weak stream 
Reduce leakage on coughing 
Reduce leakage on exercising 







F) Being Free to Drink whatever / whenever without needing 
the loo 
Go out without carrying spare underwear 
Leave the house without needing to pee 
beforehand 
Lie in bed when you wake up without 
rushing to the toilet 
Wear light trousers 










G) Work Not leave meetings / lectures to go to loo 
Complete work task eg clinic list, pool 
rotation without going to the toilet  












Discussion of themes 
 
Although most of the themes identified in both of the analyses were the 
same, there was one additional theme identified in the Fesoterodine and 
Sexual Function (FesoSF) goals group that was not apparent in the SAFINA 
study group.  There were also several differences in the importance of the 
themes between the two cohorts.  The most common theme identified in both 
analyses was goals related to OAB symptoms.   
 
OAB   
 
In the literature, urgency has been described as the cardinal symptom of 
OAB (Cardozo et al 2009) and it is the only essential symptom when making 
the diagnosis (Abrams et al 2012).  In a study by Coyne et al (2004) the 
experience of urinary urgency had a significant negative effect on HRQL and 
increased symptom bother more than incontinence, frequency, or nocturia.   
However, in the SAFINA cohort of patients the most commonly reported 
goal, listed by 47% of subjects was in relation to reducing nocturia episodes 
and only 31% of subjects listed reducing urgency as a treatment goal.  In the 
FesoSF group only 18% of women were focused on reducing nocturia 
whereas 26% listed reducing urgency as a goal.  This could suggest that in 
the SAFINA group, nocturia was their most bothersome symptom and this is 
in line with the baseline bladder diary variables with the SAFINA group 
reporting a mean number of nocturnal micturitions of 2.7 compared to 0.93 in 
the FesoSF group.  It has been shown that the number of nocturia episodes 
per night is significantly associated with a reduced number of hours of sleep 
per night, reduction in QoL and sleep quality (Irwin et al 2008).  Nocturia may 
lead to sleep insufficiency and consequently to a decrease in mental and 
physical health (Van Dijk et al 2004).  For the SAFINA patients it was 
suggested that the impact of nocturia caused the largest disruption to their 
daily functioning, perhaps as a result of sleep deprivation.  However, it has 
also been reported that symptom bother does not always correlate with 
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symptom prevalence and the most commonly reported symptoms may not 
be the most bothersome (Wang et al 2015); therefore, further investigation 
into this group is necessary to clarify. 
 
The most common goal related to OAB set by 37% of women in the FesoSF 
group was related to improving bladder control.  This was separated from 
urgency and UUI as it encompasses all the individual symptoms and implies 
an overriding mechanism to regain function.  
 
Although 132 subjects in the SAFINA group reported incontinence only 86 
(65%) of those added reducing incontinence episodes as a goal and only half 
of those reported wanting to no longer wear pads to manage their 
incontinence. In the FesoSF cohort, 85% reported incontinence, yet only 
30% wanted to no longer wear pads.  This is surprising as incontinence and 
the need to wear pads is often described as a major cause of impaired 
quality of life and a driver for patients to seek help.  In a study by Anger et al 
(2011) women with severe OAB attended focus groups and discussed their 
symptoms and treatment options.  One of the themes that emerged was that 
incontinence pads were the only management strategy that provided the 
women with the freedom to participate in and complete activities without the 
worry of leakage which would result in the need to change clothes.  Anxiety 
is often linked with OAB symptoms and it may be that for many of the OAB 
wet patients, wearing pads can help reduce anxiety as it is commonly 
adopted as a coping strategy, containing the problem.  Pad use can also be 
a security measure or a learnt behaviour so women continue to wear pads 
even if their incontinence has resolved.   This study did not record whether 
patients had reduced the size of the pads that they wore or the number used 
throughout the day but this could be an interesting area of investigation.   
 
It is also interesting to note that 47 patients in the SAFINA group and 3 
patients in the FesoSF group wanted to reduce pain associated with their 
symptoms.  Hanno et al (2009) explored the relationship between bladder 
pain syndrome and whether the sensation of urgency can overlap with the 
symptom of pain.  They suggested that it is likely that the urgency 
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experienced by these patients is different from that described by patients 
with OAB and in this cohort of patients their description of wanting to reduce 
pain could be in relation to pressure symptoms causing discomfort. 
 
Other lower urinary tract symptoms   
 
This was the second most common theme in the SAFINA trial but only the 
fifth in the FesoSF trial.  Under this theme, in both cohorts, four of the sub 
themes were all in relation to reduction of leakage during different activities 
eg during coughing, exercising and during housework.  This type of leakage 
is generally associated with SUI but can also be attributed to provoked 
detrusor contractions.  In the SAFINA study, patients recruited reported OAB 
symptoms but patients with urgency predominant mixed symptoms were also 
included.  There were no UDS performed to demonstrate the presence of DO 
or USI. Therefore it is not possible to differentiate between these groups in 
this analysis as to aetiology of the urinary leakage.  In the FesoSF study, 
although urodynamics were performed, the numbers are too small to reliably 
determine aetiology. In reality, it is unlikely that all these episodes of leakage 
are caused by an involuntary detrusor contraction and therefore these are 
not realistic goals for patients in this clinical trial.  It could be suggested that 
when these goals were discussed with the clinician, a further conversation 
may have been warranted to clarify whether these symptoms were clinically 
more stress related and if so patients should have been advised why it is 
unrealistic to expect symptom resolution from the therapy they received.  
Additionally a discussion about alternative treatments that they could be 
offered for these symptoms could then be undertaken.  
 
It could also be construed as unrealistic for patients to list ‘to empty bladder 
completely’ as a goal in these studies.  It is an accepted side effect of 
fesoterodine that approximately 7% of patients will experience the symptom 
of incomplete bladder emptying whilst taking the medication. During the 
screening phase in both trials, all subjects underwent assessment of post 
void residual and anyone with a significant residual volume was excluded 
from the trials therefore bladder emptying should not have been a problem 
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for these groups of patients.  It could however, be considered by some 
patients that they were not emptying their bladder completely as a surrogate 
measure of bladder “irritability”, if for example, the patient felt that she 
needed to void ten minutes after having just emptied her bladder.  However, 
this would usually result from their OAB causing after contractions and 
possibly poor fluid habits rather than the bladder not emptying completely.  It 
should also be noted that the SAFINA study included men and the analysis 
did not differentiate the men’s goals from the women’s.  LUTS including 
storage and voiding symptoms eg slow stream, and incomplete emptying are 
common in men and can be related to benign prostatic enlargement (Abrams 
et al 2013b).  This may account for why this theme was far more prevalent in 
the SAFINA study compared to the Feso and SF group. 
 
Finishing the task in hand  
 
This was the third most common theme in both of the studies and one that 
had not been identified in the literature.  It highlights the frustrations in daily 
life that many patients with OAB suffer.  Not having to interrupt what they are 
doing in terms of travel, social life, and every day chores are common goals 
that patients aspire to achieve from therapy and these vary minimally 
between the cohorts.  A third of all the patient goals in the SAFINA study 
were in relation to being able to complete everyday tasks without having to 
worry about their bladder.  This disruption of daily life has also been reported 
in a study by Irwin et al (2005) who found that 76% of individuals reporting 
OAB symptoms stated that the condition interfered with or made it more 
difficult to perform daily activities.  Most clinicians treating OAB patients treat 
the symptoms.  However, for the patients it is not always the symptoms they 
specifically want to change but the impact of the symptoms on their daily life.  
For many subjects completing a simple task such as taking the dog for a 
walk without needing the toilet or being able to watch a film without 
interruptions is what they would like to achieve from therapy.  Interestingly 
the SAGA tool captured these issues and should allow more focused 
treatment based on these concerns.  It is important to remember these 
motivations when planning treatment and providing bladder retraining etc. as 
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individualised management to work towards.  Thus allowing the patient to 
complete the tasks, most important to them, which may ultimately increase 





It has been reported that patients with OAB experience higher rates of 
depressive symptoms (Irwin et al 2005, Coyne et al 2008b).  In a series of 
interviews with  patients with OAB symptoms, interviewees expressed 
constant anxiety and worry about finding and reaching a toilet in time to 
prevent urine leakage and some reported anxiety that constantly needing to 
go to the toilet created feelings of hopelessness and depression (Nicolson et 
al 2008).  Those feelings of anxiety were mirrored in this analysis with many 
subjects wanting to reduce the anxiety in relation to their bladder, to stop 
worrying about finding a toilet and just to feel more in control of their bladder 
and consequently their lives.  Studies have shown that improvement of 
urinary incontinence can improve self-esteem (Hagglof et al 1998). 
 
A recent systematic review by Sakakibara et al (2013) assessed the 
literature relating to bladder dysfunction in patients with anxiety and 
depression.  They found that depression / anxiety was an obvious risk factor 
for OAB and presumed that this reflected that the bladder is under emotional 
control. They suggested that ameliorating bladder dysfunction is an important 
target in treating patients with depression/anxiety.  However, equally these 
psychological symptoms could lead to anxiety and depression due to the 
impact of OAB on the patient’s life.  This study did not assess the numbers of 
patients suffering anxiety and depression and whether their bladder 
symptoms caused the anxiety and depression or conversely whether their 
anxiety and depression caused their bladder dysfunction.  Previous work by 
Parsons et al (2004) reported that simply the need to attend a specialist 
gynaecology clinic places a significant psychological burden on women and 




A common goal in both cohorts of patients was ‘to stop toilet mapping’.  This 
is a form of coping strategy where patients plan their journeys / activities / 
shopping by the location of available toilets (Ness 2012).  It is not uncommon 
for a patient to decline visiting new places for fear that they will not be able to 
find an appropriate toilet in time.  It has been recognised as an issue and 
there are now toilet maps online for many town centres and Apps where one 
can track the location of the nearest toilet as well as special access keys to 
help overcome this barrier. 
 
Several patients in each cohort also reported fears in relation to not smelling 
of urine.  It has been demonstrated that women who are afraid of the odour 
of urine are increasingly likely to seek medical help for their UI (Hagglund et 




This theme is similar to those set out in the finishing the task at hand theme 
but the impact of bladder symptoms on work productivity has been studied.  
According to Irwin et al (2005) men are more likely than women to worry 
about the impact that OAB can have on their work life including worrying 
about interruption of meetings which was identified as an issue by subjects in 
both studies. Also this can be a major factor in deciding the type of work or 
timing of retirement.  A study assessing the impact of UI on women in the 
workplace reported a negative impact on concentration, performance of 
physical activities, self-confidence or the ability to complete tasks without 
interruption (Fultz et al 2005).  For younger patients, as seen in the FesoSF 
study, it also correlates to concerns of being able to sit through lectures and 




There have been many studies that show the negative impact of OAB on SF 
(Salonia et al 2004, Milson et al 2009).  These papers suggest many different 
reasons for this effect including embarrassment, fear of CI on penetration 
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and orgasm, loss of confidence, fear of smelling, loss of libido.  However, in 
the SAFINA study only 2 subjects reported goals in relation to SF.  It has 
also been suggested that concerns about time constraints, lack of effective 
treatments and embarrassment may prevent women initiating a discussion 
about sexual concerns with their doctors (Kingsberg 2006).  According to 
O’Donnell et al (2005) only 24% of women are not at all embarrassed to 
discuss sexual problems with a doctor in comparison to 87% when 
discussing allergies or cold/flu, and approximately a third of women would 
not initiate a discussion about sexual issues with their doctors (Coyne et al 
2007).  The very small number in this sub group could suggest that the 
clinician reviewing the goals with the patient did not broach the subject of SF 
with the subjects at the time of screening and goal setting and as the 
literature would imply that patients will rarely disclose this information without 
prompting.    
 
This suggestion would appear to be likely as in the FesoSF cohort, sex was 
the second most common theme with several subthemes related to leakage 
during intercourse, frequency of sexual activity and anxiety related to 
potential leakage and needing to void during intercourse were also noted.  
Given that the primary outcome of the FesoSF study was related to SF, the 
clinician had already initiated the discussion on the topic and the patients 
would have also completed two questionnaires specifically concerned with 
SF prior to completing the SAGA questionnaire so this may have helped the 
women to verbalise their concerns and hopes in this area without 
embarrassment. 
 
Being free to ….. 
 
This is another novel theme that only emerged from the FesoSF patients and 
focuses on the fact that women do not want to feel constrained by their 
bladder symptoms or have to prepare for everything.   Some of the sub 
themes relate to coping strategies to manage bladder symptoms e.g. 
carrying spare underwear, voiding ‘just in case’, fluid restriction, while some 
relate to constraints caused by anxiety / leakage where women will only wear 
259 
 
dark coloured trousers in order to hide any possible accidents or the desire 
to be spontaneous.    
 
Perhaps the most interesting sub theme is ‘to drink whatever / whenever 
without needing the loo’.  It could be considered that this is an unrealistic 
goal as even for women with ‘normal’ bladder function, if they drink large 
volumes of certain fluids they will need to pass urine regularly and frequently; 
however, it would be unusual for them to report symptoms of urgency or UUI.  
In situations like this patient education regarding normal and abnormal 
bladder function is helpful in the establishment of healthy bladder habits 
(Wyman et al 2009).   
 
This theme and also the ‘completing the task at hand’ theme provide new 
insights into the impact of OAB on women’s quality of life both physically and 
psychologically and are worthy of greater exploration.  Many QoL tools used 
in routine practice focus on the symptoms associated with OAB and 
minimally on role limitations as a result of symptoms.  This could raise 
questions regarding the validity of the questionnaires given the findings 
presented here as they may be missing important factors.  However, the 
International Consultation on Incontinence Questionnaire Overactive bladder 
quality of life (ICIQ OABqol) does appear to address some of these issues as 
it asks questions relating to journey planning, social activities, planning 
activities and toilet access.  Further investigation of this concept and the 
available QoL tools is recommended.   
 
Overall, the goals of the patients in each study were fairly similar in relation 
to themes and sub themes, however the prevalence of themes varied 
between the two studies.  This could potentially be due to the way in which 
the questionnaires were introduced and completed or due to the mixed 
cohort of patients in the SAFINA study compared to only female patients in 
the FesoSF study.  There may also be differences dependent on the other 
questionnaires that were completed at the same time which may provide 
inspiration for treatment goals or suggest something to aspire too.  This is 
260 
 
likely to be the reason that more patients set goals related to SF in the 
FesoSF group compared to the SAFINA group.   
 
SAFINA Goal Achievement 
 
A total of 251 subjects completed the trial and goal achievement was ranked 
for all goals set out by subjects and the level of achievement of their personal 
goals is listed in table 10.5 Approximately half of the patients in this trial 
achieved their goals following 12 weeks of therapy, with a further third 
somewhat achieving their goals. 
 
 
Table 10.5 Achievement of Goals SAFINA study 
 
Level of Achievement % of subjects 
Did not achieve 18.7 
Somewhat achieved 32 
Achieved 32.5 





Feso and SF Goal Achievement 
 
Of the 27 women enrolled, 20 completed treatment. When considering 
overall goal achievement in the FesoSF study only one subject did not 
achieve her goals with a further 35% somewhat achieving their goals.  60% 
of subjects achieved their goals with 40% of those exceeding or greatly 







Table 10.6 Achievement of goals FesoSF study 
 
Goal Achievement % of subjects 
Did not achieve  5 
Somewhat achieved  35 
Achieved  20 





A greater percentage of patients achieved their goals in the FesoSF study 
than in the SAFINA study overall but given the vast differences in the 
numbers of patients in each study it is not possible to compare this in greater 
detail.  It is however noted that the baseline severity of OAB symptoms was 
greater in the SAFINA population and this may account for the variation of 




There are several limitations to the data presented and discussed in this 
chapter.  Firstly, in both studies not all patients originally enrolled in the trials 
completed the studies, so complete data are not available for all participants.   
It is recommended that the SAGA questionnaire is completed by the patient 
with the clinician.  Given that there were 39 different sites recruiting subjects 
for the SAFINA study, there may be variation in the level of involvement of 
the clinician at each site and this can introduce a risk of bias in the goals set.  
In areas where clinician involvement was minimal this could account for 
some patients setting unrealistic goals and ultimately negatively affect goal 
achievement.  In the FesoSF study only one clinician worked with the 
patients on their SAGA questionnaires so there is uniformity in the level of 
involvement, however, this in itself could be an area of potential bias as the 




It should be noted that both of the studies discussed have slightly different 
inclusion / exclusion criteria and a large difference in patient numbers so due 
to the smaller numbers in the Feso and SF group, it may mean that the 
themes were less well defined and that they were not a directly comparable 
group.   
 
The main limitation of this data is in the methods used for analysis. The 
grounded theory approach uses a thematic analysis to generate a theory 
from the data.  As previously noted, the fundamental components of a GT 
study include openness, analysing data immediately, coding and comparing, 
memo-writing, theoretical sampling, theoretical saturation and production of a 
substantive theory (Sbaraini 2011).  However, it is recognised in this case 
that a thematic approach to the analysis of the data was used but this was 
not taken to the next stage by which a GT was produced.   
 
There is a limitation in the format of the questionnaires as there is limited 
space for patients to express their goals and this may reduce what they are 
wanting to say.  Another limitation with the use of the questionnaires is that is 
does not provide any opportunity for probing of those goals or for 
understanding the thoughts and feelings associated with them, limiting the 
text base for analysis.  This is a recognised limitation of questionnaire 
derived qualitative data (Atieno 2009).   Ideally individual patient interviews 
or focus groups should be used to allow for indepth probing of these goals.   
 
In routine practice and the clinical trial setting the SAGA questionnaire is 
designed to be completed by the patient with the clinician, however, this is 
more to ensure that the open ended goals set are feasible and realistic rather 
than deep and meaningful.  It could be questioned whether these are a true 
expression of patient goals for example if patients were unable to think of 
specific goals at the time it is difficult to know if they were prompted with 
responses or if these were really what mattered to them.  According to 
Beiske (2002) open-ended goals / questions have the advantage of offering 
a wide range of responses that help to capture the flavour of people’s 
answers, while not influencing the outcome of the question by pre-
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determining possible responses however, answers are often difficult to 
evaluate and tend to vary in clarity and depth.   
 
The SAGA questionnaire also has a section of fixed goals (the results of 
which were presented in Chapter 8).  Yet this may be even more limiting in 
understanding patients goals from treatment as fixed goals / questions 
assume a general knowledge / experience that patients may not experience 
or have a different understanding of based on personal perception which 
may be influenced by age, culture, education etc (Beiske 2002).    
 
Given these limitations, it could be questioned whether the use of this 
questionnaire in practice is really good enough to understand patients goals 
from treatment.  However, it is not feasible to perform and analyse in depth 
interviews with all patients receiving treatment for OAB and at present there 






In this chapter I have described a thematic analysis of two data sets.  This 
revealed common themes but also showed that there were some differences.  
The new themes that emerged from this data was ‘completing the task in 
hand’ and ‘being free to ..’ which have highlighted how for many patients 
their treatment aims are more focused on completion of tasks and preventing 
restrictions on everyday life rather than a specific reduction in a particular 
symptom.  This emphasised the impact that symptoms can have, and 
disruption that they can cause to their everyday activities. 
 
The most significant difference noted between the studies is the number of 
goals related to sexual function.  For many women these were very important 
goals but they needed the introduction regarding the topic and discussion 
with the researcher to encourage them to think about these and list them as 
treatment goals.  This highlights a practice recommendation that when 
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HCP’s provide counselling and discuss symptoms, goals and treatment 
outcomes, SF and the impact on this should be introduced by the HCP and 






























During the course of the main trial described previously, significant problems 
arose with recruitment of sexually active (SA) women with overactive bladder 
(OAB) into the study.  At several time points in the study, questions were 
raised to try to investigate why recruitment was so poor and to understand if 
it was a problem with the study sites, the methodology, or the sample 
population. 
 
Advice was sought from clinical and academic supervisors, the principal 
investigators at each of the other study sites and from experts in the field.  
The other clinicians reported that many women who they saw in clinical 
practice were not sexually active (NSA) or did not meet the inclusion criteria.  
They also commented that some women had not wanted to discuss sexual 
function (SF) with the clinical teams when approached (especially the male 
study staff) or did not wish to complete personal questionnaires.   
 
Despite changes to the methodology (previously discussed in chapter 9) by 
updating and expanding the inclusion criteria, recruitment rates did not 
improve and it became clear that our knowledge of the prevalence of SA in 
the study population was lacking.   It was also noted that although many 
women attending clinics in the unit report OAB, a lot were NSA for a variety 
of different reasons.  At this point the question raised was ‘What is the 
prevalence of SA in women with OAB?’   
 
To answer this question and to help understand the recruitment problems in 
the main study, it was decided to perform an investigation of the whole 
clinical population at the index site.  This was designed to gain insights into 
the prevalence of SA in women with OAB and other LUTS and to understand 
why women are not sexually active.  The findings of this investigation are 




It was also noted by the investigators that there was a group of women who 
did not wish to talk about their SF or enter a trial related to sexual outcomes.   
It has already been noted in chapter 7 that the recruiting clinicians were not 
asked to follow a standardised approach when taking a sexual history from 
women or discussing recruitment into the trial and that this would be a 
potential recommendation for future research.  However all of these 
concerns noted raised issues with communication and how women were 
identified and approached.   This led to the formulation of a further research 
question – “How do women want to be approached about the topic of SF?”  It 
was considered that if the research team could understand how best to 
initiate discussions regarding SF with women then potentially it would break 
down some of the barriers and help the team to develop enhanced 
communication skills to improve the recruitment process. 
 
In a bid to understand these communication issues, Chapter 13 details the 
findings from two focus groups for women with LUTS who attended the 
Urogynaecology outpatients department for assessment and treatment.  The 
aim of these focus groups was to understand how women want to be 
approached regarding the topic of sexual function along with any barriers 
they have encountered and what their preferences are regarding when the 
conversation should be initiated and by whom. 
This chapter details the methodology, research tools, and plans for analysis 
used to investigate these additional research questions identified.    
 
 
Research Question 1 
 
What is the prevalence of SA in women with OAB attending a London 
Urogyanecology outpatient service? 
 
To answer this question and to help understand the recruitment issues in the 
main study, it was decided to perform an investigation of the whole clinical 
population at the index site.  This was designed to gain insights into the 
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prevalence of SA in women with OAB and other LUTS and to understand 




The primary aim of this investigation was to assess the prevalence of SA in 
our OAB population.  The secondary aims were to evaluate why women 
were not sexually active (NSA), to assess if this was bothersome to them, to 
evaluate variations in SA according to UDS diagnosis and to compare 
questionnaire responses between the SA and NSA groups. 
 
The Research Tool 
 
In the healthcare setting, one way of trying to improve screening of certain 
conditions is to use validated questionnaires that can be completed by the 
patient in private, prior to consultation and used by a clinician to prompt 
further dialogue if the questionnaire suggests that this is necessary.  At the 
start of this thesis, there were no validated questionnaires to assess SF in 
women who were NSA.   
 
In 2013, the IUGA Sexual Function Working Group conducted a re-
evaluation of the PISQ, enhancing the ability to assess outcomes in women 
who are NSA (Rogers & Pons 2013b).  They noted that the original 
framework of the PISQ questionnaire had not included women without a 
partner or those who did not consider themselves to be SA and it was 
recognised that this may underestimate pelvic floor dysfunction (PFD) impact 
on SF since women with severe PFD may elect to become sexually inactive 
(Rogers et al 2013a). They published the Pelvic Organ 
Prolapse/Incontinence Sexual Questionnaire, IUGA-Revised (PISQ-IR) to aid 
clinicians to assess SF in women who were and were not SA. 
 
The PISQ-IR consists of two sections.  Section one is completed by women 
who are NSA and consists of six questions to understand reasons why they 
are NSA and their feelings / degree of bothersomeness of their sexual status.  
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Section two is completed by women who are SA (with or without a partner) 
and consists of fourteen questions incorporating sexual response, partner 
related issues, condition specific issues and assessment of satisfaction / 




It was decided to screen SF in all women attending our one stop UDS clinic.  
In our clinical practice this is the service that all women reporting LUTS 
would be triaged to following referral to the department.  All women attending 
the UDS clinic at KCH were sent the PISQ-IR (a copy can be found in the 
appendix) as part of the pre-visit information pack that also contains a three-
day bladder diary and the KHQ.  These were collected and reviewed when 
the women attended for assessment.  Initial analysis was performed using 
descriptive statistics and recorded in association with demographic data and 




Following this, the statistician used a multivariate binary logistic regression to 
analyse the risk of being SA as a function of potentially contributing factors 
identified in the PISQ-IR. All factors were entered as covariates in the initial 
model via a forced entry method. The resulting model’s goodness-of-fit was 
determined using the Hosmer-Lemeshow statistic. The proportion of variance 
in the occurrence of SSIs explained by the model was analysed using the 
Nagelkerke’s R2. 
 
The analyses were performed three times to investigate the whole cohort of 
women and two specific sub-groups relevant to the main CTIMP: - 
1. All women attending the UDS clinic  
2. Only women diagnosed with DO following UDS 
3. Only women complaining of OAB symptoms with normal UDS 




It is acknowledged that in the main study, all women with OAB or DO were 
included and for many of the outcomes assessed as one group.  However, 
for this study the decision was made to separate these into two groups to 
understand if there are differences between the groups related to prevalence 
or sexual activity even though none were identified from the outcomes in the 
main study.  
 




Research question 2 
 
How do women want to be approached about the topic of SF? 
 
In a bid to answer this research question and gain insights that may benefit 
routine clinical practice and future research studies, it was decided that a 
qualitative approach to data collection would be the most appropriate.  
According to Hammarberg et al (2016) qualitative methods are used to 
answer questions about experience, meaning and perspective, most often 
from the standpoint of the participant.  The most common methods of data 
collection in qualitative research are interviews, focus groups, observation 
and action research.  It was decided that observation and action research 
were not suited to the research question as we wanted to understand 
women’s views about the approach to SF, not just how it was performed.  In 
depth interviews would have provided us with a lot of information about 
women’s individual opinions and experiences.  However, individual 
interviews are associated with a considerable time, manpower and cost 
implication (due to transcription etc).  Focus groups are more suited when 
there is limited time / manpower, however, it was also thought that greater 
insights would be developed by the group dynamics as we were trying to 
develop ideas for future changes to approach that would be suitable for all.   
Based on this, two focus groups for women with LUTS who attended the 
Urogynaecology outpatients department for assessment and treatment were 
271 
 
undertaken.  The aim of these focus groups was to understand how women 
want to be approached regarding the topic of sexual function along with any 
barriers they have encountered and what their preferences are regarding 
when the conversation should be introduced and by whom. 
 
The role of Focus Groups 
 
The development of Focus Groups (FGs) originates from an interview 
technique called focused interviews described by Merton & Kendall (1946).   
Powell et al (1996) define a focus group as:- 
 
 ‘A group of individuals selected and assembled by a researcher to discuss 
and comment on, from personal experience, the topic that is the subject of 
the research’.   
 
Kitzinger and Barbour (1999) suggested that FGs are commonly used as a 
tool for exploring people’s views or perceptions of, attitudes towards and 
experiences of particular areas in life. According to Breen (2006) FGs can 
also complement and further explain statistical information obtained from 
other evaluative processes.   
 
In the 1990’s, FGs gained popularity as a method of collecting data through 
group discussions particularly in social science and medical research (Hyden 
and Bulow 2003).  While one to one interviews allow researchers to obtain 
individual attitudes, beliefs and feelings, focus groups can elicit a multiplicity 
of views and emotional processes within a group context and a larger 
amount of information can be gained in a shorter period of time (Gibbs 
1997).   
 
The crucial feature of a focus group is interaction as it enables the 
participants to ask questions of each other and re-evaluate their own 
understandings of their specific experiences (Kitzinger 1995).  However, in 
any group situation, there is also the potential for dominant voices, normative 
discourses and conflict and contradiction (Smithson 2000).  It is the 
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responsibility of the researcher / moderator to promote debate by asking 
open questions and probing for details, move things forward when the 
conversation has reached a conclusion and ensure that the conversation 
stays on course, as well as manage any conflict and ensure that all 
participants are actively involved in the discussions. 
 
A focus group generally involves 4-8 participants, too many and it is not 
always possible to add richness and depth to the conversation, to few can 
stall the conversation and result in a lack of opinions and views and data 
saturation will not be achieved (Wilkinson 1998).  As discussed in Chapter 9, 
data saturation is only achieved when additional data adds nothing to what 
you already know about a category, its properties and its relationship to the 
core category.  
 
FG’s are not only beneficial to the researcher but can also have benefits for 
the participants.  Goss and Leinbach (1996) reported that the opportunity to 
be involved in decision making and to be valued as experts can be 
empowering for many participants.  However, some participants may also 
find them intimidating and unenjoyable experiences. 
 
Aims / Purpose of focus group 
 
To explore with women their thoughts and feelings about being approached 




To generate ideas, for the purpose of devising recommendations for future 




Following a review of the literature (as part of the initial study and additional 
investigations undertaken), I had the opportunity to discuss practicalities and 
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problems with a researcher (Dr Angela Grainger) whose own PhD 
methodology was qualitative and incorporated FGs.  I was encouraged to 
write down what information I expected to gain from the FGs and what I 
planned to do with the information to help guide the development of the 
questions to be asked.  My expectations incorporated several different facets 
of the previous investigation findings and are set out below. 
 
What I expect to get out of this investigation:- 
 
1. An insight into the variation of patients experiences in current practice 
in relation to assessment of SA and their perceptions on the 
appropriateness / effectiveness of this so that current practice can be 
examined and a need for change identified 
 
2. An understanding of how women want to be approached on the topic 
of SA / SF when attending outpatient urogynaecology clinics so that 
clinicians can be educated and act in line with patients wishes 
 
 
3. An awareness of the barriers that patients feel prohibit or restrict their 
ability to discuss SF as they would wish to so that communication 
difficulties can be addressed and environmental issues / service 
structure changes can be considered to overcome these 
  
4. An understanding of the patient’s perceived role of the clinician and 
factors that encourage / impede discussion regarding SF to enable 
assessment of staffing in the service and develop appropriate training 




To ensure that all the women attending the focus group had appropriate 
personal experience, they were all recruited during or following attendance at 
the Urogynaecology department at KCH.  This meant that all the women 
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would have undergone some form of assessment of LUTS / POP and as part 
of routine care and been approached about SA by a member of the 
multidisciplinary team.  It was thought that a combination of new patients and 
long term patients would be ideal to elicit current and previous practice as 
well as reassessment of SA and differences in approach dependent on the 
HCP who the patient was seeing.   
 
Considerations with the planning and implementation 
 
Two FGs were undertaken during different weeks and at different times of 
day.  The dates were set based on room availability as well as my own 
availability.  One was organised for the middle of the day so that women with 
children at school would be able to attend and not miss the school runs. The 
other was organised in the evening so women who worked a ‘9-5’ job would 
be able to attend after work and negate the issue of needing leave to attend 
during work hours.  To encourage participation an incentive of a £50 Marks 
and Spencer’s gift voucher was agreed and an invitation letter including a 
brief description of the process, the times of the FGs and details of the 
incentive was developed (included in the appendix).   
 
Invitation letters were sent to potential women with their appointment letters 
for UDS clinics and bladder retraining group sessions, other invitation letters 
were handed to women by reception staff when booking follow up 
appointments and invitation letters were also left on the tables in the waiting 
areas and posted to the inside of toilet doors for the women to read.  If 
interested in attending the FG, women were asked to either let us know in 
person when they attended the clinic, email me or my colleague, or 
telephone the department (on a number with answerphone capabilities) to 
provide their name, contact details and preference for which FG they would 
like to attend.   
 
Following expression of interest, a formal patient information sheet on the 
process, including why the research is important, what is expected of them 
and the fact that the discussions would be recorded was provided either in 
275 
 
person, electronically by email or a hard copy in the post dependent on the 
patients preference (A copy of the PIS is included in the appendix). 
 
The FGs took place in the hospital, but not in the clinical department.  
However, patients were asked to meet in the main waiting area of the 
department as this is a point that they all knew in the hospital and once the 
group had assembled they were led to the alternative meeting area.  
Refreshments in the form of cold drinks, fruit and biscuits were provided and 
in view of patients presenting complaints the room booked had accessible 
toilet facilities located nearby.  All the women sat round a table with myself at 
one end to moderate and the scribe sat amongst the women.     
 
On arrival, the women were asked to complete a consent form (included in 
the appendix).  This also allowed for collection of demographic data to 
ensure that the groups were homogenous.  Demographics of the participants 
is discussed in Chapter 13.   
 
Both of the FGs were recorded onto a Dictaphone and transcribed but there 
was also a scribe in the room at the time to note down salient points, 
comments, behaviours identified. The same individual scribed for each of the 
FGs and typed up her notes by the following day to ensure that they 
remained fresh in her memory.   
 
I acted as the moderator in both of the FGs and immediately after each 
session wrote memos reflecting on comments, feelings, behaviours, how the 
participants responded to the questions and language used.  These memos 
and the scribe’s notes were then used in the analysis.   
 
The first FG was counted as a pilot study and opinions were sought from the 
scribe regarding how she though the questions came across, whether my 
level of involvement in the conversations was appropriate and whether the 
structure of the FG needed to be revised.  Two of the participants were also 
seen by myself in a clinical setting the week after and I was also able to gain 
opinions from them regarding their experience of the FG.    
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FG interview schedule 
 
To ensure consistency across the FGs an interview schedule was 
developed.  It included a welcome to all the women and an introduction to 
myself, the scribe and the clarification of our roles.   Following this I provided 
the participants with an overview of the topic and how the research questions 
had been developed.  I went on to describe their role in the session and 
confirmation of confidentiality.  Ground rules for FG etiquette including only 
talking one at a time, being respectful of other people’s opinions and allowing 
everyone a chance to vocalise their opinions were set.   
A variety of questions were posed to the groups.  Although the starting 
questions were the same in both sessions, as the moderator dependent on 
the direction of the conversation, the order of the following questions was 
changed if I felt it would further encourage an area of discussion.  All 




During the set up and development of the FGs, several ethical 
considerations were identified and potential strategies to mimise the impact 
of these developed.  It was hoped that by making the FG an informal 
process, in a different area of the hospital it would help put the participants at 
ease.  The availability of refreshments allowed for a short period of informal 
conversation prior to the start of the FG which it was hoped would help to 
establish a rapport amongst the participants.   
 
For some of the women I had actively been involved in their assessment and 
management in practice.  It was especially important for them to understand 
that I wanted to know both the positives and negatives of their experiences 
and ensure that they would be comfortable providing the information in order 





Considerations of how to manage individuals if they were too aggressive in 
their opinions or disrespectful of others were deliberated and a plan was also 
put in place of what additional support / advice women could be offered if 
concerns were raised that were causing personal distress.  This included a 
further assessment in the outpatient’s clinic, referral to the psycho-sexual 
counselling team, or to the safeguarding team if issues of domestic violence 




In this study, GT methodology (as previously described in chapter 10) was 
used to analyse the data.  On this occasion, I performed the coding and 
generation of themes from the transcripts of each FG and from memos 
written directly after the FGs.  Following this a second independent 
researcher without knowledge of this field of investigation analysed the data, 
then a discussion ensued to compare categories and agree terminology 
used. Member checking was performed by some of the participants when 
they came back to clinic appointments following the FGs and by an expert in 
the methodology.  Member checking is defined as a quality control process 
by which a researcher seeks to improve the accuracy, credibility and validity 
of what has been recorded during a research interview (Harper & Cole 
2012).   
 
In addition to the individual coding, the data were uploaded to NVivo 11 (a 
qualitative data analysis computer software package) to help sort, search 
and arrange the information and examine relationships in the data.   
Following the analysis of the data, a further literature search was performed 
to discover whether any further research had been undertaken that would 
illuminate further understanding of the data uncovered in my research.      
 
The themes and Sub themes that emerged from the data and discussions 







This chapter defined the rationale and methodology of two research 
questions that were developed from the identification of limitations in our 
original methodology that may have hindered recruitment to the main study.  
The results presented in the next two chapters will address these limitations 





























What is Sexual Activity and how prevalent 






One of the challenges identified with recruitment into the main trial was 
related to a lack of sexually active women attending the department.  As 
previously noted in chapter 11 this led to development of a new research 
question - What is the prevalence of sexual activity (SA) in women with 
overactive bladder (OAB) attending a London Urogynaecology outpatient 
service?   
 
To answer this question and to help understand the recruitment issues in the 
main study, it was decided to perform an investigation of the whole clinical 
population at the index site.  This was designed to gain insights into the 
prevalence of SA in women with OAB and other LUTS and to understand 
why women are not sexually active.  This chapter presents and discusses 




The full methodology was discussed in chapter 11.  The analyses were 
performed three times to investigate the whole cohort of women and two 
specific sub-groups relevant to the main CTIMP: - 
 
1. All women attending the Urodynamics (UDS) clinic  
2. Only women diagnosed with detrusor overactivity (DO) following UDS 
3. Only women complaining of OAB symptoms with normal UDS 
parameters.   
 
An overview of the significant results is presented in this chapter, however, 










Four hundred questionnaires were completed over 9 months.  This does not 
represent all the women attending the UDS clinic.  Twenty two women (5%) 
refused to complete the questionnaires because they did not feel it was 
appropriate or did not want to discuss the subject.  Some women were 
unable to read or write in English and although the PISQ-IR is available in 
different languages it was decided not to further investigate this group as 
they would not have been suitable for the main trial.  A further group of 
approximately 50 women ‘forgot’ to complete or return the questionnaires at 
their appointment.  This is not uncommon in routine clinical practice.  Table 
12.1 displays the presenting complaints of the women who completed the 
questionnaires. 
 
Table 12.1 Presenting complaints of Group 1 
Complaint Number of women (%) 
Urinary Incontinence (UI) 193 (48) 
Pelvic Organ Prolapse (POP) 34 (9) 
LUTS and POP 117 (29) 







Of the women assessed, two hundred and thirty two (58%) were SA and one 
hundred and sixty eight (42%) were NSA.   
Three hundred and sixty three women went on to have a full urodynamic 
assessment.  There was minimal difference in SA activity between the 
different UDS diagnoses as shown in Table 12.2.  UDS were not performed if 




































































































Eighty nine (53%) of the NSA women were NSA because of lack of a 
partner.  When the 79 women who were NSA but had a partner were asked 
to consider the reasons why they were NSA, 60% reported that this was 
secondary to their bladder symptoms, 45% due to other health problems, 
53% reported having no interest and 58% were bothered ‘A lot’ by their lack 
of sexual activity. 
 
Group 2  
 
Ninety five women were found to have DO on UDS.  Of these, 60% (n=57) 
were SA.  Of the SA women 93% (n=53) reported symptoms of UI compared 




For 47% (n=18) of the NSA group, lack of a partner was cited as the reason 
they were not SA.  Only 9 women reported having a partner and the other 
women did not answer.  When the 9 women who were NSA but had a 
partner were asked to consider the reasons why they were NSA only 33% 
(n=3) reported that this was secondary to their bladder symptoms, 55% (n=5) 
due to other health problems, 67% (n=6) reported having no interest and 
only one woman was bothered ‘A lot’ by her sexual status. 
 
Group 3  
 
Sixty seven women reported symptoms of OAB but had normal UDS 
findings.  Of these only 45% (n=30) were SA.  Of the SA women 87% (n=26) 
complained of OAB wet compared to 70% (n=26) of the women who were 
NSA. 
 
65% (n=22) were NSA because of lack of a partner.  Only 6 women reported 
having a partner and the other women did not answer.  When the 6 women 
who were NSA but had a partner were asked to consider the reasons why 
they were NSA 67% (n=4) reported that this was secondary to their bladder 
symptoms, 83% (n=5) due to other health problems, 83% (n=5) reported 
having no interest and 50% (n=3) were bothered ‘A lot’ by their sexual status. 
 
The differences in baseline characteristics between the three groups is 
presented in table 12.3.  The differences in rationale for sexual inactivity 













Table 12.3 The differences in baseline characteristics between the three 
groups. 
 












POP + LUTS 
Group 1 363 45.06 2 58% 42% 38% 
Group 2 95 49.74 2 60% 40% 32% 
Group 3 67 49.65 2 45% 55% 37% 
 
 
Table 12.4. The differences in rationale for sexual inactivity between the 
three groups 
 
Group N= Sexually 
active 
Not sexually active 
   Lack of 
partner 
With a partner 














1 363 58% 53% 60% 45% 53% 58% 
 
2 95 60% 47% 33% 55% 67% 11% 
 









Comparisons of the SA and NSA populations 
 
Several analyses were performed to attempt to compare the SA population 
to the NSA population in each group.  There were no factors identified that 
would make someone more likely to be SA than NSA.  There were no 
differences in feelings of frustration, anger and sexual inferiority between 
women who were SA and those who were NSA.   
 
To further investigate feelings of anger and frustration in the SA group, the 
patients were broken down into smaller groups according to their presenting 
complaint of either UI, POP or both.  Although, women with UI or POP 
reported similar levels of anger and frustrations, it was the women with UI 
and POP who were the most frustrated and angry with the impact that their 
condition has on their sex life.  This is demonstrated in table 12.5. 
 
Table 12.5 Breakdown of frustration and anger in the SA group according to 








Alone  (%) 
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An evaluation of the relationship between sexual status and avoiding / 
restricting sexual activity through fear of leaking urine and / or stool and / or a 
bulging in the vagina was not significant.  However, 43-73% of women report 
that fear of leakage caused them to avoid or restrict SA and this was also a 
particular concern in those women without partners.   
 
Assessment of the NSA population 
 
A detailed analysis of the NSA group was performed using a binary logistic 
regression to try to explore factors that could influence reasons for sexual 
inactivity such as age, parity, UDS diagnosis along with all the answers to 
questions 2 and 3 on the PISQ-IR.  None of the co-variates made a 
significant contribution.     
 
Assessment of Bothersomeness 
 
Bothersomeness of sexually inactivity (Question 6) was examined to 
understand if it is age dependent or related to the reason for not being SA.   
 
Group 1 
The relationship between bothersomeness and age was analysed using an 
independent T-test.  In group 1, this showed that those who were not 
bothered were, on average, 10.46 [95% CI: 4.861, 16.068] years older than 
those who were bothered (t(126) = 3.696, p <0.000).  There were no 
relationships identified in group 2.  In group 3, it revealed a significant 
difference in the mean age, with those who were bothered being, on 
average, 12.3 years (95% CI: 1.05-23.55) younger than those who were not 
(t(28) = 2.240, p = 0.033). 
 
A Binary logistic regression was used to investigate the relationship between 
bothersomeness and factors identified in Q2 among the NSA group (the 
rationale for sexual inactivity ie due to bladder problems, other health 
conditions, lack of interest). In group 1, bothersomeness was associated with 
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lack of interest in SA and being NSA due to UI/FI/POP problems. No 
relationships were identified in group 2 or 3. 
 
Assessment of the SA population 
 
Examination of the SA group was performed to determine if factors such as 
age, parity and UDS diagnosis impact upon SF.   
A Binary logistic regression was used to investigate the relationship between 




Q9 (leakage of urine and or stool with any type of sexual activity) 
The model was statistically significant χ2(10) = 29.525, p = 0.001. It 
explained 18.5% of the variance in sexual activity correctly assigned 62.6% 
of cases. Patient reported symptom of UI was the only covariate that 
significantly contributed to a person's likelihood to leak with any type of 
sexual activity. The model parameters are displayed in table 12.6. 
 
Table 12.6 Factors influencing urinary leakage during SA 




       Lower Upper 
Age -.010 .014 .469 1 .49 .990 .964 1.018 
Parity .608 .446 1.86 1 .17 1.838 .767 4.404 
Prolapse -.364 .346 1.10 1 .29 .695 .353 1.369 
UI 1.45 .479 9.27 1 .002 4.298 1.681 10.98 
FI 21.0 17889.5 .000 1 .99 1455331225. .000 . 
UDS - USI -.086 .422 .041 1 .839 .918 .401 2.098 
UDS - DO .514 .427 1.45 1 .228 1.673 .725 3.859 
UDS - VD .872 1.144 .581 1 .446 2.391 .254 22.51 
UDS - CAP -.380 .657 .334 1 .563 .684 .189 2.479 
UDS - Mixed -.276 .623 .196 1 .658 .759 .224 2.571 




The relationship between Q9 and UI was further investigated through a 
Pearson's Chi Square test. This showed that those reporting UI were 
significantly more likely to leak with any type of sexual activity than those 
without UI (χ2(1) = 14.211, p <0.000). It is interesting to note in this analysis 
that 39% of women reporting UI, never leak with any type of SA. 
 
Of the 232 sexually active women 22 were SA without a partner.  For those 
with a partner 37% reported that their partner some / most or all of the time 
had a problem that limits their SA.  In general 70% felt that their partner had 
a positive effect on their sexual desire and 65% stated that their partner had 
a positive effect of the frequency of SA.  However, being SA does not 
guarantee satisfaction with 59% women reporting that they sometimes / 
usually or always want more from their sexual encounters.   
 
The relationship between Q18 and Prolapse was further investigated through 
a Pearson's Chi Square test. This showed that those with POP were 2.5 
times more likely to avoid sex through fear of bulge /leaking than those 
without (χ2(1) = 8.339, p = 0.004) and is reported in Table 12.7.  
 
Table 12.7 Factors causing restrictions on SA 
 B SE Wald df Sig. Exp(B) 95% C.I.for 
EXP(B) 
       Lower Upper 
Prolapse 1.131 395 8.222 1 .004 3.099 1.430 6.716 
Parity .445 .427 1.084 1 .298 1.561 .675 3.607 
UI .442 .456 .937 1 .333 1.555 .636 3.802 
FI 20.157 17659.5 .000 1 .999 567646277.673 .000 . 
UDS - USI -.656 .453 2.099 1 .147 .519 .214 1.260 
UDS - DO -.260 .431 .363 1 .54 .771 .331 1.797 
UDS - CAP .881 .740 1.41 1 .23 2.414 .566 10.30 
UDS - MUI .555 .855 .421 1 .51 1.742 .326 9.310 






The model was not significant for any of the questions.   
Of the 57 SA women 6 were SA without a partner.  For those with a partner 
25% (n=14) reported that their partner some / most or all of the time had a 
problem that limits their SA.  In general 74% (n=42) felt that their partner had 
a positive effect on their sexual desire and 67% (n=38) stated that their 
partner had a positive effect of the frequency of SA.  However, being SA 
does not guarantee satisfaction with 60% (n=34) women reporting that they 




Q9 (leakage of urine and or stool with any type of sexual activity) 
 
The model was statistically significant χ2(4) = 14.405, p = 0.006. It explained 
49.4% of the variance in sexual activity and correctly assigned 74.2% of 
cases. Having at least one live birth made a significant contribution, resulting 
in a 42-fold increase in the chances of urinary incontinence during sex.  
However, the mode of delivery was not assessed in this group. 
 
The model was not significant for questions 7, 10, 11 and 18. 
 
Of the 30 SA women 2 were SA without a partner.  For those with a partner 
20% (n=6) reported that their partner some / most or all of the time had a 
problem that limits their SA.  In general 93% (n=28) felt that their partner had 
a positive effect on their sexual desire and 90% (n=27) stated that their 
partner had a positive effect of the frequency of SA.  However, being SA 
does not guarantee satisfaction with 43% (n=13) women reporting that they 
sometimes / usually or always want more from their sexual encounters.   
 
In summary, these analyses showed that more women with OAB are NSA 
compared to the other UDS findings, yet women with POP are more likely to 
avoid sex.  Younger age, lack of interest and being NSA due to bladder and 
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bowel problems are predictors of increased bothersomeness of sexual 
inactivity.  Parous women with OAB are 42 times more likely to experience 






What is sexual activity? 
 
According to Rogers et al (2018) the assessment of sexual activity status 
should be self-defined and not limited to women who engage in sexual 
intercourse, as such, in the 2018 IUGA / ICS joint report on the terminology 
for the assessment of sexual health of women with pelvic floor dysfunction 
there is no set definition for SA.  The PISQ-IR was developed by the same 
clinician and on discussion with Dr Rogers, she reported that they did not 
define SA on the PISQ-IR as they purposely wanted patients to self-assess 
SA in line with their own opinions.  However, this is likely why there was such 
an issue with item non-response.   
 
When trying to find a definition for SA, the free dictionary online defines it as 
‘activities associated with sexual intercourse’.  The medical dictionary as ‘an 
activity that is sexual in nature’. The sociology dictionary as ‘a general term 
for sexuoerotic interactions with oneself and/or others’ and the urban 
dictionary as ‘fluid exchange’.   
 
Different types of sexual acts or behaviours are well defined in the literature 
eg vaginal intercourse, anal intercourse, masturbation but no standardised 
definition of SA could be found.  To further investigate this and ensure that 
the researcher was not missing evidence, I had the opportunity to meet with 
Dr Goldstein, Past President of the International Society for the Study of 
Women's Sexual Health and current Editor in Chief of Sexual Medicine 
Review, and ask questions related to defining SA.  He stated that he was not 
aware of a set definition of SA but in his unit and practice in clinical trials 
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related to SF, they use the definition set on the Female Sexual Function 
Index (FSFI) questionnaire (previously mentioned in chapter 2).   
According to the FSFI:- 
 ‘Sexual activity can include caressing, foreplay, masturbation and 
vaginal intercourse.  Sexual intercourse is defined as penile penetration 
(entry) of the vagina.  Sexual stimulation includes situations like foreplay with 
a partner, self-stimulation (masturbation), or sexual fantasy.’ 
 
This is a far more inclusive list and defines certain sexual acts or behaviours 
which would potentially change the responses of many of the women who 
previously defined themselves as NSA.  However, it is still inadequate as in 
this definition sexual intercourse only includes penile penetration of the 
vagina and not oral, anal or urethral intercourse with alternatives such as 
fingers or sex toys. 
 
The FSFI definition also has a time stipulation associated as it only asks 
about activities in the past four weeks.  Time restrictions have been 
previously discussed as a barrier to the identification of accurate prevalence 
figures and it could be questioned whether 4 weeks is too short a time frame 
for assessment.  
 
Ultimately, this lack of a standardised definition of SA and standardised time 
frame for assessment, presents a fundamental challenge in any future 
research into sexual function in women as the population is never accurately 
described.  This will either lead to challenges in recruitment as seen in this 
study as women may think they are NSA when actually they are, or 
potentially patients who think they are SA (when if you go by the FSFI 
definition are not) and this may lead to inaccuracies in the trial outcomes.  
Therefore, the most pressing recommendation from this thesis is for a review 







Prevalence of SA 
 
This investigation has clarified the observations noted by the team in practice 
regarding the lack of suitable women to recruit into the main study as 42% of 
the women attending our UDS clinics are NSA and 55% of our OAB 
population are NSA.  This number is slightly higher than other studies that 
have reported sexual inactivity rates among women attending hospital clinics 
between 28.4-40% (Rosen et al 1993, Moreira et al 2006, Addis et al 2006).  
However, community studies have reported the prevalence of sexual 
inactivity as high as 49% (Lutfey et al 2009).  The difficulty with interpreting 
these numbers is the lack of standardisation of time scales.  This study just 
asked if women were currently SA, some of the studies assessed SA in the 
last four weeks and some in the last year, hence variations may occur.  The 
study reporting the high figure of 49% was only including those women who 
were NSA in the past four weeks so figures may be lower if a longer 
timescale was adopted.   
 
In this cohort, women with DO are the most likely to be NSA due to lack of a 
partner and the least likely due to their bladder and bowel problems.  They 
are also the least bothered overall about their lack of SA.  The women in the 
OAB group appear to be the most likely to restrict SA due not only to their 
bladder and bowel problems, but also their other health conditions.  Lack of 
interest ranged from 53-83% among the groups.  Lutfey et al (2009) found 
that 60.8% of women were NSA due to lack of a partner and 51.5% due to 
lack of interest, in their community study.   They reported that only 4.1% 
were NSA due to UI, however, this is because it was an assessment of all 
women in a community setting rather than a biased view of women referred 
to a hospital setting with a urogynaecological problem.   
 
It is important to remember when discussing the prevalence of SA in this 
cohort that it is a biased group of women as they have all made the move to 
seek help for a UI or POP problem, which is why they had been referred into 
the clinic.  There are many women in the community who have not sought 
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help for a variety of different reasons and then the impact of UI / POP on 
their SF remains unknown.  
 
Prevalence of OAB 
 
In the initial trial feasibility discussions, it was documented that 50% of our 
clinical population reported OAB symptoms and would potentially be suitable 
for the study, however, in this investigation, only 40% of the women 
attending the UDS clinic were found to have OAB / DO.  This may have also 
negatively affected recruitment in the main trial but it is important to 
remember that the women attending this clinic were only the new referrals 
and not women who had previously been investigated, therefore there was 
also a population of women attending the outpatients clinics for bladder 
retraining and medication reviews who may have been suitable for the trial 




There were no factors identified in this study to help understand who may 
and may not be SA.  This is not unexpected as SA is dependent on more 
than just age, parity and UDS diagnosis but is also under the influence of a 
wide range of external and internal factors such as religion, personal beliefs, 
family / cultural influences, education, availability of a sexual partner, views 
of peers and these were not considered in this study (Wight et al 2006, 
Villarruel et al 1998, DeLamater & Sill 2005).  For many of the women, the 
rationale is also multifactorial. 
 
Bothersomeness of sexual status 
 
The most clinically important findings from the examination of the NSA group 
is in relation to bothersomeness.  Those who reported no interest in sex, 
were 5 times more likely to be bothered by their sexual status and those who 
reported being NSA due to their bladder / bowel / prolapse condition were 




This bothersomeness or level of personal distress is one of the factors that 
differentiates a sexual dysfunction from a sexual problem that does not 
significantly affect a woman’s sexual life or sexual satisfaction (Bancroft et al 
2003, Dennerstein et al 2005).  Ferenidou et al (2008) assessed SF and 
satisfaction in women attending hospital appointments for any medical 
condition other than a sexual problem.  They found that the most bothersome 
sexual problem, reported by 17.1% of women was ‘little or no interest in sex’.   
However, it was also the condition that women are least likely to seek help 
and treatment for.  Other studies have reported the rates of low desire in 
women as 10-41% (Lewis et al 2010).   
 
The highest level of personal distress is seen among women who are NSA 
due to their UI / POP.   It has long been noted that sexual avoidance is 
common among women with UI, with reports of up to two thirds of women in 
one cohort avoiding SA, particularly in those under 65 years and unmarried 
women (Norton et al 1988).  Other studies have reported avoidance of SA 
due to prolapse as 13.9% and due to fear of incontinence as 14.9% (Knoepp 
et al 2010).  This high level of personal distress is likely to be due to the 
psychological impact of UI / POP on SF.  Roos et al (2014) studied women 
with UI and POP to determine what women perceive to be the real problem 
with FSD and stated that ‘women with POP had a negative image of their 
vagina, which caused them to be insecure about their partner's sexual 
experience, while women with UI were embarrassed about their incontinence 
and pad use, and feared smelling of urine’. These issues can lead to sexual 
avoidance and inactivity.    
 
As women with partners who are NSA due to their UI/POP have indicated 
the highest level of bother, this group warrants a particular focus and may 
benefit from referral for psychosexual counselling as well as appropriate 
management of the UI / POP.  For the women who are NSA without a 
partner further discussions are warranted to understand whether their 
bladder condition / POP is hampering their desire to find a partner and 
causing additional anxiety regarding future sexual relationships, thus 
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preventing them from being SA should they chose to be, if it is not related to 
their reason for being NSA.  
The degree of bothersomeness in the NSA group was found to be age 
related.  The average age of the NSA group in the whole population was 
54.9 years and those who were least bothered by sexual inactivity were 
found to be 10.46 years older on average.  In the OAB population, the 
average age of the NSA group was 54.5 years and those who were most 
bothered were on average 12.3 years younger.  Shifren et al (2008) 
performed a study to estimate the prevalence of self reported sexual 
problems and the extent of personal distress in women and found that the 
prevalence of distressing sexual problems peaked in middle-aged women 
(45-64 years) and then decreased with age which would fit with the picture 
of older women being less bothered.  There are many suggested reasons 
for this including the effect of the menopause, however, the mid-life and 
later life can also be times of partnership transitions via separation and 
divorce or be associated with changes in employment and financial status 
that may affect SF (DeLamater & Karraker 2009).   For some it may also be 
a time when they are assuming a care giver role or confronting illness or 
death and priorities change and all of these may impact upon sexual 
activity.  
 
Fear OF Leakage 
 
Although only 36-38% of the SA women reported leakage during sex, 61-
77% of the SA women (and 48-68% of the NSA women) avoided SA for fear 
of leakage.  As expected the diagnosis of UI was significantly associated with 
this.  In the OAB population, parous women are 42 times more likely to leak 
during sex than nulliparous women.  However, the fear of leakage appears to 
be more problematic than actual leakage itself.  This is also reflected in the 
study by Kneopp et al (2010), where only 9% of women reported leakage 
during SA but 14.9 reported avoiding SA for fear of leakage.  Fear of leakage 
can affect a woman’s motivation to be SA, her arousal and ability to achieve 
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orgasm and if she contracts her pelvic floor to prevent leakage can lead to 
dyspareunia (Roos et al 2014).   
 
Impact of POP 
 
It is interesting to note that women in the SA group with POP were 2.5 times 
more likely to avoid SA than others.  POP had a negative impact on a 
woman’s body image (Jelovsec & Barber 2006).  According to Novi et al 
(2005) women with POP were more likely to report negative emotional 
reactions associated with sex and a significantly higher rate of avoidance of 
SA due to embarrassment compared with controls.  These high avoidance 
rates were also seen in the study by Tok et al (2010) and would fit with the 
findings in this cohort. However, there were only a small number of women in 
this group (N=17), therefore further investigation with a far larger number of 
women with POP alone would be necessary to confirm or dispute this 
finding.  Recent work by Jha et al (2016) reported a study with 343 women 
undergoing surgery for POP or SUI and compared the effect of each of these 
conditions on SF.  They found that women with POP (79% vs 36%) and their 
partners (50% vs 24%) were more likely to avoid SA than those with SUI, 
which mirrors the findings in this study.    
 
In this study women with UI and concomitant POP reported the highest 
levels of anger and frustrations with their sexual lives.  This would fit with 
work previously published by Ozel et al (2006) who found that women who 
had UI and POP had significantly poorer SF than those with UI alone.  In 
clinical practice particular focus should be made to ensure that sexual 
problems are addressed as part of routine clinical care for these women. 
 
Satisfaction from sexual activity 
 
A significant proportion of women (43-60%) were not always satisfied with 
their SA.  Those with DO were the most satisfied while the OAB group were 
the least satisfied. There could be a multitude of reasons for this.  For those 
women with POP, patients have reported the sensation of obstruction within 
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the vagina and vaginal laxity as two of the main reasons for reduced sexual 
satisfaction (Srikrishna et al 2008).  It has also been observed that there is a 
significant interaction between communication and sexual satisfaction 
(Litzinger & Gordon 2005, Montesi et al 2013, McNulty et al 2016), and that 
these interpersonal factors play a major role in maintenance of sexual 
problems (McCabe et al 2010) yet marital satisfaction and communication 
with partners was not addressed in this study.  Pascoal et al (2013) 
performed an exploratory study to understand how lay people define sexual 
satisfaction and identified two themes.  The first was in relation to sexual 
pleasure including arousal, orgasm and sexual openness, the second theme 
emphasised relational dimensions including romance, expression of feelings 
and mutuality and that both areas are crucial to sexual satisfaction.   
 
Schoenfeld et al (2017) also reported that husbands positive interpersonal 
behaviour towards their wives improved sexual satisfaction. Again, this was 
not addressed in our study so it is not possible to attribute the cause of these 
high sexual dissatisfaction rates.    According to Rehman et al (2013) women 
tend to be more sexually satisfied if they are older, in a stable long term 
relationship, are more erotophilic (respond to sexual cues in a positive 
manner) and have better sexual and non-sexual communication with their 
partner. 
 
Overall, the women with OAB symptoms but normal UDS variables report the 
lowest levels of SA, report the most bother and the least sexual satisfaction 
and a greater number of them report other health conditions that also impact 
upon their sexual function.  It could be suggested in this group that women 
with OAB may have other concomitant pathologies such as urogenital 
atrophy and psychological factors that are impacting upon SF rather than just 
bladder pathology.  It could also be considered that these women are more 
aware of physical symptoms or less able to manage psychological symptoms 
as they present with similar symptoms to other women but with increased 
bother.  Further research into this group of women is needed to improve our 




Reliability and Validity of the PISQ-IR 
 
It was noted that 87 (52%) of the NSA and 83 (36%) of the SA group did not 
complete every question in the relevant section of the questionnaire.  Most 
commonly in the NSA group – if they did not have a partner they did not go 
on to complete the rest of the questions in the section.  Item non-response 
has been noted in previous work considering the scoring and development of 
the PISQ-IR (Rockwood et al 2013).  They also found that item non-response 
was higher in the NSA group ranging from 5-33% but low in the SA group (up 
to 7%).  The scoring was adjusted to allow for this, however, the rates of item 
non-response are far higher in this ‘real world’ study.  This could reflect our 
patient population, for example some may have felt that the questions were 
not relevant to them or they may not have wanted to disclose sensitive 
information.  It could be suggested that the clinician reviewing the patient and 
collecting the questionnaire should have gone through the answers in more 
depth and encouraged the women to answer all the questions.  However, the 
aim of this study was to assess prevalence of SA among the women 
attending the unit and although women were given the opportunity to discuss 
SF with the clinician as is the normal practice, particular attention to the 
answers of each question were not discussed during the consultation unless 
the patient specifically requested.  Alternatively, the high non-response could 
just be a sign of questionnaire burden as these were sent to the patients at 
the same time as a KHQ and a three day bladder diary so it may have been 
too much to complete prior to their visit to the department.   
 
Several comments were made by patients regarding the questionnaire that 
may explain some of the non-response, as they did not feel that there was a 
suitable option that explained their situation.  It was felt that all the reasons 
for not being sexually active were quite negative (no partner, pain, due to 
bladder / bowel problems).  Several women attending were Virgo Intacta 
through choice to wait until marriage and felt that there was no suitable 
reason for them to make comment.  Also, many women reported that 
although they were in a loving relationship, their partner had health issues 
causing erectile dysfunction and this was the reason for not being sexually 
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active, but this option was also not available on the questionnaire.  On further 
questioning several of the NSA women reported being intimate with their 
partners without vaginal penetration yet they felt this counted as being NSA 
despite the SA section allowing for women not having intercourse.  As 
previously noted at the start of these discussions, a sentence regarding what 
is considered as sexual activity may prove beneficial for women completing 
this questionnaire in the future.  
 
Given all the limitations and non-response noted, this study questions the 
validity of the PISQ-IR in practice.  In its simplest form, validity is the ability of 
an instrument to measure what it is intended to measure.  If the aim of the 
PISQ-IR is to assess in the first instance whether women are sexually active 
or not, then based on the fact that there is no definition of SA and the 
concerns noted by women above in relation to this, it is not a valid tool in our 
population.  This is contrary to the validation studies performed by Rogers et 
al (2013), where testing on 589 women provided baseline data and 200 post 
treatment confirmed content, and criterion validity and responsiveness.  The 
paper reports that 31 interviews were also conducted regarding the content 
of the questionnaire and this number is noted as being limited but it does 
claim that data saturation was achieved.  It does not mention in the paper 
any concerns over defining SA as raised by the cohort under investigation in 
this study.   
 
With regard to the reliability of the tool, the Rogers (2013) paper also 
assessed and confirmed the item distribution and test-retest reliability of the 
PISQ-IR.  The challenge when considering the test retest reliability of this 
tool, is in the very nature of the topic under assessment.  Sexual activity is a 
continuum and often changes over time for a variety of reasons not only due 
to health status but a variety of other factors.  Within the reliability 
assessments, the second questionnaire was sent out 3-6 months after the 
first and there is the potential for many of the women to change their SA 
status.  Interestingly, unlike the FSFI, the PISQ-IR does not set any time 
frames within which SA may have occurred, so there is the potential for a 
variety of different responses and time frames that women may establish 
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themselves when completing the questionnaire that may impact on its 
reliability.  This is however, an inherent issue for any questionnaire 
potentially assessing SA, where a time frame has not been set.   
 
This study has raised the question about the role of the PISQ-IR in routine 
clinical practice.  It may help us to gain a deeper understanding of a patients 
SF, which may help clinicians to understand which patients are most troubled 
by sexual problems and tailor assessment and therapy to meet their needs.   
However, without the clinician actively reviewing it with the patient it could 
become just another paper exercise.  It may therefore be better used in 
women who report a sexual problem when questioned instead of as a 




Overall this study provided us with a lot of useful information about our 
clinical population.  Although a high proportion of them were NSA, which 
confirmed our difficulties with recruitment to the main studies, we were 
unable to find any specific factors that were more likely to lead to sexual 
inactivity.  It did however, enhance the knowledge regarding the level of 
distress or bothersomeness experienced by people who are NSA due to their 
UI / POP and the need for further research into this area to understand the 
mechanism behind the problems and how they can be resolved.  The validity 
of the PISQ-IR has been questioned and it has highlighted the fundamental 















How do women want to be approached 






A key limitation for recruitment that was identified in the main trial was 
regarding communication and how women were identified and approached to 
enter the trial.  This is described in chapter 9 with study sites reporting that 
they did not always ask women about SA or that women had been reluctant 
to discuss SA with certain health care professionals.  A recommendation was 
made for a standardised approach to discussing SA for future studies.  
However, there is no precedent for this in the literature or recommendations 
for best practice.  Ensuing discussions led to development of a new research 
question:- 
 
‘How do women want to be approached about the topic of SF?’ 
 
To investigation this research question, two focus groups (FG) were run with 
women who had attended our department with Urogynaecological problems.  
The full methodology for this investigation was described in Chapter 11.  This 
chapter will report the themes and subthemes that emerged from the focus 





Description of participants 
 
In total, 7 women attended FG1 and 5 attended FG2.  There were meant to 
be six women in FG2 but one cancelled just before the session started as 
her train to the hospital had been cancelled so she would not make it on 
time.    
 
The youngest participant was 27 years and the oldest was 75 years. Half of 
the women were in the 41-60 age range.  In relation to ethnicity, 8 were 
Caucasian, 3 Afro-Caribbean and 1 Asian.  Three had been referred to the 
department with SUI, six had OAB / DO, two had POP in isolation while 3 of 
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the women with SUI / OAB had concurrent POP.  The final woman had been 
referred with recurrent UTIs.   
 
Parity ranged from 0-4 live births.  Half were post-menopausal.  A quarter of 
the women did not report any co-morbidities but the others had 1-3 each.  
Co-morbidities included hypertension, asthma, hypo / hyper thyroidism, 
COPD, inflammatory bowel disease, mental health complaints, and 
neurological conditions.  The patients had been under the care of the 
department for a wide range of time from one month to 18 years.  7 of the 
women were SA and 5 NSA. 
 
Two of the women were unemployed, three were retired, and the others 
worked in retail, administrative / clerical work, teaching and health care.  The 
demographics of the participants is set out in table 13.1. 
 









1 53 SUI/POP 2 01/2017 1 Retail  
2 46 DO 0 2003 1 Office 
3 61 POP 2 02/2017 1 Retail 
4 53 DO 1 2008 2 Unemploye
d 
5 73 POP/OAB 1 2010 2 Retired 
6 67 DO 0 2002 0 Retired 
7 54 SUI 1 11/2016 0 Health care 
8 40 POP 3 2008 1 Teacher 
9 42 OAB 0 2010 1 Clerical 
10 27 RUTI 0 04/2017 1 Unemploye
d 
11 43 DO/POP 4 04/2017 0 Housewife 





There were three core themes that emerged from the data.  They were:- 
 
1. Perceived barriers to discussions on sexual function 
2. Communication factors 
3. Ideas to introduce the discussion 
 
Each of the core themes had sub themes identified as demonstrated in table 
13.2. 
 
Table 13.2 Themes and sub themes identified 
 









Sex of the clinician 
Presence of a partner 
Age of clinician 
Family dynamics 










Methods of communication 
Personal feelings 
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There was considerable overlap between some of the themes and sub 
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Communication factors
Ideas to introduce the discussion
Perceived barriers to discussions on Sexual Function




Overlapping themes and subthemes
Communication factors Ideas to introduce the discussion





1. Perceived barriers to discussions about SF 
 
One of the strongest threads running through the data was related to the 
factors that women perceived to be barriers to discussions about SF. Some 
of these barriers were common to several of the women in the group and 
others were very individual perceptions.  There was no one barrier identified 




It seems quite contradictory that sexual inactivity is seen as a barrier to 
discussion of SF.  However, there were several reasons identified that 
supported this subtheme.  For some women who were NSA, the rationale for 
this was cut and dry so that further discussion would be halted.   
 
‘Mine is through choice after my husband passed away 25 years ago and I 
don’t like to talk about it’ 
 
However, for others, being NSA raised questions about their own 
relationships and lifestyle that they were unable to answer because they do 
not understand themselves. 
 
‘When I go to the doctor and he asks me why I am NSA, I don’t know the 
answer to give him because I don’t know why I am’ 
 
For several of the women, just because they were NSA at that time, they did 
not want the conversation to stop there.  They reported feelings of exclusion 
and they are missing something:- 
 
‘I don’t want to be excluded because I am NSA at the time I am being asked 
the question’   
‘That’s why I think discussing a patient’s sex life, whether or not they are 
having it, not having it, want it, why, is very important; otherwise it is a bit like 
we are being put out to grass’ 
 
For these women it was highlighted that just because they are NSA at that 
time, does not mean that they are not seeking a relationship, and that in 
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reality there are a whole different group of concerns and issues that women 
have in new sexual relationships, that they may have liked to discuss further 
with the clinician.   
 
‘I don’t have a partner at the moment, but one of my concerns with the next 
one is I am embarrassed, whereas my old partner didn’t care because he 
knew’   
 
Sex of the clinician 
 
For nine participants in the FGs the sex of the clinician was deemed to be a 
significant barrier to the discussion of SF.  All of these women expressed 
concern that they felt happier talking to a woman about SF and all agreed 
that there were increased feelings of embarrassment and personal 
discomfort / distress when the conversations were had with men.  This 
preference for a female clinician was not dependent on whether the women 
had children, however, it was the younger women who did not share the 
views of the majority of the group.  Comments included:- 
 
‘You want to die really…you feel happier with a woman, it’s not really 
something that you want a man to see’ 
‘I think also that if it’s a woman or a man asking you makes a difference.  I 
think you would be much happier telling a woman than a man’ 
 
‘Just make sure it is a woman and not a man as I think you would just be 
embarrassed saying that to a man’ 
 
‘You feel more comfortable with a woman’ 
‘I just think that if a man asks you that, you just straight away have that sort 
of embarrassment with a man, whereas, if a woman asks you, I think you feel 
that bit more comfortable’ 
 
For the other three women who were not worried about the sex of the 
clinician, they were more focused on other traits of the clinicians that they felt 
to be important such as: 
 
‘That you are comfortable with the person’ 
‘That there is consistency with who you see’ 
‘As long as they are experienced and know what they are talking about, then 
that makes me feel confident’ 
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However, when talking further about experience it was agreed by the groups 
that when it came to discussion SF it was not necessarily the consultants 
who they thought to be the experts and that again sex of the expert was 
important. 
 
‘I know that consultants are specialists, but if they are male, you are not 
going to get the answers you need as much as if you have a nurse who was 
specially trained to sensitively deal with that aspect’ 
 
Presence of a partner 
 
Another significant barrier discussed by the FGs was the presence of a 
partner in the consultation.  Only one woman reported that she did not have 
a problem discussing SF in front of her partner as they had a very open 
relationship and were happy talking about such issues.  For all the other 
women, even those who did not currently have a partner, it was felt that 
having a partner with you during the discussion would prevent women from 
being completely honest.  For some this was because the partner was not 
aware of issues and they didn’t want them to be voicing comments such as: 
  
‘Even with your husband sitting there, who you are obviously intimate with, I 
think a lot of people would not be comfortable talking about their issues with 
sex with their husband, with their husband sitting there, and more so if it is 
just a friend’  
‘The last thing I would have wanted to discuss would have been our sex life 
with him sitting there’ 
 
‘I think you have to keep the romance alive a bit: they don’t need to know 
everything’ 
 
‘He doesn’t need to know everything that’s going on down there.  He needs to 
look at that and feel good’ 
 
One of the participants told the group about the lengths that she goes to, to 
hide the bladder problems that she has had for 20 years from her husband 
and the impact that it has had on their sex life.  She went on to reveal the 




‘My husband hasn’t a clue that I am terribly incontinent because I avoid sex; 
it’s awful, but I have to wear a pad 24/7 and it’s just dripping wet.  I avoid it and 
I sleep right on the side of the bed, but I put it down to, he’s got a defibrillator, 
so I don’t want him to die!  I don’t talk to him, I can’t’ 
 
Some of the women felt that their partners were either uncomfortable being 
in those discussions or in some cases disinterested: 
 
‘It’s something they don’t want to delve into’ 
‘My husband said that he didn’t feel comfortable coming’  
‘My husband wouldn’t be interested at all’ 
 
It was felt by the groups that the scale of the barrier may be dependent on 
the length of the relationship with several women feeling that in long term 
relationships it would be less of an issue than for someone in a new 
relationship. 
 
Age of clinician 
 
Along with issues surrounding the sex of the clinician for many of the 
participants in the FGs age was also a significant barrier to discussions.  
Many of the women reported experiencing increased embarrassment 
discussing SF with younger clinicians and felt that slightly older clinicians 
conveyed more empathy and understanding.  It was also believed if the 
clinician in question was too good looking it impaired discussion.  Women 
considered that: 
 
‘I would feel more comfortable discussing it with a 65 year old guy than some 
Greek God, tanned, sitting opposite me; I could not meet their eye and discuss 
anything’ 
  
‘ I think that with age does come a bit more empathy and understanding; not 
necessarily, but I think that I would feel much better happier discussing 
things of a sexual nature, with someone who is not a young pup, for want of 
a better word.  Just because life brings about experiences, so for me age is 
just as important as gender’ 
 
‘I wouldn’t be happy telling a 25 year old, I would be embarrassed.  I would 




‘I have seen different boys; and they were boys; I’m not saying I’m that old, 
but they were just boys’  
 
Some of the group actually felt that young age was an advantage in the 
discussion as it may make the discussion more open.  
 
‘I think the younger people might be more open to talk about that sort of 
thing’ 
 
Many of the participants discussed the training of the junior doctors 
surrounding SF and suggested that in order for them to gain a deeper 
understanding of the personal discomfort that patient’s experience they 
should: 
 
‘Make them go through the questions; make them be the other person so 
they know what it’s like.  As part of training, I think that would be valuable, 




The way in which women’s views were formed on the barriers to discussions 
was often linked to their family dynamics.  Some of the women who 
appeared to be more open minded and liberal with the discussion, reported 
very open relationships with their family on the topic of sex, whereas for 
some, previous family experience seemed to add to their own barriers and 
beliefs.  Two of the very contrasting views included: 
 
‘My daughter is 19 and my son is 18 and their sex lives are completely 
different to mine at that age.  My daughter is as happy with a girl as a guy 
and is very experimental.  With both of them, nothing is off limits; nothing is 
taboo.  Their friends are all the same and they are very open and are not 
embarrassed to talk about it; I’m very fortunate like that’ 
 
‘When I was young, nobody talked about anything like that.  When you had 
your period, it was your curse; you did not talk to your mum about anything 
like that.  My mum told me about sex when I was 11.  With my children now, 






Timing of discussion 
 
There were mixed feelings within the group as to when is the ideal point in a 
consultation for the discussion of SF to be initiated.  Some felt that it was 
often asked as a final point towards the end of a discussion and that took 
away some of the importance of the discussion. They also felt that the 
clinicians didn’t really want to get into the discussion.  Others were not 
concerned where in the conversation it took place as long as it happened. 
However, everyone was in agreement that it should not be at the beginning 
of a consultation, unless that was the presenting complaint. The length of 
time that people had for the discussion was also linked into this and 
concerns were raised that it was not something that can be rushed and this 
does not always fit into short time frames especially such as those in general 
practice clinics. Some of the remarks included:- 
 
‘It’s making sure perhaps that the sex doesn’t come last, it’s in the middle, so 
there’s not that thing about, “oh, just before we finish…” however you decide 
to ask the question, because otherwise it makes it look like it’s a bit peripheral 
and it’s one of those out of the door things’ 
 
‘I leave it to the Consultant whenever they bring it up; as long as they have 
brought it up, I do want them to address it, I don’t mind if it’s at the beginning 
or the end’  
 
‘With my GP, if I know they are 10 minutes I have to book a double 





It was recognised by the groups when listening to each person’s opinions 
that the topic and reaction to discussions on SF are very different for 
everyone.  Not all patients can be grouped into certain categories and even 
though certain ways of discussion work better for some, this is still not right 
for everyone.  This subtheme indicates the recognition of woman centred 
individualised care and that no one approach is going to be acceptable for 
everyone.  This is supported by the following comments:- 
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‘I think as well that it does depend on the individual.  What you can say to 
one person you can’t say to another.  I mean we can talk quite nicely here, 
but it is not for everybody.  I don’t know how you could group everybody 
in…it’s impossible’ 
 





It was surprising to note that only one participant made reference to religious 
beliefs being a barrier to discussing SF.  All of the cultural references in the 
FGs were in association with the age of the women and the differences in the 
‘culture of youth’ compared to the older generation.  It was felt that the 
younger women were more confident discussing SF and less embarrassed 
but also that sexual practices were changing and that this may also be 
impacting upon differences in the ages.   
  
‘I speak to younger women and it seems that sex is becoming a bit of a 
performance art now, rather than just being intimate and enjoying something with 
somebody’ 
 
‘I think that the younger you are, possibly the more open you are…well not open, but 
the more confident you might feel’   
 




The environment within which the discussion takes place was believed to have 
an impact on the discussion by many of the participants.  From a physical 
environment perspective, women wanted to talk in a room and not a cubicle 
and wanted it to be secluded to ensure privacy.  They wanted a clinician who 
was going to put her at ease and had a gentle approach.  
 
‘Tucked out the way’ 
 




‘They have got to make you feel at ease.  If you’ve got someone who is really 
officious, treating it like a school exercise, you are not going to feel as 
comfortable as someone who is kinder, has the gentle approach’ 
 
‘Having someone who is quite friendly and not too many people and just 
having a nice environment so that I feel comfortable’ 
 
One of the concerns raised by several of the women was that often when 
coming to busy clinics you are seem by different clinicians each time and 
they do not know your history and you have no rapport with them and this 
can be a barrier to discussion.  
 
‘I always see a different person and I feel like no-one cares I sometimes think 
“Am I just a number”.   
 
‘If I got a different person every time I wouldn’t like it’ 
 
The presence of medical students in the consultation also garnered mixed 
reactions from the women.  Some felt that it was difficult enough having the 
conversation with one person let alone two or more whereas one found the 
presence of a student enhanced her own experience of the consultation. 
 
‘I certainly don’t want a room full of people.  If I’m knocked out unconscious 
you can do what you want, but when I’m there and I’m fully aware…’ 
 
‘At my last appointment there was a student there and in actual fact it was 
good, because she was thoroughly explaining everything to the student, so it 
meant that I could kind of understand in layman’s terms.  I don’t mind; I just 
don’t want too many people; if it was like a bunch of Consultants, then I 
wouldn’t be happy, but one or two people’ 
 
A word query search was performed to find the 50 most frequently used 
words in the theme and these are displayed in the word cloud in figure 13.2.  
In word clouds, the larger the word in the figure the more prevalent it was in 
the analysis.  The fact that the most common word is ‘person’ is not 
surprising.  Many of the conversations detail individuals experiences and the 
groups reaction to them.  Overriding discussions where related to the fact 
that each person is different and they each have their own barriers.  The 







Figure 13.2.  Word cloud for most frequently used words associated with 
barriers to discussions 
 
2. Communication factors 
 
Communication skills was a theme that overlapped with many of the other 
themes.  The establishment of solid patient –clinician relationships was a key 
feature that encouraged women to open up and feel comfortable discussing 
SF. 
 
Methods of communication 
 
When the participants were discussing communication, it was not just the 
verbal but also the non-verbal cues that the patients pick up on.  It was 
suggested that the tone of the questions was important in helping the women 
feel at ease with discussions. The establishment of rapport within the 
consultation was a high priority for a lot of the women to feel that they could 
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truly open up about their issues and associated feelings.  Women also wanted 
to be met with empathy and understanding and it was suggested that there 
were some clinicians who did not have the necessary skill to demonstrate that.  
Several of the women wanted the clinician to help rationalise the problems and 
help them to understand that it was not unique to them, and things could be 
done to help.  However, it was recognised that some women will never be 
comfortable communicating about SF, whether it be with a clinician or partner.  
Several of the women reported having written down some of the concerns / 
problems before a consultation as they felt once in there, their own personal 
communication skills may be lacking and they didn’t want things to be missed.  
Specific comments included:-   
 
‘Because it is such a highly personal thing and a lot of people would be very 
uncomfortable being asked it straight off.  I think you have got to establish, for 
want of a better way of putting it, a relationship with your patient before you 
can broach something like that’ 
 
‘Making them realise that it’s not unique to them; they are not alone in that 
problem and I think that would make them feel more comfortable discussing 
it’ 
 
‘As with any relationship, emotional, professional, whatever; it does come 
down to dynamics and maybe there are just some people who will never 
want to open up and you just have to factor that in and then there are others, 
who are probably not best professionals who aren’t best placed to be asking 
those questions because they don’t have the empathy or the understanding’  
  
‘It’s all about your tone…how you ask the questions.  That will straight away 
set me at ease or not’   
 
‘Some people just will never be comfortable discussing with someone they 
don’t know, or even with their partners.   It’s the individual personality’ 
 
‘I knew I wouldn’t say half the things and once I start crying then I can’t get it 











The most emotive subtheme that emerged and overlapped with almost every 
other theme was around the participant’s personal feelings.  These were not 
only in relation to SF but also their Urogynaecological problems.  Almost all 
of the women reported a degree of embarrassment or shame in relation to 
their problems.  Although it was noted that discussing bladder problems has 
become less of a taboo in society many women still feel isolated and that 
they are alone.   
 
‘You have got the shame of having an overactive bladder and then talking 
about very personal issues’ 
 
‘It’s almost like you are ashamed’ 
 
‘I feel ashamed’ 
 
‘I’m so fed up of feeling that no-one feels what I’m feeling’ 
 
‘I think also that now people talk about bladder problems, but when I first had 
it, there were no adverts on telly for pads and it really was taboo.  I can 
remember when you would go and buy sanitary towels and they would put 
them in a brown bag so nobody would see them.  Now it is much more talked 
about, but I still don’t feel that it is something I want to go and shout about. I 
still feel that it is something personal to you’ 
 
For many of the women, when seeking help or having conversations about 
SF, the most important thing for them was to feel that they are being listened 
to by the clinician and to feel that the clinician cares about what they are 
saying.  Many of the participants agreed the reaction of the clinician during a 
consultation was very important to their feelings and could positively or 
negatively impact on an interaction. 
 
‘As long as I can see that the person does actually care’ 
 
‘I feel I want them to get into my soul and know what I need and that they 
understand what I’m feeling and advise me’ 
 
‘I’m in tears, I just feel so awful that I just wanted the ground to swallow me 




What if we don’t ask? 
 
With so much of the focus of the discussions around discussing SF, one of 
the sub themes that emerged was related to how the participants would feel 
if they were not asked about SF or given the opportunity to discuss it, no 
matter how difficult those conversations may be.  Almost all of the women 
agreed that they felt something would be missing in their holistic assessment 
if they were not asked and even acknowledged that they understood there 
may not be treatments available but they at least wanted to talk about it.  
Comments included:- 
 
‘As long as they do address it and I have the opportunity to voice my concerns’ 
 
“Do they think - well they’re dead in the water, it doesn’t matter” 
 
 ‘I would have been quite upset as it is almost negating part of me as a woman 
and I think we all have the ability to be SA and if it becomes an exercise in 
exclusion, that would make me feel really sad’ 
 
‘Even if they can’t do anything, talk to me about it’ 
 
Two word clouds were created for this theme, one looking at the most 
frequently used words associated with communication factors (Figure 13.3) 
and the other for personal feelings (Figure 13.4).  The most prevalent words 
in the communication sub theme were person and comfortable.  Again 
referring to the individual nature of how communication is perceived and how 
by being comfortable with the clinician, the surrounding environment and the 
topic eases communication.  As previously noted these word clouds also 
demonstrate the overlap in the themes, highlighting the individual nature of 
the topic.  The universal personal feeling was that of embarrassment, 




















3. Ways to introduce the discussion 
 
This category links directly to one of the questions asked of the women in the 
FGs.  There were many discussions based not only on how they had been 
approached about SF, but also how they would have liked the topic to have 
been broached with them.  The discussions focused around three main 
areas, one on verbal questions related to how SF is introduced and how 
questions are asked, one detailing written methods of communication and 
the third theme that emerged from the data was regarding a desire for pre-
warning.  Most of the women agreed that one single method was not ideal 
and that using the written word as well as a conversation was the best 




Two thirds of the women felt that the use of a questionnaire was a useful tool 
to either introduce or further probe the topic of SF.  It was considered by the 
woman, that completing a questionnaire prior to a consultation may be taken 
as a form of consent to discuss the topic, or a way of gaining a further 
understanding of problems for the women who felt too uncomfortable 
discussing the topic directly.  Almost all of the women felt that completing a 
questionnaire was less embarrassing than having to answer the same 
questions when asked directly. Comments included:-  
 
‘For those who still feel uncomfortable talking to another being, whether they 
are female or whatever, you could offer the option of the questionnaire 
 
‘I’ll put my feelings down on paper, as I am too embarrassed to bring it up in 
the session, but if it is already on paper, then they can broach the subject for 
you and ask you more probing questions around it’ 
 
‘It would make it a lot easier, so that you can tick boxes and that might be a 
way of lessening the embarrassment for some patients’ 
 




‘I would much prefer everything to be on my questionnaire; I can be as 
honest as I want to; skip what I want to; put in what I want to and it is all done 
on paper and I don’t have to feel embarrassed or offended at my actual 
appointment’ 
 
However, many of the women did have concerns regarding the content of the 
questionnaire, feeling that issues surrounding SF do not always fit into a tick 
box in the same way as questions related to bladder function.  Several of the 
older women were also concerned about the potentially explicit nature of the 
questionnaire, feeling that questions about certain sexual practices may 
make people uncomfortable and that they should be given the choice as to 
how and if they would like to further discuss the topic of SF.  All of the 
women agreed that all questionnaires on SF should include a comments box, 
that would allow them to voice individual concerns that they had and felt that 
by putting it in writing for the HCP to read made it easier to talk about during 
the consultation.  One simple option discussed was to just have a single 
question on paper asking the woman if she would like to discuss SF and then 
a space to note concerns to discuss. Comments and suggestions included:- 
 
‘They are structured such that I did not really know what to put down on the 
form and sometimes that tick box, with something that is personal like sex, 
doesn’t always apply in the same way as; how many times do you pee a day’ 
 
‘Obviously you would have to be very cautious because, probably, if you 
were to give “do you do this, this, this and this” some peoples eyeballs might 
fall out’ 
 
‘Give them the option; there is a questionnaire we would like you to 
complete; however, it is extremely personal, some might say invasive, if you 
are comfortable with it, fine, but if not you don’t have to complete it’ 
 
‘I think a questionnaire would be good, possibly asking to tick the box if you 
would be happy to discuss those matters and I think that takes out the 
awkwardness for both parts really, when you actually get to the appointment’ 
 
‘Also a comments box, because sometimes what I hate with hospital things, I 
think “well I’m A&B but I’m not that”.  So just to be able to put a comment, 
because once I know you have read that, it’s easier for me to talk about it, 








Many of the women had ideas about how they would like to be asked 
regarding SF and suggested ways which the questions could be phrased to 
help minimise the impact.  Many agreed that by ensuring that the woman 
understands why the clinician feels it is important to ask about SF, for 
example by linking it to common problems experienced by other women, it 
may normalise the issue, reduce embarrassment and help them to not feel 
alone.  Suggestions included:-  
 
‘You can ask the question, “Are you sexually active” and if they say yes/no, 
you can tactfully ask “Is that through choice”; “would you like to be more 
sexually active, but you find that this problem prevents you, or is it because 
of other factors which are not relevant to why you are here” 
 
‘If you were to say “we find that a lot of our patients experience this”, they 
might say, “oh yes, I had that” 
 
‘I think maybe, “A lot of our patients with similar problems to yours 
experience difficulties in their sex lives; do you have any issues; are you 
sexually active; if not, is that because of your issues”.  It’s not so brutal.  “A 
lot of our patients experience problems, would that apply to you?” 
 
There were also questions about needing further clarity with terminology as it 
was felt that the term ‘sexually active’ could be misconstrued and that when 
asked about problems with SF it had quite negative connotations.  It was 
considered that for women that are in long term relationships, they may not 
have had vaginal intercourse for a long time often due to partner health 
issues, however, they still found ways to be intimate and have a happy and 
fulfilling sexual relationship.  It was felt that the terminology is too exclusive 
and directional and not representative of the population.   
 
Many of the women in the group agreed that the important thing was about 
their enjoyment and that instead of asking if their UI/POP symptoms caused 
any problems with the sexual lives, that asking instead about the impact their 
UI/POP had on their sex lives was preferable.  There was also agreement in 
the groups that at the start of the discussions the HCP should add a rider 
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that if at any point in the conversation the patient became uncomfortable they 
can stop.  Quotes included:- 
 
‘What does sexually active mean?’   
 
‘I think it is wording things so that they are as inclusive as possible so as not 
to deny someone the opportunity’ 
 
‘Are you sexually active is too directional’ 
 
‘Enjoy is a good term and I quite like impact’ 
 
‘If at any point you feel that you are uncomfortable during our chat, just stop; 





This sub theme emerged and overlapped with all of the core categories 
identified.  It was reported by the women in both FGs that when you attend a 
Urogynaecology clinic, it is not automatically considered by the patient that 
HCPs will be asking them about SF as they are concentrating on the 
presenting complaint.  By having some idea before the clinic appointment 
about what to expect on the day and the sort of questions that may be asked 
women felt that this would help them to mentally prepare for the appointment 
and consider if they wish to broach the subject of SF and what concerns they 
have.  This also overlapped with the idea of a questionnaire to complete 
beforehand as the women felt that it would help them to focus and verbalise 
their concerns.  Comments included:- 
 
‘Putting it in the letter that goes out to the patient that this is what is going to 
take place, so that the patient is mentally prepared for the questions that they 
can ask, because sometimes you go into an appointment you are not aware 
of what you can or can’t ask’   
 
‘You have got the time to think about it, rather than being under pressure and 
not remembering.  If you have the questionnaire beforehand you can think 
about what are my issues’ 
 




 ‘I think having the opportunity to think about what is happening to me and 
being able to document that before I go to my appointment, it’s very 
important.  At the appointment, I’ve probably been having a busy day and I 
won’t remember, or be embarrassed or whatever, but if it’s all down on 
paper, then I know they have all the information and they can ask me 
questions from there’ 
 
The concept of pre-warning was also discussed in relation to several of the 
barriers identified by the women in previous conversations.  It was felt that by 
knowing that these conversations were going to take place in a consultation, 
women may decide not to bring their partners with them to avoid the 
awkwardness of being asked with them present or request to see an 
alternative HCP (a female clinician) when they arrive to ensure that they saw 
someone they felt comfortable discussing identified issues with.  Quotes 
included:- 
 
‘What you wouldn’t want is to go in unaware and to be asked questions that 
actually you really want to talk about, but not with them’ 
 
‘I think you need to ask the patient before they attend the appointment, 
because I know that if I came with my husband and you said that you wanted 
to ask some sensitive questions about my sex life and would I like him to stay 
or go; I would feel really uncomfortable asking him to leave the room, I know I 
would worry about how he felt about that.  I think if possible, I would prefer to 
be asked before I arrived at the appointment; then at the appointment you 
could ask him to step outside for a while and it wouldn’t look like you have had 















Discussions   
 
The participants in each FG were quite similar and ensured that an 
appropriate range of parity / presenting conditions / social status was 
present.  Although the majority of participants were in the normal age range 
for women visiting our clinics, it would have been better to have 
representation from the under twenties and over eighties to ensure the full 
range of opinions was sought.  It is also noted that we did not have any 
women representing the LGBT community nor did we have any women in 
the post-partum period.  This may potentially mean that data have been 
missed and that some of the themes generated may be incomplete and 
invalid.   Although, in view of the aims and problems with the intended main 
trial, it may have been more appropriate to only include women with OAB / 
DO in the focus groups, in real life practice we do not separate these women 
from those presenting with other urogynaecological complaints so when 
trying to address our approach to sexual function we needed to include all 
women attending our clinics to ensure that any changes may also be 
generalisable and relevant to them as well.   
 
It was apparent from the FGs that most women do appear more comfortable 
discussing SF with a woman.  Hall et al (2002) performed a reciprocal 
likeability study and found that female clinicians like their patients more than 
male clinicians and that the patients liked their female clinicians more than 
the males.  If a patient likes his/her HCP then this is going to help them feel 
more comfortable during personal discussions.  Hojat (2007) reported that 
female clinicians score higher in empathy than their male counterparts and 
this was one of the important factors for women in the FGs.  Interviews of 
women with OAB regarding HCP-patient communication also found that 
women preferred to talk to a female HCP as many reported that their male 
clinician ‘does not understand’, ‘is not concerned’ or ‘this is not important to 
him’ and this led to an overall dissatisfaction with the quality of 




The HCPs did not consider that their age was an issue, however, for some of 
the women in the FGs if the HCP was considered to be too young, it would 
change their initial preference in sex of the clinician.  According to Fiske et al 
(1999), people stereotype on two different dimensions, the first being friend / 
foe (warmth) and the second being capability (competence).  While people 
stereotype their own preference as both warm and competent, they judge 
most outgroups ambivalently by ascribing both negative and positive 
characteristics to them.  For the women in the FGs, this is what appears to 
have happened with sex and age of the clinician.  Warm and competent is an 
older female clinician, warm but incompetent would be a young female 
clinician, cold but competent would be an old male clinician and the worst 
outcome of cold and incompetent is a young male clinician.   
 
Issues with terminology related to SA has already been reported as a 
problem in the clinical trial reported in chapters 6-9 and within the prevalence 
study in Chapter 12.  However, it was also a key point within the FG’s with 
women feeling they needed more clarity on what is actually defined as SA 
and an overall feeling that the term SA is too directional and exclusive.   
 
The sub theme that considered sexual inactivity as a barrier to discussing SF 
was quite surprising.  I was unable to find any literature relating to the 
concern that women do not understand why they are NSA or regarding the 
development of new sexual relationships and the impact that LUTS may 
have on these.  However, for a significant number of women in the groups 
this was an area of real concern and it could be hypothesised that initiation of 
new sexual relationships may also cause anxiety related to body image / 
desirability / performance and if there are additional concerns associated 
with LUTS for example fear of leakage / smelling during sex or the concerns 
over disposal of incontinence pads, these increased anxieties may further 
restrict or prevent women from engaging in new sexual relationships.  
Further research into this concept is necessary to fully understand the issue 




The sub theme ‘What if we don’t ask’ also seems contradictory.  Women 
appear to report significant barriers to discussion, however, report that they 
would feel that their assessment was incomplete if they had not been 
questioned regarding SF and that it was considered a slant on their 
womanhood when not mentioned.  This highlights the fact that although 
these discussions may be difficult for women, they are of significant 
importance and HCPs need to ensure that they work on breaking the barriers 
and taboos associated with SF, in order to provide optimal care and 
assessment of their patients.    
 
The word ‘embarrassment’ was one of the most frequently used words within 
both the FGs. The concept of embarrassment in health care has been 
proven to deter patients from seeking help (McKie 1993), add to the 
discomfort of chronic problems such as UI (US DoH 1992), and deter staff 
from broaching the topic of sexual function (Kelleher & Oxenham 1993).  
However, it is not just the embarrassment of the patient that is a barrier but 
also that of the clinician.  Meerabeau (1999) performed a review of the 
literature on embarrassment, in healthcare, particularly related to 
consultations / examinations regarding sexual issues.  She summarised that 
‘the current literature indicates that nurses and doctors have not shed the 
understandings acquired in their primary socialisation, which has taught us 
that sexuality is a private affair’.  It could be considered that helping HCPs to 
overcome their embarrassment should be the first point of training, before 
trying to break down the patient barriers to facilitate effective communication 
on issues of SF.  
 
Personal discomfort and embarrassment regarding SA has been established 
as a barrier to help seeking behaviour in women (Nicolosi et al 2006) and 
UUI is especially associated with feelings of embarrassment (Brown 1998, 
Van der Vaart et al 2002, Norton 2003).  As many of the woman attending 
our service report symptoms of UUI, it raises the questions ‘do women with 
OAB have increased levels of embarrassment discussing SA compared to 
those with other LUTS? There were no studies identified in the literature to 




One of the unexpected findings of the FGs was that some women felt that 
the subject of SF was best raised before they attended a secondary care 
service by their GP in primary care.  It was considered that often patients 
have a long term relationship with their GP and due to this already 
established rapport, initiating the conversation at this stage may be easier.  
However, concerns over GP time restraints were the limiting factor why this 
was not taking place in practice. 
 
Many of the women felt that a questionnaire, completed before their 
consultation would be preferable, to allow them to explore their own personal 
thoughts and reduce embarrassment associated with the conversations.  
This is acknowledged by Abrams et al (2017) who suggest that for patients 
who find the discussion of intimate issues with HCPs very difficult, 
questionnaires may allow these issues to be measured in private, at ease 
and more effectively before exploring the questionnaire responses in a 
clinical interview.  The women did not discuss how they would like to 
complete these questionnaires ie on paper, or online via a computer at home 
or a tablet in the outpatients setting.  It could be considered that women find 
answering questions on a computer easier than talking to someone, but it 
could also be considered impersonal and for women who are not computer 
literate a barrier.  Again, a questionnaire is not suitable for all as there will be 
women in the clinical population who are illiterate or in our diverse 
population, unable to read and write in English. 
 
One of the key points from the FGs was in relation to the desire for pre-
warning regarding the types of discussions that may take place during a 
consultation.  The concept of pre-warning about the context of consultations 
and the likelihood that intimate questions may be asked is not new.  
Tomlinson & Milgrom (1999) reported that some doctors get over their initial 
embarrassment and the shame / humiliation of the patient by giving them a 
pre-consultation questionnaire that introduces the discussion and identifies 
concerns.   This is similar to what the women in the FGs were discussing, 
however, many patients in the study disliked its anonymity and apparent 
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coldness.  This would need to be considered if some form of pre-warning 
was to be developed.    Although there are now 17 questionnaires to assess 
sexual function / sexual health and urinary symptoms in women, with a 
Grade A, B or C rating (Abrams et al 2017) none of these contain questions 
relating to whether women wish to further discuss their concerns or answers 
on the questionnaire with their HCP.  The pre-warning concept also relates to 
their decision regarding who they bring into the consultation room with them 
yet, our current practice does not advise them of possibility of intimate 
discussions taking place during their appointments or ask any form of 




When distributing invitation letters, stamped addressed envelopes for the 
service were not provided.  This could potentially mean that for women who 
do not have access to email or telephone (for example to due educational / 
social or financial reasons) they were unable to contact us to take part and 
may have had a different opinion that we have missed.  It is also recognised 
that this is a self-selecting group of women and this in itself may cause an 
inherent bias in the findings of the group.  It could be suggested that the 
women who do not come forward to discuss approaches to SF in a FG are 
also the women who struggle in clinical practice and are therefore a cohort 
that we need to understand further and who have been missed in this study.  
I also did not note the marital status of the women to ensure that there was a 
range of single, married, divorced and widowed participants as this may have 
impacted upon their opinions. 
 
Although one to one interviews may have been more appropriate to probe 
individual experience, as I wanted to generate ideas for service improvement 
and development, focus groups were chosen as the method of data 
collection.     
 
Another limitation of this study is in the reliability of thematic analysis and 
reliability of perceptions as these may not always be accurate and my own 
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opinions and beliefs could have affected the way it was performed.  Some of 
the sub themes may have be introduced by the researcher within the FG’s 
however, the aim of the FG’s was to explore the barriers etc and what 
emerges is what comes from the patients.  We were able to categorise the 
themes from the subthemes.  The fact that the second data analyser was not 
a specialist in the field of urogynaecology and through member checking it is 
hoped that personal perception as not influenced the data.  It is also 
important to remember that the data obtained from these FGs and 
subsequent analyses are very context specific and not generalisable to other 
institutions. 
 
Quality of the analysis 
 
All of the discussions in the FGs were digitally recorded and transcribed 
however, they are missing the murmurs / nods or ascents of agreement with 
statements that women may have displayed during the discussions.  These 
were recorded in the scribe’s notes and my memos which were written 
directly after the FGs and were included in the analysis.  However, there is 
the risk of a bias from my recollection.   Although the use of data tracking 
and audit trails used during this analysis (which is a key feature of GT 
methodology) should have countered this risk of bias. 
 
Directly after each FG the scribes notes and memos were analysed and the 
transcripts were typed within two days of the focus groups so that analysis 
could take place as quickly as possible and the initial analysis of the first FG 
was performed before the second took place.   
 
In order to ensure reliability and objectivity in the analysis, the second 
independent researcher was given the list of codes and asked to identify 
sentences related to each code.  Over 80% of the sentences matched the 
original reviews and those that did not match were assigned to overlapping 




There were no changes of opinions of participants in the FGs suggesting that 
there were no dominant voices that the women felt pressured to conform 
with, or change their perception/ beliefs to align with their suggestions and 
this is also a sign of good reliability.  
 
Levels of agreement were based on the transcripts, scribe notes and 
memos.  The women in the groups only completely agreed on three minor 
details:- that SF should not be the first question asked in a consultation, that 
any questionnaire developed should have a free text comments box and that 
clinicians should reassure women that conversations regarding SF can be 
stopped at any time if felt to be too distressing or personal.  Although for 
several of the other salient points there was agreement with the majority of 
women.  Although this point could be considered as a sign of poor reliability, 
it was felt that this just highlighted the individual nature of the discussions 
and the realisation that no one size will fit all in approaches to SF.   
 
Therefore, a woman centred, individualised approach is justified, but for 
many a combination of a pre-consultation questionnaire alongside direct 




It is the responsibility of the GT researcher to capture the reality of the data 
and to not allow his / her own assumptions to impact upon the analysis.  
However, in reality this is very difficult to do as when you are so involved in 
the topic and have spent a lot of time reading relevant literature, it can be 
difficult to stay impartial.  This is true not only in my role of data analyser but 
also as a moderator.  Again, this highlights the need for a method of audit 
and data tracking which is integral to GT. 
 
In my role as a moderator, I believe that I allowed an open dialogue and 
demonstrated good interpersonal skills adapting to the flow of the 
discussions and allowing each participant to voice her personal views and 
comments in a non-judgemental way.  I believe it was these communication 
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skills and the occasional humour in the conversations that influenced the 
participants to open up and be truthful. 
 
I tried to avoid giving my own personal opinion during the FGs to avoid 
influencing the discussions but on occasion I did pass comment on current 
practice in KCH / other departments or views previously expressed by other 
women. 
 
I think that I had the right level of involvement in FG1 and the conversation 
between the participants flowed very easily.  I personally found FG2 harder 
to moderate and the women at times needed more encouragement to talk 
and additional questions to further probe their views and opinions were 
necessary to get the women to elaborate.  I found this challenging as I 
wanted to probe opinions without trying to add an alternative viewpoint and 
influence the discussion. 
 
When analysing the data and reviewing the core categories and sub themes, 
I frequently went back to the questions that I asked to assess if this 
influenced the discussions.  The main point where I may have influenced the 
discussion was where I introduced the idea of a questionnaire on SF.   
Although I may have introduced the concept, the FG participants were 
completely responsible for the further suggestions regarding when it should 
be administered, what it should include and how it should be used to 
complement clinical practice.  
 
One of the most satisfying aspects of running these FGs was the comments 
from the participants after the sessions and again when they have been seen 
in clinics since.  Many of the women reported that they really enjoyed the 
session and that actually discussing problems with LUTS / SF with other 
people in a similar situation was really refreshing and helped them to realise 
that they were not alone.   
 
I personally also enjoyed the FGs as it was really nice to have an informal 
conversation with our patients with the aim of improving our service.  What I 
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would really like to do at a later date is to re-run the FGs with the same 
participants and refine and enrich the categories identified to further make 




There were many ideas that emerged from the data that could help shape 
and refine our current clinical practice.  The first is in relation to the wording 
of the outpatient appointment letter.  I will review the current template and 
add in an explanatory sentence that questions of an intimate / personal 
nature may be asked during the consultation.  This will allow the patients to 
decide if they wish to bring a partner / friend into the consultation, or allow 
them to express a preference for the clinician that they see. 
 
When searching the literature regarding pre-warning, two screening 
questionnaires for SF were discovered.  The first is the Brief Sexual 
Symptom Checklist for Women (BSSC-W).  This is a four item questionnaire 
that assesses if a woman is SA, if they experience any problems with SA and 
if they would like to discuss this with a clinician.  It was developed by the 
International Consultation in Sexual Medicine (ICSM) (Hatzichristou et al 
2004).  The questionnaire is demonstrated in Figure 13.5.  The second is the 
Sexual Complaints Screener for Women (SCS-W) which was developed by 
the Standards committee of the International Society for Sexual Medicine 
and consists of a series of questions concerning sexual experiences during 
the last 6 months (See Figure 13.6) (Porst 2009).  However, there are no 
validation studies available for these tools (Hatzichristou et al 2010) and 
there are no acknowledgements of urinary symptoms.  Potentially, a pilot 
study to assess the use of and validate a simple screening tool in practice 
based on these developed in the field of sexual medicine may prove 




Brief Sexual Symptom Checklist for Women (BSSC-W) 
Please answer the following questions about your overall sexual function 
1.Are you satisfied with your sexual function? 
□ Yes □ No 
If No, please continue. 
2 How long have you been dissatisfied with your sexual function? 
-----------------------                                                                                                             
3a. The problem(s) with your sexual function is: (mark one or more) 
1 Problem with little or no interest in sex 
2 Problem with decreased genital sensation (feeling) 
3 Problem with decreased vaginal lubrication (dryness) 
4 Problem reaching orgasm 
5 Problem with pain during sex 
6 Other: 
3b. Which problem is most bothersome (circle)  1  2  3  4  5  6 
4 Would you like to talk about it with your doctor? 
□ Yes □ No 
 



















Figure 13.6 Sexual Complaints Screener for Women (SCS-W) 
 
This screener is a series of questions concerning your sexual experiences during the last 6 months. Each question can be answered 
by circling the condition that best characterizes your personal experience. Sexual activity includes any activity aimed at 
experiencing sexual satisfaction and enjoyment. The term sexual activity does not necessarily include sexual intercourse (vaginal or 
anal penetration) 
1a) Some women experience lack of or low sexual interest/desire in sex.  Has this happened to you during the last 6 
months?   Never/almost never  Rarely   Sometimes   Often   Almost all the time/Almost always 
1b) Has this been a personal problem for you?   
Not at all   A very small problem  Some problem  A considerable problem  A very great problem 
2a) Some women do not experience physical sexual excitement (e.g., genital swelling, vaginal wetness, tingling sensation) during 
sexual stimulation and/or sexual activity.  Has this happened to you during the last 6 months?        No sexual activity  Never/almost 
never  Rarely Sometimes  Often  Almost all the time 
2b) Has this been a personal problem for you?  
 Not at all  A very small problem  Some problem  A considerable problem  A very great problem 
3a) Some women do not feel sexually turned on or do not have pleasurable sexual feelings when engaging in sexual activity.  
 Has this happened to you during the last 6 months?  
No sexual activity  Never/almost never  Rarely  Sometimes  Often  Almost all the time 
3b) Has this been a personal problem for you?   
Not at all  A very small problem  Some problem  A considerable problem  A very great problem 
4a) Some women experience difficulties reaching orgasm during sexual activities despite feeling sexually excited.   
Has this happened to you during the last 6 months?   No sexual activity  Never/almost never Rarely Sometimes Often  Almost all the time 
4b) Has this been a personal problem for you?    
Not at all A very small problem  Some problem  A considerable problem  A very great problem 
5a) Some women experience genital pain during or shortly after sexual activity.  Has this happened to you during the last 6 
months?   No sexual activity  Never/almost never  Rarely  Sometimes  Often  Almost all the time 
5b) Has this been a personal problem for you?   
Not at all A very small problem  Some problem  A considerable problem  A very great problem 
6a) Some women experience difficulties allowing vaginal penetration despite their wish to do so.   
Has this happened to you during the last 6 months?   
No sexual activity  Never/almost never  Rarely  Sometimes  Often  Almost all the time 
6b) Has this been a personal problem for you?  Not at all very small problem  Some problem   considerable problem  great problem 
7a) Some women experience persistent and unwanted genital arousal (tingling, throbbing, pulsating) in the absence of any sexual 
interest.  Has this happened to you during the last 6 months?   
No sexual activity  Never/almost never  Rarely  Sometimes  Often  Almost all the time 
7b) Has this been a personal problem for you?   
Not at all A very small problem  Some problem  A considerable problem  A very great problem 
8a) During the last 6 months, my sexual life has been:   
Very unsatisfying  Unsatisfying  Rather unsatisfying  Rather satisfying   Satisfying   Very satisfying 
10) Is there anything else you would like to tell us with respect to your sexual life?  For those who have not been sexually active during the 
last 6 months please explain why you have been sexually inactive. 







Another area for change in clinical practice that can easily be implemented is 
to provide some training and education for all members of the MDT.  This will 
include ways in which to normalise the discussion about SF and appropriate 
language to use including how to individualise assessment and adapt their 
style of questioning.  Suggestions will also include the use of diagrams to 
help explain conditions / problems to women and at what point in a clinical 
consultation these discussions are appropriate.  This training can also 
highlight the point that SA is a continuum and just because a women may not 
be SA at one point of asking, does not mean that that is always going to be 
true and that regular reassessment in required.  It is already routine practice 
to reassess SF in women post-surgery for UI / POP or post-partum, therefore 
this needs to extend to all women who are NSA attending our clinics and not 
just specific patient populations.  By engaging women in these discussions in 
a clinical setting, it may encourage women to discuss the topic of SF with 
their partners, family and friends which will help to normalise discussions and 




Overall these FG have provided us with rich and valuable data regarding 
how we are approaching the topic of SF with women attending our service.  
The key points gained from the groups related to terminology and the desire 
for pre-warning regarding these discussions.  There is the potential that 
because of inadequacies considered by some women in our approach, this 
may have negatively affected recruitment to the main study previously 
discussed.  These new insights can help to develop our clinical practice and 

























This final chapter aims to provide an overview of this thesis, highlighting the 
findings from these investigations and discussing the methodological 
limitations.  Following this, recommendations for future research to further 
enhance knowledge in this field have been reported.       
 
Overview of thesis results 
 
The purpose of this thesis was to answer the question:- 
 
 ‘Does fesoterodine have any effect on the sexual function (SF) of women 
with OAB?’  
 
This question was developed alongside the literature review reported in 
Chapters 2-5.  Chapters 6 and 7 detailed the decision making and the 
methodology selected to answer this question which was an open label 
cohort study.  Despite difficulties with recruitment (N=28 were recruited from 
a target of 132), the analysis reported in chapters 8 and 9, demonstrated 
statistically significant differences in both the primary outcomes (Change in 
item scores of the PISQ-12 and the SQOL-F at week 12 relative to baseline)  
and many of the secondary outcomes.  The findings demonstrated an 
improvement in SF following treatment with fesoterodine in women with 
OAB.  Although significant differences were found, the study design limits the 
inferences that can be made from this data.  Without a randomised 
comparison group it is not possible to determine causality.  Despite this, the 
study did confirm findings from other studies that in the clinical population 
studied, fesoterodine was a well tolerated, treatment for OAB symptoms 
which may also improve SF.  Given the limitations of the study design it 
could be argued that a larger study – as was originally intended - would add 
little of value to these findings.  
 
The analysis of the patient goals from the SAGA questionnaire, described in 
Chapter 10, provided new insights into the impact of OAB on women’s 
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quality of life both physically and psychologically.  The themes of ‘finishing 
the task in hand’ and ‘being free to’ highlighted that for many women it is not 
the symptoms of OAB that cause the greatest distress but the role and life 
limitations as a result of the symptoms.  This raises questions regarding the 
validity of current QoL questionnaires as they may be missing important 
factors that could help clinicians to tailor advice and treatment for example 
how to manage taking the dog for a walk or sitting through a film at the 
cinema without needing the toilet.  The lack of SF goals in the SAFINA study 
raises questions about whether SF is important to patients although it may 
also indicate a reluctance to identify improved SF as a goal.    
 
Two key problems emerged from the clinical trial.  Firstly, a number of 
centers did not always ask about sexual activity (SA) or reported challenges 
asking about SA despite this being part of the protocol and a fundamental 
aspect of the study.  Secondly, the lack of a standardised definition of SA 
and a standardised time frame for assessment of SA has led to assumptions 
being made about what SA constitutes and this is a substantial impediment 
to research in this field.  This meant that the populations in this trial 
(Chapters 6-9) was never accurately described and was likely to be one of 
the reasons for the poor recruitment.   
 
Following the discussions in Chapter 9 regarding methodological limitations, 
it was acknowledged that presumptions had been made in the trial regarding 
women being SA and being open to discussing SA and SF.  To understand 
how these presumptions may have had a negative effect on recruitment, two 
further research questions were raised:-   
 
1. What is the prevalence of SA in women with OAB attending a 
London Urogynaecology outpatient service?  
2. How do women want to be approached about the topic of SF?   
 
Chapter 11 described the methodology employed to answer these two new 




The SA prevalence study reported in Chapter 12, was designed to assess 
the prevalence of SA in our OAB population, to evaluate why women were 
NSA and to investigate variations between the SA and NSA groups.  It 
revealed that fewer women were SA than expected and for the majority of 
those that were NSA it was due to the lack of a partner rather than due to 
their bladder / bowel symptoms or other health conditions.  The 
psychological components of fear and anxiety related to UI and SF was very 
evident and raised several areas for further research suggested later in this 
chapter.   However, analysis also revealed problems with the validity of the 
questionnaire in particular with non-response to questions as many women 
struggled to identify themselves or fit their answers / views into the preset 
responses.    
 
The purpose of chapter 13 was to explore how women wished to be 
approached to discuss SA and SF in clinics.   Focus groups were undertaken 
to elicit women’s thoughts and views on this.  The concept of ‘pre-warning’ 
regarding the topic of SA and SF and the potential use of screening 
questionnaires were themes that emerged and provided ideas for changes in 
practice that may be implemented in clinical services and research to 
enhance the ways in which we communicate with women about SF.   These 
findings also emphasized the point that no single approach will work for 
everyone and as with all clinical encounters, care and communication should 
be individualised for each patient.  It also highlighted the point that often a 
holistic approach to SF is overlooked with the focus of consultations geared 
towards specific symptoms during sex, for example pain and UI.  Yet, the 
focus groups revealed that sexual health (including desire, sexual 
satisfaction, relationship satisfaction) is as important to women, if not more 
so than individual symptoms.   
 
At the start of the thesis, a presumption was made the SA was a term that 
was well understood by women.  There had been no indication from the 
literature review regarding the absence of a definition or the need for one 
and the term ‘sexually active’ had therefore been assumed to be good 
enough. This means that when women were asked the question ‘are you 
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sexually active?’ that there would be a common understanding of this term. 
But, as demonstrated during the focus groups and the prevalence study, 
there are many different ideas about what SA is and what it may involve.  
Potentially, given all the variations in what SA may include, this may mean 
that we missed women who would have been eligible for recruitment into the 
study or conversely that we actually recruited women who were not suitable 
and this may affected the reliability of the data.   This also has wider 
implications for all clinical research into the field and for how women are 
being advised and counselled regarding SA.   
 
Summary of Limitations 
 
The most significant methodological flaw in the study was the lack of a 
comparator or placebo arm.  As discussed in chapter 6, there were several 
reasons for this including lack of funds, provision of a placebo and 
timescales.  Future studies could potentially use a cross-over design with an 
extended wash out period at the start of the trial, as this could be considered 
to be a placebo period and used as a comparator, but this may negatively 
impact recruitment as it delays treatment.     
 
The lack of valid and reliable research tools has been highlighted as an issue 
throughout this thesis.  This is not only because of the concerns already 
raised over the definition of SA or lack of.  The only tool designed to assess 
women who are currently NSA (PISQ-IR) does not seem to be fit for purpose 
as discussed in chapter 12.   Given the subjective nature of SA 
demonstrated in the focus groups the ideal research tool will have to include 
some open ended questions to encompass all views as many women do not 
feel that they fit into a typical ‘tick box’ classification.  
 
Throughout this thesis there have been many discussions regarding the 
barriers to recruitment and one of the fundamental issues was related to how 
the clinicians approached women regarding SA and how they took a sexual 
history.  With multiple research sites and trial personnel, there may have 
been a significant variation in the way in which women were approached, 
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and the depth of discussion on sexual function.  The focus groups confirmed 
that many women consider our current approach inadequate and have 
provided ways in which our approach can be modified and developed.  For 
future studies, the findings from these focus groups would be used to 
develop a recommendation of how to approach women and take a sexual 
history and to ensure all study staff are educated appropriately to use this in 
practice.  This may reduce variations in the discussions regarding SF and 
foster more open discussions with women and potentially enhance 
recruitment. 
 
Reflections on the thesis 
 
When I started this project, I naively presumed that because the department 
had significant experience with OAB clinical research, that the traditional 
methods for recruitment employed in many other studies would work, 
regardless of the fact that this was the first study in the department looking at 
SF as a primary outcome.  
 
The main problem with my approach to this thesis was that my background 
clinical knowledge was focused on OAB and I had not considered the 
complexity regarding the definition of SA.  In line with this, I developed an 
OAB study but just changed the primary outcome to one focusing on SF.  
However, as my knowledge on SF and FSD has increased during the course 
of this work, there are many aspects of the trial protocol that I have 
recognised are not ideal in the assessment of SF (these are discussed in the 
next section).   
 
During the course of this thesis I had the opportunity to spend two days with 
Dr Irwin Goldstein (Current President of the Institute for Sexual Medicine and 
International Society for the Study of Women’s Sexual Health, Board 
member of the International Society of Sexual Medicine and founding editor 
of the Journal of Sexual Medicine) and Sue Goldstein (Sexuality Educator 
and Clinical Research Manager at San Diego Sexual Medicine Centre).  I 
had the opportunity to discuss recruitment issues with them as I has been 
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unable to find any literature related to failed recruitment in SF studies.  They 
reported that they had not had significant issues recruiting into clinical trials 
investigating SF.  However, the big difference with their population was that 
all the patients had presented with sexual problems and made the first step 
of seeking help as the problem had become distressing and bothersome.  
However, in our cohort of women, they had sought help for LUTS and not 
sexual problems and unless the sexual problems was causing them 
significant distress then they were unlikely to agree to take part in a study 
that they feel was not relevant to them.  It could be considered that we did 
not make it clear enough to women that we were not seeking those who 
reported issues with SF, but was assessing the impact of treatment on SF 
overall so that we could counsel women appropriately as to what to expect 
from treatment of their LUTS.  In future work, clarity on the patient 
information leaflets may help to address this.   
 
Ultimately, this process has demonstrated that knowledge in one aspect of 
research does not automatically mean that it is generalisable to other areas 
and that the initial stages of project development, including planning the 
methodology, reviewing the sample population and performing a pilot study 
are essential factors in successful research outcomes. 
 
Discoveries that have emerged during the time frame that this thesis was 
undertaken and how they would influence future work 
 
During the course of this thesis a number of articles / recommendations have 
been published in relation to developing / undertaking research in SF.  Based 
on this new information, there are several aspects of the study methodology 
that would need to be altered for future research.  
 
The trial only assessed change in SF over a 12 week period and it could be 
considered that this was too short term to show any long term benefit in an 
outcome which may occur infrequently.  It has since been recommended that 
all clinical studies in FSD are at least 24 weeks (Fisher et al 2017).  This 
longer time scale may allow for more meaningful data to be collected.  
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Although the CTIMP did follow up the participants at the 24 week stage, this 
was only to assess persistence with medication and adverse events but it 
should have included a further assessment of SF.   
 
The exclusion criteria were also restrictive and aimed to fit the women into a 
‘pure’ OAB / DO group.  In real world clinical practice, there are many women 
with OAB symptoms for example those with de-novo OAB following 
continence surgery or due to neurological problems that were excluded from 
this study and it could be considered that the number of ‘pure’ OAB patients 
in practice is low therefore our timescales / recruitment numbers were 
unfeasible from the outset.  If the inclusion / exclusion criteria were less 
stringent it may have helped to improve recruitment and although this could 
also be seen as a limitation to the research as the group would be less 
homogenous it would mirror the actual cohort of women that are attending 
our clinics and potentially be more clinically meaningful for practice.    
 
The choice of questionnaires used as outcome methods could also be 
criticised.  According to the recommendations by the International 
Consultation on Sexual Medicine, research into SF should include a 
validated self-reported measurement of SF which includes domains and 
subscales related to the phase of the sexual response cycle and /or DSM-5 
diagnostic categories and or questionnaires or structured interviews 
assessing SF foci and able to measure change over time with an 
intervention.  A validated measurement of sexual distress is also essential as 
evidence of distress is required to diagnosis FSD (Fisher et al 2016).  There 
was no measure of sexual distress used in the original CTIMP and this would 
need to be included in any future research.  The PROMS used as the 
primary outcome in the study, although validated may not have been the 
ideal ones to use as according to the International Consensus on Sexual 
Medicine the  FSFI should now be the questionnaire of choice in all SF 
studies (Fisher 2017).    
 
In 2013, the DMS-V (APA) revised the terminology related to SF and FSD 
(as discussed in Chapter 2).  Given the changes in terminology during the 
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course of this thesis, the biggest challenge has been deciding how to 
describe or refer to the outcomes now.  Ultimately, if the DSM-5 guidelines 
are strictly followed then none of the women who participated in this trial 
could be classed as having FSD due to their underlying LUTS and the fact 
that we did not assess the frequency and length of time with these symptoms 
and the distress that they cause.  For any future work, although we can 
assess SF and distress in these women, it is unclear how they should be 
labeled if they have poor SF and report significant distress associated with 
this as they do not fit the FSD definition due to their LUTS.   
 
Another area that was not previously considered was the potential for 
participation in the trial to act as some form of sex retraining / therapy for 
women.  In the same way that discussing issues, attending appointments 
where written and visual information is readily available and completing 
questionnaires can act as a form of bladder retraining and has been shown 
to contribute to the placebo effect in OAB trials, it is unknown if just opening 
up about issues and participating in the trial has the same effect on SF 
outcomes.  It would be interesting to further investigate this area and a 
review of the placebo effect in other sexual function trials would be a starting 
point to explore this. 
 
What have I personally learned from the investigation? 
 
Over the course of the last eight years, I have gained a varied knowledge not 
only in the topics of OAB and SF but also the wider field of urogynaecology, 
urology and sexual medicine as I have been reviewing the surrounding 
literature.  I have also gained a significant knowledge with regards to 
pharmacotherapy and have qualified as an Independent Nurse Prescriber.   
 
I have always been determined and a hard worker, particularly with regards 
to further education.  Yet, with all the challenges and difficulties along the 
way, not only with getting the CTIMP up and running but with the recruitment 
difficulties and additional investigations, has shown a resilience that I did not 




I think that the most significant lesson that I have learnt during the course of 
this thesis is ‘Don’t ever presume’.  This is not just true for the research 
methodology and trial processes but also the clinical population, terminology 
and individual patient responses.   
 
Has it changed anything for my patients? 
 
I believe that one of the most significant differences that this project has 
made to my clinical practice is in the way that I communicate with women 
about SF.  I feel far more comfortable initiating discussions, understanding 
issues and knowing how to assess women with sexual problems.  My 
increased knowledge and experience from the research has enabled me to 
share these learnings with patients, which can help to normalise the 
discussion, encouraging them to open up and potentially seek solutions and 
management strategies.   
 
I feel that this increased knowledge and confidence has also changed how I 
counsel women with regards to therapy, particularly by trying to understand 
their individual treatment goals and tailoring care to meet their needs.   
 
The work from the FGs has provided several areas for service development, 
especially simple ideas such as changing the information in our outpatients 
appointment letter to include a ‘warning’ that discussions regarding SF may 
take place during the consultation.  It is hoped that these changes may help to 
improve the overall experience of the women attending our service and 










Follow up actions 
 
There are several follow up actions that I have for the Urogynaecology 
department at KCH based on the feedback gained from the focus groups in 
Chapter 13.  These include:- 
 
 Change to the appointment letters sent to women to include a 
statement that discussions of a sexual nature may take place.  This 
will provide a pre-warning to allow the women to consider their 
thoughts and decide who will attend the appointment with them. 
 
 Validation of a screening checklist such as the Brief Sexual Symptom 
Checklist for women.  This short questionnaire could be given out to 
women when they check in for their appointments or sent out with 
their appointments.  It will not only provide pre-warning but will help 
identify women who wish to engage in further discussions regarding 
SF.  However, there are no validation studies for this tool so these 
would be needed to consider its use in routine care.  
 
 
Recommendations for future research 
 
There are several areas of development and investigation that are 
recommended by this thesis to support future work in this field.  These 
include:- 
 
 Development of a standardised definition of sexual activity (including 
time frames) 
 Development of standardised terminology for sexual dysfunction in 
women with LUTS 
 Development of a valid and reliable research tool to assess women 




 Development of a recommendation for HCP’s regarding how to 
approach women regarding SA and take a sexual history to 
standardise and aid recruitment for future studies  
 Investigation (and quantification) of the ‘placebo effect’ in clinical trials 
addressing SF 
 Investigation of how many women re-engage with SA following 
treatment for OAB 
 Review of QoL questionnaires to improve relevance to women’s daily 
life 
 
During the course of the literature review, analysis and discussions, several 
other areas for further research have also been identified.  These include:- 
 
  A systematic review of qualitative studies questioning if 
anticholinergics improve SF in women with OAB. 
 
 Does a partner’s SF improve if a woman’s UI / OAB is treated? 
 
 Investigation on the impact of OAB on the desire to start / the process 
of starting a new relationship 
 
 Anxiety has been noted throughout this thesis to have a significant 
impact on women in relation to their OAB and SF yet there are still 
many areas / questions that remain unanswered.  Just a few of those 
ideas include:- 
 
o Assessment of baseline anxiety scores - are their differences 
between those with OAB wet and dry? 
o Which came first the LUTS or anxiety 
o Assessment of anxiety scores pre and post treatment for OAB 
o Investigation of anxiety related to SF  
o Relevance of emotional factors in the development and 







The conclusions of this thesis are that there are indications that fesoterodine 
may have a positive effect on women’s sexual function.  However, it is not 
certain due to the lack of a comparator group.  The thesis also showed that 
the current tools to assess SA are limited and that the prevalence of SA in 
our population is lower to be expected.  Our current approach to discussing 
SA and SF with women is deficient and methods were identified that may 
potentially improve how women are approached regarding SA. 
 
Overall, this thesis has highlighted the inadequacies in current research 
related to SA and SF and OAB and has made recommendations to develop 
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Surgical  repair of prolapse 
Sexual dysfunction is one of the symptoms that motivates women to  seek medical help  in  the manage- ment 
of urogenital prolapse. Conservative or  surgical interventions may  be offered  to  treat the prolapse but the 
question remains as to whether treatment restores sexual function (SF).  This  article  briefly  dis - cusses the 
assessment of SF in women with a urogenital prolapse and reviews the effect of therapeutic interventions  on 
SF. 
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Pelvic organ prolapse (POP) is a very common condition, partic- 
ularly among older women. It is estimated that 50% of women who have 
children will experience some form of prolapse in later life, but because 
many women do not seek help the prevalence is  unknown [1]. It is 
generally the symptoms associated with prolapse, such as bladder, 
bowel and sexual dysfunction,  that  motivate  women  to seek medical 
help and prolapse accounts for 20% of women on the waiting  list  for  
gynaecological surgery [2]. 
Sexual health is defined as ‘a state of physical, emotional, mental 
and social well-being in relation to sexuality; it is not merely the absence 
of disease, dysfunction or infirmity’ [3]. Prevalence studies report that 
up to 64% of women attending urogynaecology clinics report some 
form of sexual dysfunction  [4]  and  urogenital  pro- lapse is more likely 
than urinary incontinence to result in sexual inactivity  and  to  be  
perceived as  affecting  sexual relations [5] 
The aim of this paper is to review the impact that current conser- 
vative and surgical therapeutic interventions for the management of 
POP has on sexual function. 
 
1.1. Pelvic  organ prolapse 
 
POPisdefinedprimarilyasanatomicalchange, iethedownward 
displacement of a pelvic organ or the different vaginal compart- 
ments and their neighboring organs [6]. Symptoms include vaginal 
bulging, pelvic pressure and low backache. Women may also 
develop prolapse related lower urinary tract symptoms and pro- 
lapse related anorectal dysfunction symptoms.  Table  1  displays the 
potential prolapse related sexual dysfunction symptoms that women  




According tothe World Health Organization International Clas- 
sifications of Diseases—10 (ICD-10), the definition of female sexual 
dysfunction (FSD) includes ‘the various ways in which an individ- 
ual is unable to participate in a sexual relationship as she would 
wish’ [7]. There are 4 major categories of dysfunction, that is desire, 
arousal, orgasmic and sexual pain disorders [8] 
Suggested areas of pathophysiology that can cause FSD are listed 
below in Fig.  1 [9]. 
Gladu reported four causes of FSD: medical illnesses (eg 
hypertension, diabetes and previouspelvic surgery), psychological 
illnesses (underlying depression, anxiety), hormonal deficiencies 
(menopausal changes) or  the  effects  of  medications  (eg  selec- tive 
serotonin reuptake inhibitors, antidepressants, tamoxifen, etc) [10]. 
POP can affect several of the areas listed above and as such 
correction of the POP alone may not improve sexual function if the 




Sexual dysfunction symptoms. 
 
Definition 
Dyspareunia Complaint of persistent or 
recurrent pain or discomfort 
associated with attempted or 
complete vaginal penetration 
Obstructed intercourse Complaint that vaginal penetration 
is impeded. Possible causes include 
narrowing or a bulge 
Vaginal laxity Complaint of excessive vaginal 
looseness 
 
 Mind and age (neurotransmitters,  medication) 
 Oestrogens  and androgens 
 Vaginal epithelium and lubrication 
 Vaginal blood flow 
 Coital incontinence 
 Scar tissue / vaginal dimensions 
 Neuropathy 
 Pelvic  floor muscles 
 
Fig. 1. Areas of pathophysiology of sexual  dysfunction. 
 
 
1.3. Urogenital prolapse and urinary incontinence 
 
The relationship between urogenital prolapse and urinary 
incontinence is well documented, 63.3% of patients with Stress Uri- nary 
Incontinence (SUI) have co-existing POP and conversely 62.7% of 
women with POP have co-existing SUI [11]. One explanation for co-
existing pelvic floor dysfunction, such as POP  and  SUI,  is  that they 
have shared risk factors,  which  would  thereby  increase  the  risk of 
both of these conditions [12]. 
Rogers et al. comparedsexual function in women with and with- 
out urinary Incontinence (UI) and/or pelvic organ prolapse (POP) 
using a validated condition-Specific questionnaire, the Pelvic Organ 
Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ), and 
concluded that PISQ scores were significantly lower among women 
with UI/POP than in those without (P = 0.003). Women with UI/POP 
have poorer sexual function, as measured by the PISQ, and report 
less frequent sexual activity [13]. In addition, women with UI/POP 
are more likely to restrict sexual activity for fear of incontinence. 
Women with POP and UI are more likely to report decreased libido, 
decreased sexual excitement, and difficulty achieving orgasm dur- 




Initial assessment should focus on symptoms experienced by women  
followed  by  a  detailed  medical  history  with   a   particu- lar focus on 
identifying other risk factors eg chronic constipation, collagen disorders 
(benign joint hypermobility/Elhers Danlos syn- drome),  and  familial 
history  of prolapse. 
Quality of Life questionnaires and symptom specific question- 
naires can beusefulin theclinical setting, particularly when women 
report a variety of bladder, bowel, and sexual dysfunction symp- 
toms. There are many validated questionnaires available eg The 
King’s Health Questionnaire (KHQ), Pelvic organ prolapse symptom 
questionnaire (POP-S) and the Prolapse and Incontinence Sexual 
Function (PISQ) questionnaire. The International Consultation on 
Incontinence(ICI) havedevelopedmodular questionnairesthat are 
availableand free todownloadto all clinicians at http://iciq.net/ 
A vaginal examination should be performed to assess for pro- lapse.  
There  are  many  different  staging  and  grading  systems  in the 
literature but the Pelvic Organ Prolapse Quantification System (POP-Q) 
is the recommended method. The choice of the woman’s position 
during examination, e.g. left  lateral  (Sims),  supine, stand- ing or 
lithotomy is that which can best demonstrate POP in  that patient and 
which the  woman can confirm as  the  maximal extent  she has 
perceived e.g. by use of a mirror or digital palpation6. 
Diagnosis is usually clinical and based on history and examina- 
tion. However, if there are urinary symptoms it may be necessary to 
consider urinalysis±a midstream specimen of urine (MSU), post- 
void residual urine volume testing, urodynamic investigations or   a 
renal ultrasound scan. If there are bowel symptoms consider ano-
rectalmanometry,  defaecatingproctographyandan endo-anal 
Libido − loss or 
decrease 
Complain of loss or decrease of 
sexual desir 
ultrasound scan. A trans-vaginal ultrasound scan will also help to 
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prolapse, particularly in women for whom bimanual examination  
is sub optimal  due to body   habitus. 
 
2. Effect  of  therapeutic interventions 
 
2.1. Management: pelvic floor muscletraining 
 
PFMT is  often  considered  as  the  first  line  in  management  of 
urogenital prolapse. Ideally, an individualised programme of pelvic 
floor should be offered by specialist women’s health physio- 
therapists [15] which may include pelvic floor exercises, vaginal 
examination and advice regarding lifestyle changes. It may also 
include the use of biofeedback or neuromuscular electrical stim- 
ulation. 
However, there is no conclusive evidence on the efficacy of 
PFMT with regards to female sexual dysfunction. In one recent RCT 
[16], where women were randomised to an intervention group (6 
months of PFMT and lifestyle advice) and a control group (lifestyle 
advice only), no significant change in the number of women being 
sexually active was reported. There were no significant differences 
between groups regarding change in  satisfaction with  frequency of 
intercourse. Women reporting improvement in sexual function 
demonstrated the greatest increase in PFM strength and endurance. 
The POPPY trial [17], a parallel-group, multicentre, randomised 
controlled trial at 23 centres in the UK, New Zealand, and Australia, 
was the largest study to investigate the effect of individualised pelvic 
floor muscle training in women with pelvic organ prolapse. Close to 
five hundred women were randomised into an individu- alised 
programme of pelvic floor muscle training or given a prolapse lifestyle 
advice leaflet. Interestingly, in the short term, i.e. at six months, sexual 
function did appear to be significantly improved, however this benefit 
did not last at the end of the year. Therefore, long-term   benefit  of   
physiotherapy  still   needs   further investiga- 
tion. 
It could also be postulated that pelvic floor strengthening leads 
to differential improvements in different domains of sexual func- 
tion, as in some studies PFMT has been shown to lead to an 
improvement in sexual desire, performance during coitus and 
achievement of orgasm with no change was seen in arousal and 
resolution [18]. 
Ultimately, sexual function may be at least partially related to 
strength of the pelvic floor as shown in retrospective review. In this 
study, women with strong or moderate pelvic floor muscle scored 
significantly higher on the orgasmic and arousal domains of the 
female sexual function index (FSFI) than women with weak mus- 
cles. In addition, the duration of PFM contraction was correlated 
with FSFI orgasmic domain and sexual arousal [19]. 
Although the evidence to support physiotherapy as a manage- ment 
option in FSD is tenuous it would seem sensible to  continue with PFMT 
as the first line option given the lack of any associated morbidity or 
mortality with  this line  of therapy. 
 
2.2. Management: vaginal pessaries 
 
At present there is not a plethora of evidence in published liter- 
ature detailing the effects of pessaries on sexual function in women 
with pelvic organ prolapse. 
Some data would suggest that, in patients with symptomatic 
pelvic organ prolapse, desire, lubrication, and sexual satisfaction 
improvesignificantlywithpessaryuse.Thefindings ofthis prospec- 
tive study suggestthat vaginalpessaries do not interfere negatively 
with sexual activity and may even improve sexual function  [20]. 
Another prospectivestudy into patient symptomsshowedasig- 
nificant improvement in sexualsatisfaction and frequency of sexual 
activity  with  pessary  use [21].  In  addition,  a trial comparing the 
effectiveness of pessaries and surgery in women with symptomatic 
pelvic organ prolapse found similar improvement in urinary, bowel, 
sexual function, and quality of life parameters using both interven- 
tions. [22] 
Contrary to popularly held belief that sexual activity is likely to 
be a relative contraindication to long term pessary treatment [23], 
evidence suggests that sexually active women are more likely to 
continue wearing their pessary than women who were not sexu- ally 
active, suggesting that long-term pessary use is acceptable to 
sexually  active women [24]. 
Consequently, whilstpessaries and surgery appeartohave com- 
parable beneficial effects, in the absence of significant serious 
morbidity and mortality with pessary this option should discussed 
with all patientswith urogenital prolapse, including thosewith sex- 
ual dysfunction. However, it is important to remember that long 
term pessary use  is  not completely  free from complications.  Up to 
56% of patients using pessaries long term are likely to report some 
complication, including bleeding, extrusion, severe vaginal 
discharge, pain and constipation [25]. Therefore all women opting 
for this treatment option should be fully informed about the risks 
and benefits and the importance of regular change of the pessary. 
 
2.3. Management: surgery 
 
Surgery is often the definitive treatment for urogenital pro- lapse 
and the lifetime risk of needing surgery is 11%, with 29.2% requiring 
repeat surgery2. Data reporting sexual function follow- ing surgical 
repair are limited and conflicting. Some studies have shown an 
improvement [26–28], whilst others have suggested a deterioration  
in  sexual function [29,30]. 
Pelvic surgery to correct urogenital prolapse may affect sexual 
function for a number of reasons including narrowing the vagina, 
reducing lubrication, and because of a risk of urinary incontinence. 
 
2.3.1. Hysterectomy 
Hysterectomy has been associated with sexual dysfunction, 
including dyspareunia as well as anorgasmia [31]. It is postulated 
that extensive dissection of the pelvic floor is implicated in pelvic 
floor neuropathy affecting the pudendal nerve, impairing vaginal 
sensation and orgasm. Recent studieshave shown that cervicalcon- 
servation at subtotal hysterectomy does not appear to confer any 
advantage over total hysterectomy with regards to pelvic organ 
function. Older reports in literature had suggested a risk of neu- 
ropathy associated with removal of the cervix, although there is now 
considerable evidence that simple abdominal or vaginal hys- 
terectomy  does not adversely  affect  sexual function [32]. 
 
2.3.2. Anterior colporrhaphy 
Repair of the anterior compartment, particularly in the absence of 
synthetic mesh augmentation has not been specifically reported to 
cause impaired sexual function and some studies report an 
improvement in sexual function following anterior colporrhaphy. 
[33] 
 
2.3.3. Posterior colporrhaphy 
Posterior colporrhapy, particuarlly levator plication, has been 
also been long implicated as a cause of postoperative dyspareunia. 
Consequently older studies report alarmingly high rates of dys- 
pareunia as well as apareunia following posterior repair [34–36]. 
However, the modern approach of site-specific repair of rectoceles 
has a much lower risk of dyspareunia [37,38]. The use of mesh in 
theposterior wallhasbeen shown to increase dyspareuniain 63% of 
women [39] and therefore the use of mesh in any routine posterior 
repair is ill advised. 
Finally, if both anterior and posterior colporrhaphy are per- 
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as this can cause mid-vaginal stenosis secondary to a constriction 
ring and create de-novo dyspareunia 
 
2.3.4. Apicalsurgery 
Vaginal vault prolapse can be  corrected  either  by  an  abdomi-  nal 
or a vaginal approach. Sacrospinous fixation (SSF) is the most 
commonly performed vaginal procedure. Sexual function after 
sacrospinous fixation can be altered  either  because  of  pain,  vagi- nal 
narrowing or pudendal nerve injury. Several studies have cited varying 
impact of SSF on sexual function, either reporting it as maintained,  
improved  or   worsened [40–43]. 
With regards to abdominal sacrocolpopexy, two randomised 
controlled studies comparing vaginal and abdominal approaches have 
reported conflicting results. One study found no significant difference 
in post-operative dyspareunia in either group, although clinically more 
patients reported dyspareunia in the vaginal group [44]. In contrast, a 
study performed by Maher et al. found no difference in sexual function 
between the two groups  postop- eratively [45].  Of  patients  not  
sexually  active  preoperatively,  28 and 21% resumed sexual activity 
postoperatively, and preoperative dyspareunia resolved in 56 and  43%  
in  the  abdominal  and  vagi- nal groups, respectively. Dyspareunia 
developed de novo in two women  in the  abdominal and  three  women  
in the vaginal group. 
 
2.3.5. Vaginal mesh 
The use of synthetic mesh augmentation at the time of repair 
remains controversial with some studies suggesting increased lev- 
elsofpersistent dyspareunia in 50% ofsexually activewomen when 
compared to native tissue repair [46]. Literature continues to pro- 
vide conflicting evidence, with a recent retrospective study of over 
200 women undergoing vaginal prolapse surgery using a synthetic 
graft reporting a positive objective and subjective outcome and sig- 
nificantly improvedquality of life at a minimum of 5 year follow-up 
[47]. 
However, a randomised controlled  trial  comparing  vaginal repair 
augmented by mesh with traditional colporrhaphy for the treatment of 
pelvic organ prolapse found similar rates of de novo dyspareunia in 
both groups. [16.7% in the  mesh  group  and  15.2%  in the no mesh 
group at 12 months] [48]. Similarly, another randomised study 
involving ninety-seven patients randomised to colporrhaphy with no 
mesh and 105 with mesh found that dys- pareunia was statistically 




For those women that are already post menopausal, urogenital 
atrophy may cause loss of lubrication and hormonal changes that 
lead to sexual dysfunction [50]. Treatment of urogenital atrophy 
with topical vaginal oestrogens can improve quality of life not only 
for the women but also for her partner [43,51]. 
Another cause  for  dyspareunia  is  poor  oestrogenisation  of the 
vaginal epithelium in those women who undergo surgical 
menopause at the time of a hysterectomy for prolapse. Therefore 
careful pre-operative counseling is essential with regard to con- 
comitant oopherectomy. 
 
2.5. Psychological impact 
 
Sexual function is related to a woman’s self-perceived body 
image and degree of bother from POP regardless of stage of pro- 
lapse therefore sexual function may be more related to a woman’s 
perception of her body image than to actual topographical changes 
from POP [52]. 
Because sexual function is complex, the physical changes from 
surgery  might  not  address  the issues contributing to sexual dys- 
 
function preoperatively. These issues, such as desire, other limiting 
medical conditions, or relationship status, might not be improved 
after the structural changes of prolapse are addressed [53]. Thor- 
ough assessment is essential to understand these underlying issues 




Sexual dysfunction is a common cause of quality of life impair- 
ment and is known to have a high prevalence in women with 
urogenital prolapse andurinary incontinence. Whilst thecauses are 
often multifactorial it is important to actively case find and screen 
women prior to conservative or surgical intervention. 
Whilst there is good evidence to suggest that PFMT improves 
sexual function the evidence supporting the use of vaginal pes- saries 
and surgical intervention is less robust and long term follow up 
studies are required to assess the impact of both native tissue repairs 
and  also repairs using synthetic material. 
As our understanding of female  sexual  dysfunction  improves  our 
ability to identify women with troublesome symptoms will increase 
allowing more effective and timely intervention which ultimately 
should improve the care of patients with urogenital pro- lapse  and  
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1 |   INTRODUCTION  
 
Overactive bladder (OAB) is the term used to describe the 
symptom complex of urinary urgency with or without 
urgency incontinence, usually with frequency and nocturia, 
in the absence of urinary tract infection or other obvious 
pathology.
1 
Prevalence studies report that 12.8% of women 
over the age of 18 years describe symptoms of OAB.
2 
It is a 
long-term fluctuating condition with up to 88% of sufferers 
reporting symptoms for more than 10 years.
3 
It affects more 
women than men under the age of 70 but above this age, the 
prevalence of OAB symptoms are more equal among the 
sexes. 
Many studies have reported the detrimentaleffect of OAB 
on an individual's quality of life by forcing them to alter their 
social, physical, occupational and sexua l activities,
4,5 
however,  it   has  been  difficult   to  determine   the specific 
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aspects of life that are affected and what treatment goals 
patients wish to achieve with treatment. Schlenk et a l. (1998) 
determined that urinary incontinence (UI) represents one of 
the most bothersome chronic diseases affecting physical 
functioning.
6 
A recent systematic review on the impact of 
quality of life of urinary incontinence and overactive bladder 
concluded that at variance with other chronic conditions, 
quality of life deterioration in UI or OAB patients is 
characterised by its hidden and embarrassing nature. This 
suggests that clinic ians need to raise awareness of the impact 
that these symptoms can have, help patients to improve their 
self-confidence to report symptoms, as well as, encouraging 
sufferers to have treatment for their condition to overcome its 
hidden nature.
7 
In research and clinical practice patient-centred out- 
comes are often utilised. These were first described by 
Brubaker and Schull (2005) who coined the term EGGS to 
facilitate  communication   about  patient-centred treatment 
outcomes—E expectations, G goal setting, G goal achieve- 
ment,  S  satisfaction.
8  
It  has  been  reported  that  positive 
INTRODUCTION: In clinical practice and in research patient-centred outcomes are 
often utilised to help improve communication between patients and clinic ians and to 
help manage e xpectations from t reatment. However, many of these goals are 
generic and do not adequately capture the details of day to day life that bother 
patients the most and that they hope will improve with therapy. This study aimed to 
understand what are the goals of patients with overactive bladder symptoms in the 
UK who were taking part in a clinical  trial and to assess goalachievement. 
METHODS: This was a qualitative analysis of the patients goals recorded using the 
Self-Assessment Goal Achievement (SAGA) Questionnaire during the UK study 
assessing flexible dose fesoterodine in adults (SAFINA) trial. Free text patient goals 
were completed at baseline and an assessment of achievement was performed at the 
end of treatment. Grounded theory was used to develop themes and sub themes. 
RESULTS: Three hundred and thirty-one patients completed the trial and 1137 open 
ended goals were set. Six themes emerged from the data including, OAB, other 
LUTS and finishing the task in hand with multiple  subthemes noted. 
CONCLUSIONS: By assessing and understanding what is important to the patient, it 
may help to tailor patient care and treatment and improve patient satisfaction. 
 
KEYWORD  S 
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physician—patient  communication  and  setting individual- 
ised treatment goals can lead to improved patient satisfac- 
tion.
9 
Also by allowing patients to set their own goals for 
treatment, and then to self-assess achievement of those goals 
may help to capture the effect of OAB and the impact of 
treatment in a more individualised, patient-centred way than 
disease specific quality of life questionnaires that are 
commonly  used.
10 
Although goal attainment scoring (GAS) has been used 
for different conditions, there were no self-completed 
instruments that would allow patients with  lower  urinary 
tract symptoms to proactively capture their treatment goals 
for discussion  with  their  healthcare provider  in routine clin 
ical or research setting, hence the development of the SA GA 
questionnaire by Brubaker et al.
11  
It  was  designed to  
improve physician-patient interaction and  to  allow goal 
achievement to be assessed in research studies. It has been 
validated and its clinical value assessed and  it  has been used 
in  many  different  research  trials  for patients with  OAB. 
The aim of this study was to analyse the goals that patients 
in a UK clinica l trial wished to achieve from treatment for 
their overactive bladder and to review goal achievement after 




2 | METHODS 
 
The UK study assessing flexible -dose  fesoterodine  in adults 
(SAFINA ) was a 12 week, multi-centre open label study 
which recruited 331 adults with OAB at  39 sites  in the UK 
from February 2009 to January 2010.
12 
The aim of the study 
was to evaluate the efficacy and safety of flexib le dose 
fesoterodine and factors associated with dose escalation in 
subjects with OA B. A ll subjects were t reated with 
fesoterodine 4 mg once  daily  for  the  first  4 weeks and were 
then given the option to dose escalate up to 8 mg for the next 
8 weeks. Treatment was  stopped at 12 weeks and subjects 
were reassessed at 16 weeks.
13 
At each visit in the study, 
patients completed a 3 day bladder diary and multiple    
questionnaires   to   identify   patient 
reported  outcomes.  A  preliminary   version  of  the Self– 
Assessment Goa l Achievement (SA GA) questionnaire was 
included in the study as an exp loratory endpoint. 
Inclusion/exc lusion criteria can be found in the main study 
paper.
12 
This study was approved by the appropriate 
Independent Ethics Committee and conducted in compli- 
ance with the ethical principles of the Declaration of Helsinki 
and the International Conference on Harmoni- sation Good 
Clinica l Practice Gu idelines. Written in- formed consent was 
obtained from each subject before entering  the study. 
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The SA GA questionnaire is a patient completed, 
physician reviewed tool to assess patient's goals for treatment 
and whether the goals are achieved for subjects suffering from 
OAB and/or other urinary tract symptoms. The SA GA 
questionnaire is in two parts. The first questionnaire contains 
nine fixed goals with a further five open-ended goals. These 
are reviewed with the clin ician in order to assess whether the 
goals are realistic. The SA GA follow up questionnaire asks 
the subject to relate the degree of achievement of the original 
treatment goals set prior to the  start of treatment. 
This paper specifically examines the open-ended goals 
that patients chose regarding what they would most like to 
achieve from therapy. To assess these goals, the responses 
were analysed thematically based on grounded theory. This 
theory was first described by Glaser and Strauss in 1976.
14 
The idea is that theory is grounded in and emerges from data. 
Constant comparison is key to the method and in this analysis, 
all goals were transcribed onto individual cards. Each patient 
goal was compared with the goals fro m previous and 
subsequent subjects. These comparisons gave rise to 
categories/themes    and    sub-themes    which    summarise 
patient's  views.  Examples    of  these  comparisons  follow: 
Example   1. ‘Reduce the number of times I go at night’, ‘to 
sleep through the night’, ‘better quality sleep’, ‘to get  up  less 
at  night’ are  all  examples   of patient set goals relating 
to nocturia, therefore, these were sorted into a subcategory of 
nocturia and as it is one of the symptoms of OAB, the 
core category  was  OAB. Example    2.  ‘To go  on  journeys 
without wo rry ing abouttoilet’, ‘to ta ke dog fo ra walkwithout 
needing the loo’, ‘ watch a film without going to the toilet’, ‘
complete a meeting at  work  without  leaving  to  go  to the  
toilet’  are  all  examples    of  patients  goals  relating to 
specific tasks that they wish to complete, therefore, each 
individual task was formed  as a subcategory while  the core 
category developed was  related  to finishing the task in hand. 
Data saturation was achieved when further set goals could 
add nothing to what was already know about a category, its 
properties, and its relationship to the core category. 
Goa l achievement was graded as follows: did not achieve 
somewhat achieved, achieved, exceeded e xpectation and 




3  | RESUL TS 
 
The baseline demographics of subjects are shown in Table 1. 
The results of the nine fixed goals from the SA GA 
questionnaire can be found in the paper by Cardozo et al. 
2012
12  
and are demonstrated in  Table 2. 
Of the 331 subjects who were assigned to treatment, 1137 
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TABLE   1  Baseline demographics and clinical characteristics (n = 331) TABLE   3 List of themes and sub-themes (n = 331) 
Variable Value  Theme Sub-themes  Number 
Sex   A) OAB Reduce nocturia  156 
Male 68 (20.5) 
  Reduce urgency  104 
Female 263 (79.5)   Reduce frequency  101 
Age (years) 
   Reduce UUI  86 
Mean (SD) 60.3 (12.4)   Reduce pain  47 




Other 6 (1.8) 
Reduce  latchkey urgency 8 
Reduce  leakage on exercising 23 
 
 
Mean (SD) 79.9 (18.4) 
Range 51–174 







C) Finishing the 
task in 
hand 
Improve  weak stream 8 
Reduce leakage during housework 4 
Reduce  leakage when swimming 3 
Car/coach  journey without stopping 78 
Shopping trip without finding  loo 56 
Walk dog 52 
Watch entire film/TV show/theatre 49 
Evening out for meal 40 
Finish activity (eg church service, 37 
football   match, bingo, hair-cut 
 
 
that emerged from the data are listed in Table 3 along with 
the number of patients expressing that subject as a treatment 
goal. 
All goals were included in the analysis regardless of 
whether it was thought that these were unrealistic. Examples 
of what may be considered as unrealistic goals include ‘to not 
have any pain’, ‘to sneeze without leaking’, ‘to fully empty 
bladder’  and are discussed below. 
Two hundred and fifty-one subjects completed the trial 
and goal achievement was ranked for all goals set out by 
subjects and the level of achievement of their personal goals 




TABLE  2 Results of fixed SAGA goals reported in the SAFINA study 
 
 
Reduce the sudden  need  to rush to the 77 
bathroom 
Go on holiday 19 
Use  public transport 16 
To queue without having to leave to 2 
go to the loo 
 
D) Psychological To stop toilet mapping 75 
 Reduce anxiety/embarrassment 21 
 Feel  in control 18 
 Feel normal/confident 15 
 To  not smell 8 
 To not plan life around bladder 6 
 To enjoy what  I am doing 3 
E) Work Not leave meetings to go to loo 14 
 To not keep leaving desk 7 
 Complete an   operating list 1 
 To be more effective  in role 1 









Reduce  my urine leakage 81% of those incontinent at 
baseline 
Reduce  difficulty  starting or maintaining a 12 
urinary stream 
Saga  fixed goal 
%  Rated  ‘very important’ 
at baseline 
Reduce frequency to the bathroom 
through the day 
66 Level  of achievement % of subjects 
White 325 (98.2) 
Weight (kg) 
B) Other LUTS Reduce  leakage on coughing 41 
Empty bladder completely 22 
Mean (SD) 7.7 
Range 0.1–53.8 
Incontinence,  n (%) 132 (39.9) 
Bladder diary variables  per 24 h,  mean (SD)  
Micturitions 12.8 (3.5) 
Nocturnal  micturitions 2.7 (1.6) 
Urgency episodes 9.1 (4.3) 
UUI episodes 2.1 (2.4) 





Exceed ed/greatly exceeded expectation 16.8 









RANTELL    ET  AL. 
 
 
4 | DISCUSSION 
 
The most common  themes identified included: 
 
4.1 | OAB 
In recent literature, urgency has been described as the cardinal 
symptomof OAB
15 
and it is the only essentialsymptom when 
making  the diagnosis.
16 
In  a  study  by  Coyne  et  al.,
17 
the 
e xperience of urinary urgency had a significant negative 
effect on HRQL and increased symptom bother more than 
incontinence, frequency or nocturia. However, in this cohort 
of patients, the most commonly reported goal, listed by 47% 
of subjects was in relation to reducing nocturia episodes and 
only 31% of subjects listed reducing urgency as a treatment 
goal. This could suggest that in this group of patients, nocturia 
was their most bothersome symptom. It has been shown that 
the number of nocturia episodes per night is significantly 
associated with a reduction number of hours of sleep per 
night, reduction in QoL and sleep quality.
18 
Nocturia may lead 
to sleep insufficiency and consequently to a decrease in 
mental and physical health.
19 
For this cohort of patients, it is 
suggested that the impact of nocturia caused the largest 
disruption to their daily functioning perhaps as a result of 
sleep deprivation. However, it has also been reported that 
symptom bother does not always correlate with prevalence 
and the most commonly reported symptoms may not be the 
most bothersome
20
; therefore, further investigation into this 
group is necessary to clarify. 
Although 132 subjects reported incontinence, only 86 
(65%) of those added reducing incontinence episodes as a 
goaland only half of those reported wanting to no longer wear 
pads to manage their incontinence. This is a surprise as 
incontinence is often described as a major cause of impaired 
quality of life and a driver for patients to seek help. In a study 
by Anger et al.,
21 
women with severe OAB attended focus 
groups and discussed their symptoms and treatment options. 
One of the themes that emerged was that incontinence pads 
were the only management strategy that provided the women 
with the freedom to participate in and complete activities 
without the worry of leakage which would result in the need 
to change clothes etc. Anxiety is often linked with OAB 
symptoms and it may be that for many of the OAB wet 
patients wearing pads can help reduce anxiety as it is 
commonly adopted as a coping strategy containing the 
problem. Pad use can also be a security measure or a learnt 
behaviour so people continue to wear pads even if their 
incontinence has resolved. This study did not record if 
patients had reduced the size of the pads that they wear or the 
number used throughout the day but this could be an 
interesting area of investigation. 
It is also interesting to note that 47 patients wanted to 
reduce pain associated with their symptoms. Hanno et al.
22 
explored the relationship between bladder pain syndrome and 
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whether the sensation of urgency can overlap with the 
symptom of pain.  They  suggested that it  is  likely  urgency 
e xperienced by these patients is different to that described by 
patients with OAB and in this cohort of patients their 
description of wanting to reduce pain could be in relation to 
pressure symptoms causing discomfort. 
 
4.2 |  Other LUTS 
Under this theme, four of the sub-themes were all in relation 
to   reduction  of  leakage   during   different   activities,   for 
e xa mple, coughing, e xe rcising and during housework. This 
type of leakage is generally associated with stress inconti- 
nence but can also be attributed to provoked detrusor 
contractions. In this study, patients recruited reported OAB 
symptoms but patients with urgency predominant mixed 
symptoms were also included. There were no urodynamics 
performed to demonstrate the presence of detrusor overac- 
tivity or urodynamic stress incontinence. Therefore, it is not 
possible to diffe rentiate between these groups in this analysis 
as to aetiology of the urinary leakage. In reality, it is unlike ly 
that all these episodes of leakage are caused by an involuntary 
detrusor contraction and, therefore, these are not realistic 
goals for patients in this clinical trial. It could be suggested 
that when these goals were discussed with the clinician, a 
further conversation may have been warranted to clarify if 
these symptoms were clinically more stress related and if so 
patients  should  have been advised  why  it  is  unrealistic to 
e xpect symptom resolution from the therapy they received. 
Additionally, a discussion about alternative treatments that 
they  could  be  offered  for these symptoms  could  then be 
undertaken. It could also be construed as unrealistic for 
patients to list ‘to empty bladder completely’ as a goal in this 
study. It is an accepted side effect of fesoterodine that 
approximately 7% of patients will e xpe rience the symptomof 
incomplete bladder emptying whilst taking the medication. 
During the screening phase, all subjects underwent assess- 
ment of post-void residual and anyone with a significant 
residual volume was excluded from the trial, therefore , 
bladder emptying should not have been a problem for this 
group of patients. It could, however, be considered by some 
patients that they were not emptying their bladder completely 
as a surrogate measure of bladder irritability, if for example, 
the patient felt that they needed to void 10 min after having 
just emptied their bladder. However, this would usually result 
from their OAB causing after contractions and possibly poor 
fluid habits rather than the bladder not emptying completely. 
 
4.3 | Finishing   the   task  in  hand 
This theme highlights the frustrations in daily life that many 
patients with OAB suffer. The patients having to interrupt 
what they are doing in terms of t ravel, social life, and every 
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fro mtherapy. A third of allthe patient goals in this study were 
in relation to being able to complete everyday tasks without 
having to worry about their bladder. This disruption of daily 
life has also been reported in a study by Irwin et al.
23 
who 
found that 76% of individuals reporting OAB symptoms 
stated that the condition interfered with or made it more 
difficu lt to perform daily activit ies. Most clinic ians treating 
OAB patients treat the symptoms. However, for the patients, 
it is not always the symptoms they specifically want to change 
but the impact of the symptoms on their daily life. For many 
subjects, completing a simple tasksuch as taking the dog for a 
walk without needing the toilet or being able to watch a film 
without interruptions is what they would like to achieve from 
therapy. Interestingly, the SAGA tool captured these issues 
and should allow more focused treatment based on these 
concerns. Therefore, it is important to remember these 
motivations when planning treatment and providing bladder 
retrain ing, etc. as individualised management to work 
towards allowing the patient to complete tasks most 
important to the patient which will ult imately improve 
satisfaction and fulfill expectations. 
 
4.4 | Psychological 
It has been reported that patients with OAB e xpe rience higher 
rates of depressive symptoms.
23,24 
In a series of interviews 
with patients with OAB symptoms, interviewees e xpressed 
constant anxiety and worry about finding and reaching a toilet 
in time to prevent urine leakage and some reported anxiety 
that constantly needing to go to the toilet created feelings of 
hopelessness and depression.
25 
Those feelings of anxiety 
were mirrored in this analysis with many subjects wanting to 
reduce the an xiety in relation to their bladder,  to  stop worry 
ing about finding a toilet and just to feel more in control of their 
bladder and consequently their lives. 
A   recent   systematic   review   by  Sakakibara    et al.
26 
assessed the literature relating to bladder dysfunction in 
patients with anxiety and depression. They found that 
depression/anxiety was an obvious risk factor for OAB and 
presumed that this reflected that the bladder is under 
emotional control. They suggested that ameliorating bladder 
dysfunction is an important target in treating patients with 
depression/anxiety. However, equally these psychological 
symptoms could lead to anxiety and depression due to the 
impact of OA B on the patient's life . This study did not assess 
the numbers of patients suffering anxiety and depression and 
whether their bladder symptoms caused the anxiety and 
depression or conversely whether their anxiety and depres- 
sion caused their bladder dysfunction. 
 
4.5 | Work 
This theme is similar to those set out in the finishing the task at 
hand theme  but  the impact  of bladder symptoms  on work 
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productivity has been studied. According to Irwin et al.,
23 
men 
are more likely than women to worry about the impact that 
OAB can have on their work life including worrying about 
interruption of meetings which was identified as an issue by 
subjects in this cohort. Also this can be a major factor in 
deciding the type of work or timing  of retirement. 
 
4.6 | Sex 
There have been many studies that show the negative impact 
of OAB on se xual function.
27,28 
These papers suggest many 
diffe rent reasons for this effect including embarrassment, fea r 
of coital incontinence on penetration and orgasm, loss of 
confidence, fear of smelling, loss of libido. However, only 
two subjects reported goals in relation to sexual function in 
this study. It has also been suggested that concerns about time 
restraints, lack  of  effective  treatments  and embarrassment 
may prevent women in itiat ing a discussion about sexual 
concerns  with    their   doctors.
29  
According  to O’Donnell 
et al.,
30 
only 24% of women are not at all embarrassed to 
discuss sexual problems with a doctor in comparison to 87% 
when discussing allergies or cold/flu, and appro ximately, a 
third of women would not initiate a discussion about sexual 
issues with their doctors.
31 
The very small number in this sub 
group could suggest that the clin ician reviewing the goals 
with the patient did not broach the subject of sexual function 
with the subjects at the time of screening and goalsetting and 
as the literature would imply that patients will rare ly disclose 
this information without prompting. 
In total, approximately, half of the patients in this trial 
achieved their goals following 12 weeks of therapy, with a 
further third somewhat achieving their goals. 
 
4.7 | Limitations 
There are several limitations to this study. Firstly, not all 
patients orig inally enro lled in the tria lcompleted the study so 
complete data are not available for all participants. It is 
recommended that the SA GA questionnaire is completed by 
thepatientwith theclinic ian. Given thatthere were 39 different 
sites recruiting subjects forthis study,there may bevariation in 
thelevelof involvementof theclin ician at eachsite andthis can 
introduce a risk of bias in the goals set. In areas where clinic ian 
involvement was minima l, this couldaccount forso mepatients 
setting unrealistic goals and ultimately negatively affect goal 
achievement. Finally, there was only a single personanalysing 
and categorising the open-ended goals and this may also 
introduce a bias in the coding system. 
 
4.8 |  Recommendations 
This study shows the use of the SAGA questionnaire as a clin 
ical tool to understand how to tailor and individualise therapy 
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5  | CONCL USI ONS 
 
The analysis of these patient goals has highlighted how for 
many patients, their treatment aims are more focused on 
completion of tasks rather than a specific reduction in a 
particular symptom. This emphasized the impact that 
symptoms can have, and disruption that they can cause to 
their everyday activities. 
The use of a more qualitative approach can help to tailor 
patient care based on perceived individual need and enable 
clin icians to support patients to develop realistic treatment 
goals. This may improve patient—clinician interactions and 
ultimately imp rove treatment outcomes. However, it is 
important to ensure that clinicians discuss all areas of 
treatment outcomes including sexual function. 
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Aim: The aim of this paper is to review the literature on the effect of lower urinary tract symptoms (LUTS) on sexual 
function and dysfunction. Methods: At the International Consultation on Incontinence-Research Society (ICI-RS) in 
2015, a multidisciplinary group presented a literature search of what is known about the effect of lower urinary tract 
dysfunction (LUTD) on sexual function (SF) in men and women. Wider discussions regarding knowledge gaps and ideal 
research methodology ensued. Results: A body of evidence supports associations between LUTS/urinary incontinence on 
SF in both men and women, but the true prevalence of the impact of LUTD on SF remains largely unknown. There is still 
reluctance among health care professionals (HCP’s) to discuss SF with patients and often patients who are not asked will 
not volunteer their problems. Conclusion: A significant knowledge gap in this area remains. Education among HCP’s on 
assessment and treatment of sexual dysfunction and communication skills are essential to encourage, and engage 
patients with HCP’s. Neurourol. Urodynam.  36:949–952,   2017.  #  2017 Wiley Periodicals, Inc. 
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INTRODUCTION 
Lower urinary trac t  symptoms  (LUTS) are  the  subjective 
in dica t or of a di se a se or c ha nge i n c o n ditio n as per cei ved by the 
patient, carer or partner, and may lead him/her to seek help 
fro m he a lt h ca re p rofe ssi o na ls. 
1 
I n 2012, the 5t h Inte rna t io na l 
Consultation on Incontinence estimated that, of the wo rld ’s 
population, 46% of the adults (22: 0 years) experienc e LUTS, 
11.8 %compla in of symptoms of an overac tive bladder (OAB ), 
8%sufferfro msome ty pe ofurin ary incontinence (UI), and 4% a 
re e stima te d to ha ve severe st re s s uri na r y inc o nti ne n ce (SUI). 
2
 UI 
is assoc iated with reduced quality of life, higher rates of de 
pre s si on, re du ce d wo rk p ro d ucti vit y, a nd de c re a se d e n jo y- 
ment ofsexual activ ity .
3 
In 2015 , at the Intern ationalConsultation on Incontinence- 
Researc h Soc iety (ICI-RS ) a mult idisc iplinary group of health 
care professionals took part in a thin k tan k questioning how 
LUTS affec tsexualfunc tion (S F)in men and women.This is the 
first of two papers  developed from the literatu re  searches 
pe rf or me d by the clini cia ns in vo lve d tha t we re pre se nted in the 
think tanks and the ensuing discussions.Literature searches 
were performed onboth Pubmed and Medline.The aimofth is 
paperis to app raise the available evidence on the etiology and 
epidemiology of the effect of LUTS on sexual function and 
dysfunction in addition to considering the commun ic ation 
issues experienced by health care professionals concerning 
the ir pa tie nts’ se x ua l fun ctio n pr o ble ms. The se c o n d pa pe r will 
su g ge st p ro p osa l s for fu rthe r re se a r ch to a n s we r the co m pre - 
hensive questions, that are still not understood. Factors 
common to men and women will in itially be discussedbefore 
focusingonmen and women separately . 
 
Sexual Function and 
Dysfunction 
It ha s be e n re po rte d t ha t, se x ua l be ha vi or a n d re la ti on s hip s 
are key components of well-being and are affec ted by soc ial 
norms , attitudes, and  health.
4 
Sexual health  is  a  state  of ph 
y sica l, e mot io na l, me nta l, a nd so cia l we ll- be i n g in re la tio n to 
sexua lity; it is not mere l y the abse nc e of dise a s e, dysfun cti on, 






Sexuallifesty les and prac tices hav e signific antly 
changed over the last 30 years as demonstrated by three 
National Surv eys of Sexual Attitudes an d Lifesty les.
1 
Sexual 
freq uen c y a nd the ra nge of pra ct ice s re p orte d re d u ce wit h a ge 
, espec ially in women. However, certain sexual behaviors 
and life style s ha ve be c o me in cre a sin gl y m ore c o m m on, for e 
xa m- ple,sexualexperiencewith same sexpartner, and hav 
ing anal sex (S ee Table I). It was no ted thateduc ation is more 
s trongly ass ociate d wit h se x ua l be ha vi or s a nd a ttit u de s t ha n 
s oci oe c o- nomic status. 
Acc ording to the Wo rld Health O rganization International 
Cla ss ifica ti o ns of Dise a se s- 10 ( IC D- 10) , the de finit io n of fema le 
sexualdy sfunction (FS D) inc ludes ‘‘the various way s in which 
anin div idualisun able top artic ipatein asexualrelationship as 
she w o ul d wi sh.’ ’ 
6 
The re a re f o ur ma j or ca te go rie s of dy sfu nc- 
tion, that is desire, arousal, orgas mic , and sexual pain 
disorders.
7 
One in 10 women may suffer from hypoactive 
sexualdesire diso rder, while the rates of o rgas mic proble ms 
range between 3.5% and 35 %.
8 
Erectile dysfunction (E D) (the 
persistent inability to attain and maintain an erection 
sufficient to permit satisfac tory sexual performance
9
) and 
premature   ejaculation are  the two  main   categories ofmale 
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Box 1  Themes Identified 
950 Rantell et al. 
TABLE  I.   Change  in Sexual  Practices  Over  the Past  30 Years 
1990 2010  
 
 
Sexual behavior W omen    Men    W omen 
Men 
 
No. of  partners  over lifetime 3.7 8.6 7.7 12.6 
No. of occasions  of SA in past month 6.1 6.4 4.8 4.9 
V aginal   sex in the past month 76.3% 72.1% 69.6% 68% 
Given or received   oral  sex in past 65.6% 69.7% 75.1% 77.1% 
month 
Anal sex  in past year 6.5% 7% 15.1% 17% 
• ‘‘ 
• open up ac an ofworms’’ 
• Lack of time / re s ou rc e s/ tra in in g 
• Conce r n about know le d g e and ability 
• Worry will c ause offense 
• Person a l discom fort 
• Lack of awa renes s about sexua l issue s 
• Opposite gende r/ra ce /a ge conce rns 
S exual experience with same sex 
partner 
3.7% 6% 16% 7.3%  
review of qualitative research in the UK revealed many 
M asturbated   in past  4/52 n/a        n/a      32.9%   66.4% 
SA, sex u al activit y. 
sexual dysfunction.
10 
A h igh prevalence and inc idence of ED 
has been shown by epide mio logic al data worldwide. The 
Ma ssa ch use t ts Ma le A gi ng St u dy ( M M A S) 
11 
re p orte d an ove ra ll 
prevalence of 52% in non-institution alized men aged 40 –70 
ye a rs ( Bost o n a re a) ; a mo n g the se me n, 17. 2%, 25. 2 %, an d 9. 6 %, 
re s pe cti ve l y suffe re d fro m mi ni ma l, mo de ra te , a nd co m ple te 
ED. In the Cologne study of men aged 30 –80 years,the overall 
prevalence ofEDwas 19 .2 %, with a steep age-related inc rease 
from 2.3% to 53.4 %.
12 
There are de monstrable differenc es 
between the sexes when assessing the type of sexual 
dysfunction as reported by the work of Richters et al.
13 
set out 
in Table II. 
There  is evidence  to show that FSD related to UI c an also 
a dve rse l y i mpa ct u po n re la ti on s hip s as me n wit h pa rt ne r s w ith 
UI reported an overall dimin ished sexual function, lower freq 
uen c y of in terc o ur se, re d uce d sa ti sfa cti o n, a nd we re m ore like ly 
to have erectile proble m s. 
14  
 
Let    s Talk About 
Sex! 
Communication betweenhealth care professionals (HCPs ) 
and patients about sexual function, and Lower urinary trac t 
dy sf un ctio n ( LU T D) ha s l o ng be e n an i ss ue . P a tie nt s will se l do m 
volunteer sexual proble ms but HC P’s enquiring is often met 
with reliefratherth ane mbarrass ment.
15
However,in a recent 
stu d y of Ame rica n o bste t ricia ns an d g y na e c olo gi sts, 63% a sk if 
the patient is sexually activ e but only 40% routinely enquire 
about sexualp roble ms .
16
Yet it has beenshown th at patients 
are more likely to seekhelp if a HCP has as ked the m about SF 
during a routine v isit in the p rev ious 3 years.
17 
In addition , 
when communicating sexual proble ms there are variations 
betweenthesexesas menpreferto discussSFwith aphysic ian 





TABLE  II.   Differences   in Types  of Dysfunction  Between  the Sexes 
 




Lack  of interest 25 55 
Coming  to orgasm  too quickly 24 12 
Inability  to come  to orgasm 6 29 
Not finding  sex pleasurable 6 29 
Pain  during intercourse 2 20 
W orry  over  how body looks 2 20 
Anxiety about performance 16 17 
V aginal dryness — 24 
Trouble  maintaining  erection 10 — 
 









How  Does LUTD  Affect Sexual Function in Men? 
 
Multifactorial aetiology of male sexual dy sfunction. From a 
physiological perspective pelvic organ functions cannot be 
regarded separately as there are countless interac tions in 
the neuronal network of the pelv is that inv olves bladder, 
bowel, a nd se x ua l fun cti on s. Furt he r mo re , va s c ula r, ho r mo 
na l, ce llu- lar, and  other fac tors comprehensively  affec t 
pelvic organ 
functions.LUTS and ED in males share 
commonpathophysio- logic al pathway s.
20–22 
An overview 
of the extensive relation- 
ship  between  ED  and  LUTS  in  men   with  e mphasis   on 
ph o sp h odie ste ra se - 5 f un cti on ha s be e n s u m ma riz e d i n Fig 
ure 1 by   Koehler   and McVary.23 
Effects  of  LUTS/incontinence  on  male   sexual   function— 
epidem iological  data.   Large   population -based  studies  
have e xte n sive ly do cu me nte d in cre a se d se x ua l d ysf u ncti o 
n ( S D) in me n with st ora ge an d v oi din g L U TS. Re co rd s fro m 
11, 3 27 me n in UK ge ne ra l pra ctice s us in g the He a lt h I mp ro ve 
me nt Ne t w or k database showed an increase in the overall 
prevalence of record e d SD from 1.7% in 2000 to 4.9% in 2007. 
24 
The odds ratio 
( O R) for ED wa s 3. 0 ( 2. 6 – 3. 4) for stora ge LU T S, 2. 6 ( 2. 4 – 2. 7) 
for voiding LUTS,and 4 .0 (3 .4 –4 .8) fo rvoiding an dsto rage 
LUTS, respectiv ely . Likewise, the EpiLUTS study , a c ross-
sec tional, po p ula ti on- re pre se nta tive s ur ve y via inte rne t co n 
du cte d in the 
UK,Sweden,and USAwith 6 ,326 men inv olved,de 
monstrated an impact of OAB on sexual health.
25 
Both O 
AB wet and O AB dry were assoc iated with worse 
sexualhealth,reduc edsexual 
ac tiv ity , and diminished enjoyment of sex (P < 0.0001 ). 
OAB dry /wet were signific ant predic tors of ED and ejac 
ulatory dysfunction (EjD) in men. Acc ording to a large study 
by Rosen 
etal., the presenc e and severity ofLUTS are independentrisk 
factors for sexua l dysfu n ctio n in olde r men. 
26  
 
How Does LUTD Affect Sexual Function in 
Women? 
 
Multifactorial aetiology  of  female  sexual   dy sfunction.   Further 
to the well studied psychological and relationship aspects, 
a variety of mostly  organic  factors  may  be  inv olved  in  
the pa th o ph y siol o gy of F S D. E n do cri ne , ne u rol o gica l, ca r di 
ova sc u- lar, dermatolog ic al, and psychiatric disorders, as 
well as surgic al and medical complic ations, and c ancer 
may lead to ce nt ra l a n d pe ri phe ra l c ha n ge s i n ce ll- to- ce ll c o 
m mu ni ca tio n, cha n ge s in e nd oc ri ne milie u, di sr upti o n in the 
h o me o sta si s of ne u rot ra n s mitte rs an d sig na l mole cu le s, tiss 
ue da ma ge , or ga n 
da ma ge , vas cu lar, a nd ne u rol o gica l c ha nge s whi c h pre di sp 
ose to FSD. 
27,28  
Effects of LUTS/incontinence on female sexual function— 
epidemiologicaldata. An inc reasing body of evidence 
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Fig. 1. Fig.  1 An overview  of  the  extensive   relationship   between  erectile   dysfunction   and   lower  urinary    tract  symptoms    in  men  with   emphasis   on  
pho sp h o di e ste r a se - 5 functi o n has been summ a ri z e d in Fig ur e 1 by Koeh l er and McVar y .
23  
 
to be quite prevalentamong womenwith LUTS and/or UI. The 
presence of severe UI doubled the odds compared to non- 
incontinent women fo r reduced libido, v aginal dryness, an d 
dysp are u nia. 
6 
Shaw (2002 ) undertook a systematic rev iew of c linic al 
papers published between 1980 and 2001 to assess the 
prevalence of sexual impairment in women with UI an d the 
prevalence of urinary leakage during  sexual  activ ity . Prev 
alence ofsexual incontinence in c linic alsettings ranged fro m 
10–56% and impairment in sexual function was reported as 
0 .6–64%. Recommendations for standard defi- nitions and  
measures of sexual incontinence  and sexual 
impairment were suggested to establish reliab le prevalence 
estimates.
34 
All types of UI were found to be associated with FSD. 
Urodynamic ally proven SUI was found to correlate with a 
dimin ished quality oflife,inc reased ris kof marital proble ms, 
and reduced sexual satisfac tion,
4 
but women with detrusor 
ove ra cti vit y an d as so ciate d UI ha d t he gre a te st de gre e of se xua l 
dysfunction. A c linic al diagnosis of O AB was also assoc iated 
with impairment  of  fe male sexual  function.  Women  with 
mi xe d UI ha d the w o rst se x ua l f u ncti on. 
35 
C o nce rni n g t he e ffe ct 
ofUIon ind iv idualdo mains offe malesexualfunc tion,while all 
type s of UI in cre a se d the ris k for FS D by 1. 6- fol d to 1. 8- fol d, pure 
Urgency UI was a risk fac tor for decreased lubric ation and 
increasedcoitalp ain while mixed UI was assoc iated with less 
sexua l satisfa c tio n. 
36 
OAB and sexual function—whatdo we actually know? Large 
epidemiolog ic al studies, such as the EpiLUTS study , c learly 
su g ge st as s ociati o ns bet wee n OA B an d se x ua l d ysf u ncti o ns, 
37 
but existing literatu re is partia lly  contradic tory. In a large 
tre a tme nt outc ome s st u d y, o nly 37 % of the fe ma le pa rtic ipa nts 
c laimed a negativ e sexual and relationship impact of OAB in 
theirliv es.Mo reover,in a multiv ariate analy sis,OAB was nota 
predictorofloss ofinterestinsex in the fe male partic ipants as 
oppo se d to the male one s and impro v em ent of OAB symp to m s 
was followed by asimilar improvementin sex liv es only in 19% 
of the patients, with another 11% even reporting a deteriora- 
tion.
38 
By contrast, other published studies, which used 
tolterodine showed beneficial effec ts of both the immediate 
release (IR) and extendedrelease (ER) formulations on sexual 
he a lth o ut co me s. Se x ua l de si re , a rou sa l, va gi na l lu bri ca tio n, 
or ga s m, an d o rga s m sa tisfa cti on i m pr o ve d f or u p to 6 m ont hs 





Se x ua l pra ctice s a re c ha ngi n g. Alth o ug h a ple th ora of st u die s 
su p po rt a ss o cia tio n s bet wee n LU T D an d se x ua l d y sfu nct io n in 
both sexes,little is known about the mechanis ms underlying 
the impac t of LUTS and LUTD on SF and vice versa. Some 
proble ms are common to both men and women but there are 
also differences that may be related to  age, ethnicity, and cult 
ura l ba ck gr ou n d. E du ca ti on a m o ng H CP ’ s on a sse s s me nt a nd 
tre a t me nt of se xua l dy sf un cti on an d c o m m uni ca ti on s kills are 
essential to encourage an initial engage ment between 
patients and HCP’s . However,this will not overcome all of the 
barrie rs identifi e d. 
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1 |   INTRODUCTION  
 
Both lower urinary tract symptoms (LUTS)  and sexual 
dysfunctions (SD) are common  conditions, their prevalence 
 
 
Dr. Alan Wein led the peer-review process as the Associate Editor responsible for 
the paper. 
Apostolos Apostolidis and Angie Rantell have equally contributed to the manuscript 
and should be considered as joint first  authors. 
increasing with advanced age and the emergence of 
comorbidities.
1–4 
Epidemiological  data but also clinical and 
basic research findings support links between LUTS and 
SD,
5–8 
particularly in men where common  oral treatments 
(phosphodiesterase type 5 inhibitors) are now available to 
manage both conditions simultaneously.
8,9 
However, the 
multifactorial    etiology   of   both   LUTS    and   SD and 
the sociocultural issues surrounding them may have 
negatively affected treatment seeking and physician–patient 
AIM : To discuss available data on the links between LUTD and se xual dysfunction, 
what is still unknown about the causative effect of disease processes on sexual function  
(SF),   and  to suggest proposals for further research. 
METHODS: At the 2015 International Consultation on Incontinence-Research 
Society (ICI-RS), a multi-disciplinary group presented a literature search of what is 
known about the effect of LUTD on SF in men and women. Wider discussions 
regarding knowledge gaps, and ideal research methodology ensued and are 
presented. 
RESULTS: The underlying mechanis ms of the impact of LUTD on SF remain 
largely unknown. Risk factors for the metabolic syndrome may cause both LUTS 
and ED in men, and their improvement may improve both conditions. In women, 
neurovascular changes may be common in LUTD and FSD. Successful LUTS 
management results in FSD improvement, but the mechanis ms are ill understood. 
Gaps in standardization of sexua l dysfunction terminology, variations of 
assessment, and treatment in clinical practice and research make most studies  not 
comparable. The sensitive knowledge and subjective nature of the problem present 
challenges and often result in neglecting it. 
CONCLUSION: Neurovascular and hormonal factors, but also indirect effects may 
lin k LUTD to SD in both sexes, but the evidence is not robust and the mechanisms 
unclear. There is a need for defining the terminology and standardizing outcomes  
assessed in clinical trials. The multifactorial nature of SF in both sexes makes trial 
design challenging and “real world” studies may prove more beneficial for patients’ 
outcomes and clinicians’ understanding. 
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communication.    Data    demonstrate    increasing patients ’ 
knowledge of both conditions in the last decades; however, 
gaps in identifying both conditions as problems and 
understanding them, particularly when possible associations 
between them  are considered,  still remain   (see   also Part  
110).11,12 
At the International Consultation on Incontinence- 
Research Society (ICI-RS) in 2015, a multidisciplinary group 
of health care professionals participated in a  think tank (TT) 
questioning how LUT dysfunction (LUTD) affects sexual 
function (SF) in men and women. In the first part, the 
panelists appraised the available evidence on the etiology and 
epidemiology of the effect of LUTD on SF in addition to 
considering the communication issues experi- enced by 
health care professionals.
10 
In the  second  part, the panel 
aimed to discuss literature data considering how the   two   
conditions   could   be   linked    (thus  including, 
possible   common    causes,  common    patients’ character- 
istics, etc.) in men and women and put forward proposals for 
further research to answer the comprehensive questions that 
are still not understood. The search terms erectile 
dysfunction, female se xual  dysfunction,  lower urinary tract 
symptoms, incontinence, metabolic syndrome, neuro- 
modulation, animal models were used in combination for a 
literature search of both PubMed and Medicine, which served 
to set the basis for the discussion of the TT. However, the 





2 | ARE THERE CAUSATIVE LINKS 
BETWEEN    LUTD   AND  SF  IN MEN? 
 
Unfavorable etio logical risk factors like diabetes mellitus 
(DM), obesity, and the metabolic syndrome promote both 
LUTS and ED progression. This association has beenwidely 
studied, a literature search (1990–2008) and a summary of 16 
well-designed studies with over 50 000 subjects highlights the 
cause-and-effect relationship between LUTS and ED.
8 
Since 
then, more evidence with the same conclusions has been 
published. A recent questionnaire-based study showed that 
OAB-wet increased the risk and severity of ED in men with 
DM type 2.
13 
The OR of ED in patients with OAB-dry or OAB-
wet compared with no OAB was 1.82 and 3.61, respectively. 
Among the OAB components, urgency urinary incontinence  
(UUI) had  the  strongest  impact on   ED (OR = 4.06), 
followed by nocturia, urgency, and frequency. These findings 
suggest a potential influence of urinary incontinence (UI) on 
male se xua l function in addition to the effect of LUTS. 
Whether this is a psychologicale ffect related to the loss of 
bladder controlor even to the use of pads/diapers or whether it 
implies a worsening of the underlying disease processes and 
mechanisms affecting SF is yet unclear. 
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The US Health Professionals Follow-up Study (HPFS) 
with 18 055 men involved demonstrated a significant increase 
in the risk of LUTS and LUTS progression with increasing 
BMI (≥35 kg/ m2 vs. <25), waist circumference (≥42 inches 
vs. <33), and weight gain beyond 21 years of age (≥50 pounds 
vs. stable).
14 
The Third  National  Health and Nutrition 
Examination Survey (NHANES III)
15 
demonstrated the 
association between markers of the metabolic syndrome such 
as oral glucose tolerance test, glycosylated   hemoglobin,    
HDL    and   LDL  cholesterol, 
triglycerides, history of DM, hypertension, and LUTS in 
elderly men. Both a history of diabetes (OR 1.67) and 
hypertension (OR 1.76), as well as increasing glycosylated 
hemoglobin (P = 0.005) showed a positive association with 
LUTS. If more than three components of the metabolic 
syndrome were present, the likelihood of LUTS further 
increased  (OR 1.80). 
The same risk factors apply for hypogonadism in men, 
which play a key role in the development of ED. Current 
evidence suggests that hypogonadism itself is an important 
risk factor for LUTS, too.
16 
In the Hypogonadism in Males 
(HIM) study of men over 45, the prevalence rates of 
hypogonadismwere 52.4% for obesity (OR 2.38), 50.0% for 
diabetes (OR 2.09), 42.4% for hypertension (OR 1.84), and 
40.4% for hyperlipidemia (OR 1.47), the four criteria of the 
metabolic syndrome.
17 
The more components of the 
metabolic syndrome are present, the higher is the prevalence 
of hypogonadismin men  with SD.
18 
These   demonstrated   correlations   between  unhealthy 
liv ing and the development of LUTS and ED also offer a 
pathway to a therapeutic approach. The Osteoporotic 
Fractures in  Men  Study  showed that obesity increases and 
physical activity decreases the risk for LUTS in older men  
(65+).
19  
In  multivariate  analyses, compared  with men 





), and obese (≥30 kg/m2) men were 29% (OR 
1.29) and 41% (OR 1.41) more likely to develop LUTS, 
respectively. Men in the highest quartile of physical activity 
were 29% (OR 0.71) and those who walked daily 20% (OR 
0.80) less likely than their sedentary peers to develop LUTS, 
adjusting for BMI. Patel & Parsons separated non- 
modifiable risk factors (age, genetics, geography) from 
modifiable ones (hormones, metabolic syndrome, obesity, 
diet, physical activity, inflammation).
20 
Beside  all  options to 
reduce weight including diet and physical activity, long- term 
testosterone therapy in obese hypogonadal men with type 2 
DM resulted in a significant and durable reduction of waist 
circumference and weight over a 6-year treatment period.
21 
However, in a study of Tamsulosin monotherapy versus 
combination therapy with Tamsulosin and solifena- cin 
improvements in voiding, storage symptoms and Qo L were  
not followed  by  erectile  function improvements.
22 
Further to the established associations between LUTS and 
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male LUTD can affect se xual function cannot be answered 
yet although mechanisms linking LUTS to ED have been 
proposed based on a wealth of preclinical and clinical 
evidence. Kohler and McVary
8 
put forward a 4-theory 
complex where altered nitric oxide (NO) levels/cyclic 
guanosine monophosphate (cGMP) pathway, autonomic 
hyperactivity (AH), increased Rho-kinase activation, and/or 
pelvic atherosclerosis may contribute to the development of 
both LUTS and ED. In vitro e xpe riments with NO donors 
showed a dose-dependent accumulation of c GMP and a time-
dependent reduction in the growth of human prostate smooth 
muscle cells.
23 
The autonomic nervous system is thought to 
be associated with prostate growth and function,
24 
while  
patients with  AH  have  increased  risk for developing LUTS, 
and α1-adrenoreceptors in the spinal cord and peripheral 
ganglia have been linked with spinal hypersensitivity to 
stimuli, bladder overactivity, and ejaculatory control.
8 
Increased Rho-kinase activation induces smooth muscle 
contraction, but also inhibits activation of eNOS in human 
endothelium. In addition, dysfunction of the Rho-pathway 
has been identified in the bladder following BOO.
8 
Pelvic 
atherosclerosis/ischemia is associated with the metabolic 
syndrome and AH, leads to enhancement   of  Rho-kinase  
activation,  and  reduces   the e xpression of NOS. In this 
respect, similar histopathologic changes were noted in 
smooth muscle of the bladder, prostate, and penis of animal 
models of hypercholesterol- emia   and pelvic ischemia.
8 
Besides  common  pathophysiological  mechanis ms, re- 
search findings suggest causative associations between BPH 
and ED. Electrophysiologicalhuman studies show that nerves 
of the prostatic capsule contribute to erectile function and 
their triggering increases intracavernous pressure.
25  
BOO was 
found to enhance the tone of the corpora cavernosal smooth 
muscle via an increase of Rho-kinase expression in the 
cavernosal tissue.
26 
In animal models, partial BOO resulted in 
morphological and innervation changes of the corpus 




3 | EFFECT OF SURGERY- 
ASSOCIATED  INCONTINENCE 
 
A long-neglected problem is the impact of post-prostatec- 
tomy incontinence (PPI) on SF with limited data available
28– 
32 
as most studies focus on sexual dysfunction 
as direct consequence of surgery. In a questionnaire based 
study, orgasm-associated incontinence after radical prosta- 
tectomy was reported by 93% of the 239 respondents.
28 
Orgasm-associated urine leakage occurred always in 16%, 
occasionally in 44%,  rarely in 33%,  and never in 7%. This 
condition  was  later called  “climacturia,”
29  
with  42% of 
patients reporting loss of at least an ounce of urine each time 
and 47% considering it a significant bother to their quality of 
life. No differences were seen in prevalence between open and 
robot-assisted radical prostatectomy (RARP), but recovery 
fro m climacturia was faster and greater  after RARP (48% 
vs. 15% at 84  months).
30  
In  a small  series, 7/11 (64%) 
patients reported the impact of PPI as a major problem during 
arousaland 4/11 (36% ) as a major problem at the time of 
orgasm.
33 
After successful surgical management of PPI, 7/11 
(64%) patients reported a marked improvement of their 




4 | WHAT WE DO NOT KNOW— 
SUGGESTIONS    FOR  RESEARCH 
 
Standard LUTS therapy in men with BPE might even 
deteriorate erectile and/or ejaculatory function. Several drugs 
like alpha-bloc kers and 5-alpha reductase inhibitors can be 
associated with bothersome sexual side effects.
34 
On the other 
hand, evidence in the recent years suggests that ED treatment 
with phosphodiesterase type 5 (PDE5) inhibitors can also 
improve LUTS.
35,36 
Such effects may be associated with a 
reduction in the growth rate of prostatic stromal cells (human) 
or of the contractile act ivity of prostatic and urethra l smooth 
muscle, in addition to a decrease of uninhibited detrusor 
contractions (animals).
37 
This gives reason for a combination 
treatment in  men  with  LUTS  and ED  that can 
improve   both   conditions.
38–40  
In   vitro   human studies 
demonstrated an additive rela xant effect of  tadalafil  and alfu 
zosin on both the prostate and the bladder.
41 
Furthermore, 
therapeutic modalities like sacral neuromodulation already 
established in the treatment of refractory UUI are being 
investigated for possible beneficiale ffects in patients with ED 
and show promising results.
42 
These approaches give plenty 




5 | ARE THERE CAUSATIVE LINKS 
BETWEEN LUTD   AND  SF  IN 
WOMEN?  
 
Improvements in women's SF fo llo wing successful treatment 
of either OAB/UI or stress UI suggest indirect effects of 
LUTD on SF. Improvement of secondary parameters as a 
result of OAB/UI (leakage during intercourse, intercourse 
interruption due to urgency, pain during intercourse) and of 
factors which have a negative effect on the satisfaction of the 
sexual  relationships as  well  as on  patients ’ self-image 
(embarrassment associated with OAB/UI, fear of leakage 
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OAB) may a lso result in improvement of FSD.
43,44 
In the case 
 
 
7  | WHAT WE DO NOT KNOW— 
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of stress UI, surgical or conservative restoration of continence 
is   commonly    associated  with   improvement   of   SF   as 







The cure of coital inconti- 
nence, achieved in 90% of surgically t reated cases, is thought 
to be a major predictor of se xual improvement,
46,47,50 
with 
improvements in coital pain
47 
and in partner-related 
aspects
48,52 
also reported to be associated with post-surgery 
SF beneficial effects. 
The use of neuromodulation to treat refractory LUTD 
could shed some light in the mechanis ms connecting LUTD 
to FSD. Almost all studies showthat sacralneuromodulation 
(SNM) improves LUTS and SF irrespective of the cause of 
LUTD.
53–56 
Their findings  suggest that neuraland vascular 
changes may be common in LUTD and FSD. In this respect, 
women with refractory OAB and non-obstructive urinary 
retention were found to have abnormal pudendal nerve 
function, which showed a trend towards improvement after 
SNM.
57 
Neurally augmented sexua l function was achieved 
by percutaneous epidural spinal cord space stimulation, 
resulting in reproducible pleasurable genital stimulation, 
increased frequency of sexual activity and lubrication, and 
improved orgasmic function.
58 
Active neurostimulation could 
also increase the vaginal pulse amplitude with both erotic and 
non-erotic stimuli.
59 
Whether neurovascular changes 
proposed in the 4-theory complex to e xpla in associations 
between male LUTS and ED also apply for LUTD and female 




6 | ARE CHANGES IN SELF- IMAGE/ 
BODY IMAGE CONNECTED TO SD 
AND  LUTS   IN WOMEN? 
 
Body image problems are known to be associated with greater 
sexual problems. There are sparse data on correlations 
between self-image and SD in women with LUTS. Sexual 
function was found to be affected by body image perception 
in women with pelvic organ prolapse.
60 
In neurological 
conditions, the presence of an indwelling catheter had a 
negative impact on female se xuality and quality of life 
(QoL). Urinary tract reconstruction restored QoL and 
markedly improved SF by improving self-image, self-esteem, 
and the ability to cope.
61 
In women undergoing surgery for 
stress UI, the goals of improving se xuality and body image 
are predictors of post-treatment SF improve- 
ment,
62 
but there is still no available literature on the impact 
of  urgency or  mixed  UI  on  patients’  self-image,  and its 
possible associations with SF. The impact of using pads and 
diapers on patients’ self-image and SF has not been studied 
either. 
SUGGESTIONS FOR  RESEARCH 
 
Data concerning the (patho) physiology of female SF have 
largely been obtained from animal studies. Animal models 
used for the study of female se xual behavior and function 
include anesthetized models of nerve stimulation, chemically 
induced responses and electrical stimulation of the central 
nervous system, reproductive behavior models, and urogeni- 
tal reflex models for the study of orgasm.
63 
However, despite 
the use of a variety of models for the study of either FSD or 
LUTD, the two conditions have not been studied in a single 
model. In addition, the translational value of these models is 
unknown, as medical treatments of SD have mostly been 
evaluated in male models. Finally, it is questionable if anima l 
models could reproduce all or most parameters involved in 
the multifactorial pathophysiology of human FSD. 
Nevertheless, an increasing amount of novel evidence 
also comes fro m human studies. Researchers in the field have 
previously identified a xes for fu rther research: (i) se xual 
differentiation of the brain, as it affects behavioral sex 
differentiation; (ii) central neurobiology of se xua l function, 
using neuroimaging methods during arousaland orgasm; (iii) 
peripheral functional anatomy, in order to address genital 
arousal and orgasm aspects; (iv) interactions between 
physiological and psychological states of women's se xual 
response. In addition, more specific clinical aspects, such as 
associations between OAB/UI and SD, the effect of OAB/ UI 
treatment on SF, associations between self-image/body image 
and SD in women with LUTS/ UI could be further 





8  | COMMU NICAT ION 
 
The overriding discussion in the ICI-RS 2015 session was in 
relation to communication and understanding what patients 
actually want. This is not only in the context of how to 
approach the topic and talk about sexual behaviors but to 
gauge how many men and women actually see sexual 
dysfunction as a problem and have the desire for t reatment. In 
order to encourage good quality trials in the area, it is felt 
necessary to develop standardized terminology for se xual 
dysfunction as well as setting recommendations for outcomes 
measures to be used so that comparisons can be made. The 
education or lack thereof for all HCP's on SF and LUTS was 
raised as an issue that needs to be addressed in clinica l 
practice to enable appropriate care to be received by patients 
who ra ise concerns and express a desire for treatment but also 
so that HCP's do not ignore the issue because they do not 
know how to handle the information the patient has given. 





APOSTOLIDIS      ET AL. | 873 
 
TA BLE   1  Proposal  for  further  research   concerning  the associations 
between LUTD and sexual dysfunction in men and women 
1. Research priorities •  Development of standardized  terminology  for 
sexual  dysfunction  in men and women 
• Routine use of standardized outcome measures 
in  clinical trials 
• Qualitative study to understand what patients 
want in relation to discussion, assessment, and 
treatment (or not) of LUTS and sexual 
dysfunction 
2. Epidemiology •  What is the true prevalence  of the problem? 
Focus should be  on patients’ perspectives  and 
wishes in a changing world with respect to 
gender,  age,  and cultural environment 
3. Basic science •  Are  there reliable  animal models to study the 
multifactorial pathophysiology of human 
FSD? 
• Can  the 4-theory  complex of interrelations 
between LUTS and sexual dysfunction be 
explored in animal models and human studies 
in  both sexes? 
4. Clinical •  What are  the psychological impacts/ 
bothersomeness for the patient and for their 
partner? 
• How  does treatment  of  LUT D affect  sexual 
function  in men and women? 
5. Research •  How  can  we  control for  external factors/ 
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and hormonal factors, but a lso indirect effects may be linking 
LUTD to SD in both sexes, but the substantiation is still not 
robust and the mechanisms unclear. The main areas of 
research have been identified to provide better assessment 
and more appropriately targeted management. There is a need 
for defining  the  terminology  and  standardizing outcomes 
assessed in clinical trials. The multifactorial nature of SF in 
men and women makes trial design challenging and “real 
world ” studies may prove more beneficial for patients’ 
outcomes and clinicians’ understanding. 
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Ramsgate Road, Sandwich, Kent, CT13 9NJ 
Telephone:  +44  (0)1304 616 161 
Fax: +44 (0)1304 656  221 
Before you contact this company: often several companies will market medicines 
with the same active ingredient. Please check that this is the correct company before 
contacting them. Why? 
 
Summary of Product Characteristics last updated on the eMC: 04/04/2011 
 
TOVIAZ 4 mg prolonged-release tablets & TOVIAZ 8 mg prolonged- 
release tablets 
 This medicine is monitored intensively by the CHM and MHRA 
 
1. NAME OF THE MEDICINAL PRODUCT 
TOVIAZ 4  mg prolonged-release tablets 
TOVIAZ 8 mg  prolonged-release tablets 
2. QUALITATIVE AND QUANTITATIVE COMPOSITION 
Each 4mg prolonged-release tablet contains fesoterodine fumarate 4 mg corresponding to 3.1 mg of fesoterodine. Each 
8mg prolonged-release tablet contains fesoterodine fumarate 8  mg  corresponding  to  6.2  mg  of  fesoterodine.  
Excipients 
Each 4 mg prolonged-release tablet contains 0.525 mg of soya lecithin and 91.125 mg lactose monohydrate. Each 
8 mg prolonged-release tablet contains 0.525 mg of soya lecithin and 58.125 mg lactose monohydrate.  For a full 
list of excipients, see section  6.1. 
3. PHARMACEUTICAL FORM 
Prolonged-release tablets 
 
The 4 mg tablets are light blue, oval, biconvex, film-coated, and engraved on one side with the letters 'FS'. 
The 8 mg tablets are blue, oval, biconvex, film-coated, and engraved on one side with the letters 'FT'. 
4. CLINICAL PARTICULARS 
 
4.1 Therapeutic indications 
Treatment of the symptoms (increased urinary frequency and/or urgency and/or urgency incontinence) that may 
occur in patients with overactive  bladder syndrome. 
 
4.2 Posology and method of  administration 
 
 
Adults  (including elderly) 
 
The recommended starting dose is 4 mg once daily. Based upon individual response, the dose may be increased  
to 8 mg once daily. The maximum daily dose is 8 mg. 
 
Full treatment effect was observed between 2 and 8 weeks. Hence, it is recommended to re-evaluate the efficacy 
for the individual patient after 8 weeks  of treatment. 
 
Tablets are to be taken once daily with liquid and swallowed whole. TOVIAZ can be administered with or without 
food. 
 
In subjects with normal renal and hepatic function receiving concomitant administration of potent CYP3A4 












Renal  and  hepatic impairment 
 
The following table provides the daily dosing recommendations for subjects with renal or hepatic impairment in 
the absence and presence of moderate and potent CYP3A4 inhibitors (see sections 4.3, 4.4, 4.5 and 5.2). 
 
 
TOVIAZ is contraindicated in subjects with severe hepatic impairment (see section 
4.3).  Paediatric population 
TOVIAZ is not recommended for use in children and adolescents below 18 years of age due to lack of data on 
safety and efficacy (see section  5.2). 
 
4.3 Contraindications 
• Hypersensitivity to the active substance or to peanut or soya or any of the excipients 
 
• Urinary retention 
 
• Gastric retention 
 
• Uncontrolled narrow angle  glaucoma 
 
• Myasthenia gravis 
 
• Severe hepatic  impairment (Child Pugh C) 
 
• Concomitant use of potent CYP3A4 inhibitors in subjects with moderate to severe hepatic or renal impairment 
 
• Severe  ulcerative colitis 
 
• Toxic megacolon. 
 
4.4 Special warnings and precautions for use 
TOVIAZ should be  used  with  caution in patients with: 
 
- Clinically significant bladder outflow obstruction at risk of urinary retention (e.g. clinically significant prostate 
enlargement due to benign prostatic  hyperplasia,  see section 4.3) 
 
- Gastrointestinal obstructive  disorders  (e.g. pyloric stenosis) 
 
- Gastro-oesophageal reflux and/or who are concurrently taking medicinal products (such as oral 
bisphosphonates) that can cause  or exacerbate oesophagitis 
 
- Decreased  gastrointestinal motility 
 
- Autonomic neuropathy 
 
- Controlled  narrow-angle glaucoma 
Moderate(3)  or potent(4) CYP3A4 inhibitors 
None 













Should be avoided 
4 mg 
Should  be avoided 
Potent 
Should be avoided 
Contraindicated 
Contraindicated 
Should  be avoided 
Contraindicated 
(1) Mild GFR = 50-80 ml/min; Moderate GFR = 30-50 ml/min; Severe GFR = <30 ml/min 
(2)  Cautious dose increase. See sections 4.4, 4.5 and 5.2 
(3)  Moderate  CYP3A4 inhibitors. See section 4.5 










Caution should be exercised when prescribing or uptitrating fesoterodine to patients in whom an increased 
exposure to the active metabolite (see section 5.1) is expected: 
 
- Hepatic impairment (see sections 4.2, 4.3 and 5.2) 
 
- Renal impairment  (see section 4.2, 4.3 and 5.2) 
 
- Concomitant administration of potent or moderate CYP3A4 inhibitors  (see sections 4.2 and  4.5) 
 
- Concomitant administration of a potent CYP2D6 inhibitor (see  sections  4.5 and 5.2). 
 
In patients with a combination of these factors, additional exposure increases are expected. Dose dependent 
antimuscarinic side effects are likely to occur. In populations where the dose may be increased to 8 mg once 
daily, the dose increase should be preceded by an evaluation of the individual response and tolerability. 
 
As with all medicinal products indicated for the treatment of overactive bladder, organic causes must be excluded 
before any treatment with antimuscarinics is considered. Safety and efficacy have not yet been established in 
patients with  a neurogenic cause for detrusor overactivity. 
 
Other causes of frequent urination (treatment of heart failure or renal disease) should be assessed before 
treatment with fesoterodine. If urinary tract infection is present, an appropriate medical approach should be 
taken/antibacterial therapy should  be started. 
 
The concomitant use of fesoterodine with a potent CYP3A4 inducer (i.e. carbamazepine, rifampicin, 
phenobarbital, phenytoin, St John's Wort) is not recommended (see section 4.5). 
 
As with other antimuscarinics, fesoterodine should be used with caution in patients with risk for QT-prolongation 
(e.g. hypokalaemia, bradycardia and concomitant administration of medicines known to prolong QT interval) and 
relevant pre-existing cardiac diseases (e.g. myocardial ischaemia, arrhythmia, congestive  heart  failure),  (see 




TOVIAZ prolonged-release tablets contain lactose. Patients with rare hereditary problems of galactose 








Caution should be exercised in coadministration of fesoterodine with other antimuscarinic agents and medicinal 
products with anticholinergic properties (e.g. amantadine, tri-cyclic antidepressants, certain neuroleptics ) as this 
may lead to more pronounced therapeutic- and side-effects (e.g. constipation, dry mouth, drowsiness, urinary 
retention). 
 
Fesoterodine may reduce the effect of medicinal products that stimulate the motility of the gastro-intestinal tract, 




In vitro data demonstrate that the active  metabolite of fesoterodine does  not  inhibit CYP1A2,  2B6,  2C8,  2C9, 
2C19, 2D6, 2E1, or 3A4, or induce CYP1A2, 2B6, 2C9, 2C19, or 3A4 at clinically relevant plasma concentrations. 
Thus fesoterodine is unlikely to alter the clearance of medicinal products that are metabolised by these enzymes. 
 
CYP3A4  Inhibitors 
 
Potent  CYP3A4 Inhibitors 
 
Following inhibition of CYP3A4 by co-administration of ketoconazole 200 mg twice daily, Cmax and  AUC  of the 
active metabolite of fesoterodine increased 2.0 and 2.3-fold in CYP2D6 extensive metabolisers and 2.1 and 2.5- 
fold in CYP2D6  poor  metabolisers, respectively.  Therefore, the  maximum  dose  of  fesoterodine should  be 
restricted to 4 mg when used concomitantly with potent  CYP3A4 inhibitors  (e.g.  atazanavir, clarithromycin, 
indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir (and all ritonavir boosted PI-regimens), 
saquinovir and telithromycin  (see sections 4.2 and 4.4)). 
 










Following blockade of CYP3A4 by coadministration of the moderate CYP3A4 inhibitor fluconazole 200 mg twice a 
day for 2 days, Cmax and AUC of the active metabolite of fesoterodine increased approximately 19% and 27%, 
respectively. No dosing adjustments are recommended in the presence of moderate CYP3A4 inhibitors (e.g., 
erythromycin, fluconazole, diltiazem, verapamil and  grapefruit  juice). 
 
Weak  CYP3A4 Inhibitors 
 
The effect of weak CYP3A4 inhibitors (e.g. cimetidine), was not examined; it is not expected to be in excess of 




Following induction of CYP3A4 by coadministration of rifampicin 600 mg once a day, Cmax and AUC of the active 
metabolite of fesoterodine decreased by approximately 70% and 75%, respectively, after oral administration of 
fesoterodine  8 mg. 
 
Induction of CYP3A4 may lead to subtherapeutic plasma levels. Concomitant use with CYP3A4 inducers (e.g. 
carbamazepine, rifampicin, phenobarbital, phenytoin, St John's Wort) is not  recommended (see  section  4.4). 
 
CYP2D6  Inhibitors 
 
The interaction  with CYP2D6 inhibitors was  not tested clinically.  Mean Cmax and  AUC  of the active  metabolite are 
1.7 and 2-fold higher, respectively, in CYP2D6 poor metabolisers as compared to extensive metabolisers. Co- 
administration of a potent CYP2D6 inhibitor may result in increased exposure and adverse events. A dose 
reduction to 4 mg may be needed (see section 4.4). 
 
Oral  contraceptives 
 
Fesoterodine does not impair the suppression of ovulation by oral hormonal contraception. In the presence of 
fesoterodine there are no changes in the plasma concentrations of combined oral contraceptives containing 




A clinical study in healthy volunteers has shown that fesoterodine 8 mg once daily has no significant effect on the 
pharmacokinetics or the anticoagulant activity of a single dose of warfarin. 
 
4.6 Pregnancy and lactation 
Pregnancy 
 
There are no adequate data from the use of fesoterodine in pregnant women. Reproductive toxicity studies with 
fesoterodine in animals show minor embryotoxicity (see section 5.3). The potential risk for humans is unknown. 




It is not known whether fesoterodine is excreted into human milk; therefore, breast-feeding is not recommended 
during treatment  with TOVIAZ. 
 
4.7 Effects on ability to drive and use machines 
No studies on the effects on the ability to drive and use machines have been performed. As with other 
antimuscarinic agents, caution should be exercised when driving or using machines due to possible occurrence of 
side effects such as blurred vision, dizziness, and somnolence (see section 4.8). 
 
4.8 Undesirable effects 
 
 
The safety of fesoterodine was evaluated in placebo-controlled clinical studies in a total of 2859 patients with 
overactive bladder, of which 780  received placebo. 
 
Due to the pharmacological properties of fesoterodine, treatment may cause mild to moderate antimuscarinic 
effects  like dry mouth, dry eye, dyspepsia and constipation.  Urinary retention  may occur uncommonly. 
 
Dry mouth, the only very common event, occurred  with a frequency of 28.8% in the  fesoterodine group  
compared to 8.5% in the placebo group. The majority of ADRs occurred during the first month of treatment with  
the exception of cases classified as urinary retention or post void residual urine greater than 200 ml, which could 























The table below gives the frequency of treatment emergent adverse reactions from placebo-controlled clinical 
trials and from post-marketing experience. The adverse reactions reported in this table are those events that 
were very common ( 1/10), common ( 1/100 to  <1/10), uncommon ( 1/1,000 to <1/100) or rare ( D 
1/10,000  to < 1/1,000). 
 
Within each  frequency grouping,  undesirable effects are  presented  in  order  of decreasing seriousness. 
 
 
In clinical trials of fesoterodine, cases of markedly elevated liver enzymes were reported with the occurrence 
frequency no different from the placebo group. The relation to fesoterodine treatment is unclear. 
 
Electrocardiograms were obtained from 782 patients treated with 4 mg, 785 treated with 8 mg, 222 treated with   
12 mg fesoterodine and 780 with placebo.  The  heart  rate corrected  QT interval in fesoterodine treated patients 
did not differ from that seen in placebo treated patients. The incidence rates of QTc 500  ms post baseline or 
QTc increase of 60 ms is 1.9%, 1.3%, 1.4% and 1.5%, for fesoterodine 4 mg, 8 mg, 12 mg and placebo, 
respectively. The clinical relevance  of these  findings will depend on  individual patient  risk factors and 
susceptibilities present (see section 4.4). 
 
Post-marketing cases of urinary retention requiring catheterization have been described, generally within the first 
week of treatment with fesoterodine. They have mainly involved elderly ( 65 years) male patients with a 




Overdose with antimuscarinic agents,  including  fesoterodine  can  result  in  severe  anticholinergic  effects. 
Treatment should be symptomatic and supportive. In the event of overdose, ECG monitoring is recommended; 
standard supportive measures for managing QT prolongation should be adopted. Fesoterodine has been safely 
administered in clinical studies  at doses up to 28 mg/day. 
 
In the event of fesoterodine overdose, treat with gastric lavage and give activated charcoal. Treat symptoms as 
follows: 
 















Dizziness;  Headache   Dysgeusia; 
Somnolence 










































ALT increased; GGT 
increased 














− Convulsions or pronounced excitation: treat  with  benzodiazepines 
 
− Respiratory  insufficiency: treat  with artificial respiration 
 
− Tachycardia: treat  with beta-blockers 
 
− Urinary retention: treat  with catheterisation 
 
− Mydriasis: treat with pilocarpine eye drops and/or place patient in dark room. 
 
5. PHARMACOLOGICAL PROPERTIES 
 
5.1 Pharmacodynamic properties 
Pharmacotherapeutic group: Urinary antispasmodics,  ATC  code:  G04B  D11. 
 
Fesoterodine is a competitive, specific muscarinic receptor antagonist. It is rapidly and extensively hydrolysed by non-
specific plasma esterases to the 5-hydroxymethyl derivative, its primary active metabolite, which is the main active  
pharmacological principle  of fesoterodine. 
 
The efficacy of fixed doses of fesoterodine 4 mg and 8 mg was evaluated in two Phase 3 randomised, double-blind, 
placebo-controlled, 12-week studies. Female (79%) and male (21%) patients with a mean age of 58 years (range 19-
91 years) were included. A total of 33%  of patients were 65 years of age and 11% were 75  years of age. 
 
Fesoterodine treated patients had  statistically significant  mean  reductions  in the  number  of micturitions  per  24 
hours and in the number of urge incontinence episodes per 24 hours at the end of treatment compared to placebo. 
Likewise, the response rate (% of patients reporting that their condition has been “greatly improved” or “improved” 
using a 4-point Treatment  Benefit  Scale) was significantly greater with fesoterodine  compared to placebo. 
Furthermore, fesoterodine improved the mean change in the voided volume per micturition, and the mean change   




























#  primary end points 
 
Cardiac electrophysiology: The effect of fesoterodine 4 mg and  28  mg on  the  QT  interval  was  thoroughly 
evaluated in a double-blind, randomised, placebo- and positive-controlled (moxifloxacin 400 mg) parallel group 
study with once-daily treatment over a period of 3 days in 261 male and female subjects aged 45 to 65 years. 
Change from baseline in QTc based on the Fridericia correction method did not show any differences between the 
active treatment and placebo group. 
 
5.2 Pharmacokinetic properties 
Absorption 
 
After oral administration, due to rapid and extensive hydrolysis by non-specific plasma esterases, fesoterodine 
was not detected in plasma. 
 
Bioavailability of the active metabolite is 52%. After single or multiple-dose oral administration of fesoterodine in 
doses from 4 mg to 28 mg, plasma concentrations of the active metabolite are proportional to the dose. 
Maximum plasma levels are reached after approximately 5 hours. Therapeutic plasma levels are achieved after 




Plasma protein binding of the active metabolite is low with approximately 50% bound to albumin and alpha  1- 
acid glycoprotein. The mean steady-state volume of distribution following intravenous infusion of the  active 




After oral administration, fesoterodine is rapidly and extensively hydrolysed to its active metabolite. The active 
metabolite is further metabolised in the liver  to  its  carboxy,  carboxy-N-desisopropyl,  and  N-desisopropyl 
metabolite with involvement of CYP2D6 and CYP3A4. None of these metabolites contribute significantly to the 
antimuscarinic activity of fesoterodine. Mean Cmax and AUC of the active metabolite are 1.7 and 2-fold higher, 




Hepatic metabolism and renal excretion contribute significantly to the elimination of the active metabolite. After 
oral administration of fesoterodine, approximately 70% of the administered dose was recovered in urine as the 
active metabolite  (16%),  carboxy  metabolite  (34%),  carboxy-N-desisopropyl  metabolite  (18%),  or  N- 
desisopropyl metabolite (1%), and a smaller amount (7%) was recovered in faeces. The terminal half-life of the 
active metabolite following oral administration is approximately 7  hours and is  absorption  rate-limited. 
 
Age  and gender 
 
No dose adjustment is recommended in these subpopulations. The pharmacokinetics of fesoterodine are not 
significantly influenced by age and gender. 
 






The pharmacokinetics of fesoterodine have not been evaluated in paediatric 
patients.  Renal impairment 
In patients with mild or moderate renal impairment (GFR 30 – 80 ml/min), Cmax and AUC  of the active 
metabolite increased up to 1.5 and 1.8-fold, respectively, as compared to healthy subjects. In patients with 
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Hepatic  impairment 
 
In patients with moderate hepatic impairment (Child Pugh B), Cmax and AUC of the active metabolite increased 
1.4 and 2.1-fold, respectively, as compared to healthy subjects. Pharmacokinetics of fesoterodine in patients with 
severe hepatic impairment have not been  studied. 
 
 
5.3 Preclinical safety data 
In non-clinical  safety  pharmacology,  general  toxicity,  genotoxicity  and  carcinogenicity  studies  no  clinically 
relevant effects have been observed, except those related  to the  pharmacological effect of the active  substance. 
 
Reproduction studies have shown minor embryotoxicity at doses close to maternally toxic ones (increased 
number  of resorptions, pre-implantation and post-implantation  losses). 
 
Supratherapeutic concentrations of the active  metabolite of fesoterodine, have been shown to inhibit K+ current  
in cloned human ether-à-go-go-related gene (hERG) channels and prolong action potential duration  (70%  and 
90% repolarisation) in canine isolated Purkinje fibres. However in conscious dogs, the active metabolite had no 
effect on  the  QT interval and  QTc interval at plasma exposures at  least 33  fold higher than mean peak free 
plasma concentration in human subjects who are extensive metabolisers and 21  fold higher than measured in 
subjects who are poor CYP2D6 metabolisers after fesoterodine 8 mg once daily. 
 
6. PHARMACEUTICAL PARTICULARS 
 













Titanium dioxide (E171) 










6.3 Shelf life 
2 years 
 
6.4 Special precautions for storage 
Do not store above  25°C. 
 
Store in  the  original package  to protect from moisture. 
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TOVIAZ 4 mg tablets and TOVIAZ 8 mg tablets are packed in aluminium-aluminium blisters in cartons containing   
7, 14, 28, 56, 84, 98 or 100 tablets. In addition, TOVIAZ 4 mg and 8mg tablets are also packed in HDPE bottles 
containing  30 or 90 tablets. 
 
Not all pack  sizes  may be marketed. 
 
6.6 Special precautions for disposal and other handling 
Any unused  product  or  waste material should be disposed  of in accordance  with  local requirements. 
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A 12 week, single centre, open label study to evaluate the effect 
of fesoterodine flexible dosing regimen on the sexual function of 
women with overactive bladder. 
Protocol Summary 
 
Background and Rationale 
 
The Overactive bladder Syndrome (OAB) is the term used to describe the symptom 
complex of urinary urgency with or without urge incontinence, usually with 
frequency and nocturia1. It is reported that the prevalence of OAB in the general 
population is 14-16%2. OAB is a distressing problem that can seriously affect an 
individual’s quality of life by forcing them to alter their social, physical, occupational 
and sexual activities. Anticholinergic drugs (also known as antimuscarinics) are the 
mainstay of treatment for OAB symptoms. In the UK in 2007, 2.85 million 
prescriptions were written for anticholinergic drugs3. Fesoterodine fumarate is a 
new addition to this class of drug and is available as sustained release tablets in 
flexible dosing (4mg and 8mg). 
 
Several reports have shown the negative impact of OAB on sexual health. 
Rogers et al4 compared sexual function in women with and without urinary 
Incontinence (UI) and/or pelvic organ prolapse (POP) using a validated condition- 
Specific questionnaire, the Pelvic Organ Prolapse/Urinary Incontinence Sexual 
Questionnaire (PISQ), and concluded that PISQ scores were significantly lower 
among women with UI/POP than in those without (P = 0.003). Women 
with UI/POP have poorer sexual functioning, as measured by 
the PISQ, and report less frequent sexual activity. In addition, women with 
UI/POP are more likely to restrict sexual activity for fear of incontinence. Women 
with POP and UI are more likely to report decreased libido, decreased sexual 
excitement, and difficulty achieving orgasm during intercourse when compared to 
women with UI alone5. Yib et al6 showed that marital relationships and sexual 
function were negatively affected in women who had urinary stress incontinence 
(USI) or detrusor overactivity (DO). In a report to study the relation between 
different types of incontinence and sexual health, Urwitz-Lane7 showed that 
among sexually active women with urinary incontinence, sexual function as 





Some studies have reported that antimuscarinics have a positive impact  on 
sexual health. Hajebrahimi et al8 evaluated the impact of tolterodine IR on sexual 
function in patients with OAB. A total of 30 sexually active women with OAB from 
20 to 52 years were included. All patients filled out the International Consultation 
on Incontinence Questionnaire (ICIQ) and the Arizona Sexual Experience Scale 
(ASEX) before treatment and at the end of each month of treatment until 3 
months. The results showed an improvement in the mean total ASEX score 
relative to baseline at the first (P<0.01), second (P<0.01), and third (P<0.01) 
follow-ups. The mean scores for sexual desire, arousal, vaginal lubrication, 
orgasm, and orgasm satisfaction improved significantly (P<0.01) with each follow- 
up. They concluded that tolterodine IR significantly improves sexual function of 
women  with OAB.  Improvement  is seen  in  all  domains  of sexual  function.  In 
another report, Rogers et al9 evaluated the impact of extended release (ER) 
tolterodine on sexual health and anxiety scores in women with OAB. 413 women 
were randomised to either tolterodine ER or placebo. Assessments  used  
included bladder diaries, the Sexual Quality of Life Questionnaire – Female 
(SQOL-F), Pelvic Organ prolapse / Urinary Incontinence Sexual Questionnaire 
(PISQ) and the Hospital Anxiety and Depression (HAS) scale. Overall the study 
found that OAB symptoms improved with tolterodine ER as well as an 
improvement in the sexual health and anxiety scores. 
 
As fesoterodine is relatively new to the UK market there are currently no clinical 
trials looking at its impact on sexual function. This study is funded by an 
Investigator Initiated grant from Pfizer Ltd. 
 
 











The primary objective is to assess the impact on sexual function, of 12 weeks 





 To assess the use of flexible dosing of fesoterodine on micturition frequency 
per 24 hours, nocturnal micturitions per 24 hours, urinary urgency 
incontinence episodes per 24 hours and urgency episodes per 24 hours after 
12 weeks compared to baseline. 
 To assess the effect of flexible dose fesoterodine on treatment satisfaction 
and health related quality of life measure at 12 weeks compared to baseline. 
 To assess the tolerability of flexible dose fesoterodine in women with OAB. 
 To assess the impact of fesoterodine on bowel function. 
 
Primary Endpoint 
Change in item scores of the Pelvic Organ Prolapse and Urinary Incontinence 
Sexual Questionnaire – short form (PISQ-12) and the Sexual Quality of Life 




 Change in mean number of micturitions per 24hours at week 12 relative to 
baseline. 
 Change in mean number of nocturnal micturitions per 24 hours at week 12 
relative to baseline in subjects with >0 episodes during the 3-day baseline 
diary period. (Nocturnal micturitions are defined as those occurring between 
the time the subject goes to bed with the intention of sleeping and the time 
she rises to start the next day). 
 Percentage change in urinary urgency incontinence (UUI) episodes per 24 
hours at week 12 relative to baseline in subjects with >0 UUI episodes during 




 Change in mean number of urgency episodes per 24 hours at week 12 
relative to baseline. (Urgency episodes are defined as those with a Patient 
Perception of Intensity of Urgency Score (PPIUS) rating of ≥3 in the diary. 




Patient Perception of Bladder Condition (PPBC) 
 Change in PPBC at week 12 relative to baseline. 
 
King’s Health Questionnaire (KHQ) 
 Change in total score of each domain at week 12 relative to baseline. 
 
Patient Assessment of Constipation Quality of Life Questionnarie (PAC-QOL) 
 Change in total score of each domain at week 12 relative to baseline 
 
Self Assessment Goal Achievement Questionnaire (SAGA) 
 Achievement of patient orientated goals at 12 weeks relative to baseline. 
 
Assessments 
This is a single centre open label study which will aim to enter 130 female  subjects 
with OAB symptoms. The study will be carried out at  the  Urogynaecology 
department at King’s College Hospital, London. 
Sexual function and efficacy assessments will be evaluated via 3-day bladder 
diaries and questionnaires (KHQ, PISQ-12, SQoL, PAC-QoL, SAGA, PPBC). 




Subjects must meet all of the following inclusion criteria to be eligible for  enrolment 
into the trial. 




2. Overactive bladder symptoms (subject reported) for ≥3 months prior to 
screening visit according to ICS guidelines. 
3. Mean urinary frequency of ≥8 micturitions per 24 hours as verified by the 
screening bladder diary prior to baseline / Visit 2. 
4. Mean number of Urgency episodes ≥3 per 24 hours as verified by the 
screening bladder diary prior to baseline / Visit 2. 
5. Sexually active with a mean frequency of sexual activity ≥1 per week. 
6. Able and willing to complete the micturition bladder diaries and all trial related 
questionnaires, comply with scheduled clinic visits and clinical trial 
procedures. 
7. Capability of understanding and having signed the informed consent form 
after full discussion of the treatment and its risks and benefits. 
 
Exclusion Criteria 
Subjects presenting with any of the following will not be included in the trial. 
1. Any condition that would contraindicate the use of fesoterodine including, but 
not limited to: hyposensitivity to the active substance (fesoterodine fumarate) 
or any of the excipients, or to peanut or soya; urinary retention; gastric 
retention; uncontrolled narrow angle glaucoma; myasthesia gravis; moderate 
or severe hepatic impairment (Child Pugh C); severe renal impairment; 
severe ulcerative colitis; and toxic megacolon. 
2. Stage 3 or greater pelvic organ prolapse, defined as tissue protuding to or 
beyond the introitus in lithotomy position at rest (without increase in intra 
abdominal pressure). 
3. History of lower urinary tract surgery (eg. Incontinence surgery, 
diverticulectomy, OTIS urethrotomy) with the exception of any minor surgery 
(eg. Cystoscopic procedures). 
4. A known history of interstitial cystitis or a significant pain component 
associated with OAB symptoms, uninvestigated haematuria, urogenital 
cancer, interstitial or external radiation to the pelvis or external genitalia, or 
bladder outlet obstruction, radiation cystitis, genitor-urinary tuberculosis, 
bladder calculi, urethral obstruction or detrusor-sphincter dysynergia. 
5. Subjects with bladder stones. Subjects with a previous history of bladder 




6. Previous history of acute urinary retention requiring catheterisation, clinically 
relevant bladder outlet obstruction or severe voiding difficulties in the 
judgement of the investigator prior to Visit 2 (baseline). 
7. Use of an indwelling or an intermittent self-catheterisation programme. 
8. Symptoms of incontinence being predominantly stress urinary incontinence 
as determined by the investigator. 
9. Urinary tract infection (UTI) as shown by the results of the urinalysis at 
screening or recurrent urinary tract infections (RUTIs) defined as treatment 
for UTI ≥3 times in the last year. 
10. Use of any electrostimulation, bladder training, or pelvic floor exercises (with 
certified incontinence practitioners) within 4 weeks prior to Visit 1 
(Screening). 
11. Treatment with antimuscarinic OAB medication with 2 weeks prior to Visit 2 
(baseline), including any preparation containing: darifenacin, oxybutynin, 
propiverine, tolterodine, fesoterodine, solifenacin and trospium. 
12. Initiation of treatment during the 12 week trial period with: 
a. Any drug treatment for OAB 
b. Any drugs with significant anticholinergic, antispasmodic, 
parasympathetic, or cholinergic agonistic effects 
13. Intermittent or unstable use of diuretics or alpha blockers, or tricyclic 
antidepressants, oestrogen therapy and any 5AR inhibitors or initiation of 
such treatment(s) within 2 weeks prior to Visit 2 (baseline). 
14. Treatment with moderate or potent CYP3A4 inhibitors, such as grapefruit 
juice, macrolide antibiotics (erythromycin, clarithromycin), 
immunosuppressants (cyclosporine), azole antifungal agents (ketonazole, 
itraconazole), protease inhibitors within 3 weeks prior to Visit 2 (baseline), or 
the expectation to start such a treatment during the trial. 
15. Administration of medication capable of inducing hepatic enzyme 
metabolism or transport (eg barbiturates, rifampicin, carbemazipine, 
phenytoin, primidone, or St John’s Wort). 
16. Participated in any clinical trial or received an investigation drug within 4 
weeks prior to Visit 2. 





18. Female subjects who are pregnant, nursing, or who are intending to become 
pregnant during the trial or within three months after  the completion of the 
trial. 
19. Female subjects of childbearing potential who are heterosexually active but 
not using an adequate form of contraception. Reliable contraception 
methods defined as hormonal methods of contraception (including oral, 
patches, injected, implants, IUDs, condom with spermicidal 
foam/gel/film/cream/suppository, tubal ligation male partner who has had a 
vasectomy for a least 4 months. 
20. Subjects who have any medical (including known history of major 
haematological, renal, cardiovascular or hepatic abnormalities) or 
psychological condition or social circumstances that would impair their ability 
to participate reliably in the trial, or those who may increase the risk to 
themselves or others by participating. 
21. Has any current malignancy except 
a. Those ≥5 years ago without recurrence 
b. Excised basal cell skin carcinoma or squamous cell cancer 
22. Subjects who, in the opinion of the investigator, are not likely to complete the 
trial for any reason. 
 
Statistical Methods 
Wilcoxon Signed Ranks will be used to compare baseline and 12 week KHQ, Pac- 
QoL, SQoL and PISQ-12. 
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End of Tx 
Week 12 
(or early termination) 
(±7days) 
Written informed consent X X   
Demographics & Medical History  X   
Physical exam  X   
Inclusion / exclusion criteria  X   
Body mass index (BMI)  X   
Urine dipstick test and post void 
residual measurement 
 X   
Urine pregnancy test for women of 
child bearing potential 
 X  X 
Menopausal status  X  X 
PISQ-12  X  X 
SQoL  X  X 
PPBC  X  X 
KHQ  X  X 
PAC-QoL  X  x 
SAGA  X  X 
Dispense 3 day bladder diary & 
PPIUS 
X X X  
Evaluation of bladder diary & 
PPIUS 
 X X X 
Adverse events  X X X 
Concomitant medication and non 
drug treatment 
X X X X 
Dose assessment and titration   X  
Dispense study medication  X X  
Study medication return / count   X X 
Assess drug compliance   X X 
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1. Background & Rationale 
 
The Overactive bladder Syndrome (OAB) is the term used to describe the 
symptom complex of urinary urgency with or without urge incontinence, usually 
with frequency and nocturia1. It is reported that the prevalence of OAB in the 
general population is 14-16%2. OAB is a distressing problem that can seriously 
affect an individual’s quality of life by forcing them to alter their social, physical, 
occupational and sexual activities. Anticholinergic drugs (also known as 
antimuscarinics) are the mainstay of treatment for OAB symptoms. In the UK in 
2007, 2.85 million prescriptions were written for anticholinergic drugs3. 
Fesoterodine fumarate is a new addition to this class of drug and is available as 
prolonged release tablets in flexible dosing (4mg and 8mg). 
Several reports have shown the negative impact of OAB on sexual health. 
Rogers et al4 compared sexual function in women with and without Urinary 
Incontinence (UI) and/or pelvic organ prolapse (POP) using a validated condition- 
specific questionnaire, the Pelvic Organ Prolapse/Urinary Incontinence Sexual 
Questionnaire (PISQ), and concluded that PISQ scores were significantly lower 
among women with UI/POP than in those without (P = 0.003). Women 
with UI/POP have poorer sexual functioning, as measured by 
the PISQ, and report less frequent sexual activity. In addition, women with 
UI/POP are more likely to restrict sexual activity for fear of incontinence. Women 
with POP and UI are more likely to report decreased libido, decreased sexual 
excitement, and difficulty achieving orgasm during intercourse when compared to 
women with UI alone5. Yib et al6 showed that marital relationships and sexual 
function were negatively affected in women who had urinary stress incontinence 
(USI) or detrusor overactivity (DO). In a report to study the relation between 
different types of incontinence and sexual health, Urwitz-Lane7 showed that 
among sexually active women with urinary incontinence, sexual function as 
assessed by the PISQ-12 (shortened version of the PISQ) does not differ 
according to type of incontinence. 
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Some studies have reported that antimuscarinics have a positive impact  on sexual 
health. Hajebrahimi et al8 evaluated the impact of tolterodine Immediate Release 
(IR) on sexual function in patients with OAB. A total of 30 sexually active women 
with OAB from 20 to 52 years were included. All patients filled out the International 
Consultation on Incontinence Questionnaire (ICIQ) and the Arizona Sexual 
Experience Scale (ASEX) before treatment and at the end of each month 
of treatment until 3 months. The results showed an improvement in the mean total 
ASEX score relative to baseline at the first (P<0.01), second (P<0.01), and third 
(P<0.01) follow-ups. The mean scores for sexual desire, arousal, vaginal 
lubrication, orgasm, and orgasm satisfaction improved significantly (P<0.01) with 
each follow-up. They concluded that tolterodine  IR significantly improves  sexual 
function of women with OAB. Improvement is seen in all domains of sexual 
function. In another report, Rogers et al9 evaluated the impact of  extended release 
(ER) tolterodine on sexual health and anxiety scores in women with  OAB.    413  
women  were  randomised  to  either  tolterodine  ER  or  placebo. 
Assessments used included bladder diaries, the Sexual Quality of Life 
Questionnaire – Female (SQOL-F), Pelvic Organ prolapse / Urinary Incontinence 
Sexual Questionnaire (PISQ) and the Hospital Anxiety and Depression (HAD) 
scale. Overall the study found that OAB symptoms improved with tolterodine ER 
as well as an improvement in the sexual health and anxiety scores. However, 
improvements in sexual function were not the primary outcomes for these  studies. 
Fesoterodine is a relatively new antimuscarinic to the UK market and there are 
currently no clinical trials looking at its impact on sexual function. 
This trial will be conducted in compliance with the principles of the Declaration of 
Helsinki and the principles of-GCP. The protocol has been submitted for  approval 
by an NHS Research Ethics Committee (REC). 
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2 Trial Objectives and Design 
 
2.1. Trial Objectives 
 
Null Hypothesis 
Fesoterodine has no effect on sexual function in women complaining of 
overactive bladder syndrome. 
 
Primary Objective 
The primary objective is to assess the impact on sexual function, after 12 




 To assess the use of flexible dosing of fesoterodine on micturition 
frequency per 24 hours, nocturnal micturitions per 24 hours, urinary 
urgency incontinence episodes per 24 hours and urgency episodes per 
24 hours after 12 weeks compared to baseline. 
 To assess the effect of flexible dose fesoterodine on treatment 
satisfaction and health related quality of life measure at 12 weeks 
compared to baseline. 
 To assess the tolerability of flexible dose fesoterodine in women with 
OAB. 
 To assess the impact of fesoterodine on bowel function. 




Change in item scores of the Pelvic Organ Prolapse and Urinary Incontinence 
Sexual Questionnaire – short form (PISQ-12) and the Sexual Quality of Life 
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 Change in mean number of micturitions per 24hours at week 12 relative 
to baseline. 
 Change in mean number of nocturnal micturitions per 24 hours at week 
12 relative to baseline in subjects with >0 episodes during the 3-day 
baseline diary period. (Nocturnal micturitions are defined as those 
occurring between the time the subject goes to bed with the intention  of 
sleeping and the time she rises to start the next day). 
 Percentage change in urinary urgency incontinence (UUI) episodes per 
24 hours at week 12 relative to baseline in subjects with >0 UUI 
episodes during the 3-day baseline diary period. 
 Change in mean number of urgency episodes per 24 hours at week 12 
relative to baseline. (Urgency episodes are defined as those with a 
Patient Perception of Intensity of Urgency Score (PPIUS) rating of ≥2  in 
the diary. 
 Percentage change in urgency episodes per 24 hours at week 12 
relative to baseline. 
 
Subtracted Cystometry (in forty subjects only) 
 Change in first sensation 
 Change in maximum cystometric capacity 
 Change in time to first detrusor contraction 
 Presence of detrusor overactivity 
 
Patient Questionnaires 
Patient Perception of Bladder Condition (PPBC) 
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 Change in PPBC at week 12 relative to baseline. 
 
King’s Health Questionnaire (KHQ) 
 Change in total score of each domain at week 12 relative to baseline. 
 
Patient Assessment of Constipation Quality of Life Questionnaire (PAC-QOL) 
 Change in total score of each domain at week 12 relative to baseline 
 
Self Assessment Goal Achievement Questionnaire (SAGA) 





2.2 Trial Design 
 
This is a multi centre open label study which will aim to enter 132 female 
subjects with OAB symptoms. The study will be carried out at the 
Urogynaecology department at King’s College Hospital, London and St. Mary’s 
Hospital, Paddington, Medway Maritime Hospital, Kent and Croydon University 
Hospital, London. 
Sexual function and efficacy assessments will be evaluated via 3-day bladder 
diaries, questionnaires (KHQ, PISQ-12, SQoL, PAC-QoL, SAGA, PPBC) and 
urodynamics. Tolerability and safety will be evaluated at every visit with 
recording of adverse events. 

























Visit 3 End 














X     
Demographics & 
Medical History 
X     
Physical exam X     
Inclusion / 
exclusion criteria 
X X    
Body mass index 
(BMI) 
X     
Urine dipstick test and post void 
residual 
measurement 
X     
Urine pregnancy test for women of 
child bearing 
potential 
X   X  
Menopausal 
status 
X   X  
PISQ-12  X  X  
SQoL  X  X  
PPBC  X  X  
KHQ  X  X  
PAC-QoL  X  X  
SAGA  X  X  
Dispense 3 day 
bladder diary & PPIUS 
X X X   
Evaluation of 
bladder diary & PPIUS 
 X X X  
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  X   
Dispense study 
medication 
 X X   
Study medication 
return / count 
  X X  
Subtracted 
cystometry 





  X X x 
Assess treatment 
continuation 





3 Trial Medication 
 
3.1 Investigational Medicinal Product 
Fesoterodine fumarate is an antimuscarinic agent developed for the treatment of the 
symptoms that may occur in patients with OAB syndrome. Fesoterodine was granted a 
marketing authorization in Europe in May 2007. It is manufactured and supplied by Pfizer 
Ltd. 
 
The study drug will be supplied in two different strengths as described below: 
 
 
 Fesoterodine fumarate prolonged release 4mg tablets 
 Fesoterodine fumarate prolonged release 8mg tablets 
Festerodine commercial stock will be ordered in and used for trial patients. 








































3.2 Dosing Regimen 
 
The study drug will be dispensed according to the following schedule: 
Visit 2 (Week 0) – 28 tabs of  4mg tablets 
Visit 3 (Week 4) –56 tabs of 4mg tablets or 56 tabs of 8mg tablets, depending on 
the dose selection for each individual subject at this visit (based upon a discussion 
between the subject and the investigator of the efficacy  and tolerability reported 
by the subject, the investigator will either increase the dose  to 8mg for those 
subjects who desire greater symptom improvement and report good tolerability, or 
will continue the subject on the 4mg dose for the remaining 8 weeks of the study). 
 
No dose adjustments will be allowed after visit 3 during the last eight weeks of the 
treatment phase. 
 
One tablet should be taken with water at approximately the same time every day. 
It should be swallowed whole without chewing. Fesoterodine can be  administered 
with or without food. 
 
3.3 Drug Accountability 
All Investigational Medicinal Product (IMP) supplies will be stored in accordance 
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with applicable regulatory requirements. 
 
The investigator will be responsible for recording the receipt, administration and 
return of all trial medication, and for ensuring the supervision (via the hospital 
pharmacy) of the storage and allocation of trial medication. A complete inventory 
will be performed of the trial medication upon delivery to the site. 
 
Overall IMP accountability logs will be completed during the trial. The subject must 
return all trial medication, whether full, partially full or empty, to the investigator and 
the investigator must retain these packs at the site until accountability has been 
completed. At the end of the trial excess IMP will be destroyed and adequately 
documented. 
 
3.4 Subject Compliance. 
Subjects must be informed by the investigator that it is extremely important to take 
their daily study medication as instructed. Subjects will return all medication packs 
at Visits 3 and 4 and compliance assessed.  The investigator will  review the 
amount of unused medication and assess whether this is consistent with the 
dosing instructions and the time between visits. The investigator will record the 
number of doses missed or extra doses taken and the reasons why directly into 
the CRF if this information is available. 
Lack of study compliance is defined as one or more of the following: 
 
 Less than 80% or greater than 120% study medication compliance 
 
If the tablet count of the returned medication indicates that the subject has not 
taken all prescribed study drug, the subject should be counselled about the 
importance of compliance and how to take study medication. 
If the subject has been non-compliant in any area defined above, the subject’s 
participation in the study should be re-evaluated. 













3.5 Concomitant Medication 
All medications with the exceptions of those listed below will be permitted concurrently 
with the study medication. If a patient needs to start one of the excluded medications 
during the study they will be withdrawn. 
1. Treatment with antimuscarinic OAB medication within 2 weeks prior to 
Visit 2 (baseline), including any preparation containing: darifenacin, 
oxybutynin, propiverine, tolterodine, fesoterodine, solifenacin and 
trospium. If any of these preparations are started during the study the 
patient will be withdrawn. 
2. Initiation of treatment during the 12 week trial period with: 
 
a. Any other drug treatment for OAB including all the 
antimuscarinics listed in point 1 
b. Any drugs with significant anticholinergic, antispasmodic, 
parasympathetic, or cholinergic agonistic effects 
3. Intermittent or unstable use of diuretics or alpha blockers, or tricyclic 
antidepressants, oestrogen therapy and any 5AR inhibitors or initiation 
of such treatment(s) within 2 weeks prior to Visit 2 (baseline) or during 
the study. 
4. Treatment with moderate or potent CYP3A4 inhibitors, such as grapefruit 
juice, macrolide antibiotics (erythromycin, clarithromycin), 
immunosuppressants (cyclosporine), azole antifungal agents 
(ketonazole, itraconazole), protease inhibitors within 3 weeks prior to 
Visit 2 (baseline), or the expectation to start such a treatment during the 
trial. 
5. Administration of medication capable of inducing hepatic enzyme 
metabolism or transport (eg. rifampicin, carbamazepine, phenobarbital, 
phenytoin, or St John’s Wort) at any point during the study or within the 
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6 weeks prior to Visit 2 (baseline). 
 
6. Treatment with potent CYP2D6 inhibitors such as bupropion,  cinacalcet, 
fluoxetine, paroxetine or quinine at any point during the study 
 
4 Selection and Withdrawal of Subjects 
4.1 Inclusion Criteria 
Subjects must meet all of the following inclusion criteria to be eligible for 
enrolment into the trial. 
1. Female outpatients aged 18 – 80 years. 
2. Overactive bladder symptoms (subject reported) for ≥3 months prior to 
screening visit according to ICS guidelines. 
3. Mean number of Urgency episodes ≥3 per 24 hours as verified by the 
screening bladder diary prior to baseline / Visit 2. 
4. Sexually active 
5. Able and willing to complete the micturition bladder diaries and all trial 
related questionnaires, comply with scheduled clinic visits and clinical 
trial procedures. 
6. Capability of understanding and having signed the informed consent form 
after full discussion of the treatment and its risks and benefits. 
7. Able to speak, read and write in English. 
 
 
4.2 Exclusion Criteria 
Subjects presenting with any of the following will not be included in the trial. 
1. Any condition that would contraindicate the use of fesoterodine including, 
but not limited to: hyposensitivity to the active substance (fesoterodine 
fumarate) or any of the excipients, or to peanut, lactose or soya; urinary 
retention; gastric retention; uncontrolled narrow angle glaucoma; 
myasthesia gravis; moderate or severe hepatic impairment; severe renal 
impairment; severe ulcerative colitis; and toxic megacolon. 
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2. Stage 3 or greater pelvic organ prolapse, defined as tissue protuding to 
or beyond the introitus in lithotomy position at rest (without increase in 
intra abdominal pressure). 
3. History of lower urinary tract surgery (eg. Incontinence surgery, 
diverticulectomy, OTIS urethrotomy) with the exception of any minor 
surgery (eg. Cystoscopic procedures). 
4. A known history of interstitial cystitis or a significant pain component 
associated with OAB symptoms, uninvestigated haematuria, urogenital 
cancer, interstitial or external radiation to the pelvis or external genitalia, 
or bladder outlet obstruction, radiation cystitis, genitor-urinary 
tuberculosis, bladder calculi, urethral obstruction or detrusor-sphincter 
dysynergia. 
5. Subjects with bladder stones. Subjects with a previous history of bladder 
stones may be included. 
6. Previous history of acute urinary retention requiring catheterisation, 
clinically relevant bladder outlet obstruction or severe voiding difficulties 
in the judgement of the investigator prior to Visit 2 (baseline). 
7. Use of an indwelling or an intermittent self-catheterisation programme. 
8. Symptoms of incontinence being predominantly stress urinary 
incontinence as determined by the investigator. 
9. Urinary tract infection (UTI) as shown by the results of the urinalysis at 
screening or recurrent urinary tract infections (RUTIs) defined as 
treatment for UTI ≥3 times in the last year. 
10. Use of any electrostimulation, bladder training, or pelvic floor exercises 
(with certified incontinence practitioners) within 4 weeks prior to Visit 1 
(Screening). 
11. Treatment with antimuscarinic OAB medication with 2 weeks prior to Visit 
2 (baseline), including any preparation containing: darifenacin, 
oxybutynin, propiverine, tolterodine, fesoterodine, solifenacin and 
trospium. 
12. Initiation of treatment during the 12 week trial period with: 









EudraCT Number – 2010-023851-27 
 
 
a. Any other drug treatment for OAB 
b. Any drugs with significant anticholinergic, antispasmodic, 
parasympathetic, or cholinergic agonistic effects 
13. Intermittent or unstable use of diuretics or alpha blockers, or tricyclic 
antidepressants, oestrogen therapy and any 5AR inhibitors or initiation 
of such treatment(s) within 2 weeks prior to Visit 2 (baseline). 
14. Use of potent CYP3A4 inhibitors, such as grapefruit juice, macrolide 
antibiotics (erythromycin, clarithromycin), immunosuppressants 
(cyclosporine), azole antifungal agents (ketonazole, itraconazole), 
protease inhibitors within 3 weeks prior to Visit 2 (baseline), or the 
expectation to start any during the trial. 
15. Administration of medication capable of inducing hepatic enzyme 
metabolism or transport (eg rifampicin, carbamazepine, phenytoin, 
phenobarbital, or St John’s Wort) at any point in the study or within the  6 
weeks prior to Visit 2 (baseline). 
16. Treatment with potent CYP2D6 inhibitors such as bupropion,  cinacalcet, 
fluoxetine, paroxetine or quinine at any point during the study 
17. Participated in any interventional clinical trial or received an 
investigational drug within 4 weeks prior to Visit 2. 
18. History of alcohol abuse and /or any other drug in the opinion of the 
investigator. 
19. Female subjects who are pregnant, nursing, or who are intending to 
become pregnant during the trial or within three months after the 
completion of the trial. 
20. Female subjects of childbearing potential who are heterosexually active 
but not using an adequate form of contraception. Reliable  contraception 
methods defined as hormonal methods of contraception (including oral, 
patches, injected, implants, IUDs, condom with spermicidal 
foam/gel/film/cream/suppository, tubal ligation male partner who has had 
a vasectomy for a least 4 months). 
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21. Subjects who have any medical (including known history of major 
haematological, renal, cardiovascular or hepatic abnormalities) or 
psychological condition or social circumstances that would impair their 
ability to participate reliably in the trial, or those who may increase the 
risk to themselves or others by participating. 
22. Has any current malignancy except 
c. Those ≥5 years ago without recurrence 
d. Excised basal cell skin carcinoma or squamous cell cancer 
23. Subjects who, in the opinion of the investigator, are not likely to complete 
the trial for any reason. 




4.3 Selection of Participants 
Patients will be recruited from the urogynaecology clinics at King’s College 
Hospital NHS Foundation Trust and St. Mary’s Hospital (Imperial College 
Healthcare NHS Trust) and referred from Guy’s and St Thomas’ NHS Foundation 
Trust. These clinics include general outpatients, urodynamics and nurse led clinics. 
All patients that enter the trial will have had urodynamics performed as part of their 




4.4 Randomisation Procedure / Code Break 
 
No randomisation will take place in this study therefore there will be no need for a 
code break procedure. Subjects who meet all the inclusion and exclusion criteria 
listed will be administered the trial treatment. 
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4.5 Withdrawal of Subjects 
The investigator may decide to take the subject out of the study if: 
 They do not follow the directions of the study doctor
 They develop a serious illness that is not related to taking part in the study
 The investigator decides that the study is not in the subjects best interest
 Regulatory Authorities, or Research Ethics Committee, decide to stop the study
 They become pregnant, intend to become pregnant, or are breast-feeding a child 
during this study
 If there are compliance issues
 If the subject withdraws consent
 If subjects no longer meet the inclusion / exclusion criteria
 
If subjects are taken out of the study they may undergo some tests if they consent to do 
so. These include: 
 A completed bladder diary will be collected and evaluated
 Sitting blood pressure and pulse rate will be measured
 Women of child bearing potential will need to provide a sample of urine for a 
pregnancy test
 Subjects will be asked to complete 6 questionnaires which will take approximately 30 
minutes
 Subjects will be asked if they have had any new symptoms or worsening of existing 
symptoms and if they have taken any new medication or treatments since their last 
visit.
 The investigator will review the amount of unused study medication the subject has 




4.6 Expected Duration of Trial. 
Participants will be receive active treatment in the trial for 12 weeks and will then 
have a telephone follow up at 24 weeks. The end of the trial is defined as the  last 
patient last visit. 













5 Trial Procedures 
5.1 By Visit 
If the subject agrees to take part in this study, after signing the informed consent form, 
the following tests will be carried out to determine whether they are eligible to take part 
in this study. 
 
Visit 1 (Screening visit) 
At the screening visit: 
 Weight, medical history (including any medication and non-drug treatment) and 
demography will be taken.
 Sitting blood pressure and pulse will be taken
 A physical examination will be conducted by a physician
 subjects will provide a sample of urine for the following-:
- A urine dipstick test will be performed on a sample of urine to exclude blood 
and infection 
- A urine pregnancy test for women of child bearing potential will be performed 
 Subjects will be issued with a 3-day bladder diary to complete and provided with 
instructions on how and when to complete the diary. The diary is provided for them 
to record details of the number of times they pass urine and related information and 
the completed diary will be collected at the next visit. The diary should be completed 
for the three (3) days prior to the next visit.
 Subjects will be provided with a questionnaire (SAGA) to help identify and help the 
study team understand what they would like to achieve in regards to their bladder 
conditions. They will also be provided with instructions on how to complete the 
questionnaire. Subjects will be able to review this at home and either complete this 
at home or complete it at the next visit.
 
If subjects meet all of the study entry requirements at this point and they agree to 
participate in the study, the clinic/research staff will ask them to return for Visit 2 (baseline 
visit). 













A patient card will be provided to the subjects to act as an appointment reminder which 
will also include emergency contact details of the research team. 
 
Visit 2 (Week 0) (Baseline) 
At this visit, following assessment of eligibility by a delegated physician , subjects will be 
informed whether they are eligible to take part in this study. If they are eligible and still 
wish to participate, the next step is for them to have the baseline visit. Visits 1 and 2 can 
be combined if patients have completed a bladder diary as part of routine care and have 
received a patient information leaflet at least 48 hours prior to the appointment. In these 
cases, data from routine care prior to completion of a consent form may be used. 
 
At the baseline visit-: 
 A completed bladder diary will be collected and evaluated
 Subjects will be asked to complete 6 questionnaires which will take approximately 30 
minutes (These can be completed at home if preferred)
 Subjects will be asked if they have had any new symptoms or worsening of existing 
symptoms and if they have taken any new medication or treatments since the last 
visit.
 Subjects will be given another 3-day diary (plus instructions) to complete the three 
days prior to the next visit (visit 3). The completed diary will be collected at the next 
visit.
 Subjects will be given a supply of IMP (fesoterodine 4mg) to take once a day at 
approximately the same time each day over the next 4 weeks.
 
Visit 3 (Week 4) 
Four (4) weeks later subjects will return for visit 3. During this visit: 
 A completed bladder diary will be collected and evaluated.
 Subjects will be asked if they have had any new symptoms or worsening of 
existing symptoms and if they have taken any new medication or treatments since 
their last visit.
 The investigator will review the amount of unused study medication subjects have
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returned to assess compliance. 
 Subjects will be given another 3-day diary (plus instructions) to complete the three 
days prior to the next visit (visit 4). The completed diary will be collected at the 
next visit.
 The dose of IMP will be reviewed by the study doctor and if applicable the dose 
maybe increased and recorded in notes and CRF.
 Subjects will be given a supply of IMP either fesoterodine 4 mg or fesoterodine 8 
mg depending on discussions with the investigator.
 
Visit 4 (Week 12 End of Treatment or Early Termination Visit) 
Eight (8) weeks later subjects will return for visit 4. During this visit: 
 A completed bladder diary will be collected and evaluated
 Women of child bearing potential will need to provide a sample of urine for a 
pregnancy test
 Subjects will be asked to complete questionnaires which will take approximately 30 
minutes (These can be completed at home prior if preferred).
 Subjects will be asked if they have had any new symptoms or worsening of existing 
symptoms and if they have taken any new medication or treatments since their last 
visit.
 The investigator will review the amount of unused study medication subjects have 
returned to assess compliance. .
 For those women who have consented to having urodynamics they will undergo 
subtracted cystometry at this visit. (This will only be for the first 40 subjects in the 
trial who consent to having subtracted cystometry performed at week 12)
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Telephone Follow UP (24 Weeks) 
 Subjects will be asked if they are still taking fesoterodine (as prescribed by their 
GP) or if they are taking any other anticholinergic medication or no therapy. 
 If subjects have decided to stop all therapy they will be asked to explain their 
decision for this. 
 Subjects will be asked if they have experienced any adverse events on 
completion of the trial. 
 
Unscheduled Visits 
During the course of the study subjects might have an additional visit for safety related 
issues. At this visit the following will be performed: 
• Sitting blood pressure and pulse rate will be measured 
• Subjects will be asked if they have had any new symptoms or worsening of existing 
symptoms and if they have taken any new medication or treatments since their last 
visit. 
• The investigator will review the amount of unused study medication the subject has 
returned to assess whether this has been taken correctly. 
 
5.2 Safety Monitoring - Laboratory Tests 
A urine dipstick test for red blood cells, white blood cells, glucose, protein and nitrites 
will be performed by the investigator on site at the screening visit for trial qualification. 
 
A urine pregnancy test (B-hCG) will be performed by the investigator on site at the 
screening visit for women of child bearing potential for trial qualification and at Visit 4. 
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6 Assessment of Efficacy 
 
6.1.1 Primary Efficacy Parameters 
Prolapse and Incontinence Sexual Quality of Life Questionnaire (PISQ-
12) PISQ-12 is a self administered questionnaire consisting of 12 items. 
Sexual Quality of Life Questionnaire (SQoL) 
 
SQoL consists of a set of 18 statements, each asking about thoughts and 
feelings that subjects may have about their sex life. The statements may 
be positive or negative.  Subjects respond on a 6-point Likert scale 
ranging from completely agree to completely disagree.  It will be 
administered at visit 2 and 4. 
 
 
6.1.2 Secondary Efficacy Parameters 
Bladder Diary 
 
Each subject will complete a bladder diary for 3 consecutive days immediately 
preceding each clinic visit to record details of micturitions (frequency, urgency, 
urgency urinary incontinence) as follows: 
 Time arose and time went to bed 
 
 Time of every micturition 
 
 Volume of every micturition 
 
 The subject will rate their feeling of urgency associated with each micturition 
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Patient Perception of Bladder Condition (PPBC) 
 
PPBC is a self administered, single item, validated questionnaire that asks 
subjects to describe their perception of their bladder related problems. The  PPBC 
will be administered at Visit 2 and 4. 
 
 
King’s Health Questionnaire (KHQ) 
 
The KHQ is a self administered questionnaire containing 21 questions that are 
scored in nine domains (general health perception, incontinence impact, role 
limitations, physical limitations, social limitations, personal relationships, emotions, 
sleep/energy, severity of urinary symptoms). It will be administered at visit 2 and 4 
 
Patient Assessment of Constipation Quality of Life (PAC-QoL) 
 
A self administered questionnaire containing 28 items group into 4 subscales 
covering worries and concerns, physical discomfort, psychosocial discomfort and 
satisfaction. Responses are measured on a five point likert scale. It will be 
administered at visit 2 and 4. 
 
Self Assessment Goal Acheivement Questionnaire (SAGA) 
 
The SAGA questionnaire is a patient completed, physician reviewed tool to assess 
treatment goals and achievement of goals for subjects suffering from OAB and/or 
other urinary tract symptoms. The SAGA questionnaire is comprised of 2 parts. 
 
 
The first SAGA assessment questionnaire will be provided to the subject at the end 
of screening visit, when the investigator should take time to explain the 
questionnaire. It rates the importance to the subject of her treatment goals. It 
contains 9 fixed goals and a further 5 open ended goals. The subject should 
complete the questionnaire at home prior to the baseline visit, prior to interacting  
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with the investigator. At visit 2, the subject and the investigator should review the 
competed questionnaire in order to assess whether the goals are realistic. If 
necessary, the investigator may explain to the subject that her goals are unrealistic 
and the subject must adjust/revise her selections before the questionnaire is 
finalised at visit 3. 
 
 
The second part will be provided to the subject along with their SAGA first 
assessment (for reference). SAGA follow up questionnaire asks the subject to rate 
the degree of achievement of the subjects treatment goals set at the beginning of 
the treatment. There is also a one item measure relating to subjects rating the 
extent to which they have achieved all their goals set. It should be completed as 
the first activity of the final visit, prior to any interaction between the 
subject and the investigator.















Subtracted Cystometry (Urodynamics) 
Subtracted cystometry  measures the relationship between the detrusor pressure 
 
and bladder volume on filling and between the detrusor pressure and urine flow 
rate on voiding. During the procedure a pressure line and filling catheter are 
inserted into the bladder and a pressure line into the rectum (or vagina) and the 
bladder is filled with saline. Any changes of pressure in the bladder are recorded 
during this time. Once the bladder is full the filling catheter is removed. Patients 
may be asked to perform a cough provocation test to assess for stress 
incontinence and provoked detrusor overactivity . Finally patients will void into a 
flowmeter to assess the pressures within their bladder as they void. The test takes 
approximately 15 minutes. 
This test will be performed at Visit 4 in the first forty subjects who have consent ed 
to this assessment. For all trial participants after this they will not have subtracted 
cystometry but will follow all other trial procedures. All patients entering the trial will 
have already had this procedure completed as part of their standard medical 
investigation. The data from this previous test for the forty patients will be used to 







6.2 Procedures for Assessing Efficacy Parameters 
The investigator will review all of the completed questionnaires with the subjects 
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to ensure that they have been completed correctly. 
 
The investigator will perform the subtracted cystometry on the sub group of 
women. The standard department protocol will be followed for all patients and the 




6 Assessment of Safety 
 
6.1 Specification, Timing and Recording of Safety Parameters. 
A physical examination will be performed at the screening visit for assessment of 
trial qualification. Collection and reporting of AE will start following the first dose of 
the IMP until the last dose of the trial medication. Reporting of SAE’s will continue 
until 28 days after stopping trial medication. 
 
 
6.2 Procedures for Recording and Reporting Adverse Events 
 
The Medicines for Human Use (Clinical Trials) Regulations 2004 and Amended 
Regulations 2006 gives the following definitions: 
 
Adverse Event (AE): Any untoward medical occurrence in a subject to whom a 
medicinal product has been administered including occurrences which are not 
necessarily caused by or related to that product. 
Adverse Reaction (AR): Any untoward and unintended response in a subject to 
an investigational medicinal product which is related to any dose administered to 
that subject. 
Unexpected Adverse Reaction (UAR): An adverse reaction the nature and 
severity of which is not consistent with the information about the medicinal product 
in question set out in: 
The  summary  of product characteristics (SmPC)  for  that product (for 
products with a marketing authorisation) 
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The Investigator's Brochure (IB) relating to the trial in question (for any 
other investigational product) 
 
Serious adverse Event (SAE), Serious Adverse Reaction (SAR) or 
Unexpected Serious Adverse Reaction (USAR): Any adverse event, adverse 
reaction or unexpected adverse reaction, respectively, that 
Results in death; 
Is life-threatening; 
Required hospitalisation or prolongation of existing hospitalisation; 
Results in persistent or significant disability or incapacity; 
Consists of a congenital anomaly or birth defect. 
Important medical events that may not be immediately life-threatening or result in 
death or hospitalisation but may jeopardise the patient or may require intervention 
to prevent one of the other outcomes listed in the definition above should also be 
considered serious. 
 
Although not a serious adverse event, any unplanned pregnancy will also be 




King’s College Hospital NHS Foundation Trust as sponsor has delegated the 
delivery of the Sponsor’s responsibility for Pharmacovigilance (as defined in 
Regulation 5 of the Medicines for Human Use (Clinical Trials) Regulations 2004 to 
the King’s Health Partners Clinical Trials Office (KHP-CTO). All reports of SAEs, 
SARs and SUSARs will be reviewed and signed by the Medical Investigator, for 
seriousness and causality. 
 
 
All SAEs, SARs and SUSARs (excepting those specified in this protocol as not 
requiring reporting) will be reported immediately by the Chief Investigator to the 
(KHP-CTO) in accordance with the current Pharmacovigilance Policy. 
 
 
The  KHPCTO  will  report  SUSARs  (Suspected  Unexpected  Serious  Adverse 
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Reactions) and other SARs to the regulatory authorities (MHRA, competent 
authorities of other EEA (European Economic Area) states in which the trial is 
taking place. 
The Chief Investigator will report to the relevant ethics committees. Reporting 
timelines are as follows: 
 SUSARs which are fatal or life-threatening must be reported not later than 7 
days after the sponsor is first aware of the reaction. Any additional relevant 
information must be reported within a further 8 days. 
 SUSARs that are not fatal or life-threatening must be reported within 15 days 
of the sponsor first becoming aware of the reaction. 
 The Chief Investigator will provide a Development Safety Update Report 
(DSUR) which will be distributed to the KHP-CTO (on behalf of the sponsor), 
MHRA and the REC. 
 
 
6.3 Treatment Stopping Rules 












This is an open label study and no blinding will take place. There is no evidence to 
suggest selection or performance bias as all participants will initially be assigned 
the same dose of medication for the first 4 weeks of the study before they are 
offered the option to dose escalate for the remaining 8 weeks of the trial. All 
subjects will be treated equally throughout. However, as this study is not placebo  
controlled, it  will  not possible to  assess  the  potential  of the   placebo 













There are a total of 6 questionnaires to be completed on two occasions during  the 
study. This may introduce an element of questionnaire fatigue or respondent 
burden. All patients will be informed of what is required of them during the trial and 
all the questionnaires included have been designed to be easy to respond to and 
not too lengthy. 
At each visit the researcher will go through all completed questionnaires with the 
patient to ensure that all the questions have been answered and to avoid missing 
data in the final analysis. 
 
7.1 Sample Size 
We are planning investigate change in sexual function, using the sexual quality of 
life questionnaire (SQOL_F) and the prolapse and incontinence sexual 
questionnaire (PISQ_12) as measures of sexual function at baseline and 12 
weeks after intervention. Prior data indicates {Roger R 2008} that a difference in 
the response to SQOL_F (Primary outcome) of matched pairs is normally 
distributed with standard deviation 19.2 and a difference in the mean response of 
6.4. We used these estimates to calculate sample size using 95% power, and 
two sided alpha level of 0.05. The number of participants required to detect the 
difference described at the significance level described, would be 120 patients. 
Allowing for about 10% dropout the number required would be 132. 
 
 
Rogers R et al (2008) Efficacy of tolterodine on overactive bladder symptoms  and 
sexual and emotional quality of life in sexually active women. Int Urogynaecol J, 
19, 11, 1551-7. 













No randomisation will take place in this study. All subjects meeting the entry 
criteria will receive the study drug. 
 
7.3 Analysis 
At week 4 demographics will be compared among those who dose escalate and 
those who don’t to ensure that there are no differences between the two groups. 
Significance will be at the 5% level. We anticipate that the design of the study  will 
minimise missing data and intention to treat is not applicable in these 
circumstances. 
Wilcoxon Signed Ranks and Students paired t-test will be used to analyse medians 
and means respectively comparing baseline and week 12 for KHQ, Pac- QoL, 
SQoL and PISQ-12.  Comparisons of the difference in baseline and 12  week 
PPBC scores will also be analysed. Multivariate linear regression will be used to 
examine changes in KHQ, Pac-QoL, SQoL and PISQ-12 at week 12. 
To assess changes in first sensation to void and maximum cystometric capacity 
paired T tests will be performed. The time to first contraction will be analysed using 
a Kaplan Mayer test and compared using a log rank test. 
A regression analysis will be performed to assess if change in quality of life scores 
are related to changes in the urodynamic variables. 
 
 
9. Trial Steering Committee 
 
This study does not have a trial steering committee. The protocol has been 
externally peer reviewed by medical consultant with experience in designing and 
completing CTIMP’s. 
 
10 Direct Access to Source Data and Documents 
The Investigator(s) will permit trial-related monitoring, audits, REC review, and 
regulatory inspections (where appropriate) by providing direct access to source 
data and other documents (ie patients’ case sheets, blood test reports, X-ray 
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reports, histology reports etc). 
 
 
11 Ethics & Regulatory Approvals 
 
The trial will be conducted in compliance with the principles of the Declaration of 
Helsinki (1996), the principles of GCP and in accordance with all applicable 
regulatory requirements including but not limited to the Research Governance 
Framework and the Medicines for Human Use (Clinical Trial) Regulations 2004, as 
amended in 2006 and any subsequent amendments. 
 
This protocol and related documents will be submitted for review to a Research 
Ethics Committee (REC), and to the Medicines and Healthcare products 
Regulatory Agency (MHRA) for Clinical Trial Authorisation. 
 
Any subsequent protocol amendments will submitted to the REC and Regulatory 
Authorities for approval, and the study will comply with all regulations including 
pharmacovigilance reporting. 
 
Annual progress and safety reports and a final report at conclusion of the trial will 
be submitted to the KHP-CTO (on behalf of the Sponsor), the REC and the MHRA 
within the timelines defined in the Regulations 
 
 
12 Quality Assurance 
 
Monitoring of this trial will be to ensure compliance with Good Clinical Practice and 
scientific integrity will be managed and oversight retained by the King’s Health 
Partners Clinical Trials Office Quality Team. 
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13 Data Handling 
 
The Chief Investigator will act as custodian for the trial data. The following 
guidelines will be strictly adhered to: 
 
Patient data will be anonymised. 
 All anonymised data will be stored on a password protected computer. 
 All trial data will be stored and archived in line with the Medicines for Human 
Use (Clinical Trials) Amended Regulations 2006 as defined in the King’s 
Health Partners Clinical Trials Office Archiving SOP. 
 
 
14 Publication Policy 
 
It is intended that the results of the study will be reported and disseminated at 
international conferences and in peer-reviewed scientific journals. 
 
15 Financial Aspects 
 
Funding to conduct the trial is provided by an Investigator Initiated Research 
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Did participant complete the trial? 
Yes, Please provide date of last visit: 
 
     __ / / 2 0     __ 
(DD / MMM / YYYY) 
 
No, Please provide date of withdrawal and complete 
below: 
 
     __ / / 2 0     __ 
(DD / MMM / YYYY) 
Early Withdrawal: please tick most appropriate reason for participant not completing the trial: 
 
Adverse Events related: please state related AE:      
Participant’s decision, specify:    
Investigator’s decision, specify:     
Sponsor’s decision 
Lost to follow up 
 
Other, specify:    
Fesoterodine and sexual function 













Protocol Number: 2010-023851-27 




Principal Investigator’s Signature Statement: 
 
I have reviewed this CRF and confirm that, to the best of my knowledge, it accurately reflects the study 
information obtained for this participant. All entries were made either by myself or by a person under my 
supervision who has signed the Delegation and Signature Log. 
 






















  / /    
(DD / MMM / YYYY) 
ONCE SIGNED, NO FURTHER CHANGES CAN BE MADE TO THIS CRF 















Patient Information Sheet 
 
1. Introduction 
You are being invited to take part in a study. Before you decide to take part, it is important for 
you to understand why this research is being done and what it will involve. Please take time to 
read the following information carefully and discuss it with others if you wish. Ask us if there is 
anything that is not clear or if you would like more information. Take time to decide whether or 
not you wish to take part. 
 
2. What is the purpose of the study? 
You are being asked to take part in a research drug study because you have symptoms which 
include having to pass urine frequently (and sometimes a desire to pass urine which is difficult 
to control). You may also have incontinence (the accidental loss of urine). Your doctor has 
concluded that your symptoms are most likely due to an overactive bladder (OAB). 
 
The study will involve the drug fesoterodine fumarate (from now on referred to as 
fesoterodine), which is a drug already licensed and routinely used in the UK for this condition. 
 
The study aims to assess whether this drug improves sexual function in women with 
overactive bladder. In addition it also aims to demonstrate if the drug reduces the amount of 
times patients need to pass urine. It will also assess how well tolerated fesoterodine is and 
look at how many women feel they need to change the dose of the medication to best 
manage their symptoms. 
 
3. Why  have I been chosen? 
You have been identified as potentially meeting the eligibility criteria for this trial. We are  
looking to recruit 130 women from our clinics to participate in this  study. 
 
4. Do I have to take part? 
It is up to you to decide whether or not to take part. If you do decide to take part you will be 
given this information sheet to keep and given time to review  the information. 
 
If you decide not to take part, you do not have to give a reason. If you decide to take part you 
are still free to withdraw at any time and without giving a reason. A decision to withdraw at    
any time, or a decision not to take part, will not affect the standard of care you receive. If you 
decide to withdraw, any data (information) collected up to the point you withdraw may be used 
in order to preserve the value of the study, however no further information will be collected. 
 
 










5. What will happen to me if I take part? 
If you decide to take part in this study, your involvement will last approximately 12 weeks. You 
will be asked to visit your study doctor or nurse initially to determine eligibility, and then return for 
a further three (3) visits for study drug and assessments. You may also  have  further  bladder 
function tests performed at the end of the study if you are one of the first forty patients who enter 
the study. 
 
You will be required to sign an informed consent form once all the study information has been 
clearly explained to you, including the risks and  benefits of  taking part  and  any procedures and 
tests to be performed and you have been given enough time to consider whether you   wish to 
take part in this study. Your study doctor will be available to answer any questions you may have 
and will also sign the consent form. You will be  given a  copy of  the information sheet and 
consent form for your records. 
 
If you agree to take part in this study, after signing the informed consent form the following 
tests will be carried out to determine whether you are eligible to take part in this study. These 
tests / procedures are called "screening" procedures: 
 
Visit 1 (Screening visit) 
At your screening visit: 
 Your weight, medical history (including any medication and non-drug treatment) and 
demography will be taken.
 Your sitting blood pressure and pulse will be taken
 A physical examination will be conducted.
 You will need to provide a sample of your urine  for the following-:
- A urine dipstick test will be performed on a sample of urine to exclude blood and 
infection 
- A urine pregnancy test for women of child bearing potential  will be performed 
 You will be issued with a 3-day bladder diary to complete and provided with instructions 
on how and when to complete the diary. The diary is provided for you to record details of 
the number of times you pass urine and related information and the completed diary will 
be collected at your next visit. The diary should be completed for the three (3) days prior 
to your next visit.
 You will be provided with a questionnaire to help identify and help the study team 
understand what you would like to achieve in regards to your bladder conditions. You will 
also be provided with instructions on how to complete the questionnaire. You will be able 
to review  this at home and either complete this at home or complete it at your next visit.
 
 



















If you meet all of the study entry requirements and you agree to participate in the study, the  
clinic/research staff will ask you to return for Visit 2 (baseline  visit). 
 
 
Visit 2 (Week 0) (Baseline) 
At this visit you will be told if you are still eligible to take part in this study. If  you are eligible  
and still wish to participate, the next step is for you to have the baseline visit. 
 
At the baseline visit-: 
 Your completed bladder diary will be collected and  evaluated
 You will be asked to complete 6 questionnaires which will take approximately 30 minutes 
in total
 You will be asked if you have had any new symptoms or worsening of existing symptoms 
and if you have taken any new  medication or treatments since your last visit.
 You will be given another 3-day diary (plus instructions) to complete the three days prior 
to the next visit (visit 3). The completed diary will be collected at your next visit.
 You will be given a supply of study medication (fesoterodine 4mg) to take once a day at 
approximately the same time each day over the next 4 weeks. You should take your study 
medication with water and it should be swallowed whole without chewing. Your study 
medication can be taken with or without food.
 
Visit 3 (Week 4) 
Four (4) weeks later you will return for visit 3. During this  visit: 
 Your completed bladder diary will be collected and  evaluated.
 You will be asked if you have had any new symptoms or worsening of existing 
symptoms and if you have taken any new  medication or treatments since your last visit.
 Your study doctor will review the amount of unused study medication you have 
returned to assess whether this has been taken correctly.
 You will be given another 3-day diary (plus instructions) to complete the three days 
prior to the next visit (visit 4). The completed diary will be collected at your next visit.
 Your dose of study medication will be reviewed by the study doctor and if applicable 
your dose maybe increased
 You will be given a supply of study medication either fesoterodine 4 mg or fesoterodine 
8 mg depending on discussions with your study doctor. You will need to take this once  
a day at approximately the same time each day over the next 8  weeks.
 
Visit 4 (Week 12 End of Treatment or Early Termination  Visit) 
Eight (8) weeks later you will return for visit 4. During  this visit: 
 Your completed bladder diary will be collected and  evaluated
 Women of child bearing potential will need to provide a sample of urine for a pregnancy test
 











 You will be asked to complete questionnaires which will take approximately 30 minutes
 You will be asked if you have had any new symptoms or worsening of existing symptoms 
and if you have taken any new  medication or treatments since your last visit.
 Your study doctor will review the amount of unused study medication you have returned 
to assess whether this has been taken correctly.
 If you are one of the women having bladder function tests (urodynamics) performed the 
following will happen at this visit.   Two tubes (a catheter and a pressure line) are   
inserted into the bladder and a pressure line is inserted into the rectum (or vagina). The 
bladder is then filled with saline. Any changes of pressure in the bladder are recorded 
during this time.  Once the bladder  is full the catheter is removed.  Patients may be
asked to cough to assess for bladder symptoms. Finally patients will urinate into a 
flowmeter to assess the pressures within their bladder as it empties. The test takes 
approximately 15 minutes. There is a slight chance that you will experience some 
discomfort when you urinate for a couple of hours after the test. There is a 1% risk of 




Telephone Follow up (Week 24) 
Three months after you have completed the trial the team will call you at home. During this 
conversation: 
 You will be asked if you are currently taking any medication for your bladder and if so 
which one. 
 If you have stopped taking any bladder medication you will  be asked why 
 You will be asked if you have had any new symptoms or worsening of existing 




During the course of the study you might have an additional visit for safety related issues. At 
this visit the following may be performed: 
• Your sitting blood pressure and pulse rate will be  measured 
• You will be asked if you have had any new symptoms or worsening of existing symptoms 
and if you have taken any new  medication or treatments since your last visit. 
• Your study doctor will review the amount of unused study medication you have returned 
to assess whether this has been taken correctly. 
 
What happens to my urine samples? 
Any urine samples that you have given will be destroyed immediately after use and will not be  
used for any other purpose. 
 
 












You will be reimbursed for any reasonable extra expenses (such as travel, car parking expenses) 
needed to take part in this study (up to a maximum of £20 per visit on receipt of  valid travel 
tickets or car parking vouchers). 
 
The payment will be made in the form of a crossed cheque that must be paid into a bank account 
bearing your name or by cash. You are responsible for paying tax on this payment if this is 
appropriate to your circumstances. 
 
If you one of the participants asked to have additional urodynamics performed at Visit 
4 you will be offered £50 for any discomfort or inconvienience this may cause. 
 
There will be no other payment for participation in the study. 
 
 
6 What do I have to do? 
If you decide to take part in this study you will be asked  to: 
 Keep all  scheduled appointments.
 Take the study medicine exactly the way you are told. Do not stop taking the medicine 
without first talking to the study doctor.
 Do not give the medicine to anyone else. Keep the medicine out of the reach of children.
 Store the medication according to instructions.
 Do not take any other medicines for overactive  bladder and/or incontinence
 Tell your study doctor about any medications that you take, even if it is medicine you buy 
without a prescription or is a herbal remedy.
 Notify your study doctor if you are allergic to peanuts or soya.
 Notify your study doctor if you eat or drink grapefruit.
 Tell your study doctor about any side effect, injury, symptom or complaint you experience, 
by using the contact numbers at the end of  this patient information sheet.
 If applicable, avoid becoming pregnant, breast feeding while on the study and for 28 days 
after your last dose of fesoterodine by using suitable contraception approved by your  
study doctor. You should not breast feed whilst you are in the  study




















 You will be provided with a card, which says that you are taking part in this study. Carry 
this card with you at all times, and show it to any doctors, nurses or pharmacists. Please 
return the card at the end of the study. 
 Complete the diary for the three days prior to your visit 2, 3 and  4. 
 
7 What is the drug or procedure that is being tested? 
The drug being studied is called fesoterodine which helps to relax the bladder. It was  developed 
for the treatment of overactive bladder with symptoms of urgency urinary incontinence, urgency, 
and urinary frequency. 
 
In May 2007 it was approved in Europe and in March 2008 it was approved in the UK. The 
fesoterodine Prolonged Release  tablet is suitable for once-daily administration. 
 
For the first four weeks of drug treatment in this study you  will  take one tablet of fesoterodine  4 
mg at approximately the same time every day. After the first four weeks following on from 
discussions with your study doctor you will either take one 4mg tablet or be increased up to  take 
one 8 mg tablet, at approximately the same time every day, for the duration of the study. 
 
8. What are the alternatives for diagnosis or  treatment? 
You do not have to be in  this study to receive treatment for your overactive bladder.  There  
may be other ways to treat your condition  including-: 
 Other already approved medications, which could include fesoterodine, as recommended 
by your regular doctor
 The use of behavioral techniques that can improve  bladder control
 Surgical interventions to control overactive bladder  symptoms
 
Your study doctor can tell you more about these other treatments and their benefits and risks. 
 
 
9 What are the side effects of any treatment received when taking part? 
As with all studies, the drug treatment and other therapies may involve risks that are already 
known as well as risks that are currently unknown. Based on studies and the experience of 
other people who have received fesoterodine some side effects may occur. If any information 
on new risks or side effects becomes available during the course of the study then you will be 
informed. This information may affect your decision about continuing in the study. 
 
Very common side effects (occurring in 10% of patients) 
 
 



















Common side effects (occurring in 1-10% of patients) 
• Dry eye 
• Stomach ache 
• Constipation 
• Diarrhoea 
• Trouble digesting food (dyspepsia) 
• Feeling sick (nausea) 
• Pain or discomfort when emptying the bladder (dysuria) 
• Difficulty in sleeping (insomnia) 





You should use caution in driving, operating machinery, or doing other dangerous activities 
until you know how fesoterodine affects you. Blurred vision and drowsiness are possible side 
effects of medicines such as fesoterodine. 
 
Most of the people who have experienced these side effects considered them to be mild or 
moderate, and most of them decided to continue treatment despite the side effects. 
 
However if you suffer from any of these side effects listed, or you notice any which are not  listed 
here please report these as soon as they occur whether or not you think that they are linked to 
the study drug. 
 
Finally, other side effects that are not known at this time could occur during your treatment. 
 
 
If you do experience any side effects or discomfort during the study you should inform your study 
doctor either at the next visit or sooner if you wish by using the telephone contact  number at the 
end of this information sheet. Your study doctor will advise you what to do. 
 
10. What are the possible disadvantages and risks of taking  part? 
 
 
There could be risks to an unborn child in this study. If you are pregnant or may become pregnant 
during the study, these risks could affect you or your unborn child. Unless you have been 
surgically sterilised (you have had your womb and/or ovaries removed) or are postmenopausal 
you must agree to use birth control during the study. Your study doctor must approve the form of 
birth control. Acceptable  contraceptive methods: 
 
 Hormonal methods of contraception (including oral, patches, injected, implants, IUDs 
(intrauterine device)) at least 14 days prior to the first dose of trial  medication; 
 Placement of a copper-containing intrauterine device (IUD); 
 














 Condom  with spermicidal foam/gel/film/cream/suppository 
 Tubal ligation 




If you are abstinent but become sexually active at any time during the study, you should use one 
of the contraceptive methods above. 
If you could become pregnant, you will have a pregnancy test at the beginning of the study to 
ensure that you are not pregnant. You will also have another test at the end of the study. This 
test might not detect an early pregnancy. Pregnancy tests may be repeated during the study.    If 
you think you are pregnant, tell the study doctor  immediately. 
 
Pregnancy will be a reason to stop study treatment. If you become pregnant during the study, 
you may be discontinued from study participation for safety reasons. In either case, please make 
your obstetrician aware of your study participation. Your study doctor will  ask that you,  or your 
obstetrician, provide updates on the progress of your pregnancy and its outcome. The study 
doctor will make this information available  to  the  sponsor for safety monitoring follow- up. 
 
You will not be able to take part in this study if you are  breast-feeding. 
 
 
There is a possibility that fesoterodine might not work for you or might not work as well as another 
medicine. 
 
If you have private life/medical insurance please check with the insurance company, before 
agreeing to take part in this study, to ensure that your participation will not affect your cover. 
 
11. What are the possible benefits of taking part? 
The medicine you receive may help relieve your symptoms of your overactive bladder, but  
this cannot be guaranteed and you may not receive any direct benefit from taking part in this 
study. 
 
The information we gain from this study might help us to treat future patients with overactive 
bladder. 
 
12 What if new information becomes available? 
Sometimes during the course of a study, important new information becomes available about the 
drug that is being studied. If this happens, your study doctor will tell you about it and discuss with 
you whether you want to continue in the study. If you decide to withdraw your  study doctor will 
make arrangements for your care to continue. If you decide to continue in the 
 














study you will be asked to sign an updated informed consent form which includes the new 
information and will be given a copy of this form to  keep. 
 
Also, on receiving new information your study doctor might consider it to be in your best interests 
to withdraw you from the study. He/she  will  explain the reasons why it is best that  you do not 
continue on study and will  arrange for your ongoing medical care. 
 
13 What happens when the study stops? 
At the end of the study you will no longer receive fesoterodine as part of the clinical trial. It is 
unlikely that fesoterodine would be available to you in the community. Your study doctor or nurse 
will assess your symptoms and suggest alternative medications which your GP can continue to 
prescribe for you. 
 
As with any study, there is a possibility that this study could  close  early  due  to  various reasons 
such as no beneficial effect, unacceptable side effects being reported or unexpected reasons. If 
at any time during the study you develop an illness or condition, which in  the  opinion of the study 
doctor makes it unsafe for you to continue, you will be withdrawn from the study and a final 
assessment will be made. 
 
14 Removal from the study 
Your study doctor or the sponsor may decide to take you out of the study if: 
 You do not follow the directions of the study doctor
 You develop a serious illness that is not related to taking part in the study
 Your study doctor decides that the study is not in  your best interest
 Regulatory Authorities, or Research Ethics Committee, decide to stop the study
 You become pregnant, intend to become pregnant, or are breast-feeding a child during 
this study
 
If you are taken out of the study you may undergo some tests. These include: 
 Your completed bladder diary will be collected and  evaluated
 Your sitting blood pressure and pulse rate will be  measured
 Women of child bearing potential will need to provide a sample of urine for a pregnancy 
test
 You will be asked to complete 6 questionnaires which will take approximately 30 minutes
 You will be asked if you have had any new symptoms or worsening of existing symptoms 
and if you have taken any new  medication or treatments since your last visit.
 Your study doctor will review the amount of unused study medication you have returned 
to assess whether this has been taken correctly.
 














The tests are to protect your safety. The study doctor may also recommend other treatments. 
 
15 Withdrawal from the study 
If you decide to withdraw from the study you should tell the study doctor. If you withdraw from 
the study without telling the study doctor, you may be contacted to confirm whether you have 
withdrawn or wish to continue your participation in the study. If you do withdraw from the  
study, no new information about you will be collected by study personnel, although  
information about you that has already been collected may continue to be used in order to 
preserve the value of the study. If you have any questions or concerns about this, it is 
recommended that you contact the study doctor. 
 
16 What if something goes wrong? 
We do not expect you to suffer any health problems by taking part in this study. 
If taking part in this study harms you, there are no special compensation arrangements. If you 
are harmed due to someone’s negligence, then you may have grounds for a legal action, but 
you may have to pay for it. 
If you wish to complain about any aspect of the way you have been approached or treated 
during the course of this study, the normal National Health Service complaints mechanisms 
will be available to you. 
 
17 Will my taking part in this study be kept confidential? 
If you join the study, the doctors, nurses and other personnel involved in this study may need 
access to your medical history, including your past medical records and test results, for the 
purposes of this study. By signing the consent form you agree that the study personnel can 
contact your family doctor and other health care providers to gain access to your medical history 
during this study. 
 
In addition, some parts of your medical records and the data collected will be looked at by 
monitors, auditors, ethics committees, authorised persons from King’s College Hospital NHS 
Trust (the sponsor of  this research), and representatives of  regulatory authorities, to check  that 
the study is being carried out correctly.. All will have a duty of confidentiality to you as a research 
participant. By signing the consent form you agree to this  access for the  current study. 
 
Any records identifying you will be kept confidential and won’t be made publicly available. 
 
 
With your consent your family doctor (General Practitioner)  will be told that you have decided  
to take part in this study. 
 
18 Your right to access health information 
You have a right to ask for access to the health information that the study doctor holds about 














you and to ask for changes if your health information if not correct or is incomplete, in accordance 
with UK law. Any request for access or changes should be made to the study doctor. 
 
19 What will happen to the results of the study? 
Once all the study results are available your study doctor will be happy to discuss this with  
you. A final report will be produced and may be published. A copy of the publication will be 
available from King’s College Hospital on request. Please note that your name will not appear 
in the final report or publication. This study is part of an educational  project. 
 
20 Who is funding the study? 
This study is being funded by an Investigator Initiated Research Grant from Pfizer Ltd. Some 
members of the Urogynaecology team perform consultancy work for Pfizer Ltd. 
 
21 Who has reviewed this study? 
The study has been approved by Cambridge East Research Ethics Committee and the 
Medicines and Healthcare Products Regulatory Agency  (MHRA). 
 
22 Contact names and telephone numbers for further  information 
For any concerns or other questions about this study, or any questions about a study related 
injury please contact: 
 
Angie Rantell 0203 299 3568 
For emergencies only please contact: Katherine Monk Ward 0203 299 3317 
 
 
For any concerns about your rights as a participant or any complaints please contact the 
Patient Advice and Liaison Service (PALS). This is a service that offers support, information 
and assistance to patients, relatives and visitors. They can also provide help and advice if  
you have a concern or complaint that staff have not been able to resolve for you. The PALS 
office is located on the ground floor of the Hambleden Wing, near the main entrance on 
Bessemer Road - staff will be happy to direct you. 
Tel: 020 3299 3601 
Textphone: 020 3299 1878 





Before you sign the informed consent form, you should ask questions about anything that you do 
not understand. The study staff will answer any questions before,  during and after the  study. 
 
Thank you for taking the time to read this information  sheet. 
 
 

















Centre: King’s College Hospital 




A 12 week, single centre, open label study to evaluate the effect of 
Fesoterodine flexible dosing regimen on the sexual function of women with 
overactive bladder 
 
Name of Researcher: Professor Linda Cardozo, FRCOG and Angie Rantell BSc (Hons) 
RN. 
 
Please initial box 
 
1. I confirm that I have read and understand the information sheet 
(version 2.0 dated 24/01/2013) for the above study.  I have had the 




2. I understand that my participation is voluntary and that I am free to withdraw 




3. I understand that relevant sections of any of my medical notes and data 
collected during the study may be looked at by responsible representatives of 
the sponsor or the NHS trust, the ethics committee and regulatory authorities, 
where it is relevant to my taking part in this research. I give permission for 
these individuals to have access to my records 
 
 
4. I agree to my GP being informed of my participation in the study 
 
 
5. I agree to have urodynamics performed at Visit 4 
 
 









Name of Patient Date  Signature 










When completed: Original for researcher site file; a copy for the participant; a copy for the medical 
notes. 













    
  
 




Dear Doctor ................................................ 
 
 
RE: Patient .............................................................. 
 
Your patient has agree to participate in a clinical study entitled ‘A 12 week, single 
centre, open label study to evaluate the effect of Fesoterodine flexible dosing 
regimen on the sexual function of women with overactive bladder’. 
 
The study will last approximately 12 weeks and requires 4 visits and their 
involvement will include the following procedures:- 
 
 Weight, medical history and demography will be taken 
 Blood pressure and pulse will be taken 
 Physical examination 
 Urine dipstick 
 Urine pregnancy test for women of child bearing potential 
 Completion of questionnaires 
 Completion of bladder diary 
 Assessment of adverse events and concomitant medications 
 
During the study your patient will receive Fesoterodine. Known side effects of 
Fesoterodine include:- 
 
 Dry mouth 
 Constipation 
 Drowsiness 
 Blurred vision 
 Urinary retention 
 
Most of the people who have experienced these side effects consider them to be 
mild to moderate, and most of them decide to continue treatment despite the side 
effects. 
 
Certain concomitant medications are prohibited, these include:- 
 
 Any drug other than the study drug for overactive bladder 
 Any drug with significant anticholinergic or antispasmodic effects 



























 Intermittent or unstable use of diuretics or alphablockers or tricyclic 
antidepressants, oestrogen therapy and any 5AR inhibitors. Stable 
usage/dosage is allowed 
 Any investigational drug, medical procedure or dietary supplement 
 
I would appreciate it if you would contact me should your patient need any changes 
to their medications during the time that they are participating in this study. 
 
I would also appreciate it if you could contact me if your patient reports any adverse 
events to you. 
 
If you would like to see a copy of the inclusion / exclusion criteria and / or if you 
know of any reason why your patient should not continue in the study I would be 
grateful if you could let me know as soon as possible. 
 











Senior Urogynaecology Nurse Specialist 


















We are inviting you to take part in a study that involves a medication called Fesoterodine. 
This is a licensed drug that is routinely used in UK to treat patients with an overactive 
bladder (having to go frequently and urgently to the toilet). 
The aim of this study is to assess if this drug improves sexual function as well as improving 
your bladder symptoms. 
We would like you to take part in our study.  To be eligible you must be: 
 Female, age 18-80 years old 
 Sexually active 
 Have a strong, sudden urge to go to the toilet 
 
 
This is a 12 week study. You will only need to attend 4 clinic appointments and you will be 
reimbursed for any extra expenses such as travel and car parking expenses (maximum £20 
per visit) 
If you would like to be part of the study please leave your name 
and telephone number on this form and hand it in to the nurse 
or receptionist during your visit. 
 
 
Name Telephone   
Alternatively for further information please contact 
Urogynaecology: Angie Rantell or Sarah Ferdinand on 0203 299 
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Sexual Quality of Life Questionnaire-Female 
(SQoL-F) 
 
This questionnaire consists of a set of statements, each asking about thoughts 
and feelings that you may have about your sex life. The statement may be 
positive or negative. 
 
You are asked to rate each one according to how much you agree or disagree 
with the statement by circling one of six response choices. 
 
In answering these items the following definitions apply: 
 
Sex life: is both the physical sexual activities and the emotional sexual 
relationship that you have with your partner. 
 
Sexual activity: Includes any activity which may result in sexual stimulation or 
sexual pleasure such as intercourse, caressing, foreplay, masturbation (self 
masturbation or your partner masturbating you) and oral sex (your partner 




Usually, the first answer that comes into your head is the best one so please do 
not spend too long on each question. 
 
All your answers will be completely confidential 
SQoL-F version 5: 29/10/99 











1. When I think about my sex life, it is an 









































4. When I think about my sex life, I feel 













5. When I think about my sex life, I feel 























































9. When I think about my sex life, I feel 



















































13. When I think about my sex life, I feel 








































16. When I think about my sex life, I worry 













17. When I think about my sex life, I feel 













18. When I think about my sex life, I am 






















Patient Perception of Bladder Condition (PPBC) 
 
 
Which of the following statements describes your bladder 
condition best at the moment? 




My bladder does not cause me any problems at all  
My bladder causes me some very minor problems  
My bladder causes me minor problems  
My bladder causes me moderate problems  
My bladder causes me severe problems  















1. How would you describe your health at the present? 












2. How much do you think your bladder problem affects your life? 
 
Please tick one answer 
 












Please turn the page 



























Below are some daily activities that can be affected by bladder problems. 
How much does your bladder problem affect you? 
 
We would like you to answer every question. Simply tick the box that applies to you 
 
 
 1 2 3 4 
3. ROLE LIMITATIONS Not at all Slightly Moderately A lot 










(cleaning, shopping etc) 
 
B. Does your bladder problem affect your 
job, or your normal daily activities 
outside the home? 
 
1 2 3 4 
4. PHYSICAL/SOCIAL LIMITATION Not at all Slightly Moderately A lot 
 
A Does your bladder problem affect 
your physical activities (e.g. going 
for a walk, running, sport, gym etc)? 
B. Does your bladder problem affect 
your ability to travel? 
 
C. Does your bladder problem limit 
your social life? 
 
D. Does your bladder problem limit 




















































A. Does your bladder problem 
affect your relationship with 
your partner? 
B. Does your bladder problem 
affect your sex life? 
C. Does your bladder problem 









 1 2 3 4 
6. EMOTIONS 
 
A. Does your bladder problem make 
















you feel depressed? 
 
B. Does your bladder problem make 
you feel anxious or nervous? 
 
C. Does your bladder problem make 





8.Do you do any of the following? If so how much? 
1 2 3 4 
Never Sometimes Often All the time 
A. Wear  pads to keep dry? 
B. Be careful how much 
fluid you drink ? 
 
C. Change your underclothes 
because they get wet? 
 

























All the time 
A. Does your bladder problem 
affect your sleep? 
B. Does your bladder problem make 









































FREQUENCY: going to the toilet very often 
1. A little 2.Moderately 3. A lot 
URGENCY: a strong and difficult to control desire to pass urine 
1. A little 2.Moderately 3. A lot 
STRESS INCONTINENCE: urinary leakage with physical activity eg. coughing, running 
1. A little 2.Moderately 3. A lot 
INTERCOURSE INCONTINENCE: urinary leakage with sexual intercourse 
1. A little 2.Moderately 3. A lot 
We would like to know what your bladder problems are and how much 
they affect you ? From the list below choose only those problems that 
you have at present. Leave out those that don’t apply to you. 
 






NOCTURIA: getting up at night to pass urine 





URGE INCONTINENCE: urinary leakage associated with a strong desire to pass urine 





NOCTURNAL ENURESIS: wetting the bed at night 







































1. A little 2.Moderately 3. A lot 
English (UK) PAC-QOL 2.0-Sd (28-item, Standard version) 
PAC-QOL© 2001 Johnson & Johnson, All rights reserved 












PATIENT ASSESSMENT OF CONSTIPATION 

The following questions are designed to measure the impact constipation has had on your daily life during 
the past 2 weeks. For each question, please tick one box. 
 
 
The following questions ask you about 
the intensity of your symptoms. To 
what extent, during the past 2 weeks... 
 
 

















































The next few questions ask you about 
the effects of constipation on your 
daily life. How much of the time, during 









































































4. have you felt the need to open your 
bowel but not been able to? 
5. have you been embarrassed to be 
with other people? 
6. have you been eating less and less 
because of not being able to have 
bowel movements? 
English (UK) PAC-QOL 2.0-Sd (28-item, Standard version) 
PAC-QOL© 2001 Johnson & Johnson, All rights reserved 











The next few questions ask you about 
the effects of constipation on your 
daily life. To what extent, during the 
past 2 weeks... 
 
 


















7. have you had to be careful about 
what you eat? 
 
8. have you had a decreased appetite? 
 
9. have you been worried about not 
being able to choose what you eat 
(for example, at friend’s)? 
 
10. have you been embarrassed about 
staying in the toilet for so long when 
you were away from home? 
 
11. have you been embarrassed about 
having to go to the toilet so often 
when you were away from home? 
 
12. have you been worried about having 
to change your daily routine (for 


































































































The next few questions ask you about 
your feelings. How much of the time, 













All of the 
time 
4 
13. have you felt irritable because of 
your condition? 
14. have you been upset by your 
condition? 
15. have you felt obsessed by your 
condition? 
16. have you felt stressed by your 
condition? 
17. have you been less self-confident 
because of your condition? 























































































English (UK) PAC-QOL 2.0-Sd (28-item, Standard version) 
PAC-QOL© 2001 Johnson & Johnson, All rights reserved 












The next questions ask you about your 
feelings. To what extent, during the 
past 2 weeks... 
 
Not at all 
0 
 











19. have you been worried about not 
knowing when you are going to be 



















































20. have you been worried about not 
being able to open your bowels 
when you needed to? 
21. have you been more and more 
bothered by not being able to open 
your bowels? 
 
The next questions ask about your life 
with constipation. How much of the 













All of the 
time 
4 
22. have you been afraid that your 









































23. have you felt that your body was not 
working properly? 
24. have you had fewer bowel 
movements than you would like? 
 
The next questions ask you about how 
satisfied you are. To what extent, 
during the past 2 weeks... 
 
Not at all 
0 
 











25. have you been satisfied with how 





























































26. have you been satisfied with the 
regularity with which you open your 
bowels? 
27. have you been satisfied with your 
bowel function? 










SELF ASSESSMENT GOAL ACHIEVEMENT QUESTIONNAIRE (SAGA) 
 
Protocol No: Subject ID: 
 




 The questionnaire is designed to help us understand the goals men and women have for their bladder 
conditions while on treatment
 
 In this questionnaire, the term “goal” refers to something you would like to achieve in regards to your 
bladder conditions.  A goal is something that is observable and measurable
 
 In this questionnaire, the expression “treatment goal” refers to the goals you may have for your badder 
conditions, for example, reducing the number of times you urinate throughout the day, reducing the 
sudden need to rush to urinate, reducing when you experience urine loss or leakage, reducing the 
number of times you get up at night to go to urinate or reducing the sensation of pain or pressure in your 
lower abdomen.
 
 Please read each questions carefully and answer as best as you can and without help from 
anyone
 
 There are no wrong answers
 The information you provide will be discussed with your physician to better understand the goals 









SELF ASSESSMENT GOAL ACHIEVEMENT QUESTIONNAIRE (SAGA) 
 
Protocol No: Subject ID: 
 




This is a list of treatment goals related to symptoms that people with bladder conditions commonly 
experience. Please review the list and indicate how important it is for you to achieve each goal. Please tick 
only ONE box for each question. 
 





















1.    Reduce the number times 














2. Reduce the number of 
times I get up at night to 













3. Reduce the sensation of 














4. Reduce the sensation of 
pressure that prompts me 













5. Reduce the difficulties I 














6. Reduce the difficulty 














7. Reduce the urine loss 
when I cough, laugh, 

























9. Reduce the sudden need 





















SELF ASSESSMENT GOAL ACHIEVEMENT QUESTIONNAIRE (SAGA) 
 
Protocol No: Subject ID: 
 




People have treatment goals for their bladder conditions (for example, improve weak stream, be able to 
watch a movie from beginning to end without having to go to the toilet, reduce pain while urinating). Please 
list (up to five) treatment goals you have for your bladder condition and indicate how important it is for you to 
achieve each goal.  Please tick only ONE box for each question. 
 











































































SELF ASSESSMENT GOAL ACHIEVEMENT QUESTIONNAIRE (SAGA) 
 
Protocol No: Subject ID: 
 




Please review the goals that are listed on pages 2 and 3. List the top five goals that you want to achieve the 
most. In the “Goal No” column, please indicate the number of the goal you are referring to (Nunber 1-14). In 












Eg. For most important goal 
 
 
Goal No 1 
 
 
Today I urinate on average 15 times a day, I would like 
to urinate 10 times 
 
 































SELF ASSESSMENT GOAL ACHIEVEMENT QUESTIONNAIRE (SAGA) 
 
Protocol No: Subject ID: 
 




 The questionnaire is designed to help us understand the goals men and women have for their bladder 
conditions while on treatment
 
 In this questionnaire, the term “goal” refers to something you would like to achieve in regards to your 
bladder conditions.  A goal is something that is observable and measurable
 
 In this questionnaire, the expression “treatment goal” refers to the goals you may have for your badder 
conditions, for example, reducing the number of times you urinate throughout the day, reducing the 
sudden need to rush to urinate, reducing when you experience urine loss or leakage, reducing the 
number of times you get up at night to go to urinate or reducing the sensation of pain or pressure in your 
lower abdomen.
 
 Please read each questions carefully and answer as best as you can and without help from 
anyone
 
 There are no wrong answers
 The information you provide will be discussed with your physician to better understand the goals 









SELF ASSESSMENT GOAL ACHIEVEMENT QUESTIONNAIRE (SAGA) 
 
Protocol No: Subject ID: 
 




Below is a list of symptom goals that people with bladder conditions commonly experience. At your last visit 
you indicated how important each of these goals was to you. Since your last visit, please indicate to what 
extent you feel you have achieved each goal.  Please tick only ONE box for each question. 
 















1.   Reduce the number times 














2.   Reduce the number of 
times I get up at night to 













3.    Reduce the sensation of 














4.    Reduce the sensation of 
pressure that prompts me 













5.    Reduce the difficulties I 














6.    Reduce the difficulty 














7.    Reduce the urine loss 
when I cough, laugh, 

























9. Reduce the sudden need 





















SELF ASSESSMENT GOAL ACHIEVEMENT QUESTIONNAIRE (SAGA) 
 
Protocol No: Subject ID: 
 




Below is a list of goals that you said were important to you at your last visit. Since your last visit, please 
indicate to what extent you feel you have achieved each goal. Please tick only ONE box for each question. 
 


































































When answering the following 















15. Overall, to what extent have you 




















IMPORTANT – PLEASE READ INSTRUCTIONS CAREFULLY 
 
It is very important that you fill in the chart overleaf as accurately as possible over a 3 
day period prior to attending your test. 
 
It is designed to help us take a closer look at your fluid intake and output, and leakage 
if any. It also helps us to plan the right treatment for you. 
 
For each day, record how much (mls. if possible) and what time you drink and write 
it down in the IN column. 
 
When you go the toilet, measure the urine you pass using a jug (mls. if possible) and 
write it down in the OUT column. 
 
If you leak urine, put an X, yes or √ in the WET column. If you experience urgency i.e 
a sudden desire to pass urine that is difficult to defer please score 0, 1, 2, 3 or 4 
according to the urge score that is described on the next page. Then according to how 





TIME DAY 1    
 IN OUT WET URGE 
SCORE 
07: 10 am  140 mls   
08: 30 am 250 mls    
10: 40 am  90 yes  
12: 00 
noon 
 150  2 
12:45 pm 200 mls    
02: 00 pm  60  0 
 
This means that you passed 140 mls at 07:10 am and had 250 mls of a drink (maybe 
a cup of tea with breakfast). At 10:40 you leaked urine and passed 90 mls. At 12:00 
noon you had ‘moderate urgency’ with a score of 2 which according to the urgency 
score means ‘you could postpone voiding for a short while without fear of wetting 
yourself’. 
 
Please write the time you got up and time you went to bed at the top and bottom of 
the chart for each day. This allows us to see the difference between what is 









Urogynaecology Department, King’s College Hospital 
Bladder Diary 
Time got up: Time got up: Time got up: 
 Day 1    Day 2    Day 3   
Time In Out Wet Urge 
Score 
Time In Out Wet Urge 
Score 
Time In Out Wet Urge 
Score 
               
               
               
               
               
               
               
               
               
               
               
               
               
               
               
               
               
               
               
Time went to bed: Time went to bed: Time went to bed: 
Urge score 
0 No urgency: I felt no need to empty my bladder but did so for other reasons 
1 Mild Urgency:  I could postpone voiding for as long as necessary without fear of wetting myself 
2 Moderate Urgency: I could postpone voiding for a short while without fear of wetting myself 
3 Severe Urgency: I could not postpone voiding but had to rush to the toilet in order not to wet myself 




















14 June 2012 
 
angela.rantell@nhs.net 
Telephone: 01223 597653 
Facsimile: 01223 597645 
 
Miss Angela Rantell 
Professor of Urogynaecology 
King's College Hospital 
King's College Hospital NHS Foundation Trust 
3rd Floor, GJW 
Denmark Hill 
London   SE5 9RS 
 
 
Dear Miss Rantell 
 
Study title: A 12 week, single centre, open label study to evaluate 
the effect of fesoterodine flexible dosing regimen on the 
sexual function of women with overactive bladder. 
REC reference: 12/EE/0029 
Protocol number: AMRPhD1 
EudraCT number: 2010-023851-27 
 
Thank you for your letter of 12 June 2012, responding to the Committee’s request for further 
information on the above research and submitting revised documentation. 
 
The further information has been considered on behalf of the Committee by the Chair. 
 
Confirmation of ethical opinion 
 
On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for the 
above research on the basis described in the application form, protocol and supporting 
documentation as revised, subject to the conditions specified below. 
 




The favourable opinion applies to all NHS sites listed in the application, subject to 
management permission being obtained from the NHS/HSC R&D office prior to the start of 











The Committee has not yet been notified of the outcome of any site-specific assessment 
(SSA) for the non-NHS research site(s) taking part in this study. The favourable opinion 
does not therefore apply to any non-NHS site at present. We will write to you again as 
soon as one Research Ethics Committee has notified the outcome of a SSA. In the 
meantime no study procedures should be initiated at non-NHS sites. 
 
Conditions of the favourable opinion 
 
The favourable opinion is subject to the following conditions being met prior to the start of 
the study. 
 
Management permission or approval must be obtained from each host organisation prior 
to the start of the study at the site concerned. 
 
Management permission ("R&D approval") should be sought from all NHS organisations 
involved in the study in accordance with NHS research governance arrangements. 
 
Guidance on applying for NHS permission for research is available in the Integrated 
Research Application System or at http://www.rdforum.nhs.uk. 
 
Where a NHS organisation’s role in the study is limited to identifying and referring potential 
participants to research sites ("participant identification centre"), guidance should be sought 
from the R&D office on the information it requires to give permission for this activity. 
 
For non-NHS sites, site management permission should be obtained in accordance with the 
procedures of the relevant host organisation. 
 
Sponsors are not required to notify the Committee of approvals from host organisations 
 
Clinical trial authorisation must be obtained from the Medicines and Healthcare 
products Regulatory Agency (MHRA). 
 
The sponsor is asked to provide the Committee with a copy of the notice from the MHRA, 
either confirming clinical trial authorisation or giving grounds for non-acceptance, as soon 
as this is available. 
 
It is the responsibility of the sponsor to ensure that all the conditions are complied 




The final list of documents reviewed and approved by the Committee is as follows: 
 
Document Version Date 
Covering Letter from Angie Rantell  22 December 2011 
Covering Letter from Angie Rantell enclosing revised IRAS 
and scientific critique emails 
  
GP/Consultant Information Sheets Version 1.0 04 May 2011 
Investigator CV - Angela Marie Rantell  09 November 2011 
Other: Summary of Product Characteristics - Toviaz  04 April 2011 
Other: CV of Linda Cardozo (Academic Supervisor)  10 November 2011 
Other: Article used to inform the power calculation   
Other: Data from TESA Study   









Other: The Impact of Fesoterodine on Quality of Life   
Participant Consent Form Version 1.4 13 October 2011 
Participant Information Sheet Version 1.8 09 March 2012 
Protocol Version 1.9 23 May 2012 
Questionnaire: Sexual Quality of life Questionnaire - Female 
(SQoL-F) 
  
Questionnaire: Patient Perception of Bladder Control 
(PPBC) 
  
Questionnaire: Patient Assessment of Constipation - PAC- 
QOL 
  
Questionnaire: Pelvic Organ Prolapse / Urinary 
Incontinence Sexual Function Questionnaire PISQ-12 
  
Questionnaire: The King's Health Questionniare   
Questionnaire: Self Assessment Goal Achievement 
Questionnaire - SAGA 
  
REC application Submission Code 
48710/279901/1/636 
04 January 2012 
Referees or other scientific critique report - email from Philip 
Toozs-Hobson 
 01 June 2010 
Referees or other scientific critique report - email from 
Noreen Hasmi 
 05 February 2010 
Response to Request for Further Information from Angie 
Rantell 
 07 February 2012 
Response to Request for Further Information from Angie 
Rantell 
 09 March 2012 
Response to Request for Further Information from Linda 
Cardozo 
 02 April 2012 
Response to Request for Further Information from Angie 
Rantell, Urogynaecology Nurse Specialist 
 12 June 2012 
 
Statement of compliance 
 
This Committee is recognised by the United Kingdom Ethics Committee Authority under the 
Medicines for Human Use (Clinical Trials) Regulations 2004, and is authorised to carry out 
the ethical review of clinical trials of investigational medicinal products. 
 
The Committee is fully compliant with the Regulations as they relate to ethics committees 
and the conditions and principles of good clinical practice. 
 
The Committee is constituted in accordance with the Governance Arrangements for 
Research Ethics Committees and complies fully with the Standard Operating Procedures for 
Research Ethics Committees in the UK. 
 




The attached document “After ethical review – guidance for researchers” gives detailed 
guidance on reporting requirements for studies with a favourable opinion, including: 
 
Notifying substantial amendments 
Adding new sites and investigators 
Notification of serious breaches of the protocol 
Progress and safety reports 












The NRES website also provides guidance on these topics, which is updated in the light of 




You are invited to give your view of the service that you have received from the National 
Research Ethics Service and the application procedure. If you wish to make your views 
known please use the feedback form available on the website. 
 
Further information is available at National Research Ethics Service website > After Review 
 
12/EE/0029 Please quote this number on all correspondence 
 











Enclosures: “After ethical review – guidance for researchers” [SL-AR1] 
Copy to: Jackie Pullen jackie.pullen@kcl.ac.uk 




















Ms J L Pullen 
KING'S COLLEGE LONDON 
JOINT CLINICAL TRIALS OFFICE, 16th FLOOR, TOWER WING 





Dear Ms J L Pullen 
 











NOTICE OF ACCEPTANCE OF AMENDED REQUEST 
 
I am writing to inform you that the Licensing Authority accepts your amended request for a clinical trial 




The authorisation is effective from the date of this letter although your trial may be suspended or 
terminated at any time by the Licensing Authority in accordance with regulation 31. You must notify 
the Licensing Authority within 90 days of the trial ending. 
 
Finally, you are reminded that a favourable opinion from the Ethics Committee is also required before 























Medicines and Healthcare products Regulatory Agency 
151 Buckingham Palace Road London SW1W 9SZ 









      
 
Dear Miss Rantell, 
 
Study Title: Fesoterodine and sexual function 
 
Condition of approval: This study has been approved however the portfolio adoption 
is still outstanding. Any participants recruited before portfolio adoption will not be 
eligible for CLRN support costs or generate any income for the Woman’s Health 
Division. 
 
In accordance with the Department of Health’s Research Governance Framework for Health 
and Social Care, all research projects taking place within the Trust must receive a favourable 
opinion from an ethics committee and approval from the Department of Research and 
Development (R&D) prior to commencement. 
 
Ethics number: 12/EE/0029 
CSP number: 48710 
EudraCT Ref: 2010-023851-27 
Sponsor: King’s College Hospital 
Funder: Pfizer Ltd 
End date (as per ethics application): 1/12/2014 
Protocol: v1.9 
Site: King’s College NHS Foundation Trust 
R&D approval Date: 16 July 2012 
 
R&D have reviewed the documentation submitted for this project and I am pleased to inform 
you that subject to the condition detailed above, we are approving the work to proceed within 
King’s College Hospital NHS Foundation Trust. The study has been allocated the Trust 
R&D registration number KCH12- 074. Please quote this registration number in any 
communications with the R&D Department regarding your project. 
 
Conditions of NHS Permission for research: 
The Principal Investigator must notify R&D of the actual end date of the project. 
The Principal Investigator is responsible for ensuring that Data Protection procedures 









   The project must follow the agreed protocol and be conducted in accordance with all 
Trust Policies and Procedures especially those relating to research and data 
management. 
R&D must be notified of any changes to the protocol prior to implementation. 
Please submit a copy of the progress report on the anniversary of the Ethics 
favourable opinion (14/6/12) 
 




Please ensure that you are aware of your responsibilities in relation to The Data Protection 
Act 1998, NHS Confidentiality Code of Practice, NHS Caldicott Report and Caldicott 
Guardians, the Human Tissue Act 2004, Good Clinical Practice, the NHS Research 
Governance Framework for Health and Social Care, Second Edition April 2005 and any 
further legislation released during the time of this study. 
Members of the research team must have appropriate substantive or honorary contracts with 
the Trust prior to the study commencing. Any additional researchers who join the study at a 
later stage must also hold a suitable contract. 
 
If the project is a clinical trial under the European Union Clinical Trials Directive the 
following must also be complied with: 
 
1. The EU Directive on Clinical Trials (Directive 2001/20/EC) and UK’s implementation of 
the Directive: The Medicines for Human Use (Clinical Trials ) Regulations 2004; 
2. The EU Directive on Principles and Guidelines for Good Clinical Practice (EU 
Commission Directive 2005/28/EC); and UK’s implementation of the Directive: The 
Medicines for Human Use (Clinical Trials) Amendment Regulations 2006; 
 
Amendments 




It is obligatory that an annual report is submitted by the Chief Investigator to the research 
ethics committee, and we ask that a copy is sent to the R&D Department. The yearly period 
commences from the date of receiving a favourable opinion from the ethics committee. 
 
Should you require any further information please do not hesitate to contact us. 
 
 

















PISQ-IR: Sexual Function for Women with: POP, Urinary 































Q1 Which of the following best describes you: 
 
 
Not sexually active at all 1 G º Go to item Q2 (Section 1) 





Q2 The following are a list of reasons why you might not be sexually active, for each one please indicate how 











a  No partner G1 G2 G3 G4 
b  No Interest G1 G2 G3 G4 
c Due to bladder or bowel problems 
(urinary or fecal incontinence) or due to 
prolapse (a feeling of or a bulge in the 
vaginal area) G1 G2 G3 G4 
d   Because of my other health problems G1 G2 G3 G4 
e   Pain G1 G2 G3 G4 
 
Q3 How much does the fear of leaking urine and/or stool and/or a bulging in the vagina (either the bladder, 
rectum or uterus falling out) cause you to avoid or restrict your sexual activity? 
 
1 G Not at All 
2 G A Little 
3 G Some 
4 G A Lot 
 
Q4 For each of the following, please circle the number between 1 and 5 that best represents how you feel 
about your sex life. 
 
   
RATING 
   
a. Satisfied 1 2 3 4 5 Dissatisfied 
b. Adequate 1 2 3 4 5 Inadequate 
Section 1: For those who are not Sexually Active 















a. I feel frustrated by my sex life 
b. I feel sexually inferior because of my 
incontinence and/or prolapse 
 
c. I feel angry because of the impact that 
incontinence and/or prolapse has on my 
sex life 
Q6 Overall, how bothersome is it to you that you are not sexually active? 
 
1 G Not at All 
2 G A Little 
3 G Some 
4 G A Lot 
 















































Q7 How often do you feel sexually aroused (physically excited or turned on) during sexual activity? 
 
1 G Never 
2 G Rarely 
3 G Sometimes 
4 G Usually 
5 G Always 
 













a. Fulfilled G1 G2 G3 G4 G5 
b. Shame G1 G2 G3 G4 G5 
c. Fear G1 G2 G3 G4 G5 
 
Q9 How often do you leak urine and/or stool with any type of sexual activity? 
 
1 G Never 
2 G Rarely 
3 G Sometimes 
4 G Usually 
5 G Always 
 
Q10   Compared to orgasms you have had in the past, how intense are your orgasms now? 
 
1 G Much less intense 
2 G Less intense 
3 G Same intensity 
4 G More intense 
5 G Much more intense 
Section 2: For Those Who are Sexually Active 
The remaining items in the survey are about a topic that one is not often asked to report on in a 











Q11   How often do you feel pain during sexual intercourse?  (If you don’t have intercourse check this box G 
and skip to the next item.) 
 
1 G Never 
2 G Rarely 
3 G Sometimes 
4 G Usually 
5 G Always 
 
Q12   Do you have a sexual partner? 
 
1 G Yes º Go to Q13 
2 G No º Skip to Q15 
 
Q13 How often does your partner have a problem (lack of arousal, desire, erection ,etc.) that limits your 
sexual activity? 
 
1 G All of the time 
2 G Most of the time 
3 G Some of the time 
4 G Hardly ever/Rarely 
 












a.  Your sexual desire G1 G2 G3 G4 
b.  The frequency of your sexual activity G1 G2 G3 G4 
 
Q15   When you are involved in sexual activity, how often do you feel that you want more? 
 
1 G Never 
2 G Rarely 
3 G Sometimes 
4 G Usually 
5 G Always 
 
Q16 How frequently do you have sexual desire, this may include wanting to have sex, having sexual 
thoughts or fantasies, etc.? 
 
1 G Daily 
2 G Weekly 
3 G Monthly 











Q17   How would you rate your level (degree) of sexual desire or interest? 
 
1 G Very high 
2 G High 
3 G Moderate 
4 G Low 
5 G Very low or none at all 
 
Q18 How much does the fear of leaking urine, stool and/or a bulging in the vagina(prolapse) cause you to 
avoid sexual activity? 
 
1 G Not at All 
2 G A Little 
3 G Some 
4 G A Lot 
 
Q19 For each of the following, please circle the number between 1 and 5 that best represents how you feel 
about your sex life. 
 
    
RATING 
   
a Satisfied 1 2 3 4 5 Dissatisfied 
b Adequate 1 2 3 4 5 Inadequate 
c Confident 1 2 3 4 5 Not Confident 
 

















b.  I feel sexually inferior because of my 
incontinence and/or prolapse G1 G2 G3 G4 










d. I feel angry because of the impact that 
incontinence and/or prolapse has on my 





















King’s College Hospital NHS 







My name is Angie Rantell and I am the Lead Nurse in the Urogynaecology 
Department at King’s College Hospital. I am currently undertaking a PhD assessing 
the impact of bladder symptoms on the sexual function of women attending our unit. 
 
As part of the study I am planning to run two focus groups.  A focus group is where 
we assemble a group of women to discuss a topic and provide feedback. I specifically 
wish to encourage women in this group to discuss how they feel about discussing 
sexual function with health care professionals and how you feel it is best for us to 
approach this subject during a consultation. 
 
If you would be happy to join in one of these focus groups then please let me know 
either by email or by telephone – details below. 
 
angela.rantell@nhs.net 
0203 299 3457 (answerphone is checked daily) 
 
The discussion will last approximately 1 hour and you will be provided with 
refreshments and receive a Marks and Spencer’s gift voucher to compensate you for 
your time. You will be asked to complete a consent form at the start of the focus 
group but your identity will remain anonymous for the course of the discussion and in 
any write up and evaluation of the outcomes. You will be free to leave at any time 
during the discussion. 
 
If you wish to participate, I look forward to hearing from you or if you would like 
further information before joining please do contact me by phone or email. 




May – Arrive at 2pm, discussion to start at 2.30, finish by 3.30 
Wednesday 10
th 
May - Arrive at 6pm, discussion to start at 6.30, finish by 7.30 
Both will take place at King’s College Hospital, Denmark Hill, London, SE5 9RS. 
Further information will be provided on agreement to attend. 




Lead Nurse Urogynaecology 
















Patient Information Sheet 
 
1. Introduction 
You are being invited to take part in a focus group. Before you decide to take part, it is 
important for you to understand why this research is being done and what it will involve. 
Please take time to read the following information carefully and discuss it with others if you 
wish. Ask us if there is anything that is not clear or if you would like more information. 
 
2. What is the purpose of the study? 
The focus group aims to encourage women who have been seen in the Urogynaecology clinic 
in King’s College Hospital to help us to understand how sexual function should be discussed 
during a consultation in a gynaecology clinic. We wish to understand how you would like 
clinicians to approach the subject and the barriers that hinder discussion. We are happy to 
hear from women who are or are not sexually active. 
 
3. Why have I been chosen? 
You have been identified as a potential participant in this focus  group.  We would like to 
recruit 20 women from our clinics to participate in two groups. 
 
4. Do I have to take part? 
It is up to you to decide whether or not to take part. If you do decide to take part you will be 
given this information sheet to keep and given time to review the information. 
If you decide not to take part, you do not have to give a reason. If you decide to take part you 
are still free to withdraw at any time and without giving a reason. A decision to withdraw at 
any time, or a decision not to take part, will not affect the standard of care you receive. 
 
5. What will happen to me if I take part? 
If you take part in this study, your involvement will last approximately 1 .5 hours. The first 30 
minutes will be for administrative tasks when you will be required to sign an informed consent 
form to agree to participate. Following this you will  be asked to participate in a discussion  with 
a group of women for approximately one hour. We hope you share your personal views with us 
and comment on other women’s ideas to help us to understand why you agree or disagree with 
their views. If you have had particular experiences (good and bad) that have helped to shape 
your views we would encourage you to share these with us. 
 
. 









6. What do I have to do? 
If you wish to take part in this study you will be asked to: 









 Attend the focus group at the time agreed
 Participate in the discussion
 Share your own views on the topic
 
7. What are the possible benefits of taking part? 
 
 
The information we gain from this study might help us to approach the topic of sexual function 
in women attending the gynaecology clinics in a more thoughtful, user friendly manner. 
 
8. What are the possible disadvantages and risks of taking part? 
 
 
There are no physical risks to participation and it will not affect your care within the department. 
However, you will be asked to share your personal opinions and possible experiences with 
other women. Although we will not be making reference to any individuals diagnosis or 
treatment plan during the course of the session, potentially, women may feel embarrassed 
about the discussions given the sensitive nature of the topic. 
 
9. Payment 
You will receive a £50 Marks and Spencer’s voucher at the end of the group session to 
reimburse you for your time. 
 
10. Will my taking part in this study be kept confidential? 
If you join the focus group, the nurses and other hospital personnel involved in this study may 
need access to your medical history for the purposes of this study. By signing the consent form 
you agree that the study personnel can access your medical history. 
No names will be used during the discussions and your identity will be kept anonymous 
during the focus group. 
Some of the data collected may be seen by monitors, auditors, ethics committees and other 
authorised individuals from King’s College Hospital NHS Trust (the sponsor of this research), 
and representatives of regulatory authorities, to check that the study is being carried out 
correctly. They will all have a duty of confidentiality to you as a research participant. By signing 
the consent form you agree to this access for the study. 
Any records identifying you will be kept confidential and won’t be made publicly available. 
 
 
11. What will happen to the results of the study? 
Once all the focus group results are available the study nurse will be happy to discuss this 
with you. A final report will be produced and may be published. A copy of the publication will 
be available from King’s College Hospital on request. Please note that your name will not 
appear in the final report or publication. This study is part of an educational project. 









12. Who is funding the study? 
This study is being funded by an Investigator Initiated Research Grant from Pfizer Ltd. Some 
members of the Urogynaecology team perform consultancy work for Pfizer Ltd. 
 
13. Contact names and telephone numbers for further information 
For any concerns or other questions about this study, please contact: 
 
Angie Rantell 0203 299 3568 
angela.rantell@nhs.net 
 
For any concerns about your rights as a participant or any complaints please contact the 
Patient Advice and Liaison Service (PALS). This is a service that offers support, information 
and assistance to patients, relatives and visitors. They can also provide help and advice if 
you have a concern or complaint that staff have not been able to resolve for you. The PALS 
office is located on the ground floor of the Hambleden Wing, near the main entrance on 
Bessemer Road - staff will be happy to direct you. 
Tel: 020 3299 3601 
Textphone: 020 3299 1878 




Before you sign the informed consent form, you should ask questions about anything that you 
do not understand. The study staff will answer any questions before, during and after the study. 
 
Thank you for taking the time to read this information sheet. 
















Centre: King’s College Hospital 





Assessing the Sexual function of women attending a gynaecology clinic 
 
Name of Researcher: Professor Linda Cardozo, FRCOG and Angie Rantell BSc (Hons) 
RN. 
 
Please initial box 
 
1. I confirm that I have read and understand the information sheet 
(version 1.0 dated 12/04/2017) for the above study.  I have had the 




2. I understand that my participation is voluntary and that I am free to withdraw 




3. I understand that relevant sections of any of my medical notes and data 
collected during the study may be looked at by responsible representatives of 
the sponsor or the NHS trust, the ethics committee and regulatory authorities, 
where it is relevant to my taking part in this research. I give permission for 
these individuals to have access to my records 
 
 









Name of Patient Date  Signature 






















Cathy Davis – Nurse Specialist – scribe 
Patient 1;2;3;4;5;6;7 
Reason behind the group: as part of my work I was trying to investigate how treatment affects  sexual 
function in women with an overactive bladder. When women come to see us in the Urogynaecology 
clinic, what are the issues about discussing sexual function; what do we do well; what do we do badly; 
how do you want us to approach it. I want you to tell me your experiences; how you think something 
should be done; what you would like from us and I will have a few questions to prompt along the way. 
 
Confidentiality: Everything will stay in this room; please feel free to share – you don’t have to share 




When you have been to your GP, you get referred to the Urogynaecology Clinic and we are going  to 
see you and start taking a history; how do you think we should approach the subject of sexual 
activity and sexual function? 
 
Patient 1: I think it depends on the person who is coming along; there could be a religious issue and 
that has to be taken into consideration. Some people are more broad minded than others and are able 
to discuss things quite openly and then equally, you will have some patients who are quite closed up 
and would feel quite uncomfortable, so there are quite a few things to take on board. I think having a 
written question and answer, rather than a verbal conversation, would make it a lot easier, so that 
you can tick boxes and that might be a way of lessening the embarrassment for some patients. 
 
So, depending what you tick on the form means we would bring up the subject or not? 
 
Patient 1: Yes, or you could even have a question on the form e.g. if there was some sexual activity, 
then you could fill in a box, possibly. 
 
Patient 5: I think the doctors should be allowed to express their concern with sexual activity before 
the patient comes, because a lot of people have got more trust in the doctors than when they are 
coming here for the first time. They won’t seem so uncomfortable when they come here. From 
experience, I feel that. 
 
Patient 2: I think questionnaires are a good way of maybe gaining consent, in the broad sense of the 
word. The problem is that it is all down to the questions; I did feel that some of the questions now 
would not apply to me. If I remember rightly, they are structured such that I did not really know what 
to put down on the form and sometimes that tick box, with something that is personal like sex, doesn’t 
always apply in the same way as; how many times do you pee a day; how many times do you have to 
get up in the night. So that would be my caution against; I am going on personal experience and the 









Patient ?: I don’t mind generally chatting, especially if the clinician is female it’s a lot easier. I have had 
to have an examination by the two Gynae guys and they have always been either older men or female 
and they were a lot younger than me and that was excruciatingly embarrassing…it was just awful.  I 
know they have to do it, but I felt very embarrassed. 
 
Patient ?: Age is an interesting thing, but maybe we will come on to that. 
 
Patient 7: I also think a lot of patients come with somebody; a friend, husband. Even with your 
husband sitting there, who you are obviously intimate with, I think a lot of people would not be 
comfortable talking about their issues with sex with their husband, with their husband sitting there, 
and more so if it is just a friend. I think you need to be mindful of the fact that, if you have a patient in 
front of you who has someone with them, you are less likely to get as much information and them be 
as open as you would need them to be with their companion in the room. 
 
Patient 6: I have been coming for a lot of years and had a lot of things done, but I agree with you; I 
have had men to do the one where you do the weeing and all that sort of thing and it is totally 
embarrassing when you have to wee and then come back. You want to die really…you feel happier 
with a woman, but I think that because of what we do, it’s not really something that you want a man 
to see. I’m sure they don’t think anything of  it and I’ve always found them to be really lovely, but  you 
think why a man would want to do this. I have been coming a lot of years, but I have never been put 
in a place where I have felt uncomfortable; it has always been on a form. Nobody has really asked me 
where I felt embarrassed. I’ve never been put in that position. It is something you want to gloss over; 
for me, having an overactive bladder has made me ashamed to tell people I’ve got it.  Even girlfriends; 
I go away with my girlfriends once a year and because I wear a pad; if share with someone and I hide 
it and not let them see that I wear them because they make jokes about the Tena lady on the TV and 
I feel embarrassed, so I hide it. It’s one of those things that you don’t really want to talk about.  I don’t 
know if you agree? 
 
Patient 2: I definitely concur. You have got the shame of having an overactive bladder and then talking 
about very personal issues. I agree with Patient 7; I am not in a partnership any more and I would not 
have wanted to discuss our sex life with him alongside me. It does not matter for me so much if it is a 
man or a woman, but I think that, not to big up Kings, this is a much better department than in some 
other places. There were things within the dynamics of me and that partnership and I am very open-
minded, the last thing I would have wanted to discuss would have been our sex life with him sitting 
there. 
 
Patient 6: I would say that as well. I don’t know if you all agree; it’s not one of those things that you 
don’t really want to talk about. It’s almost like you are ashamed. Even my husband asked me today 
where I was going.  I said I was just going up the hospital and he asked if it was getting any better  and 
I said yes, but he doesn’t really want to know. It’s something they don’t want to delve into. 
 
Patient 5: I have a different experience because I went through a very, very early menopause, so my 
husband grew up with me going through all that, so I’m not embarrassed of talking to a man, not all 
men; my son understands; my husband; close family and the doctors. 
 
But with the bladder problem though, do you still talk about it? 
 
Patient 5: I still talk about it to my family and anyone. I really do find you do benefit from it; they 
understand, so when I’m going out anywhere, they say that they will have to make sure we are near 









Patient ?: I find my friends easier to talk to; we are the same age and got the same issues, especially 
if you’ve had a couple of kids; we have a joke and laugh about it, but it’s not something I would discuss 
with people at work. 
 
Patient 2: I’ve noticed; I don’t have children and am in my late 40s, but with friends that have, there 
is a bit of this; I went to the gym and had a little bit of an accident; so it has opened up; but for years, 
having had an overactive bladder all my life and the shame throughout my whole life and the impact 
that that has had on my sexuality; it is very difficult to just turn that around in 5 minutes.  When I  had 
to do the whole urodynamics testing and I have had it done twice here now and the second time, the 
young gynaecologist came and asked if he could do an internal examination and I don’t have an issue 
with that so much; whether it is a man or a woman. 
 
Patient 3: I do agree, but I don’t discuss sex life with my son, he is a doctor. I came here with a prolapse 
problem. At that moment I was going through a hard time, so I thought that it was best to open out 
with him. I told him my problem and he was very open with me and he helped me. 
 
Did it feel better talking to him? 
 
I felt better; I felt, well he is a doctor; let me ask him about it, because the operation is going to take 




Thinking about when people come to clinic that have bladder or prolapse problems, that aren’t 
sexually active; what are people’s views on how far health care professionals should delve into why 
they are not sexually active? 
 
It depends whether it was relevant or not. I think a lot of the time it wouldn’t be, would it? 
 
Ultimately, it is trying to understand the difference between not sexually active because of lack of 
a partner or through choice; or because of a problem that we could potentially help with. 
 
Patient 5: Mine is through choice after my husband passed away 25 years ago. 
 
If someone asked you that, you would be happy to share that with them? 
Patient 5: Yes. 
Patient 4: I have not been sexually active over the past years and I find it embarrassing to talk about 
it; especially when some of my friends ask how come I am not doing it and then I get all embarrassed 
about it and people are always question about it and I get embarrassed and sometimes I even lie about 
it and say I am having it and I’m not. One of my friends said that she sees I have two children, but she 
has never seen me with a man; what is wrong with you. I am very embarrassed and I say  that my 
partner is living abroad; I find different excuses. Then I go to the doctor and he will ask me why I am 
not sexually active and sometimes I do not know the answer to give him because I don’t know. 
 
Patient 2: Talking from personal experience; I think it is important not to exclude people, or having a 
conversation with people, because just because they are not sexually active, that is only at the time 
you are asking them and also, there are all sorts of reasons; we were talking about the shame over so  









around, that if I had not been asked that question, I would have been quite upset because it is almost 
negating part of me as a woman and I think we all have the ability to be sexually active and if it 
becomes an exercise in exclusion, that would make me feel really sad. 
 
Patient 6: Do you think that they are linked then? Do you think the overactive bladder is linked? 
 
There is evidence to say that women with an overactive bladder have less sexual activity and some 
avoid sexual activity; more with prolapse; but that’s ultimately what we are trying to understand 
when we are asking the questions. Is it because of the bladder, bowel or prolapse problem, or is it 
because of external reasons that we don’t need to go into. 
 
Patient 7: You have basically touched on what I was going to say which was, how you ask the question. 
You can ask the question, “Are you sexually active” and if they say yes/no, you can  tactfully ask “Is 
that through choice”; “would you like to be more sexually active, but you find that this problem 
prevents you, or is it because of other factors which are not relevant to why you are here” and 
depending on how they answer then that would depend on how you perceive. 
 
Patient 4: Since I had my hysterectomy done, I have not got a partner, but am not really interested 
because I do not feel that I want to have sex and that’s over about 10 years and I have not had 
intercourse since then. Now the bladder problem, the prolapse problem, everything put me off. I have 
no feeling down below. 
 
Patient 6: I think also that now people talk about bladder problems, but when I first had it, there were 
no adverts on telly for pads and it really was taboo. I can remember when you would go and buy 
sanitary towels and they would put them in a brown bag so nobody would see them. Now it is much 
more talked about, but I still don’t feel that it is something I want to go and shout about. I still feel 




If, when you came into clinic we didn’t ask about it; what would make you volunteer something 
about it or ask questions yourself? 
 
Patient 7: If you felt it was an issue for you and you weren’t embarrassed to do so; but I think a lot of 
people, it might be an issue for them and if you don’t ask them, they are not going to speak up. 
 
Patient 6: I think that if you feel it is linked to the problem, I think you should ask; only if you think it 
was relevant. You are not asking just to be nosey, but if it is linked to the problem, then you should 
ask. 
 
Patient ?: I think Patient 7 touched on it and it’s having a question or even a consent to ask would you 
be happy to discuss your sex life, or it would be in similar terms and then you are giving some agency 
to us women to then go forward with that and I think the other important thing is menopause, which 
I haven’t hit yet, I am Perimenopausal and I think that it is very important that historically, women of 
a certain age, once child rearing years have gone, it’s almost as if you don’t matter; it’s like you retreat 
back into being a shadow. That’s why I think discussing a patient’s sex  life, whether or not they are 
having it, not having it, want it, why, is very important; otherwise it is a bit like we are being put out 
to grass. 
 
Patient 7: I think another thing you have to differentiate between is what has started off as not having 









been without it for so long, you have lost that sex drive. So there is nothing to say that a woman, if 
she met a man that she was interested in, that he might actually resurrect that sex drive in her, but a 
lot of women will just dismiss it because they don’t have a sex drive anymore; but what started that? 
Was it abstaining because of the problem and then you have now gone without for so long; naturally 
that is what happens to human beings, men and women, the sex drive disappears and that is a bit 
more difficult to get around, because I think a lot of women might just go without because they are 
no longer feeling that sex drive because they have gone without it so long; but they could actually 
resume a very healthy sex life with the right person and with their problem being sorted out. 
 
Anybody else have any comments on that? 
 
Patient ?: It has always been on the form, going back and back, it’s always a question isn’t it, but you 
don’t think it is very important, maybe. 
 




One of the other things, when it comes to asking women about sexual activity, we know that certain 
type of sexual activity are actually linked to certain types of problems; so we know, for women who 
come with recurrent urine infections, potentially it can be because of sexual practice, anal sex and 
things like that. What are people’s views on, if they say they have bladder and bowel symptoms and 
they are sexually active; how do you feel when someone asks you if you are having vaginal sex, anal 
sex, masturbation and that sort of thing? 
 
Patient 1: I was asked that a number of years ago, it wasn’t for urogynae, but it was for piles. That was 
quite embarrassing, because I wasn’t expecting the question. As I was being examined, the consultant 
asked if I have anal sex (intercourse) and I was so taken aback that I asked him if he did.   It took me 
off guard and I didn’t expect it; it was very embarrassing. 
 
Patient 2: I can’t remember where I saw it, but a couple of weeks’ ago I read an interesting article, 
that given that sexual practices are changing, whatever that means, that there does need to be more 
questions asked about those individual practices. Otherwise you are not getting a full picture. If 
someone is engaging in a particular practice and that is causing an issue… 
 
The latest National Survey showed that, yes, sexual practices are changing. For women over the past 
30 years, more women are having same sex relationships; more women are having anal sex; more 
women are masturbating in comparison to numbers years ago and less women are having vaginal 
intercourse. 
 
Patient 7: Is that vaginal intercourse per se or less women are having it as the general form of sex? 
 
As the general form of sex. 
 
Patient 6: Do you think that that is linked to problems? 
 
We don’t know. 
 
Patient 7: My daughter is 19 and my son is 18 and their sex lives are completely different to mine at 









nothing is off limits; nothing is taboo. Their friends are all the same and they are very open and are 
not embarrassed to talk about it; I’m very fortunate like that. 
 
Patient 6: When I was young, nobody talked about anything like that. When you had your period, it 
was your curse; you did not talk to your mum about anything like that. My mum told me about sex life 
when I was 11. With my children now, if I say anything about it they tell me to shut up because they 
can’t bear it! 
 
Patient ?: So women are having less vaginal sex. Well can’t you mix and match; have oral and  vaginal. 
 
Many women are mixing and matching. As their primary type of sexual activity, less women are 
having vaginal sex. 
 
Patient ?: Maybe it’s because it’s less of a case of years ago with the lights out and the nighty went 
over the head. 
 
Patient ?: Attitudes have changed though haven’t they.  Even sex education for my children at 14  and 
18; when my son came back and told me about sex education, I nearly fell over; it was very graphic; 
but my son, even at age 14, was quite happy to tell me what was discussed and it brought  up lots of 
things; specific acts, which I was quite shocked at, because I didn’t talk to my mother  about it.  People 
are more open now. 
 
Patient 6: My son is a school teacher of seniors and he has a transgender in his class. That is a whole 
new thing of how to handle that. He is a PE teacher and this is a girl who wants to be a boy.  When  he 
tells me how he has to hide it from the other kids and has to still address him as a boy because he 
hasn’t changed yet. His partner is a primary school teacher who teaches little ones and even then, 
with the 4 and 5 year olds, she can still tell sometimes by how they play, that they are not coming from 
very good homes, because of how they play with one another. This is  something you would  not have 
thought of with a 5 year old where they are coming from homes where things aren’t right. You have 
all these things that we wouldn’t even have dreamt about. 
 
Patient ?: I suppose the overactive bladder is seen, well I’ve got this idea, that it is for older ladies, but 
actually, if I have had it all my life, then many other women have had it all their life. So, when  you are 
doing a sexual practices questionnaire, obviously you would have to be very cautious because, 
probably, if you were to give “do you do this, this, this and this” some peoples eyeballs might fall out.  
So that is a really difficult one. 
 
Patient 6: But that probably would really help you though wouldn’t it, if people were really honest? 
Alright, my days are gone, but for people who are in that age group, I suppose that would be really 
helpful, but I don’t know if people would want to do it. 
 
Patient 7: I think, given the option, if they are happy to complete a very personal questionnaire; 
explain it would be very useful and it might help in their treatment. Give them the option; there is a 
questionnaire we would like you to complete; however, it is extremely personal, some might say 
invasive, if you are comfortable with it, fine, but if not you don’t have to complete it. 
 
Patient 2: But then, if say you are using the example, I presume you are talking about UTIs and anal 
sex. They might not be having UTIs at all, it might not be relevant, so then is it better to have a  casual 
conversation with the female patient, because then you are a bit more led…I sometimes wonder, it’s 











So that’s a really interesting question for you all…do you think people always tell the truth? Do  you 




What do you think people aren’t truthful about? 
 
Patient 7: They don’t want to be judged primarily. People make a judgment on you within the first few 
minutes; although clinicians don’t do that, but you do feel that, you do feel like you are being judged. 
 
Patient 6: Even if you did do all those things that you were saying, would you want to tell people, 
because would you not be ashamed? Would you think “I’m not telling them that”…even if you did do 
it; you would really want to…they would think this and that. With drink; when it’s on the form, you 
think “what should I put?”…do you put what I think they want me to put. 
 
Patient 7: My ex-husband was actually an alcoholic unfortunately. I had been  telling him for years  he 
had a problem, sometimes he listened; sometimes he didn’t. After we divorced, he asked me to go 
with him as he had to have a medical and one of the questions the GP asked him was how much he 
drank.  He came out and he was really shaken and he said “I really have got a problem haven’t I?” I 
asked what the doctor had said and he said “he asked what I drank and I lied; I halved it and he still 
turned around and called me an alcoholic”. He completely lied even though it was very serious and 
important that he was honest. 
 
There is evidence to say that, when men are asked to say about sexual function the most  commons 




So what do you think the particular aspects of sexual function that women are probably least  likely 
to be honest about? 
 
Group: Number of partners; how many times they do it. Number of partners is probably the biggest 
one. 
 
Patient ?: If they are having relationships with more than one person – a lady might be in a 
relationship, but may actually have someone on the side and be less likely to admit to that. 
 
Patient ?: That’s really important, because you tend to think in terms of questionnaires that its…you 
might be single like me, or you might have a partner; but if people are having affairs; they might, they 
might not, but it does have a bearing. 
 
Patient ?: Again, if you are asking these questions with the husband there and she’s having an affair 
and she is asked how many times a week she is having sex! 
 
Patient ?: I think men are a lot more het up about prowess than women; although, I think that may be 
changing now, because with the increase in pornography; not my cup of tea; but I speak to younger 
women and it seems that sex is becoming a bit of a performance art now, rather than just being 









this/that”, so it’s almost taking on that male thing. But what you have just said about multiple 




So coming back to that clinic appointment when we are asking questions…when do you think it is 
appropriate to ask you about sexual function and activity? At what point in the conversation? At 
what point in your journey?  Is it something we should be going into on the first appointment?  Is  it 
one of the first questions we should ask? 
 
Patient 7: Because it is such a highly personal thing and a lot of people would be very uncomfortable 
being asked it straight off. I think you have got to establish, for want of a better way of putting it, a 
relationship with your patient before you can broach something like that. 
 
Patient 6: I think also that if it’s a woman or a man asking you makes a difference. I think you would 
be much happier telling a woman than a man. 
 
Patient 3: Yes, you feel more comfortable with a woman. When I came the first time, she asked me 
when did you last have sex and her colleague was sitting there as well and I didn’t know what to say, 
I just said, last week, even though I hadn’t. I just had to say, thinking she might think I wasn’t having 
any personal relationship, but because of the prolapse, I just didn’t feel comfortable at that time and 
that was the only reason. 
 
Patient ?: JB is lovely, but I could not sit here and talk to him in the same way. 
 
Patient 7: If you are going to introduce that conversation with a patient, it would be better to have a 
female nurse or doctor, someone trained to specifically cover that are, rather than…I know that the 
consultants are specialists, but if they are male, you are not going to get the answers that you need as 
much as if you had somebody, a nurse who was specially trained to sensitively deal with that aspect. 
 
Patient 6: I think it depends who asks you the question and how comfortable you feel with them. 
Someone like yourself, you would feel quite comfortable saying that. 
 
Patient ?: sorry ange…can’t hear this so good! 
 
Patient 6: If you have said that it would be helpful to us…if you said, “I’m not asking this to be nosey, 
but it would really help us in our research if I ask you this question” so that people know that you are 
not asking it as a matter of course. 
 
Patient ?: I don’t think it is just for research, it’s for the benefit of the patient too. 
 
Patient 2: I also, it’s relevant to the question but perhaps going off on a little bit of a tangent, but 
budgets are being cut and I was reading about somewhere in Germany where they were using, and I 
don’t like the term peer support, but they were not exactly focus groups, so that the information  was 
captured where there wasn’t the time or the resources to have a woman or a nurse on, rather than 
clamming up in front of a male doctor or consultant. 
 
Patient 7: Maybe also, for those who still feel uncomfortable talking to another being, whether they 











So, as well as the questionnaire, what other things can we as clinicians do to make you more 
comfortable to discuss that with us? What are you looking for to feel that comfort to be able to 
discuss? 
 
Patient 6: I don’t think you could do any more really. I think, just make sure it is a woman and not a 
man and I think you would just be embarrassed saying that to a man…well most people, not 
everybody, but I think if it was a woman asking it, I don’t think you could do any more. 
 
Patient 7: I think maybe if you make them feel that they are not alone; if you were to say “we find that 
a lot of our patients experience this”, they might say, “oh yes, I had that”, but also it would  cover the 
bit where you are making them realise that it’s not unique to them; they are not alone in that problem 
and I think that would make them feel more comfortable discussing it. 
 
Patient 6: I just think that women make a joke of it. I work with a girl who says about the advert for 
Tena lady…why is she smiling…I wouldn’t be smiling if I was weeing myself jumping up and down…and 
because people make jokes like that: she’s one of the girls I go away with I wouldn’t dare say that I 
wear them. 
 
Group: She is probably wearing them. She’s wearing Always, couldn’t afford the Tena’s. It’s a jealousy 
thing. 
 
Patient 6: That’s why I hide mine, because I don’t want anyone to see them. I feel ashamed and I  feel 
that if they know I wear them, they probably wouldn’t, but I don’t want to be the butt of their jokes, I 
don’t want them to see that I wear them, which is silly really. 
 
Patient ?: Can I ask why more women are not offered things like TVT’s, because I think so many women 
assume that they have to live with this problem and their only way of getting through life is with pull-
up pants and Tena lady? 
 
Going off on a tangent; it’s actually because it is not suitable for all women. People with  overactive 
bladder and things like that, doing a TVT will make them worse and so it is not a suitable form of 




Apart from being a woman, what other factors may prevent you from opening up? Ignore the fact 
that it’s a man, if it is a woman asking the questions, what other things may prevent you from 
opening up to the woman and answering questions about sexual function? 
 
Patient ?: I think it just depends on the individual. Some people just will never be comfortable 
discussing with someone they don’t know, or even with their partners. It’s the individual  personality. 
 
Patient 7: I also think it is depending who is asking the questions; they have got to make you feel at 
ease. If you’ve got someone who is really officious, treating it like a school exercise, you  are not going 









Patient ?: As with any relationship, emotional, professional, whatever; it does come down to dynamics 
and maybe there are just some people who will never want to open up and you just have to factor 
that in and then there are others, who are probably not best professionals who aren’t best placed to 
be asking those questions because they don’t have the empathy or the understanding. We are talking 
about men and women, but I have come across male doctors in the past who have had far more 
empathy than women doctors. 
 
Patient 6: I just think that if a man asks you that though, you just straight away have that sort of 
embarrassment with a man, whereas, if a woman asks you, I think you feel that bit more comfortable. 
I know that they would not just be asking you for the sake of it, but for me being an older lady, I just 
feel that I don’t know if I could answer. 
 
Patient ?: Well it’s a bit like personal grooming, the number of women that say “I’ve got a Gynae 
appointment tomorrow and I haven’t had a wax”, but you think to yourself, I’m sure they are really 
not bothered. 
 
Patient ?: I know it sounds silly, but I would feel more comfortable discussing it with a 65 year old guy 
than some Greek God, tanned, sitting opposite me; I could not meet their eye and discuss anything. 
 
Patient ?: That’s an interesting thing…age. I think that with age does come a bit more empathy and 
understanding; not necessarily, but I think that I would feel much better happier discussing things of 
a sexual nature, male or female, with someone who is not a young pup, for want of a better word. Just 




Anything about the environment you are doing it in. A lot of you have gone through Urodynamic 
tests or come along to different clinic appointments, Nurse-led or Physiotherapy and they are all  in 
slightly different environments that have made you feel more comfortable? What environment 
would make you the most comfortable to chat openly and honestly? 
 
Patient 3: If it was a mature person, then you would be more comfortable, but young doctors have  to 
learn as well. They need to be there as well, but you do feel, oh it’s a young person. 
 
Patient 6: Is that the one where they x-ray you…that is sole destroying that one. 
 
Patient ?: I was so glad I did it though, because when I was first diagnosed 10 years ago, it was just a 
relief. Your office is quite nice…that’s the nicest office. You and the other lady that I see are both so 




We mentioned earlier about when friends or relatives or partners come to the appointment with 
you. If we wanted to ask questions and your partners were there, what are you views on whether 
we ask your partner to leave the room and then ask you questions; how do you want us to broach 
the subject, because ultimately there are times when we have to ask you certain questions, but yes 
we understand that if there are people with you, you may not want them to know  the answers, so 









Patient 7: I think you need to ask the patient before they attend the appointment, because I know 
that if I came with my husband and you said that you wanted to ask some sensitive questions about 
my sex life and would I like him to stay or go; I would feel really uncomfortable asking him to leave the 
room, I know I would worry about how he felt about that. I think if possible, I would prefer to be asked 
before I arrived at the appointment; then at the appointment you could ask him to step outside for a 
while and it wouldn’t look like you have had them banished from the room. 
 
Group: I wouldn’t bring my friend along. Nor me. Some people would. Ultimately, you may want to lie 
or not be truthful. 
 
I think often women and men, when they are coming for an appointment they worry that they are 
not going to remember everything, so they have someone else there to help them go through 
everything to make sure they have understood everything and remember everything, but it is how 
close is that person and what do you want them to know. 
 
Patient ?: I think it is up to the individual. I feel more comfortable coming alone. Even when I did have 
problems going back a few years ago, my husband said that he didn’t feel comfortable coming, so I go 
home and tell him what was going on. 
 
Group: My husband wouldn’t be interested at all. I’m sure there are plenty of people who come  with 
somebody. 
 
Patient ?: I think your point about there being a sort of proviso in the appointment letter; I haven’t 
mentioned before that sometimes the way the appointment letters are structured I can’t work out 
what’s going on, but so people are aware that there might be a part of the consultation where it might 




There is a group of people who come along to appointments and they haven’t completed any 
paperwork and they haven’t done the questionnaires and there is a group of people who either 
can’t read or write or don’t have the appropriate language skills to have been able to answer in 
advance.  How do you think we can get around that? 
 
Patient 7: You can only phone. I think you need to speak to the patient. You can’t assume that they 
have read the letter, or that they have received it. Sometimes you get told on the phone about the 
appointment, but you don’t always receive the back-up letter, so I think the safest way is to speak to 
the patient. 
 
Patient ?: Language is an interesting one. It could be someone who speaks a different linguistic 
language or maybe who has communication difficulties and their opinions are just as relevant and 
important as ours. 
 
Patient 7: There is  also the ethnic issue where some women have to have a chaperone, in which  case 
only a woman could approach those questions. But I don’t know what you do then about  asking the 
guy to leave the room. I think that from a medical point of view that’s okay, providing it’s a female, if 
they can’t be left alone with males. 
 
Patient 6: None of us are perfect, but I think if people haven’t filled in the forms and not done their 









don’t adhere, not that you necessarily want to wash your hands of them, but there is only a certain 
amount that you can do. 
 
Patient  ?:  People  have  got  to  help  themselves. It  is  like  a  smoker,  people  have  got  to  help 
themselves and obviously, everyone here wants to get better. 
 
Patient 6: And this is  a valuable resource; if people are a bit half-hearted about it; nobody likes  




This is for each of you individually to give me an answer on this one. If you were coming into the 
clinic again, what would be the biggest faux pas or mistake that someone could make when initiating 
the subject of sexual activity with you? 
 
Patient ?: You have to ask the question haven’t you, but maybe we don’t mind sitting around the table 
and talking about it, but the individual most probably wants to be taken aside very quietly and asked 
the question. I remember when I was working with the elderly I used to have to bring them, but even 
though they knew me, they wanted to talk about that privately. 
 
Patient 2: It’s not a faux pas as such, but “are you sexually active”. What does sexually active mean? 
We talked about people being in long term relationships and not having sex from one year to the next.  
I felt that is a difficult question because, I felt that when someone asks me that, it is something I get a 
bit fed up about, I would like to be in a relationship. I think it is wording things so that they  are as 
inclusive as possible so as not to deny someone the opportunity, so maybe not say “are you sexually 




So maybe a better question for you would be; when you are in a consultation and someone is going 
to ask you about sexual activity or sexual function, what is the question you would like them to ask 
you? 
 
Patient 6: I think the thing would be to say “are you sexually active at the moment”. 
 
So, just coming out with “are you sexually active at the moment”, you would be happy with? 
 
Patient 6: Yes, “are you sexually active at the moment, only it is an issue that we need to know about, 
not to be personal, but it does help with our thing” 
 
Patient ?: Or “are you sexually active and maybe if you’re not would you like to be sexually active”, 
just so you are opening it out a bit. So when I first saw Angie a year ago, so I came 10 years ago and 
when I filled in the form I was sexually active then; two weeks later the four year relationship came to 
an end, thankfully, so by the time I saw her, I was not sexually active. Had I filled in that form a little 
bit later, I would not have been sexually active; I wouldn’t probably even have met Angie and I 
wouldn’t have had the discussions that I have had now. 
 
Patient 6: But if you go into a new relationship now, would having an overactive bladder affect you. 
 









Patient ?: If you say no you could just gloss over it altogether. 
 
Patient 6: But if you met a new partner now would you tell him that you have got an overactive bladder 
or would you just not mention it. 
 
Patient ?: That would depend on the guy. 
 
Patient 6: This is what I’m saying; my husband would never really talk about it. When I had my 
hysterectomy I got up that morning and my friend took me to hospital and he called up the stairs  “let 
me know when you want me to come and see you” and went out the front door, because he just didn’t 
and couldn’t talk about it…you know, just let me know when you want me to come in and see you. 
 
Patient ?: I just think that there are a lot of women, there are quite a few women, we are not just 
talking about sexual activity, we are talking about sexual satisfaction. 
 
Patient 6: It’s not something you would tell someone on your first date. 
 
Patient ? No. But that’s an interesting point is sexual satisfaction, because… 
 
Patient ? I think it depends on the relevance of asking the question of are you sexually active. If you 
are asking the question in relation to their problem, then I think you would have to expand on that. 
 
Patient ? That’s my point, if you think it’s to do with your problem then I think you would feel happier. 
 
The general rule of when people are trained to do histories is that they say “are you sexually active, 
yes or no” and if you say no, a lot of people don’t ask any more questions, if you say yes, they say 
ask if you have any problems. 
 
Patient ? I think maybe, “A lot of our patients with similar problems to yours experience difficulties in 
their sex lives; do you have any issues; are you sexually active; if not, is that because of your issues”. 
It’s not so brutal. “A lot of our patients experience problems, would that  apply to you?” 
 
Patient ? Then you are not closing the discussion down because yes and no, that’s it, the conversation 
has gone dead. 
 
Patient ? Nothing’s black and white is it. There are shades of grey in between, many shades of grey. 
 
Group: Fifty shades of grey! 
 
Patient 4: That is true, when they ask that question and you say no, some doctors leave it alone; they 
don’t ask a further question. 
 
Patient ? That can be completely misleading to your case and then that goes back to us being  women 
who are in their 40’s and above and it’s almost “well they’re dead in the water, it doesn’t matter”. 
 
Patient ?: Maybe there should be a questionnaire saying about each individual and ask them if they 









gone through different things haven’t we, so there are a lot of people who have gone through that 
and can’t identify that it’s a problem. 
 
Patient ? Is the most recent questionnaire, am I right in thinking, because I cocked up filling it in…if 
you’ll pardon the pun…was it the questionnaire that “Are you sexually active now, if no…there were 
loads of questions that I missed out. 
 





Looking back on the sexual satisfaction point of view; again, there is a lot of evidence to say that 
people with bladder and prolapse problems have reduced satisfaction with sexual activity, so when 
we are trying to understand the impact of symptoms on people, we often ask that. What do you feel 
is the best way to ask about satisfaction of your sex life other than…? 
 
Group: How would you rate your partner on a scale of 1-10? 1 – Diabolically bad! 
 
Patient 3: I think it all depends on your partner as well, how he feels. When I came here she asked me 
and I said no, because I was scared as well because my prolapse is really bad. My husband does 
understand, you know, he won’t bother me at home.  That helps. 
 
Patient 6: I don’t think there is any other way to ask it really. 
 
Patient ?: Do you have an enjoyable sex life, if you are sexually active? Does your bladder affect  your 
sex life? 
 
Group: Does it have a negative impact on your sex life. 
 
Do you think the term “Does it have a negative impact on your sex life?” Is that a term that 
everybody will find comfortable? 
 
Group: No, not for everyone. I thought that was quite good actually.  Yes, for me too.  It might not  be 
appropriate for all. Do you have as much enjoyment as you did before you had your problem? Does it 
affect your enjoyment? Enjoy is a good term and I quite like impact because it’s a bit sort of…Someone 
find her a man please. A young doctor…preferably not in gynaecology…a young cardiologist…I should 
imagine after a day with us women, it would expect a lot of these guys would be gay, there’s no way 
they would find women attractive when they have been looking at that all  day long! Do you have 
many gay gynaecologists?  Yeah they say don’t they, with a chef, the last  thing they want to do is go 
home and cook. 
 
Patient ?: I remember going to see Professor Cardozo once at her private practice and she had a big 
chair with stirrups and your bits are on the edge and she just sort of comes towards you. I just went, 
“Oh my goodness, how do you do this all day?” so she went, “what do you mean, looking up  people’s 
fannies?” That just made me laugh! 
 
Patient ?: I think it is down to the dynamics of the individual and there are certain things  that…I think 
“enjoyment”…I think if you want sort of hard facts “impact” and if you were doing clinical study.  I 









Patient 6: I think as well that it does depend on the individual. What you can say to one person you 
can’t say to another. I mean we can talk quite nicely here, but it is not for everybody. I don’t know 
how you could group everybody in…it’s impossible. 
Patient ?: It’s a bit like how people refer  to  their vulva/vagina, you know bits.  I mean “nunny” is fine 
if you are four… 
Patient ?: I know I shouldn’t say this, but because I worked with the elderly, I used to go to a couple 
who were 89 and 90 and he said, “Bit of sex in my life at the moment” not sexual, they would pleasure 
each other in different ways and he said he enjoyed it much more than when they were young. 
 
Do you know, I was doing a literature search this morning and sexual activity in later life; for men, 
it reduces the risk of heart disease and helps you live longer and from a psychological point of view; 
if you maintain some sexual intimacy, that doesn’t mean have intercourse, just have sexual 
intimacy, reduces depression, improves well-being and anxiety and gives a feeling of secureness and 
comfort. 
 
Group: My husband is like that, he will be happy. That’s why I think it’s so important, because it’s all 
linked into emotional well-being. Maybe that’s why so many people have got anxiety and  depression, 
maybe.  But it’s got to be with the right person. 
 
We have covered a huge amount this afternoon ladies, thank you. We have looked at the gender 
and the age of the person who is having the conversation. We have looked at types  of  questioning. 
We have looked at how to introduce and how to always buffer the question to make it less blunt 
and more open. We have looked at opening up the questions. Talking about medications; partners 
and we have looked at honesty within the questions and answers. 
 
Does anyone have any other burning comments that they think will be useful to us to ensure that 
our approach to women about sexual activity and function really improves. 
 
Group: I don’t think there is anything else you can say really. There is no other way you can put it. I 
just think that it’s just really good that you are focusing on it, rather than just pushing it under the 
carpet. There’s no other way, you’ve just got to ask. It’s got to be done in a dignified way. In all the 
years I’ve been coming to her, it has been. 
 
I know I’m fabulous, but what about the rest of them? 
 
Group: Some of them go in a bit too…I’ve never come across it. You just sit there quietly, talk  quietly. 
 
Don’t leave the doors open…don’t shout across the waiting room. 
 
Patient ?: That’s an interesting point…that the whole thing around sex…you know how sometimes, I 
would imagine, as somebody leaves that they sometimes might think…”oh well actually”…and it’s 
making sure perhaps that the sex doesn’t come last down on the questionnaire, it’s in the middle, so 
there’s not that thing about, “oh, just before we finish…” however you decide to ask the question, 
because otherwise it makes it look like it’s a bit peripheral and it’s one of those out of the door things. 
 









Do you have the tick now…oh okay! 
 
Patient ? Don’t say, “We’ve got 10 students with us today, do you mind if they sit in”. 
Patient ? You made a point though, your son being a doctor, that young doctor’s do need to learn. 
Patient ? I thought, let me ask him, because he is in Portsmouth, so I said it is a very long waiting list 
here can I come down there. He said it was the same there. He asked me how long I have had this 
thing and I told him after December, it just came out of nowhere. I had to see the doctor. I felt 
comfortable talking to him. Even when I came to see Dr Jo I was happy. It was okay, whatever she had 
to ask, she had to ask, because it’s for your benefit. 
 
Group: But not everyone thinks like that. I don’t think anyone would think that  a doctor or nurse was 
being nosey though. When she asked me about sex, I wasn’t bothered. Just because of periods, having 
your smear test and everything, women are a bit more, you know. 
 
Patient ?: Doctors do need to learn. I think perhaps, out of all us women; you would know who it 
would be appropriate to say “would you mind if this doctor sat in and asked a few questions”. I’m not 
saying everybody, but maybe someone who has already answered some questions and if you know 
that they are alright doing it and you have a doctor who is training, perhaps you could say “would you 
mind, we have a doctor who is training, would you mind if they sat in on our appointment and ask you 
some questions?” and I think the majority of women who are comfortable to talk probably wouldn’t 
have an issue with that. 
Patient ?: If you redesigning things, would there be any facility, feedback is too formal a term, but if 
someone did have a conversation and they were left a bit uncomfortable, or they felt that the 
conversation wasn’t…so for the younger doctors that are going through their paces pre-consultant, or 
even consultant, so that there was some way to refine their approach. 
 
That’s an interesting idea. 
 
Patient ?: I think they would need someone, for instance like yourself, they should perhaps sit in with 
someone like yourself asking the questions, to see how it’s done. 
Patient ? But then also would there be some facility for, let’s say women had been asked about things, 
but how it could be done better if something was implemented. 
 
In their training they have something where someone pretends to be the patient and they give 
feedback on their history taking, but that’s only in their training. 
 
Patient ?: If you were implementing something within the Trust, maybe a pilot scheme, that might be 
something to consider. 
Patient ?: I wouldn’t be happy telling a 25 year old, I would be embarrassed. I would blush. I would be 
embarrassed. 
 
Group: Then you are not going to get the answers you want. Make them go through the questions; 
make them be the other person so they know what it’s like. As part of training, I think that would be 
valuable, because they would know that it is uncomfortable. They could think how their mum’s would 
feel. Kid’s this age, they know everything. When you get angry, they say you’re having one of those 
days.  Do men have a lot of sexual problems? 
 
Yes…erectile dysfunction. 
















Ladies in the group; I am going to ask you lots of different questions and ask you for comments on 
them. I am going to start you off with a big question, just to ease you in gently. 
 
Question 1: 
When you come to a Gynaecology clinic, do you think it is appropriate for us to ask you about sexual 
function and sexual activity? 
 
Patient 2: Yes, I don’t have a partner at the moment, but one of my concerns with the next one is I am 
embarrassed, whereas my old partner didn’t care because he knew. If I get nervous I need to for a 
pee, so I want to go pee before sex and then I want to go straight after, because I don’t want to get 
an infection, so yes, I think this is important. 
 
Patient 1: As long as it is a female consultant, I would feel more comfortable. 
 
Patient 6: I agree with you…that was my first thought, I prefer to have a female to talk to. 
 
Patient 5: Yes, I am absolutely fine with that as well. I think you may encounter different views and 
possibly different age groups. I think the younger people might be more open to talk about that sort 
of thing, possibly. 
 
Patient 3: It does not bother me whoever, if it is a male or female. With a female I  would feel  better, 
but I would not worry if it was a male. 
 
Patient 1: Maybe putting it in the letter that goes out to the patient that this is what is going to take 
place, so that the patient is mentally prepared for the questions that they can ask, because sometimes 
you go into an appointment you are not aware of what you can or can’t ask. If they ask you when you 
are there or they ask you at the end if you have got any more questions, you may be embarrassed or 
you can’t remember at the time. 
 
Question 2: 
So apart from the possibility of a questionnaire, how else do you think we should approach the topic 
when we are chatting to you? 
 
Patient 6: I have written something out as I am not very articulate. It’s not terribly long, it just happens 
to be my view. This is the Consultant…It must be very difficult to share with everyone; I am so glad 
that you have come to me. Forget about your nerves; I am just delighted that you are giving me the 
opportunity to possibly use my knowledge …?... many years experiencing this problem. If at any point 









am so pleased that at least you have taken the first step on the way to request help. Take as long as 
you like before answering. The first question is “How long have …? Do you recall how far back this 
began? Now, after all this time, how does it make you feel? More delicately, you intimate relationship; 
have you been able to discuss this with your partner? How are you coping? (making a joke of 
it…avoidance) How does it make you feel about yourself … does it make you feel at ease? What would 
make you better within yourself?  How do you feel now that you have opened up to  me? I would love 
to see you again. Think carefully about our discussion and take  care. 
 
So you were the Healthcare Professional, that’s the sort of thing you would say? 
Patient 6: That’s how I would go about it, yes. 
Are there any other ways that you think it would be best to be asked, or any ways and any other 
approach that you think is useful? Anything, so a questionnaire or having it in a letter or being  sent 
a questionnaire beforehand to say “do you want to speak about this; do you have any problems”.  
What are your views on something like that? 
 
Patient 5: I think a questionnaire would be good, possibly asking to tick the box if you would be happy 
to discuss those matters and I think that takes out the awkwardness for both parts really, when you 




For women who aren’t currently sexually active, do you think that we should be probing deeper as 
to why they are not sexually active, or how far within the questions about your sexual activity do 
you think it is appropriate for us to ask you? 
 
Patient 5: Only if it is related to the problems that certain patient has really. You have to know that 
patients background to make that question relative, otherwise you could be probing too deep. 
 
Patient 1: Or, as you said, if it is on the questionnaire, then that patient has the option if they want  to 
discuss it. Maybe putting it in the questionnaire puts the onus on the patient if they want to discuss it 
any further. 
 
Patient 6: I think if you are not going to discuss it, I don’t really know why you are there. 
 
Because you’d still have a discussion about your bladder symptoms; this is only talking about your 
sexual dysfunction on top of that. 
Patient 2: I’m not in a relationship at the minute, but I know when I was with my ex, we were discussing 
my bladder infections and I felt quite comfortable with it. It puts me off now thinking, touch wood, I 
have not had any bladder infections this year. I mean at one point I was on antibiotics for a year and 
then stopped them and since I have been single it’s a lot better. So for me, the sexual bit does worry 
me, because, I don’t know, is it because they just bruise me and I get infections. Is it  in my mind and 
then I get an infection because I get nervous. I think it is quite relevant and it has  put me off…I’m quite 
happy being single at the minute, but I know if someone comes along I don’t want to think “I can’t go 









And what would you like someone to ask you to try and find  out that information?  How would you 
like them to phrase it? 
 
Patient 2: I think the questionnaire bit, to give a multiple choice, but also a comments box, because 
sometimes what I hate with hospital things, I think “well I’m A&B but I’m not that”. So  just to be  able 
to put a comment, because once I know you have read that, it’s easier for me to talk about it, rather 
than me to sit there and bring it up. 
 
Patient 6: That’s a very important issue, the fact that you are left to comment when you are  between 
two. 
 
Patient 1: Also, you have got the time to think about it, rather than being under pressure and not 
remembering. If you have the questionnaire beforehand you can think about what are  my issues  and 
like number 2 said, you can put things in the comments. 
 
Patient 2: If you’ve put it there, even if you don’t bring it up, the doctor has read it and they ask you a 
direct question, you don’t tend to lie then; but if they don’t say anything, then you don’t say anything, 
but if they know and they probe on that, they have raised it and they show they are interested then. 
Sometimes, I’ve said it to you, I always see a different person here and I feel like no-one cares, because 
every time I’ve seen a guy before you, they would all read my notes and go through all the things and 
go off and I just think “am I just a number”.  So coming on this, I see you   or the other lady and I know 
where I am and usually it’s literally like they are just reading it in front  of me and then asking me to 
repeat my symptoms and then if I said anything different, off they would go and then they would come 
back and I found it really frustrating. 
 
So you find the familiarity of the person you are seeing actually helps you to open up more. 
 
Patient 1: I don’t so much mind, as long as what I put on paper and then they can relate it back to me, 
I’ll put my feelings down on paper, as I am too embarrassed to bring it up in the session, but if it is 





When it comes to the actual person asking and I know some of you have made comments about it 
being women, now is it any woman clinician, so Doctor, Nurse, Physiotherapist; is it a specific group 
of, Consultant or Doctor, or something like that? 
 




Are there any other attributes of that Healthcare Professional that you want them to have to  
make you feel safe enough to open up about things? 
Patient ?4: I think I would like them to be a little bit ?approachable. 
 
Patient 6: I would prefer to know that they had read my notes before actually I’m sitting in front of 









Patient 2: I think that before I started this group, that was one of my pet hates here. I think I have seen 
Dr Cardozo as many as maybe three times. I have seen you a lot. But before you, I have seen different 
boys; and they were boys; I’m not saying I’m that old, but they were and they were just…I would just 
come in after waiting about ½ hour and they were just reading it in front of me.  I felt that I was a 
number. If I could have just changed, I would have, but I know Cardozo’s brilliant and that’s the reason 




Do you think age is important in the person who is asking the questions? Do you think that the way 
that they explain things…any of those factors important when they are checking to you about it? 
 
Patient 2: No, just as long as they are experienced and know what they are talking about, then that 
makes me feel confident. 
 
Patient 6: I’m 75... 
 
You don’t look it! 
 
Patient 6: I am and I wouldn’t like to be confronted by a 23-year-old, I would feel very awkward. 
 
Patient 5: That’s what I was saying earlier. I think that the younger you are, possibly the more open 
you are…well not open, but the more confident you might feel. It would not bother me how old the 
person was, as long as they knew my case. 
 
Patient 6: Because of my age, years ago we didn’t talk about things like this. 
 
So that actually brings us nicely into…there is research that has been done across the UK over the 
past 30 years. It’s called the Natsal study and it looks at changes in sexual practice over the years. 
So they started asking a group of women 30 years ago, questions about their sexual activity and 
they have repeated it and I think it is around 10,000 men and women and looked at the change in 
sexual practices. So from 30 years ago to now, women are having more sexual partners than they 
used to; they are having more same-sex relationships; they are masturbating more than they used 
to and they are having less vaginal sex and more types of other sex, be that oral, anal, that sort of 
thing. So when we are coming to try and understand sexual practices, obviously, we need to 




So what is your opinion about asking you questions more in depth about the type of sexual  activity 
you are having and the type of partners you are having that with? How do you feel about that? 
 
Patient 5: I think the more you know about us and what we are doing, the more you are able to help 
us, but again, it comes to having something beforehand, when you write to us, to ask us if we are 









Patient 2: For me, anal does not rock my boat in any way, but I know that a lot of people half my  age, 
it’s all the rage for them. I think you just do a number 2 out of that end, personally, but each to their 
own. If you do the questionnaire, for me that will be easy because I’ll just skip that or put n/a; rather 
than if you say to me “do you have anal” I would still say “no”. 
 
So you would rather fill that in in a questionnaire rather than be asked about it? 
Patient 2: Definitely. 
Patient 1: I would much prefer everything to be on my questionnaire; I can be as honest as I want to; 
skip what I want to; put in what I want to and it is all done on paper and I don’t have to feel 
embarrassed or offended at my actual appointment. 
 
Patient 3: I wouldn’t mind being asked when I go to the clinic; “are you having any sex” but yeah, I 
think that crosses the line…goes to the next level. I feel that the person asking you…it is very hard to 
not feel awkward and you can see that. 
 
Group: If someone you don’t know asks “do you do anal?” 
 
You would be amazed… 
 
Patient 1: You could even put in the questionnaire, are they happy to discuss it further. Maybe we are 
happy to put it on a questionnaire, but we don’t want to discuss it at the appointment; or maybe they 
are quite free and will have a discussion about what they do, what they use and who they do it with. 
So maybe to have a really in depth questionnaire would be quite good. 
 
Patient 3: I suppose it’s actually having those; it might be someone who is not having a problem with 
it, they might think it’s irrelevant. 
 
Patient 2: I think that if you are having anal, you are really likely to have bladder infections. I think it 
would be quite relevant. Maybe that’s even one of the reasons why it’s just not my bag anyway. If it 
was, that would put me off straight away, because I don’t think it’s hygienic, personally. 
 
That is why we ask certain women, because for women get recurrent e-coli infections; that and 
wearing thongs are often the two most common reasons as to why it happens. So in order for us  to 
be able to educate and advice on good practices… 
 
Patient 1: But it could be something that you put into a leaflet that covers all of these subjects, so that 




If, when you are in a consultation and someone doesn’t ask you, or there isn’t an information leaflet, 
no questionnaire to fill out beforehand; if you had a problem that was impacting on your sex-life, 
or your bladder symptoms were a problem or causing problems, would you actually volunteer it to 
the Healthcare Professional you were seeing and if you were to volunteer it, how would you 









Patient 2: When I was in my last long-term relationship, I did voice that, but before I was coming here, 
I went to see my GP and I specifically asked for a woman, because I felt uncomfortable. I kept on 
getting bladder infections, cystitis, thrush and then it put me off and I said that I was with this man for 
about 5 years and I wasn’t going to not have sex; they gave me an antibiotic to take before sex, which 
would prevent it; now, if I hadn’t brought that up I never would have known that and it would have 
kept happening, so I did; but I couldn’t just walk into a room and say, this is what’s happening. I had 
to build up the courage, go to a woman and then say what was happening and as I say, I have got that 
antibiotic now. 
 
Patient 1: I think, because of the “Embarrassing Bodies”, whatever is a problem to me, I now do go 
and talk to my doctor about it; but before Embarrassing Bodies, I probably would have kept it to 
myself; I would just struggle my way through it, unless it was really impacting on my life;  but  because 
of Embarrassing Bodies, I talk about things now. 
 
Group: Sorry, but I can’t watch that. I can’t watch it either. I’m embarrassed to watch. I’m embarrassed 




Is it something that you would, when you are speaking to a Healthcare Professional, is it that you 
go there directly with that specific issue or is it that you talk about something else and work your 
way into it?  Is that a conversation opener for you or… 
 
Patient 2: For me, I hate going to the doctors and I work, I never have time, I hate waiting. I want to 
get straight there and I want to be in and out. I’ve requested either Dr Abraham or Dr ?, he 
understands. 
 




Is there anything about the clinical environment that makes you less willing to open up about things; 
is it when you are in certain clinic spaces, or if there are other people in the room, medical students 
or anything like that? 
 
Patient 2: I don’t like that; even here, when I had one procedure, they asked; I feel uncomfortable, I 
have my legs in the sling and I suppose I do feel uncomfortable. If I’ve got a man; I haven’t given birth; 
I haven’t gone through childbirth; I don’t even like smears.  I certainly don’t want a room full  of people. 
If I’m knocked out unconscious you can do what you want, but when I’m there and I’m fully aware… 
 
Patient 5: I’ve had 3 kids…I’m not bothered whatever, but everyone’s different. 
 
Patient 1: I don’t mind. At my last appointment there was a student there and in actual fact it was 
good, because she was thoroughly explaining everything to the student, so it meant that I could kind 
of understand in layman’s terms. I don’t mind; I just don’t want too many people; if it was like a bunch 
of Consultants, then I wouldn’t be happy, but one or two people, I don’t want it to be in a cubicle, it’s 











When we are looking at the consultation that you have with us as a whole, is there any point 
where…what point should we be bringing it up? Is it at the start of the conversation? Should we 
look at something else first? Should it be towards the end of the consultation? Where would you 
want it to be? 
 
Patient 2: I think what number 1 said; when we get that letter, you should have that in there; you 
know, the tick boxes, so once that’s in there, we turn up for the appointment, we feel comfortable 
because we’ve given you the answers and you can go from there. So I think if that went out in the first 
place, that’s your answer straight away. Whereas, if you just go in and you ask about that I  might 
think, ? , but if you do that questionnaire thing, I think that answers it straight away. 
 
Patient 6: I agree with number 2. With that questionnaire, if you left a big gap at the bottom where 
you could make your own, real comments; not just on the side; you could really say what your problem 
is. 
 
Patient 3: I would be quite happy to be asked as  part of the symptoms in the consultation. When  you 
go there they usually say “do you have this, this, this”. It could slot in as a symptom as well and that 
kind of normalises it. It kind of puts it in with everything else rather than being a special part of the 
problem. 
 
Patient 2: I do think that, it’s not just urinary, but with a lot of things; when doctors do that; at the 
minute they are going on about my blood pressure and they start asking me do I have all these 
symptoms and I think, yeah I do, or no I don’t and I think if I had wrote it in that questionnaire first, it 
is almost like now, I go home and I think, what have I missed. I think that there can be the error that 
people put these things in your head that you didn’t even know and then you suddenly question do I 
have this, do I have that.  So I believe in that questionnaire. 
 
Patient 1: I leave it to the Consultant whenever they bring it up; as long as they have brought it up, I 
do want them to address it, I don’t mind if it’s at the beginning or the end; as long as they do  address 




When you are asked about it and when you have the opportunity to voice those concerns, what is 
it you want back from the clinician; what is it that you are hoping that they will give back to you 
once you’ve voiced those concerns? 
 
Patient 2: As I said, when I was with my partner and I got the antibiotics before sex, I want an answer; 
I’m quite an impatient person and sometimes I expect you to fix it because I’ve said it, just like that. I 
know that’s realistic and even with my bladder tablets and trial and error, the first one  put me in 
hospital for the weekend here, because my belly distended. It put me off and I wouldn’t take another 
one and then I’m on a different one now.  I just want it fixed.  That’s the only thing and I think it’s the 
same for everyone. They don’t like having to try and find a medicine that  suits, because you have to 
wait so long to get into your next appointment and at that same time it’s impacting on your life. I just 
want an answer. I would, in an  ideal world, like to be given two  different tablets and say, look try 









for that one; instead of having to wait, make another appointment, come back and then go on the 
next one. 
 
Patient 1: I would like options; so maybe it’s just the leaflet you can go with, injection or maybe tablets 
and I want to know what are my options and as number 2 said, I want to come away with something, 
I don’t want them to say “well there’s nothing I can do”. I do want some sort of answers that I feel 
that it was not a waste of an appointment and that my needs have been met at my appointment. 
 
Patient 6: I feel I want them to get into my soul and know what I need and know that they understand 
what I’m feeling and advise me, or at least talk about it; even if they can’t do anything, talk to me 
about it. 
 
Patient 2: I agree with that; I’m so fed up of feeling that no-one feels what I’m feeling, then you’ve 
suddenly got my discomfort; because when you are there with some of the young guys and I’m in 
tears, I just feel so awful that I just want the ground to swallow me up and this young guy, you can see 
he’s dying, he will get up and talk to someone and come back and I just feel that I’ve wasted all this 
time in an appointment with a student who didn’t know and didn’t have any understanding of what I 
felt like, so again it goes back to the familiarity with people. I think consistency with who you see is a 
really big part. 
 
Patient 5: I would like some information; whether it’s a leaflet or a website you could refer me to, to 
give me some time to read up about it myself as well. Something like that really, so that I could actually 
read; take it in; take it on board. 
 




When you are having these conversations, what sort of time do you want to…you know, with GP’s, 
sometimes you get 10 minute consultations, how do you think those conversations fit into them? 
 
Patient 2: With my GP, if I know they are 10 minutes I have to book a double appointment; I can’t do 
it in 10 minutes.  I have also before, went to the walk-in centre at St Thomas’ and they referred me  to 
a doctor and they gave me antibiotics straight away. So I do find that a struggle; they are like, if you 
can’t take the day off work you aren’t that ill; I didn’t say I was dying, I just said I was infected and it is 
really impacting my life and I don’t know if I’m going to make it to work; you know without getting off 
to find a toilet; I’ve squat behind a car; before I had all my tablets and everything, touch wood, I don’t 
have any of this now, but they don’t realise the impact. 
 
So when you are chatting to a doctor or nurse in a clinic, what makes you feel like they are rushing 
you or they are not giving you the time to actually address your concerns? 
 
Patient 2: My doctor, not here, they have told me before “you are only here for one thing, we’ve got 
10 minutes”. They have said that to me, so if I’ve gone “can I have something for my eczema” and 
then I say “and can” they say no, one thing, you’ve got a 10 minute appointment, you need to book a 









Patient 6: You are talking about one thing, but often things are related; even if it’s urinary, it can be 
partially to something else and they can’t put it all together. 
 
Patient 1: Maybe they can ask you at the time of booking your appointment how long you think you 
want; 10 minute or 20 minute; maybe you have something simple that you just need 10 minutes;  but 
maybe you do have more or you are a person who likes to talk and have that interaction so you will 
need longer. 
 
So is that just in your GP practices, or has anyone had any experience of that here? 
Group: I haven’t really been rushed, not here or at my GP. Not here. 
Patient 2: For me, it’s very much at my GP. I have told Dr Abraham that if it wasn’t for him, I would 
leave the surgery and find another one. I don’t think it happens so much at the hospital because you 
schedule your appointments and you pretty much stick to them, unless  there’s  an  emergency. That’s 
the way it is here anyway, which is why I didn’t opt to ever change, even though I never saw Dr 
Cardozo. 
 
Patient 5: I’ve never felt rushed here. To be fair, I don’t think I’ve ever felt rushed at my GP. Sometimes 
I feel that they don’t listen to me, or they don’t have the time to listen to me, but I very rarely go to 
my GP and if I do, I go in to say please can you just refer me back to Kings. As long as I know what I 
need and thankfully, touch wood, so far I have done so as long as I stay on top of it. Here I have always 
had fantastic service. 
 
Patient 1: I usually go in with a list of points that I want to discuss and questions that I want answering.  
I’ve never felt rushed at the end. 
 
Patient 2: I did get approached by, I was here one day and I said no. It was that TV programme here, 
24 hours in A&E and I had come with a bladder infection and that’s an embarrassing thing anyway. 
They came up and I’m not being funny or bigging myself up, they said I looked like the only normal 
person in A&E at 3am, because I just can’t go through the night and the camera people came and I 
said no just please go away and then other people were treating it like it was a celebrity thing. 
 
I think, one of the things that we always say in clinic is that we may run late and you may have to 
wait longer in the waiting room for the appointment, but it’s because we won’t rush anyone out 
and give people the time to they need to talk, because they don’t get it at their GP’s, so we’d rather 
give you that time and run a bit late. 
 
Patient 6: I agree, I’ve never, ever been rushed here, whereas with the GP it’s, “you’ve got 10 minutes, 
don’t discuss anything else”. 
 
Patient 5: Actually I had my referral the other day and what I liked about that was I had the option to 
call them between certain hours or I could e-mail. If I e-mailed, I could put in which date I would like 
to avoid or which dates I preferred, which really suited me because I had to look through my 
calendar…it was really nice to have that option. 
 









It’s only happened in the past few weeks and it’s only with physiotherapy at the moment. It’s due 
to the fact that the management of the administration has gone from the Women’s department to 
the Physiotherapy department and the way the appointments are being booked and the waiting 
list. It’s down to this is the new option to try and make it all easier being as it’s no longer being 




When you come to clinic and when we are asking the topic about sexual activity and sexual function; 
if you have your partner in the clinic room with you, or your friend in the  clinic room with you, how 
do you feel then about us asking the subject, when there is someone else there and do you think it 
changes the way you are going to talk about it with us? 
 
Patient 2: I wouldn’t take them in anyway. I don’t know why they need to; whether it was my partner 
or my friend. I think you can keep the romance alive a little bit; they don’t need to know everything.  I 
was with someone for 5 years; if he took me to the hospital, he certainly didn’t come  to my 
appointment with me. Maybe if it was a heart attack or something different; he doesn’t need to know 
everything that’s going on down there. He needs to look at that and feel good. 
 
Patient 6: I wouldn’t dream of bringing my husband. 
 
Patient 1: I would…I wouldn’t mind, but I wouldn’t have my friend; I wouldn’t even have my sister, 
but my partner. 
Group: Have you had kids? Yes with my ex-husband. But I’ve been told you have no inhibitions  when 
you’ve had a family. That’s what my sister and my family. I don’t know really, I think it comes down to 
the number of medical procedures you’ve had. It’s not just down to children. My partner would 
probably ask questions.  It depends who is in the room with them. 
 
Many women bring someone with them for an appointment, especially if it is their first time coming, 
because sometimes you don’t always remember everything that’s said to you and all that 
information, so having someone else there to keep track of things; but it is that, if it is someone that 
you are not necessarily, you know, if you had a friend in there, would you open up and be honest 
about if you were having problems with sexual function and things like that? 
 
Patient 5: I suppose if you’ve had the questionnaire beforehand and you ticked whatever boxes and 
been asked whatever questions, then you as the patient would be prepared as to whether or not those 
questions are going to be asked of you; so if you took that person in, you would know either way. 
 
Patient 2: I think it is how you ask. I am very independent, even when I have been I a relationship; but 
then I’ve got other friends who do have partners and they do everything, so I do think that it is relevant 




What about if you are going to be sending out a questionnaire to look at this; would you, do you 
think, take offence to say “if you have a partner with you at the appointment, would you like us to 









Patient 6: Obviously I wouldn’t be offended because I wouldn’t take him in. 
 
Patient 3: I suppose I would do is not take them in. If I knew those things were going to  come up  and 
I suppose it’s good to have something said beforehand so you would know they were going to come 
up. I suppose what you wouldn’t want is to go in unaware and to be asked questions that actually you 
really want to talk about, but not with them. So if you know in advance what’s going to be asked, you 
can decide who to bring and whether you want to bring them in the room or not. I suppose once they 
are in, I would find it a bit weird if to ask them to leave. 
 
One of the things that I did before chatting with you ladies, last year, I actually did something similar 
amongst clinicians, looking at Gynaecologists, Urologists, Obstetricians, Nurses, Physio’s, about how 
they felt about discussing sexual function with patients. If there were people,  particular types of 
people, that they found it more difficult to approach, or to ask questions; how in depth they went 
and one of the questions was actually around, how honest and open patients actually are with you 
and if you ask a man or a woman a certain question about their sexual activity, what things do you 
think they most likely may not be completely honest about. So for example, when they ask “what 
do you think men may not be honest about”, it was generally, well maybe the number of sexual 
partners they’ve had; about erection quality; how long they last, were typical the male bravado and 




Do you think there are any things that women may not give us the true answers to? 
 
Patient 2: I mean I have no inhibitions so I would say how many sexual partners, but I know a lot of 
people, even my friends, who lie. I went to school with them; I grew up with them and they are married 
now and I’ve been there, you know, when they do truth/dare and they all say “how many partners 
have you had” and they say three and I think, yeah put a zero on the end…I know. I think women do 
lie about that just as much, especially for me, I find more so with my married friends. I also think there 
are misconceptions about what is deemed good and what isn’t. 
 
Anyone else any ideas of either what you may have not necessarily been honest about in clinics with 
us, or things that you think people wouldn’t 100% admit to? 
 
Patient 5: Possibly the quality, the enjoyment side of it. Drug taking; that sort of thing. 
 
Patient 2: One of my friends is a Policewoman and you know, I’m in my 40’s now. I did so much LSD in 
my teens and twenties; we all did it together. We are not allowed to speak about it now, it’s like she 
was this completely different person because she married a cop.  I’m like, surely you shouldn’t  be 
ashamed of what you did 27 years ago; we all grew up; we all did this.  If she was still doing it now I 
would understand, but yes, I do think that people look at appearances and what they perceive; people 
lie about that. 
 
Patient 5: Casual sex as well. 
 
Why do you think people aren’t necessarily honest about those sort of things, if they are having a 
problem and a Healthcare Professional is asking them a direct question, what do you think is it  









Patient 5: You’re being judged, I suppose. 
 
Patient 2: Their own self-esteem. When you actually say out loud sometimes what you’ve done, it 
sounds a lot worse than when you are actually doing it, you know. As you get older, you look at things 
differently. I have no embarrassment about what I did in my younger years, but I have a lot of friends 
and colleagues that make out they were saints. To me, I don’t understand it, but obviously I respect 
their wishes and that’s how they are. In front of my cop friends, it’s like we didn’t have that childhood 
and she won’t even acknowledge it or anything. 
 
Patient ?5: Would there be anything about, so say if they are asking you about things that you have 
done and it might be related to a problem that you now have, obviously you don’t want the blame for 
it, or let’s say you keep having these e-coli infections and they ask you “are you having anal” and you 
say “no!, no!”, it’s not my fault obviously. I go to my GP and I say, my leg hurts and they say, “well you 
should stop smoking!”.  It’s that sort of thing. 
 
Patient 2: I agree with that, because some doctors do. I’m an ex-smoker, I quit when I was 25, 20 years 
now, but sometimes it still winds me up. They ask me the question “do you smoke” I say “no” and they 
say “have you ever smoked” and I say “yes” and they tick that box as if I’ve been really naughty.  Some 




Going back to the partner point of view, do you think women are generally open about these things 
with their partners? Do you think that if the woman has incontinence, do you think the partner 
always knows, or do you think they hide it? 
 
Patient 2: I think it comes with how comfortable you get with that partner; it’s not something you 
would share straight away. Like I say, it’s an inhibition, if I get with a new partner; whereas with my 
ex, I didn’t care. He used to call me the phantom pisser because I used to get up three times in the 
night and this is before I ever come to Gynae. I lived with him for years and that was a private joke, 
but now, if I got with a new partner, I probably wouldn’t be staying at his until I felt that  comfortable. 
 
Patient 6: My husband hasn’t a clue that I am terribly incontinent because I avoid sex; it’s awful, but I 
have to wear a pad 24/7 and it’s just dripping wet. I avoid it and I sleep right on the side of the bed, 
but I put it down to, he’s got a defibrillator, so I don’t want him to die! I don’t talk to my partner, I 
can’t. 
 
Patient 1: I’m the opposite; we talk about everything. I’ll probably go home this morning  and  discuss 
this. I am happy for him to be in the room with me; if I need to go to the loo during sex, we’ll stop and 
I say I need to go, so he completely understands, but it’s a long term partner so it’s very comfortable. 
I think if it was someone new, I would be exactly the same as you. I would be embarrassed. 
 
Patient 2: For me, since I’ve been on Mirabegron, it’s improved a lot than it ever was. Without them 
tablets, I would have nightmares before I would even consider going into a relationship, but the 
tablets that I do have do make a big difference. I’m not in a sexual relationship at the moment to 











So, looking at, you know I’m going to throw out an open question now, because we are coming up 
towards the end of an hour and I want you to tell me, each individual view on, what for you is the 
ideal way for you to be introduced to the idea of discussing sexual function and bladder problems 
and actually have it brought into your treatment? So whether it be having a questionnaire and 
having someone talk it through; whether it be just having someone ask you a certain way or bring 
it into the topic; what is your personal ideal way of someone ask you? 
 
Patient 2: Questionnaire and then they bring it in, because I feel that I’ve already raised it without 
saying it myself and I’m not embarrassed; then doctors tend to probe then when  they read things; do 
you ever get infections; do you have sex; it’s just like a robot to me, whereas if I’ve wrote things like 
that, they’ll ask what were your symptoms, how often do you have those; they will probe from there. 
So for me, I think the questionnaire with a multiple choice and a big comment box where I  can add 
my own bits and they’ve read my notes before I turn up, because that’s one thing I’ve really hated 
about here, I think that to me would work for pretty much 99% of people. You are always going to 
have a few that might have trouble with writing and that, so it won’t work for them and some people 
can’t express themselves, but number 6 wrote all her words down and she felt quite confident and 
comfortable, so that whole writing thing would work for them. 
 
Patient 5: I agree with you and I think a big area for comments, but I would like them to be really 
friendly. 
 
Patient 3: I actually came in for a scan and I didn’t need anything further, so for me it was quite a short 
term visit, so I don’t know if I would require all that on a one off or my first visit, but say I was in a 
situation where I had to come back regularly, I suppose at that stage the questionnaire would be really 
useful, but I would say that for my initial, potentially not having to come back, just the first  one, I think 
it would be okay just to be asked about it and not go into long thing about it. 
 
Patient ?: I agree, obviously mine is more long-term, so I think a questionnaire, to be able to think 
about it comfortably. 
 
Patient 1: I agree, I think having the opportunity to think about what is happening to me and being 
able to document that before I go to my appointment, it’s very important. At the appointment, I’ve 
probably been having a busy day and I won’t remember, or be embarrassed or whatever, but if it’s all 
down on paper, then I know they have all the information and they can ask me questions from there. 
Having someone who is quite friendly and not too many people in the room and just having a nice 
environment so that I do feel comfortable to talk about it. Having something to take away with you; a 
website to look at, a plan of medication or something so that I feel that my appointment was 
worthwhile and I do feel I have got something from it. 
 
Patient 2: At one point a few years back, this made me quite depressed and I actually did that before 
going to my doctor because I knew if I went in there, I wouldn’t say half the things and once I start 
crying then I can’t get it out anyway, so I wrote down everything I was feeling and they did send me 
to a counsellor, but it was partly because of this because I felt that I was living on tablets, always 
going to pee, if I’d been out drinking I would have to get off the tube and I would have to pee behind 









over on the bridge, because I knew I couldn’t get home and it was only a 10 minute journey, I knew I 
just couldn’t do it.  I really got quite depressed. 
 
So a questionnaire is a good idea and it is something we can definitely look at; however, we are in 
a room with people that are actively helpful towards they are trying to improve things and fill out 
the questionnaires, but a lot of people don’t fill out the questionnaires, either because of problems 
that they can’t read; it’s the wrong language or something like that and we can’t create something 
for every single language available; or because people just don’t fill out their things before they 
come and see us.  How do you think it’s best to get those people? 
 
Patient 6: I think to ask them if they would appreciate a questionnaire or not, because also a lot of 
people look at a questionnaire like they do filling the form for stickers for the Disabled. It’s another 
task, it’s rather clinical, got to get it done, without any emotions they just fill it in. I would like to be 
asked if I want a questionnaire or not. 
 
Patient 1: If for whatever reason the questionnaire wasn’t completed, then the Consultant or Nurse 
or whoever should know how to the subject. 
 
Patient 2: I didn’t realise how many people in their 20’s actually can’t read and write. I’ve got a couple 
that when we’ve done their payroll forms, they have literally only been able to write their first names, 
couldn’t even write their surname and some of them I know and they will never say and I will do it for 
them, because they can barely read or write and this is English people as well as Eastern Europeans. I 
think it’s quite shocking in this day and age. I don’t originate from London; I’ve been here for 25 years 




Do you think we should change our approach based on the age of the patient? Do you think I should 
be asking exactly the same questions that I should be asking a 20-year-old or do you think age is a 
factor that should make us change our approach to things? 
 
Patient 2: I think you should ask them how they would like to be. We can tailor it to you, or would you 
feel comfortable if I give you the generic form. I think more that will come into it than age  would be 
religion. I have some Muslim friends; they are not going to  answer you no matter what  you do. Not 
all of them; I’ve got some quite Western ones and some; I don’t know what you call the opposite.  So 
I think religion would impact more than age. 
 
Patient 5: I don’t think it should be changed for age; I think you could give them the option. Some 
people won’t be confident or happy talking about it and others will. 
 
Patient 1: Maybe explaining the importance; I think if I was in my teens I wouldn’t really see the 
importance of the impact of me coming forward and expressing myself. If it’s all explained to us, 
whether it be in a letter or at our appointment, the importance of what we are doing and why we  are 
doing it and the long term benefits; that would be a good idea as well. 
 
Patient 2: It is how we approach it as well; a totally different thing; I left Guy’s Hospital, my 
orthopaedics, the surgeon said to me after one answer, “well if that didn’t work nothing can help 









experience”, but some of the Consultants, this is what I’ve encountered; they really live 
on  a different planet. 
 
So the empathy towards the patient 
is important. Question 20: 
So we have covered a lot. We’ve covered lots of bits and pieces. Does anybody have any 
final thoughts of the day? What do you think the most important thing for us to consider 
is when we  are approaching the subject of sex, with women, what do you think are the 
most important things to ask? 
 
Patient 2: It’s all about your tone…how you ask the questions. That will straight away set 
me at ease or not. As long as I can see that the person does actually care. 
 
Patient 6: I think that is of prime importance, that you are comfortable with the person. 
 
Patient 1: I first saw the Consultant and she was very good, she explained the whole 
procedure to me. She told me what was going to happen and told me who would be in 
the room. By the time I  had the procedure the nurse was in the room and there were 
more people, so I think that confidentiality where I could speak openly and comfortably 
without feeling there were lots of people around was important. 
 
Patient 3: I always think that everything is normalised, otherwise when you get to that 
part to the consultation, it’s just awkward. 
I’m going to bring it to an end there ladies. We have had a really good discussion. Thank 
you for being honest and opening up and giving us opinions, it has been really useful. 
Hopefully, I’m going to work on getting some things out of this, along with the one I did 
last week and if you are interested at looking at what we come out with, then please get 
in touch and I will, once I’ve written it up, be more than welcome to have a read of it. It 
probably will be written into a paper that will publish looking at opinions and things like 






















Additional information from Chapter 7 
 
 
Table 1. REC submissions since initial favourable opinion 
 
Date Submission Notes 
14/06/2012 Confirmation of favourable ethical 
approval 
 
24/01/2013 Confirmation of minor amendment 1 Change in supply of IMP 
from trial stock to 
commercial stock 
28/05/2013 Confirmation of substantial 
amendment 1 
Additions of GSTT as a 
Patient identification 
centre 
26/06/2013 Confirmation of annual progress 
report  
 
25/09/2013 Confirmation of substantial 
amendment 2 
Addition of Imperial as a 
research site 
21/05/2014 Confirmation of substantial 
amendment 3 
Addition of Croydon and 
Medway sites 
04/07/2014 Confirmation of annual progress 
report 
 
20/11/2014 Confirmation of substantial 
amendment  4 
Change in PI at Medway 
site 
20/07/2015 Confirmation of annual progress 
report  
 
05/08/2015 Confirmation of minor amendment 2 Updated SMPC for 
fesoterodine 
25/09/2015 Confirmation of substantial 
amendment 5 
Change to protocol for 
bladder diary variables 
and sexual activity 
inclusion criteria 
12/02/2016 Confirmation of substantial 
amendment  6 
Extension of trial until 
31/12/2016 
26/11/2016 Confirmation of annual progress 
report  
 















1 05/11/2009 Put into KHPCTO 
CTIMP template 
1.1 05/05/2010 1.1-1.7 changes as per 
the KHPCTO prior to 
submission 
1.2 08/11/2010 As above 
1.3 01/02/2011 As above 
1.4 16/06/2011 As above 
1.5 10/06/2011 As above 
1.6 13/10/2011 As above 
1.7 18/11/2011 (First submitted to 
ethics) 
1.7-1.9 changes as 
requested by the ethics 
committee 
1.8 06/02/2012 As above 
1.9 23/05/2012 (First Approved by 
ethics) 
As above 
2.0 24/01/2013 Change in drug supply 
from trial drug to 
commercial stock 
2.1 01/07/2013 Addition of GSTT as a 
PIC 
2.2 28/08/2013 Addition of Imperial site 
2.3 23/12/2013 Addition of Croydon 
and Medway sites 
2.4 17/11/2014 Change in PI at 
Medway 
2.5 17/08/2015 Change to protocol 











Regression Models reported from Chapter 8 
 
 
In order to determine if SF and QoL outcomes were independent of UDS 
variables regression models were developed and analysed at week 0 and 
week 12.  UDS variables were not a good predictor of any of the scores on 
the PISQ-12, SQOL-F or PAC-QOL.  The results of the regressions with the 
KHQ were not significant. All confidence intervals are reported in 
parentheses. 
 
Regression PISQ at week 0 
A regression model was produced to compare the association between 
urodynamic parameters with PISQ score at week 0, which produced an 
adjusted R^2 of -0.020. This was associated with a non-significant F-ratio (F 
= 0.904, p = 0.468) indicating that this model was not a good predictor of 
PISQ score. The model parameters are summarised in the table 8.10 below:  
  
Table 8.10 Linear model of predictors of PISQ-12 scores at week 0  
 
 
B SE B 𝛽 t p 
Constant 16.35 (-2.17, 
34.86) 



































Regression PISQ at week 12 
 
A regression model was produced to compare the association between the 
change in urodynamic parameters with a change in PISQ score over the 12 
week period, which produced an adjusted R^2 of 0.95. However this was 
associated with a non-significant F-ratio (F=6.376, p = 0.28), indicating that 
this model was not a good predictor of a change in PISQ score. The model 
parameters are summarised in table 8.11.  
  
Table 8.11 Linear model of predictors of change in PISQ-12 scores over 12. 
 
  b SE 
B 
𝛽 t p 
Constant 6.8 (-121.1, 
134.7) 
10.1   0.678 0.621 
First Sensation Volume 0.12 (-1.34, 
1.57) 





































Regression SQOL-F at week 0 
 
A regression model was produced to compare urodynamic parameters with 
SQOL-F score at week 0, which produced an adjusted R^2 of -0.175. This 
was associated with a non-significant F-ratio (F = 0.254, p = 0.857) 
indicating that this model was not a good predictor of SQOL-F score. The 
model parameters are summarised in table 8.12. 
 
 
Table 8.12 Linear model of predictors of SQOL-F scores at week 0. 
  
 
b SE B 𝛽 t p 
Constant 68.54 (22.41, 
114.66) 
21.17   3.237 0.007 
First Sensation 
Volume 
-0.065 (-0.231, 0.1) 0.076 -0.33 -0.862 0.406 
Max Cystometric 
Capacity 


























Regression SQOL-F at week 12 
 
A regression model was produced looking at the association between the 
change in urodynamic parameters and a change in SQOL-F score over the 
12 week period, which produced an adjusted R^2 of 0.74. However this was 
associated with a non-significant F-ratio (F=0.959, p = 0.618), indicating that 
this model was not a good predictor of a change in SQOL-F score. The 
model parameters are summarised in table 8.13.  
 
Table 8.13 Linear model of predictors of change in SQOL-F scores over 12. 
 
  b SE B 𝛽 t p 
Constant 54.1 (-743.3, 
851.5) 





































Regression KHQ at week 0 
 
A regression model was produced to compare urodynamic parameters with 
KHQ score at week 0, which produced an adjusted R^2 of 0.478. This was 
associated with an F-ratio (F = 3.358, p = 0.059) that approached, but did 
not reach, significance. This suggests that while the urodynamic parameters 
included did not produce a good predictive model for KHQ score, there was 
a marginal trend in this direction. The model parameters are summarised in 
table 8.14. 
 
Table 8.14 Linear model of predictors of KHQ scores at week 0. 
 
  b SE B 𝛽 T p 
Constant 866.3 (551.2, 
1181.4) 



































Regression KHQ at week 12 
 
A regression model was produced to compare the change in urodynamic 
parameters with a change in KHQ score over the 12 week period, which 
produced an adjusted R^2 of 0.94. However this was associated with a non-
significant F-ratio (F=5.247, p = 0.308), indicating that this model was not a 
good predictor of a change in KHQ score. The model parameters are 
summarised in table 8.15. 
 
Table 8.15 Linear model of predictors of change in KHQ scores over 12. 
 
 
B SE B 𝛽 t p 
Constant 115.7  (-2563.1, 2794.4) 210.8   0.549 0.681 
First Sensation 
Volume 




























Regression PAC-QOL at week 0 
 
A regression model was produced to compare urodynamic parameters with 
PAC-QOL score at week 0, which produced an adjusted R^2 of 0.055. This 
was associated with a non-significant F-ratio (F = 1.293, p = 0.322), 
indicating that this model was not a good predictor of PAC-QOL score. The 
model parameters are summarised in table 8.16. 
 
Table 8.16 Linear model of predictors of PAC-QOL scores at week 0. 
 
  b SE B 𝛽 T p 






































Regression PACQOL at week 12 
 
A regression model was produced to compare the change in urodynamic 
parameters with a change in PAC-QOL score over the 12 week period, 
which produced an adjusted R^2 of 0.95. However this was associated with 
a non-significant F-ratio (F=6.467, p = 0.28), indicating that this model was 
not a good predictor of a change in PAC-QOL score. The model parameters 
are summarised in table 8.17 below:  
 
Table 8.17 Linear model of predictors of change in PAC-QOL scores over 12 
weeks. 
 
  b SE B 𝛽 t p 
Constant 19.2 (-396.9, 435.3) 37.8   .586 0.662 
First Sensation Volume -.97 (-5.7, 3.8) 0.37 -0.985 -2.601 0.234 
Max Cystometric 
Capacity 
.34 (-2.5, 3.2) 0.23 0.767 1.525 0.273 
Detrusor Contraction 
Time 






















Chapter 12 - Full Results 
 
Results 
Four hundred questionnaires were completed over 9 months.  This does not 
represent all the women attending the UDS clinic.  Twenty two women 
refused to complete the questionnaires because they did not feel it was 
appropriate or did not want to discuss the subject.  Some women were 
unable to read or write in English and although the PISQ-IR is available in 
different languages it was decided not to further investigate this group as 
they would not have been suitable for the main trial.  A further group of 
approximately 50 women ‘forgot’ to complete or return the questionnaires at 
their appointment.  This is not uncommon in routine clinical practice.  Table 
11.1 displays the presenting complaints of the women who completed the 
questionnaires. 
 
Table 12.1 Presenting complaints of Group 1 
 
 
Complaint Number of women (%) 
Urinary Incontinence (UI) 193 (48) 
Pelvic Organ Prolapse (POP) 34 (9) 
LUTS and POP 117 (29) 



















Of the women assessed, two hundred and thirty two (58%) were SA and one 
hundred and sixty eight (42%) were NSA.   
Three hundred and sixty three women went on to have a full urodynamic 
assessment.  There was minimal difference in SA activity between the 
different UDS diagnoses as shown in Table 11.2.  UDS were not performed 
if the patient had a symptomatic UTI or if it was felt to be unnecessary for 
their further management. 
 





























































































Eighty nine women (53%) of the NSA women were NSA because of lack of 










asked to consider the reasons as to why they were not SA, 60% reported 
that this was secondary to their bladder symptoms, 45% due to other health 
problems, 53% reported having no interest and 58% were bothered ‘A lot’ by 
their lack of sexual activity. 
 
Group 2 
Ninety five women were found to have DO on UDS.  Of these, 60% (n=57) 
were SA.  Of the SA women 93% (n=53) reported UI compared to 100% of 
the NSA women.   
For 47% (n=18) of the NSA group, lack of a partner was cited as why they 
were not SA.  
Only 9 women reported having a partner and the other women did not 
answer.  When the 9 women who were NSA but had a partner were asked 
to consider the reasons why they were NSA only 33% (n=3) reported that 
this was secondary to their bladder symptoms, 55% (n=5) due to other 
health problems, 67% (n=6) reported having no interest and only one 
woman was bothered ‘A lot’ by her sexual status. 
 
Group 3  
Sixty seven women reported symptoms of OAB but had normal UDS 
findings.  Of these only 45% (n=30) were SA.  Of the SA women 87% (n=26) 
complained of OAB wet compared to 70% (n=26) of the women who were 
NSA. 
65% (n=22) were NSA because of lack of a partner.  Only 6 women reported 
having a partner and the other women did not answer.  When the 6 women 
who were NSA but had a partner were asked to consider the reasons as to 
why they were NSA 67% (n=4) reported that this was secondary to their 
bladder symptoms, 83% (n=5) due to other health problems, 83% (n=5) 











The differences in baseline characteristics between the three groups is 
presented in table 11.3.  The differences in rationale for sexual inactivity 
between the three groups is demonstrated in table 11.4 
Table 12.3 The differences in baseline characteristics between the three 
groups. 












POP + LUTS 
Group 1 363 45.06 2 58% 42% 38% 
Group 2 95 49.74 2 60% 40% 32% 
Group 3 67 49.65 2 45% 55% 37% 
 
 
Table 12.4. The differences in rationale for sexual inactivity between the 
three groups 
Group N= Sexually 
active 
Not sexually active 
   Lack of 
partner 
With a partner 














1 363 58% 53% 60% 45% 53% 58% 
 
2 95 60% 47% 33% 55% 67% 11% 
 












Comparisons of the SA and NSA populations 
 
Several analyses were performed to attempt to compare the SA population 
to the NSA population in each group.   
 
Group 1 
To investigate factors such as age, parity, UDS diagnosis, associated faecal 
incontinence that would make someone more likely to be SA than NSA, a 
binary logistic regression was used.  The odds ratio for the UDS categories 
compared the observed category to the category "No active diagnosis" 
(NAD).  The model was not statistically significant χ2(8) = 8.838, p = 0.356. 
It explained 2.9% of the variance in sexual activity and correctly assigned 
61.0% of cases. None of the covariates examined made a significant 
contribution to determining whether our subjects were sexually active or not. 
No multicollinearity was identified between the variables (Tolerance >> 0.1 
and VIF <<10).  
The model parameters are displayed in the table 11.5. 
 
Table 12.5      Binary logistic regression for factors influencing SA 
 B 
 






       Lower Upper 
Parity -.413 .301 1.875 1 .171 .662 .367 1.195 
POP .028 .246 .013 1 .908 1.029 .636 1.665 
UI .079 .310 .064 1 .800 1.082 .589 1.988 
FI -.651 .632 1.062 1 .303 .522 .151 1.799 
USI .521 .316 2.717 1 .099 1.684 .906 3.131 
DO .139 .301 .213 1 .644 1.149 .637 2.073 
VD -.302 .737 .168 1 .682 .740 .175 3.134 
CAP .271 .462 .343 1 .558 1.311 .530 3.243 
Mixed .859 .537 2.560 1 .110 2.361 .824 6.760 










POP – pelvic organ prolapse, UI – urinary incontinence, FI – Faecal incontinence, USI – 
urodynamic stress incontinence, DO – detrusor overacitivty, VD- voising difficulties, CAP – 
low capacity bladder, Mixed – mixed urinary incontinence 
The relationships between sexual activity and feelings of frustration, 
inferiority and anger about levels of sexual activity were analysed using 
Pearson's Chi square test, which looks for differences between the observed 
and expected numbers of participants in each category (We compared the 
answers to Q5 a,b and c to Q20 a,b and d to determine if women who are 
NSA are more frustrated / angry that those who are SA). 
 
Group 1 
There was no significant relationship between feelings of frustration (χ2(1) = 
0.54, p = 0.822), inferiority (χ2(1) = 1.125, p = 0.315), or anger (χ2(1) = 
0.120,   p = 0.737) and sexual activity.  
 
Group 2 
There was no significant relationship between feelings of frustration (χ2(1) = 
0.145, p = 0.703), inferiority (χ2(1) = 0.321, p = 0.517), or anger (χ2(1) = 
0.187, p = 0.665) and sexual activity.  
 
Group 3 
There was no significant relationship between feelings of frustration (χ2(1) = 
2.911, p = 0.088), inferiority (χ2(1) = 1.609, p = 0.205), or anger (χ2(1) = 
0.001, p = 0.977) and sexual activity.  
 
To further investigate feelings of anger and frustration in the SA group, the 
patients were broken down into smaller groups according to their presenting 
complaint of either UI, POP or both.  Although, women with UI or POP 










and POP who were the most frustrated and angry with the impact that their 
condition has on their sex life.  This is demonstrated in table 11.6. 
 
Table 12.6 Breakdown of frustration and anger in the SA group according to 








Alone  (%) 
(N=17) 







 A D U A D U A D U A D U 
I feel 
frustrated 






































































A= agree, D= disagree, U= unanswered 
 
The relationship between sexual status and avoiding/restricting sexual 
activity through fear of leaking urine and/or stool and/or a bulging in the 
vagina was analysed using Pearson's Chi square test, which looks for 
differences between the observed and expected numbers of participants in 
each category.  
 
Group 1 
In the SA population, 38% of women reported sometimes / usually or always 
leaking urine with any type of SA and 66% state that fear of leakage caused 
them to avoid SA at times.  In the NSA population 48% reported that the fear 
of leakage caused them to avoid or restrict SA yet 45% of these women did 










The Chi square test showed that fear was not associated with any 




In the SA population, 39% (n=22) of women reported sometimes / usually or 
always leaking urine with any type of SA and 61% (n=35) stated that fear of 
leakage caused them to avoid SA at times.  In the NSA population 55% 
(n=21) reported that the fear of leakage caused them to avoid or restrict SA 
yet 81% (n=17) of these women did not have a partner.   
The chi square test showed that this fear was not associated with any 




In the SA population, 47% (n=14) of women reported sometimes / usually or 
always leaking urine with any type of SA and 73% (n=22) stated that fear of 
leakage caused them to avoid SA at times.  In the NSA population 43% 
(n=16) reported that the fear of leakage caused them to avoid or restrict SA 
yet 75% (n=12) of these women did not have a partner.   
The chi square test showed that this fear was not associated with any 
differences in sexual behaviour between the two groups (χ2(1) = 3.337, p = 
0.068).   
 
Assessment of the NSA population 
 
A detailed analysis of the NSA group was performed to try to explore factors 
that could influence reasons for sexual inactivity such as age, parity, UDS 












A Binary logistic regression was used to investigate the relationship between 
each part of Question 2 and Question 3 and covariates among the NSA 
group. The odds ratio for the UDS categories compared the observed 
category against the category NAD.  No multicollinearity was identified 
between the variables (Tolerance >> 0.1 and VIF <<10) :- 
 
Q2a (No partner)  
The model was not statistically significant χ2(7) = 5.678, p = 0.578.  
Q2b (no interest)  
The model was not statistically significant χ2(7) = 9.158, p = 0.242.  
 
Q2c (due to bladder / bowel problems) 
The model was not statistically significant χ2(7) = 15.691, p = 0.028. It 
explained 20.1% of the variance in sexual activity correctly assigned 63.3% 
of cases. None of the covariates examined made a significant contribution, 
however, trends were noted that the older the woman, the more likely she 
was not have sex due to UI/FI/POP, but increasing parity appeared to 
counteract this.    
 
Q2d (other health problems) 
The model was not statistically significant χ2(7) = 15.250, p = 0.033.  
Q2e (pain) 
The model was not statistically significant χ2(7) = 8.669, p = 0.277.  
Q3 (fear of leakage restricting SA) 














A Binary logistic regression was used to investigate the relationship between 
each part of Question 2 and Question 3 and covariates among the NSA 
group including parity, UI, Faecal Incontinence (FI) and POP. None of the 
covariates examined made a significant contribution to determining whether 
our subjects were sexually active or not. No multicollinearity was identified 
between the variables (Tolerance >> 0.1 and VIF <<10) 
 
Q2a (No partner)  
The model was not statistically significant χ2(2) = 1.804, p = 0.406.  
Q2b (no interest)  
The model was not statistically significant χ2(2) = 1.917, p = 0.384.  
Q2c (due to bladder / bowel problems) 
The model was not statistically significant χ2(2) = 1.502, p = 0.472.  
Q2d (other health problems) 
The model was not statistically significant χ2(2) = 3.766, p = 0.152.  
Q2e (pain) 
The model was not statistically significant χ2(2) = 0.763, p = 0.683.  
Q3 (fear of leakage restricting SA) 















A Binary logistic regression was used to investigate the relationship between 
each part of Question 2 and Question 3 and covariates among the NSA 
group including parity, UI, FI and POP. None of the covariates examined 
made a significant contribution to determining whether our subjects were 
sexually active or not. No multicollinearity was identified between the 
variables (Tolerance >> 0.1 and VIF <<10) 
 
 Q2a (No partner)  
The model was not statistically significant χ2(4) = 5.973, p = 0.201.  
Q2b (no interest)  
The model was not statistically significant χ2(4) = 1.689, p = 0.793.  
 
Q2c (due to bladder / bowel problems) 
The total model was statistically significant χ2(4) = 9.338, p = 0.025. It 
explained 43.1% of the variance in sexual activity correctly assigned 66.7% 
of cases. However, none of the covariates examined made a significant 
contribution.   
 
Q2d (other health problems) 
The model was not statistically significant χ2(4) = 5.336, p = 0.149.  
Q2e (pain) 
The model was not statistically significant χ2(4) = 1.395, p = 0.707.  
Q3 (fear of leakage restricting SA) 











Assessment of Bothersomeness 
Bothersomeness of sexually inactivity (Question 6) was examined to 
understand if it is age dependent or related to the reason for not being SA.   
 
Group 1 
The relationship between bothersomeness and age was analysed using an 
independent T-test. This showed that those who were not bothered were, on 
average, 10.46 [95% CI: 4.861, 16.068] years older than those who were 
bothered (t(126) = 3.696, p <0.000). 
A Binary logistic regression was used to investigate the relationship between 
bothersomeness and factors identified in Q2 among the NSA group (the 
rationale for sexual inactivity ie due to bladder problems, other health 
conditions, lack of interest). Following the initial model (demonstrated in 
table 11.7), a reduced model was produced using covariates identified as 
significant predictors in the initial model (Wald statistic significant at α < 0.1) 
and this is shown in table 11.8. 
The Reduced model was statistically significant χ2(2) = 26.532, p <0.000. It 
explained 33.6% of the variance in sexual activity correctly assigned 80.0% 
of cases. The Hosmer & Lemeshow test indicated that the model fitted the 
data well (χ2(2) = 0.013, p = 0.994). No multicollinearity was identified 
between the variables (Tolerance >> 0.1 and VIF <<10).  
Those who had no interest in sex were almost 5 times more likely to be 
bothered by their sexual inactivity, while those who were NSA due to their 















Table 12.7 Initial model assessing bothersomeness in the NSA group 
 B SE Wald df Sig. Exp(B) 95% C.I.for 
EXP(B) 
       Lower Upper 
No 
Partner 
.321 .612 .274 1 .600 1.378 .415 4.576 
No 
Interest 
1.778 .696 6.517 1 .011 5.917 1.511 23.170 




.679 .776 .765 1 .382 1.972 .431 9.026 
Pain .100 .795 .016 1 .899 1.106 .233 5.254 
Constant -1.117 .519 4.635 1 .031 .327   
 
Table 12.8 Reduced model assessing bothersomeness in the NSA group 




       Lower Upper 
No 
Interest 
1.566 .648 5.834 1 .016 4.789 1.344 17.068 
UI/FI/POP 2.189 .529 17.114 1 .000 8.925 3.164 25.174 

















The relationship between bothersomeness and age was analysed using an 
independent T-test. No relationship was identified (t (28) = 1.522, p = 0.139). 
A Binary logistic regression was used to investigate the relationship between 
Q6 and factors identified in Q2 among the NSA group. The model was not 
statistically significant χ2(2) = 8.077, p = 0.152.  
 
Group 3 
The relationship between bothersomeness and age was analysed using an 
independent T-test. This indicated a significant difference in the mean age, 
with those who were bothered being, on average, 12.3 years (95% CI: 1.05-
23.55) younger than those who were not (t(28) = 2.240, p = 0.033). 
A Binary logistic regression was used to investigate the relationship between 
Q6 and factors identified in Q2 among the NSA group. The model was not 
statistically significant χ2(5) = 5.076, p = 0.298.  
 
Assessment of the SA population 
Examination of the SA group was performed to determine if factors such as 
age, parity and UDS diagnosis impact upon SF.   
 
Group 1 
A Binary logistic regression was used to investigate the relationship between 
questions 7,9, 10, 11 and 18 and co-variates among the SA group. The odds 
ratio for the UDS categories compared the observed category to the 
category "No active diagnosis" (NAD).  No multicollinearity was identified 












Q7 (sexual arousal)  
The model was not statistically significant χ2(10) = 10.156, p = 0.427.  
 
Q9 (leakage of urine and or stool with any type of sexual activity) 
The model was statistically significant χ2(10) = 29.525, p = 0.001. It 
explained 18.5% of the variance in sexual activity correctly assigned 62.6% 
of cases. Patient reported symptom of UI was the only covariate that 
significantly contributed to a person's likelihood to leak with any type of 
sexual activity. The model parameters are displayed in table 11.9. 
 
Table 12.9 Factors influencing urinary leakage during SA 




       Lower Upper 
Age -.010 .014 .469 1 .49 .990 .964 1.018 
Parity .608 .446 1.86 1 .17 1.838 .767 4.404 
Prolapse -.364 .346 1.10 1 .29 .695 .353 1.369 
UI 1.45 .479 9.27 1 .002 4.298 1.681 10.98 
FI 21.0 17889.5 .000 1 .99 1455331225. .000 . 
UDS - USI -.086 .422 .041 1 .839 .918 .401 2.098 
UDS - DO .514 .427 1.45 1 .228 1.673 .725 3.859 
UDS - VD .872 1.144 .581 1 .446 2.391 .254 22.51 
UDS - CAP -.380 .657 .334 1 .563 .684 .189 2.479 
UDS - Mixed -.276 .623 .196 1 .658 .759 .224 2.571 
Constant -1.1 .695 2.79 1 .09 .313   
 
The relationship between Q9 and UI was further investigated through a 
Pearson's Chi Square test. This showed that those reporting UI were 
significantly more likely to leak with any type of sexual activity than those 
without UI (χ2(1) = 14.211, p <0.000). The results are displayed graphically 
below in Figure 11.1. It is interesting to note in this analysis that 39% of 










Figure 12.1 Relationship between diagnosis of UI and leakage during SA 
 
 
Leakage During SA 
 
 
Q10 (intensity of orgasms)   
The model was not statistically significant χ2(10) = 14.812, p = 0.139.  
 
Q11 (pain during intercourse) 












Of the 232 sexually active women 22 were SA without a partner.  For those 
with a partner 37% reported that their partner some / most or all of the time 
had a problem that limits their SA.  In general 70% felt that their partner had 
a positive effect on their sexual desire and 65% stated that their partner had 
a positive effect of the frequency of SA.  However, being SA does not 
guarantee satisfaction with 59% women reporting that they sometimes / 
usually or always want more from their sexual encounters.   
 
When assessing levels of sexual desire or interest in the SA group, 20% 
report this as high or very high, 48% as moderate and 31% as low or none 
at all.  This is not age dependent with an average age for each group as 
49.2, 49.1 and 49.3 years respectively.   
A Binary logistic regression was used to investigate the relationship between 
Q18 (fear of leakage or bulge restricting SA) and covariates among the 
Sexually Active group. The model was statistically significant χ2(9) = 25.880, 
p = 0.002. It explained 16.8% of the variance in sexual activity and correctly 
assigned 62.6% of cases. Prolapse was the only covariate that significantly 
contributed to fear that restricts sexual activity. No multicollinearity was 
identified between the variables (Tolerance >> 0.1 and VIF <<10). The 
model parameters are displayed in the table 11.10 below. 
 
The relationship between Q18 and Prolapse was further investigated 
through a Pearson's Chi Square test. This showed that those with POP were 
2.5 times more likely to avoid sex through fear of bulge /leaking than those 
















Table 12.10 Factors causing restrictions on SA 
 B SE Wald df Sig. Exp(B) 95% C.I.for 
EXP(B) 
       Lower Upper 
Prolapse 1.131 395 8.222 1 .004 3.099 1.430 6.716 
Parity .445 .427 1.084 1 .298 1.561 .675 3.607 
UI .442 .456 .937 1 .333 1.555 .636 3.802 
FI 20.157 17659.5 .000 1 .999 567646277.673 .000 . 
UDS - USI -.656 .453 2.099 1 .147 .519 .214 1.260 
UDS - DO -.260 .431 .363 1 .54 .771 .331 1.797 
UDS - VD 20.863 19428.0 .000 1 .99 1150478420.798 .000 . 
UDS - CAP .881 .740 1.41 1 .23 2.414 .566 10.30 
UDS - 
Mixed 
.555 .855 .421 1 .51 1.742 .326 9.310 




A Binary logistic regression was used to investigate the relationship between 
questions 7,9, 10, 11 and 18 and co-variates including parity, UI, FI and 
POP among the SA group. No multicollinearity was identified between the 
variables (Tolerance >> 0.1 and VIF <<10):- 
 
Q7 (sexual arousal)  











Q9 (leakage of urine and or stool with any type of sexual activity) 
The model was not statistically significant χ2(4) = 2.088, p = 0.720.  
 
Q10 (intensity of orgasms)   
The model was not statistically significant χ2(4) = 8.983, p = 0.062.  
 
Q11 (pain during intercourse) 
The model was not statistically significant χ2(4) = 2.907, p = 0.573.  
 
Q18 (fear of leakage or bulge restricting SA) 
The model was not statistically significant χ2(4) = 7.543, p = 0.110.  
 
Of the 57 SA women 6 were SA without a partner.  For those with a partner 
25% (n=14) reported that their partner some / most or all of the time had a 
problem that limits their SA.  In general 74% (n=42) felt that their partner had 
a positive effect on their sexual desire and 67% (n=38) stated that their 
partner had a positive effect of the frequency of SA.  However, being SA 
does not guarantee satisfaction with 60% (n=34) women reporting that they 
sometimes / usually or always want more from their sexual encounters.   
When assessing levels of sexual desire or interest in the SA group, 21% 
(n=12) reported this as high or very high, 47% (n=27) as moderate and 32% 
















A Binary logistic regression was used to investigate the relationship between 
questions 7,9, 10, 11 and 18 and co-variates including parity, UI, FI and 
POP among the SA group. No multicollinearity was identified between the 
variables (Tolerance >> 0.1 and VIF <<10):- 
 
Q7 (sexual arousal)  
The model was not statistically significant χ2(3) = 2.334, p = 0.506.  
 
Q9 (leakage of urine and or stool with any type of sexual activity) 
The model was statistically significant χ2(4) = 14.405, p = 0.006. It explained 
49.4% of the variance in sexual activity and correctly assigned 74.2% of 
cases. Having at least one live birth made a significant contribution, resulting 
in a 42-fold increase in the chances of urinary incontinence during sex.  
However, the mode of delivery was not assessed in this group. 
 
Q10 (intensity of orgasms)   
The model was not statistically significant χ2(3) = 4.301, p = 0.231.  
 
Q11 (pain during intercourse) 
The model was not statistically significant χ2(4) = 4.955, p = 0.292.  
 
Q18 (fear of leakage or bulge restricting SA) 











Of the 30 SA women 2 were SA without a partner.  For those with a partner 
20% (n=6) reported that their partner some / most or all of the time had a 
problem that limits their SA.  In general 93% (n=28) felt that their partner had 
a positive effect on their sexual desire and 90% (n=27) stated that their 
partner had a positive effect of the frequency of SA.  However, being SA 
does not guarantee satisfaction with 43% (n=13) women reporting that they 
sometimes / usually or always want more from their sexual encounters.   
When assessing levels of sexual desire or interest in the SA group, 20% 
(n=6) reported this as high or very high, 50% (n=15) as moderate and 30% 
(n=9) as low or none at all.   
 
In summary, these analyses showed that more women with OAB are NSA 
compared to the other UDS findings, yet women with POP are more likely to 
avoid sex.  Younger age, lack of interest and being NSA due to bladder and 
bowel problems are predictors of increased bothersomeness of sexual 
inactivity.  Parous women with OAB are 42 times more likely to experience 
CI than nulliparous women with OAB. 
 
 
 
 
 
 
 
 
 
 
